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Estimated prevalence rates of autism spectrum disorders (ASDs) have increased at 
an alarming rate over the past decade; current estimates stand as high as 1 in 110 
persons in the population with a higher ratio of affected males to females.  In addition 
to their emotional impact on the affected persons and their family members (in fact, 
the latter are often unrecognized unaffected patients” themselves), the economic 
and social impacts of ASDs on society are staggering.  Persons with ASDs will need 
interdisciplinary approaches to complex treatment and life planning, including, but 
not limited to, special education, speech and language therapy, vocational skills 
training and rehabilitation, social skills training and cognitive remediation, in 
addition to pharmacotherapy.  The current book highlights some of the recent research 
on nosology, etiology, and pathophysiology. Additionally, the book touches on the 
implications of new research for treatment and genetic counseling.  Importantly, 
because the field is advancing rapidly, no book can be considered the final word or 
finished product; thus, the availability of open access rapid publication is a mechanism 
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The broadening of the definitional criteria of autism spectrum disorders (ASDs) and 
increased recognition of these syndromes have led to dramatic increases in their es-
timated prevalence; prevalence estimates of ASDs in the USA are approximately 1 in 
110 children with a three to four time greater male to female predominance. These 
disorders occur commonly as co-morbid conditions in several Mendelian genetic 
disorders due to the effects of a single major gene (e.g., tuberous sclerosis). Im-
portantly, although these Mendelian disorders appear to be unrelated to each other, 
recent advances in bioinformatics and “network analyses” suggest that they may in-
deed be related to each other; the points of convergence can include development 
and architecture of the synapse, and early developmental events in neurogenesis, 
neuronal cell migration and synaptogenesis. Additionally, areas along the human 
genome are emerging as “hotspots” for microdeletions and microduplications, re-
ferred to as Copy Number Variants (CNVs); the density of these CNVs may contrib-
ute to increased risk of neurodevelopmental syndromes, including ASDs. Remarka-
bly, although the 1970’s was focused on elucidating descriptive differences between 
ASDs and schizophrenia presenting in childhood; the emerging data on CNVs sug-
gest that ASDs and schizophrenia, or at least their genetic mechanisms, may be more 
similar than initially appreciated. In any event, the genetic data are also suggesting 
molecular targets; for example, microdeletions at the 15q13.3 locus suggest that hap-
loinsufficiency of a gene product of this locus (i.e., CHRNA7), which codes for the 
α7 nicotinic acetylcholine receptor (α7 nAChR) subunit, may be causally associated 
with ASDs. Thus, selective nicotinic acetylcholine receptor agonist strategies should 
be explored for their potential therapeutic benefit. The high prevalence of these dis-
orders, their impact on the identified affected patient and the unrecognized unaf-
fected family members (including sibs), accessibility of Array Comparative Genomic 
Hybridization screening technologies, elucidation of associations with candidate 
susceptibility genes, along with CNVs and complex genetics are raising profound 
ethical questions, heightening the challenges of genetic counseling. The staggering 
challenges of genetic counseling are further compounded by issues of imprinting 
(i.e., homologous maternal and paternal chromosomes may have different patterns 
of cytosine methylations and certain genetic disorders differ depending on genetic 
variations within one of the affected parental chromosomes [e.g., Angelman and 
X Preface 
 
Prader-Willi syndromes]) and variable “penetrance” (i.e., there is a broad array of 
possible phenotypes). The chapters contained in this book highlight some of these 
emerging issues. 
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Department of Psychiatry and Behavioral Sciences 
Eastern Virginia Medical School 
825 Fairfax Avenue, Suite 710 
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Early Detection of Autism Spectrum Disorders 
Jariya Chuthapisith and Nichara Ruangdaraganon 
Department of Paediatrics, Faculty of Medicine Ramathibodi Hospital 
Mahidol University, Bangkok 
Thailand 
1. Introduction 
Autism spectrum disorders (ASDs) are neurodevelopmental disorders characterized by 
distinctive language impairments, social and communicative deficits, and patterns of 
restricted and stereotyped behavior. In the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition, text revision (DSM-IV-TR) (American Psychiatric Association, 
2000), pervasive developmental disorders (PDDs) are also referred to as autistic disorder 
(AD), Asperger’s disorder, PDD not otherwise specified (PDD-NOS), childhood 
disintegrative disorder, and Rett Disorder. However, the diagnostic boundaries between 
these PDD subtypes remain unclear, the symptoms and behaviours lie on a continuum and 
have considerable clinical heterogeneity (Szatmari, 1999). In this review, therefore, ASDs are 
referred to as the diagnostic category of PDDs.  
2. Diagnosis of ASDs 
The manifestations of ASDs vary from mild to severe and pervasive impairment. Currently, 
the diagnosis of ASDs is based on the criteria developed in the DSM-IV-TR and the 
International Classification of Diseases, 10th revision (ICD-10) (World Health Organization 
(WHO), 1992) and is supported by standardized diagnostic instruments. According to the 
DSM-IV-TR criteria, the impairments of ASDs consist of three main impairments which 
must all be presented for diagnosis.  
2.1 Impairment in social interaction is defined by various symptoms including impairment 
in the use of nonverbal behaviours (e.g. eye contact, use of gestures and facial expressions); 
lack of showing, bringing or pointing out objects; odd relationships of approaches to others; 
and lack of social or emotional reciprocity.  
2.2 Impairments in communication consist of delay in or total lack of spoken language, 
inability to initiate or sustain a conversation with others, stereotyped or repetitive use of 
language, and lack of social imitative play.  
2.3 Restricted repetitive and stereotyped patterns are behaviours, interests and activities as 
manifested by an inability to cope with change, a dislike for any interruption to routine, 
preoccupation with specific subjects or activities, repetitive or stereotyped motor mannerisms 
such as hand flapping or twisting, and persistent preoccupation with parts of objects.  
Early diagnosis for ASDs is undoubtedly important and is considered as a clinical best 
practice. Early detection of ASDs leads to an early intervention (Rutter et al., 2006). 
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However, diagnosis before the age of 3 years remains a challenge (Baron-Cohen et al., 1996). 
Some symptoms of ASDs may overlap with normal developmental variance. Also, ASDs are 
a continuum of disease which has a wide range of individual differences. Distinctions 
between autistic disorder and PDD-NOS remain unstable. A study reported that up to 50% 
of PDD-NOS cases, who were diagnosed before age 3 years, could have been 
overdiagnosed, whereas around 22% were underdiagnosed (Chawarska et al., 2007). This 
was due to the fact that diagnosis depends on clinical judgments which sometimes may not 
agree with the DSM-IV-TR diagnostic criteria especially evaluating a young child. Some of 
the criteria in the DSM-IV-TR can not apply to young children. In other words, many of the 
characteristic behaviours in the DSM-IV-TR are not apparent before 36 months. For 
example, a child age less than 16-month-old typically can engage in parallel play but has not 
yet developed reciprocal peer relationships. Thus, the criteria of failure to develop age-
appropriate peer relationships need to be adapted (Martinez-Pedraza & Carter, 2009). The 
criteria of stereotyped and repetitive use of language can be difficult to discriminate 
between repetitions of the last word in young typically developing children and echolalia in 
children with ASDs. Furthermore, the criteria “restricted repetitive and stereotyped patterns 
of behaviour, interests and activities” may not appear in young children. These may appear 
later after the third birthday in some cases (Gray & Tonge, 2001; Turner, 1999). Therefore, 
making a diagnosis in children younger than 2 years of age is very challenging. 
3. Early signs of ASDs 
Many research studies have concluded that the first signs and symptoms of ASDs are 
evident by 12 to 18 months of age (De Giacomo & Fombonne, 1998; Young et al., 2003). 
Research on early signs and symptoms of ASDs in young children have focused on parental 
retrospective reports, early home videos of children later diagnosed with ASDs, and studies 
on siblings of children with ASDs. The emergence of ASDs signs and symptoms involve the 
area of social skill deficits, language skill deficits and unusual repetitive or stereotypical 
behavioural patterns. Signs and symptoms that are predictive of ASDs in young children 
are, namely: 
3.1 Social skills deficits 
Social skills are one of the most important areas in defining ASDs in very young children. In 
typically developing children, social development is acquired parallel to overall 
development (e.g. language, motor and cognitive development). In the very young children 
whose language skills are limited, social development depends very much on clinical 
observations. The manifestation is a lack of or a decreased drive to connect with others, 
including share feelings, thoughts and actions. Children who have ASDs have limited or 
reduced eye contact, fail to orient their name being called, limited imitation, limited 
responding to reciprocal social games, and lack of showing or bringing an object to a 
caregiver.  
The important characteristic in helping make a diagnosis in very young children is lack of 
“joint attention” (JA) (Charman, 2003; Dawson et al., 2002; Turner et al., 2006). JA refers to 
the capacity of the child to coordinate attention with a social partner in relation to an object 
or event (Rapin & Tuchman, 2008). JA normally appears to develop between 8-16 months. In 
8-10 months old typically developing children, the child will follow the caregiver’s gaze 
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when the caregiver looks at an object or event. This development milestone is called “gaze 
monitoring”. Around 10-12 months of age the child can follow the caregiver’s point and can 
look back at the caregiver. At approximately 12-14 months the child will request for objects 
by pointing. In detail, the child will look back and forth between the object and caregiver to 
reassure that the caregiver understands his or her need, so called protoimperative pointing. 
At 14-16 months when the protodeclarative pointing develops, the child will look 
alternatively between the object and the caregiver. The goal is to share social experience, not 
the desired object (Johnson & Myers, 2007). Other nonverbal gestures, including facial 
expression, usually help discriminate the difference between these two types of pointing. 
Children with ASDs can not achieve these skills at an age-expected time or some can achieve 
partially but do not qualitatively achieve the skill completely. Some children may have no 
pointing at all but use their caregivers’ hands point to the desired object. Some children look 
at the object but do not look at the caregiver to connect socially. A study in infant siblings of 
children with ASDs stated that the inability to shift one’s attention (between child, parent 
and object) may be the first reliable sign of ASDs (Zwaigenbaum et al., 2005). In brief, lack of 
or delayed JA skill that is discrepant from overall functioning is a core feature of the ASDs 
diagnosis.  
Since JA skills may not be observed in typically developing children younger than 1 year of 
age, responding to their name being called is a skill that the child should achieve. Children 
with ASDs usually fail to respond to their name being called. Some children with ASDs may 
respond to environmental sounds well enough to reassure the caregivers that their children 
can hear. Home videos of 1-year-old children who later were diagnosed with ASDs found 
that orienting to name being called is one of the most consistent deficits for affected children 
at that age (Baranek, 1999; Osterling & Dawson, 1994).  
Delay in play skills is one of the features associated with diagnosis of ASDs. In respective 
order, play starts with sensory-motor, functional, constructive, and pretend or imaginary 
play. In typically developing children, approximately 4 months old, sensory-motor play 
begins. At 12-14 months of age, the child plays in a more functional manner. Pretend play 
starts around 16-18 months of age and increases gradually in complexity. Lack of or delay in 
pretend play or play that never passes the sensory-motor play stage serves as a 
distinguishing characteristic of ASDs. Although, some children with ASDs progress to 
functional play, the quality of play is significantly different from typically developing 
children by around age 2 years i.e. play is less purposeful, less symbolic and less in 
complexity (McDonough et al., 1997; Sigman et al., 1999; Stone et al., 1990). Some children 
with ASDs play or manipulate objects in a stereotypic or ritualistic manner such as lining 
up, banging, and mouthing objects. They usually prefer playing alone and have trouble 
incorporating into social play. This sophisticated social play may not develop which further 
worsen social skills development. 
Although, there is a possibility to detect social skills deficits in children younger than 1 year 
of age, the reliability remain problematic before 18 months (Rutter, 2006). Special 
consideration should focus on gaze monitoring, joint attention, responding to being called 
by name, and play skills.  
3.2 Early language skills deficits 
Generally, absence of language skills appears at around age 2, which may lead to diagnosis 
of ASDs. In order to diagnose of ASDs earlier, delay in language development should be 
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detected as soon as possible. A study among the siblings of children with ASDs 
demonstrated that during the first year of life, infants later diagnosed with autism vocalized 
less than low-risk control infants. Moreover, delays in verbal skills and early language 
comprehension were evident (Zwaigenbaum et al., 2005). Regarding language 
abnormalities, both expressive and receptive language deficits should be monitored. 
Typically, infants start to babble by 6 months of age, followed by advances in complexity 
which includes several phonemes. Later, jargoning (i.e. adds inflection to utterances in an 
attempt to tell a story) develops at approximately 10 -12 months of age. Lack or delay of an 
alternating to-and-fro pattern of vocalizations between infant and parent, delay of onset of 
babbling, and decrease or no use of pre-speech gestures (e.g. pointing, showing, nodding) 
are characteristic of ASDs (Wetherby et al., 2000; Johnson & Myers, 2007).  
Repeating words in particular the last one or two words of a sentence right after being heard 
can be observed in typically developing children under the age of 2 years, which mimicks 
the ASDs symptom of immediate echolalia. However, the typically developing child will 
pass through this brief stage and will acquire functional language. In children with ASDs, 
this imitation still persists as expressive language after the age of around 2 years and 
beyond. Furthermore, the children with ASDs mostly repeat words in an odd intonation or 
repeat exactly the same intonation as they heard (Martinez-Pedraza & Carter, 2009). 
In young children with ASDs, receptive language ability is often impaired. They initially do 
not respond to their names when called by a caregiver. After language is present, children 
with ASDs are unable to initiate or sustain conversation. Some children have 
comprehension deficits, particularly in complex sentences or questions. Children with ASDs 
also show deficits in non verbal communication; for example, they look at others less, have 
less social smile, lack appropriate gestures, have less pointing or have difficulty following a 
point, show objects less and have a lack of appropriate facial and emotional expression. 
These non verbal communication deficits are linked closely to lack of social skills 
development (Martinez-Pedraza & Carter, 2009). 
There is approximately one fourth to one third of children with ASDs whose parents 
reported a significant loss or regression in language development. The regression 
characteristically occurs between 15-24 months of age (Lord et al., 2004; Luyster et al., 2005). 
Although, some parents reported normal development prior to regression, studies showed 
that some children with ASDs have subtle language and social impairments before the onset 
of regression (Richler et al., 2006; Werner & Dawson, 2005).  
3.3 Restrictive interests, stereotypic and repetitive patterns of behaviours 
Stereotypies and repetitive behaviours are not specific to children with ASDs. Children who 
have globally developmental delay (GDD) and children with sensory impairment may 
demonstrate stereotypies. Even in typically developing children, stereotypies may present 
e.g. flapping their hands when excited (Johnson, 2008). Stereotypies and repetitive 
behaviours in children with ASDs usually are not common in very young children 
(Charman & Baird, 2002; Cox et al., 1999; Moore & Goodson, 2003). Children with ASDs are 
preoccupied with sameness and routines, so interruption or changes in routine lead to 
tantrum and emotional disturbance. Some display sensory abnormalities: hypo- or hyper-
responsive to sensory stimuli. Some children show an unusual and preoccupation with a 
topic of interest such as train schedules, solar system, dinosaurs, etc. However, this strong 
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interest may not present in young children with ASDs. These patterns of behaviours vary 
among young individuals with ASDs. Therefore, diagnosis of ASDs in very young children 
should focus on social skills and language skills deficits rather than stereotypies and 
repetitive behaviours. 
4. Screening tools for ASDs 
The American Academy of Pediatrics (AAP) recommends ASDs screening in children age 18 
and 24 months as part of developmental surveillance during regular health visits (Johnson & 
Myers, 2007). There are many valuable screening tools designed, such as the Checklist for 
Autism in Toddlers (CHAT) (Baron-Cohen et al., 1992; Baron-Cohen et al., 1996), the 
Modified Checklist for Autism in Toddlers (M-CHAT) (Kleinman et al., 2008; Robins et al., 
2001), the Screening Test for Autism in Two-Year-Olds (STAT) (Stone et al., 2000) and the 
Pervasive Developmental Disorders Screening Test-II (PDDST-II) (Siegel, 2004). All of these 
tools, except the STAT, are designed as first-level screens (i.e. the tools are administered to 
all children to differentiate children who are at risk of ASDs from the general population).  
Baron-Cohen et al conducted a study using the CHAT to administer in a primary health care 
setting to identify 18-month-old children at risk of ASDs. The study included both direct 
observation and a questionnaire for parents. The CHAT focuses on 3 key items which are 
gaze monitoring, protodeclarative pointing and pretend play. Findings from the study in the 
general population demonstrated that, the CHAT had a specificity of 98%-100% and a 
sensitivity of 18%-38% (Baird et al., 2000; Baron-Cohen et al., 1992; Baron-Cohen et al., 1996; 
Scambler et al., 2001). Attempts to improve sensitivity by modifying the cut-off criteria 
resulted in decrease in positive predictive value (from 75% to 5%). Overall, use of the CHAT 
as a screening tool remains problematic owing to low sensitivity (Bryson et al., 2003).  
The M-CHAT is a screening tool for children 16 to 48 months and was developed to improve 
prediction of the CHAT. In the M-CHAT, there is no observation component, but includes a 
wider range of signs and symptoms of ASDs. This parental questionnaire consists of 23 (yes-
no) items. Children who fail any three items or two critical items are considered to be at risk 
for ASDs. Items that were found to be the best predictors for ASDs were protodeclarative 
pointing, response to name, interest in peers, bringing things to show parents, following a 
point, and imitation. The reported sensitivity and specificity of the M-CHAT were around 
89% and 93%, respectively (Dumont-Mathieu & Fein, 2005). However, the positive 
predictive value (PPV) was low (0.11±0.05) when it was used alone as a screen for ASDs in a 
community-based sample. The follow-up interview was reported to be able to significantly 
increase the PPV (Kleinman et al., 2008). Overall, the M-CHAT showed higher sensitivity 
than the CHAT and is possibly useful in identifying children in need of further assessments, 
but should not be used as a screen to exclude the possibility of ASDs (Eaves et al., 2006; 
Barbaro & Dissanayake, 2009). 
The STAT is a second-level screen (that is, the tool is used to differentiate children who are 
at risk of ASDs from those at risk of other developmental disorders). It was designed to be 
used in children aged 2-3 years. The STAT includes 12 pass/fail items and is administered in 
a play-like setting in order to observe social-communicative behaviours. The test lasts 
approximately 20 minutes to complete. The estimated sensitivity and specificity were 95% 
and 73%, respectively (Stone et al., 2008). However, increased validity in larger studies and 
community-based samples are required.  
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The PDDST-II has both a first and second level screen versions. It is a parental questionnaire 
that can be used with children under 6 years of age. To date, the clinical validity remains 
unclear because it has not yet been published in a peer-reviewed journal (Volkmar et al., 
2005). 
5. Diagnostic instrument for ASDs 
Currently, there are standardized instruments to facilitate diagnosis in ASDs. The Autism 
Diagnostic Interview – Revised (ADI-R) (Le Couteur et al., 2003; Lord et al., 1994) and the 
Autism Diagnostic Observation Schedule (ADOS) (Lord et al., 2000a) are well validated and 
currently their combination with clinical judgment based on the DSM-IV-TR criteria are 
considered as the “gold standard” for diagnosis of ASDs (Battaglia, 2007). However, these 
instruments should be used with caution in very young children or children with a mental 
age less than 24 months (Stone et al., 1999).  
The ADOS is the most widely used standardized semistructured assessment of 
communication, social interaction and play. The scenarios for interaction with the child are 
used in the ADOS and require a well-trained interviewer. The ADOS consists of 4 modules 
devised for individuals with varying developmental and language level. Each module lasts 
approximately 40 minutes. The ADOS provides an algorithm to differentiate between 
autism, ASD and not ASD. Alpha coefficients are 0.86-0.91 for the social domain (across 
modules), 0.74-0.84 for communication, and 0.63-0.65 for repetitive behaviours (modules 1 
and 2) (Lord et al., 2000a). In younger children, especially younger than 15 months of age, 
the sensitivity is excellent, the specificity is doubtful (Chawarska et al., 2007; Lord et al., 
2000b; Risi et al., 2006). Luyster et al developed the toddler version of the ADOS (ADOS-
Toddler Module or ADOS-T) which can be used for children under 30 months of age who 
have non-verbal mental ages of at least 12 months. The ADOS-T has acceptable internal 
consistency and excellent inter-rater and test-retest reliability (Luyster et al., 2009). 
However, larger samples of children and long follow-up studies need further replication.  
The ADI-R is a standardized parental interview conducted by a trained interviewer. The 
interview covers the past developmental history and current functioning of individuals. The 
tool consists of 111 questions and takes about 2-3 hours. The ADI-R is designed to use in 
children about 4-5 years old. The ADI-R provides an algorithm to differentiate between 
autism and not autism. The ADI-R is reliable and valid. The inter-rater reliability on 
individual algorithm items ranges from 0.63 to 0.89.The internal consistency (alpha 
coefficients) is 0.69-0.95 (Lord et al., 1994). However, the time needed for administration 
precludes its use in clinical settings. Moreover, further study is needed for identifying ASDs 
in preschool children (Le Couteur et al., 2008; Mazefsky & Oswald, 2006; Risi et al., 2006). 
The Developmental, Dimensional and Diagnostic Interview (3Di) is a new structured 
computerized interview for the diagnosis of ASDs and extends to co-morbid disorders. 
There are total 266 questions on autistic spectrum disorders (ASD) symptoms and 53 
questions for an abbreviated interview. The questions in the interview are clustered 
according to domains of function: reciprocal social interaction skills, social expressiveness, 
use of language and other social communication skills, use of gesture and non-verbal play, 
and repetitive/stereotyped behaviours and routines. To reduce a risk of respondent bias, 
breaking down complex questions and scattering their components throughout the 
interview were done. A study reported that test-retest and inter-rater reliabilities were 
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excellent. The sensitivity and specificity were estimated about 100% and 97%, respectively. 
Both the original 3di and the short version demonstrated high agreement with the ADI-R 
(Santosh et al., 2009; Skuse et al., 2004). Moreover, the short version takes less time to 
perform compared with the ADI-R. However, the study was limited to mild cases of ASDs; 
and so far limited numbers of young children have been tested.  
The Autism Observation Scale for Infants (AOSI) (Bryson et al., 2008) is a diagnostic 
instrument that was developed for infants aged 6-18 months. The instrument consists of 18-
item direct observational measure. Various activities were developed to assess the infant’s 
target behaviours. These target behaviours are visual tracking and attentional 
disengagement; coordination of eye gaze and action; imitation; early social-affective and 
communicative behaviours; behavioural reactivity; and various sensory-motor behaviours. 
The inter-rater reliability ranges from 0.68 to 0.94 at 6, 12 and 18 months. Test-retest 
reliability is acceptable. The AOSI takes approximately 20 minutes to administer. Although, 
the AOSI is a useful diagnostic instrument for young children, it is not yet proposed to be 
used. 
In brief, although there have been a number of screening and diagnostic instruments to 
facilitate ASDs diagnosis, a comprehensive evaluation for suspected ASDs should be 
performed. Such evaluations include a developmental history, parental interview, thorough 
physical examinations, clinical observations, developmental evaluations, assessment of the 
strengths and weaknesses of the child, assessment of family functioning, administration of 
standardized diagnostic instruments that operationalize the DSM criteria, and measures of 
cognitive and adaptive functions. Such comprehensive approaches together with early 
detection can lead to early intervention and result in improvement of the long-term 
functioning of children with ASDs. 
6. Summary 
Early detection of ASDs provides the best opportunity for early intervention, which results 
in significantly improved outcomes for children with ASDs. Awareness of the importance of 
early diagnosis and treatment has increased attention on knowledge of the very early 
manifestations of ASDs. Early manifestations include abnormalities in social interaction, 
communication and behaviours. Firstly, regarding social interaction, a lack of eye contact, 
orienting to name call, imitation, joint attention and limited responding to reciprocal play 
skills are the markers that should be of concern. Secondly, in the area of communication, any 
lack or delay of communication skills including verbal and non-verbal communication are 
indicative signs of ASDs. Lastly, the abnormal or unusual behaviours (i.e. repetitive and 
stereotypic behaviours, restrictive interests, preoccupied with sameness/ routine and 
sensory abnormalities) can be apparent in young children, however, these behaviours may 
not serve as important predictors of ASDs as the social and communication impairments.  
Although, there are screening instruments to help identify children with ASDs in 
community-based samples, there is no screening instrument that provides adequate 
sensitivity and specificity for universal screening (Barbaro & Dissanayake, 2009). According 
to standardized diagnostic instruments, there have been many studies showing that the 
ADI-R and the ADOS have been well validated and are the instruments to accurately 
diagnose ASDs as early as 2 years. The combination of the ADOS and the ADI-R in 
conjunction with clinical diagnosis based on the DSM-IV-TR are recommended when 
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diagnosing very young children with ASDs. In clinical practice where diagnostic 
instruments are not applicable, developmental surveillance with proper guidance is a 
recommended approach. Further prospective studies in young children should be 
conducted to provide evidence-based diagnosis for young children, especially under the age 
of two. Those developing research offer hope for better outcomes for children with ASDs. 
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diagnosing very young children with ASDs. In clinical practice where diagnostic 
instruments are not applicable, developmental surveillance with proper guidance is a 
recommended approach. Further prospective studies in young children should be 
conducted to provide evidence-based diagnosis for young children, especially under the age 
of two. Those developing research offer hope for better outcomes for children with ASDs. 
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Pervasive Developmental 
Disorder- not Otherwise Specified: 
Specifying and Differentiating 
Koray Karabekiroglu 
Ondokuz Mayis University 
Turkey 
1. Introduction 
Pervasive Developmental Disorders (PDD), also called Autism Spectrum Disorders (ASD), 
are defined in terms of abnormalities in social and communication development in the 
presence of marked repetitive behaviour and narrow interests (APA, 1994). The DSM-IV 
(APA, 1994) and ICD-10 (WHO, 1993) provide diagnostic criteria for autism and related 
disorders such as Asperger syndrome (AS), Rett’s, and childhood disintegrative disorder. 
Unfortunately, the diagnostic category of pervasive development disorder-not otherwise 
specified (PDD-NOS) does not have specific criteria and is often seen as a catchall diagnosis 
for children who do not fit the criteria for one of the other pervasive developmental 
disorders (Filipek et al., 1999).   
According to Cohen & Volkmar (2005) classification systems should aim at improving 
communication, through their features (internal consistency, use easiness, good definition of 
categories) and being widely accepted. The accuracy of early diagnosis, as well as 
developmental pathways that are observed in young children with ASD have both 
theoretical and practical importance (Luyster et al., 2005). An empirically developed 
dimensional approach that defines the spectrum on multiple dimensions may offer several 
advantages. It may, for example, result in more correspondence between the results of 
genetic research and the phenotype of autistic disorders, provided the pathology can be 
summarized by empirical and valid behavior dimensions (Volkmar et al., 2004; van Lang et 
al., 2006; Hus et al., 2007).  
It is now well recognized that children with PDD vary in the number and severity of 
symptoms (Szatmari et al., 2002). In DSM-IV, a diagnostic category within PDD, which is 
called “pervasive developmental disorder-not otherwise specified” (PDD-NOS), defines 
children with symptoms such as restricted social interaction, poor verbal and non-verbal 
communication skills, strict and/or stereotypical behaviors but without full diagnostic 
criteria of autism (APA, 1994). Epidemiological data suggest that PDD-NOS is at least twice 
as common as autism in the general community (Chakrabatri & Fombonne, 2001). One or 
more of the following conditions may lead to a PDD-NOS diagnosis (1) onset of the disorder 
after 3 years of age, (2) atypical symptoms with regard to the 12 criteria of autism specified 
in DSM-IV, (3) fewer than 6 criteria and thus subtreshold (Walker et al., 2004). A categorical 
system like DSM-IV can be very useful for diagnosing prototypic manifestations of a 
disorder, but it is less useful in encompassing what may be, in its broader manifestations, a 
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“spectrum disorder” (Tanguay, 2004). An assumption of the autism-spectrum model is that 
autism conditions lie on a continuum of social-communication skills (Baron-Cohen et al., 
2001; Wakabayashi et al., 2007). A continuum view shifts us away from categorical diagnosis 
and towards a quantitative approach. 
Diagnostic agreement for PDD-NOS is generally considered to be weak (Tanguay, 2004). 
Walker and colleagues presented compelling evidence, both from the literature and from 
their study, that attempting to improve the DSM-IV criteria for PDD-NOS can be quite 
frustrating (Walker et al., 2004). Many of the symptoms of PDD-NOS can occur in non-PDD 
conditions, such as severe mental retardation or language delay, and they may present with 
similar developmental history (Bishop et al., 2006). Furthermore, clinical presentation of 
PDD-NOS may resemble presenting symptoms in high functioning autism, Asperger’s 
disorder, reactive attachment disorder, and psychotic disorders, and the differential 
diagnosis may be highly complicated. 
Studies on the distinction between Autistic Disorder (AD) and Pervasive Developmental 
Disorder Not Otherwise Specified (PDD-NOS) have been inconclusive (Snow & Lecavalier, 
2011). The field is in need of more studies examining subtype differences. As the diagnostic 
validity of PDD-NOS is still open to question, and to explore proposed underlying factors, 
we have to assign cases based on a valid clinical assessment. Therefore, we still need to 
investigate further the clinical features of children with PDD-NOS that distinguish them 
from children with autism and other non-PDD conditions. 
2. Autism, PDD-NOS, and ADHD 
Barkley (1990) reported that it is common for children with PDD-NOS to be initially given a 
diagnosis of Attention Deficit/Hyperactivity Disorder (ADHD). Jensen et al., (1997) 
reported that 74% of the children in their study diagnosed with PDD-NOS were originally 
diagnosed with ADHD. Another study showed that children with PDD-NOS and ADHD 
did not differ from each other with respect to total number of autistic symptoms, general 
psychopathology, or attention difficulties (Luteijn et al., 2000). Methods for differentiating 
PDD-NOS from the non-PDD disorders, such as attention deficit hyperactivity disorder 
(ADHD), are not well established. Several investigators concluded that it is difficult to make 
a distinction between ADHD and PDD by using the present diagnostic criteria in DSM-IV 
(Bryson et al., 2008; Gökler et al., 2004). The characteristics that differentiated children with 
PDD-NOS from those with autism and non-PDD disorders were also explored by Buitelaar 
et al., (1999). Four criteria discriminated autism from PDD-NOS most effectively: children 
with autism more often demonstrated restricted patterns of interest, lacked varied make-
believe play, failed to use nonverbal behavior, and had an earlier age of onset. In another 
study (Allen et al., 2001), the PDD-NOS group (including both high- and low-functioning 
children) did not differ significantly from the autism or non-PDD groups on measures of 
language or adaptive functioning but did show less restricted stereotyped behaviors than 
the high-functioning autism group. 
In a very recent study (Snow & Lecavalier, 2011), authors examined the validity of PDD 
NOS by comparing it to autistic disorder (AD) and other developmental disorders (DD) 
on parent-reported behavior problems. Fifty-four children with PDD-NOS were 
individually matched on age and nonverbal IQ to 54 children with AD and 54 children 
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with DD. The only difference between PDD-NOS and AD groups was higher scores in the 
PDD-NOS group on two items measuring Anxiety/Depression. Cognitive functioning 
may be a more salient variable than subtype when studying psychopathology in 
individuals with ASDs. 
In a study (Karabekiroglu & Akbas, in press) designed to explore whether PDD-NOS 
encompassed a distinct cluster of symptoms and clinical profile or not, we investigated 
differential features of PDD-NOS such as presenting symptoms, developmental history, and 
comorbidity with respect to autism and ADHD. The study involved 188 children (PDD-NOS 
n=94; ADHD n=47; autism n=47) (male n=150, female n=38) who were 5.5(±2.5) years old on 
average (range 2-11 yrs.). The children with Asperger Syndrome were excluded. Preliminary 
PDD-NOS screening scale (PPSSS) was developed based on the ‘presenting’ symptoms of 
PDD-NOS that were systematically collected in a pilot group of children (Table 1).  
The clinical diagnoses and comorbidities were based on the comprehensive mental status 
examination, Schedule for Affective Disorders and Schizophrenia for School Age Children-
Present and Lifetime Version-Turkish Version (K-SADS-PL-T), and the consensus between 
two child and adolescent psychiatry specialists. The prevelance rates of the most common 
presenting symptoms in the PDD-NOS and autism groups showed a similar pattern of 
distribution from most common to the least (Figure 1), even when the results were corrected 
for age. However, almost all of these symptoms are reported significantly less in prevalence 
in the PDD-NOS group. 
In this study, ADHD was also explored as a co-morbid diagnosis; 38.3% of the children in 
the PDD-NOS group and 53.2% of the children with autism fullfilled ADHD criteria (p>.05). 
Compared with children in the PDD-NOS group, children in the ADHD group had 
significantly higher rates of co-morbid disruptive behavior disorders (27.6% vs. 9.6%), 
learning disorders (14.9% vs. 5.3%), elimination disorders (12.8% vs. 2.1%), tic disorders 
(8.5% vs. 2.1%), social anxiety disorder (8.5% vs. 2.1%) and lower rates of co-morbid 
obsessive compulsive disorder (2.1% vs. 23.4%). The rates of other co-morbid disorders, 
such as depression, language disorders, and sleep disorders, were found to be similar across 
diagnostic groups. The findings of this study reveal that the PDD-NOS group had a high 
number of features in common with the autism and the ADHD groups, in terms of 
presenting and/or reported symptoms and developmental history. Similar to previous 
studies (Volkmar, et al 1993), gender distribution was similar for all groups (in each group 
more than 75% of the patients were male). A recent study has suggested that approximately 
70% of children with ASDs have at least one comorbid psychiatric disorder (Simonoff et al., 
2008). The most prevalent comorbid disorders were anxiety disorders (42%), oppositional or 
conduct disorders (30%), and ADHD (28%). 
In our study (Karabekiroglu & Akbas, in press), as shown in Table 1 and Figure 1, the 
prevelance rates of the most common presenting symptoms in the PDD-NOS and autism 
groups had a similar pattern of distribution from more to less common. However, almost all 
of these symptoms were reported significantly less in children diagnosed with PDD-NOS 
than children with autism. The autism and the PDD-NOS shared a common clinical 
symptom profile on the first clinical admission. On the other hand, the children with ADHD 
had a distinct set of symptoms. The results suggest that PDD-NOS may be assumed as a 
quantitative partial subtype of autism, and it represents a less severe form that lies on a 
continuum of social-communication skills.  
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Preliminary PDD-NOS Symptom 
Screening Scale (PPSSS) Items  
 
Presence of the symptoms 


















1. poor social interaction 59.6 97.9 8.5 <.001 1:2; 1:3; 2:3 
2. hyperactivity 56.4 80.9 89.4 <.001 1:2; 1:3 
3. not speaking/ language 
retardation 53.2 97.9 6.4 <.001 1:2; 1:3; 2:3 
4. aggressiveness  33.0 46.8 61.7 N.S.  
5. stubbornness 31.9 46.8 44.7 N.S.  
6. inattentiveness 30.9 66.0 91.5 <.001 1:2; 1:3; 2:3 
7. obsessions 29.8 27.7 14.9 N.S.  
8. not responsive to social stimuli 25.5 95.7 40.4 <.001 1:2; 2:3 
9. stereotypies 24.5 59.6 6.4 <.001 1:2; 1:3; 2:3 
10. impatience and/or 
impulsiveness 23.4 48.9 78.7 <.001 1:2; 1:3; 2:3 
11. fastidiousness, choosyness 23.4 10.6 10.6 N.S.  
12. echolalia 22.3 14.9 - N.S.  
13. highly interested in television 20.2 46.8 17.0 <.001 1:2; 2:3 
14. conduct problems 21.3 36.2 40.4 N.S.  
15. articulation and/or prosody 
problems  18.1 8.5 4.3 N.S.  
16. lack of eye contact 14.9 59.6 - <.001 1:2; 1:3; 2:3 
17. multiple fears 14.9 8.5 17.0 N.S.  
18. sleep problems 14.9 10.6 27.7 N.S.  
19. tactile oversensitivity 12.8 25.5 6.4 N.S.  
20. confusing pronouns 11.7 12.8 - N.S.  
21. shyness 11.7 6.4 17.0 N.S.  
22. emotional lability 11.7 - 27.7 <.001 1:3; 2:3 
23. tics 10.6 4.3 10.6 N.S.  
24. poor appetite 7.4 25.5 21.3 N.S.  
25. inappropriate laughing 4.3 17.0 2.1 N.S.  
26. persistence with sameness 2.1 12.8 6.4 N.S.  
27. frequent startles 1.1 10.6 8.5 N.S.  
Table 1. Preliminary PDD-NOS Symptom Screening Scale (PPSSS) item distributions of 
patients in each diagnosis group  
 

























































































Fig. 1. The significantly discriminative symptom percentages of the diagnostic groups 
3. Cluster and factor analysis 
To identify ASD subgroups, several investigators used cluster and factor analysis based on 
social functioning, intelligence, developmental milestones, and so forth. Various clusters 
were reported (Eaves et al., 1994; Prior et al., 1998; Sevin et al., 1995; Waterhouse et al., 1996; 
Wing & Gould, 1979). But these findings were not replicated and the clusters identified were 
not adopted or replicated in later studies. Despite several studies with ASD, clinical validity 
and differential features of PDD-NOS are yet to be consistently established. A very recent 
study (Shumway et al., 2011) examined the relationship between onset status and current 
functioning using a recently proposed onset classification system in 272 young children with 
autism spectrum disorder (ASD). Participants were classified into one of the following 
groups, based on parent report using the Autism Diagnostic Interview—Revised: Early 
Onset (symptoms by 12 months, no loss), Delay and Regression (symptoms by 12 months 
plus loss), Plateau (no early symptoms or loss), and Regression (no early symptoms, 
followed by loss). Findings indicate that current functioning does not differ according to 
onset pattern, calling into question the use of onset categorizations for prognostic purposes 
in children with ASD.  
A previous study performed a factor analysis on a sample of variant categories of PDD, and 
two factors emerged. One factor represented autistic symptoms and another represented 
level of functioning (Szatmari et al., 2002). More recent studies used a factor analytic 
approach based on particular diagnostic instruments, such as the Autism Diagnostic 
Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS) 
(Tadevosyan-Layfer et al., 2003; Tanguay, 2004). The results suggested that there is a 
developmental continuum from affective reciprocity to emotional joint attention to verbal 
joint attention and to intuitive social knowledge (Tanguay, 2004). Tadevosyan-Layfer et al. 
(2003) found six factors: spoken language, compulsions, developmental milestones, savant 
skills, sensory aversion, and social intent. 
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In our study (Karabekiroglu & Akbas, in press), including all subjects in all diagnostic 
groups (PDD-NOS n=94; ADHD n=47; autism n=47) (male n=150, female n=38) who were 
5.5(±2.5) years old on average (range 2-11 yrs.), a principal axis factor analysis with Promax 
rotation revealed ten factors; seven were found to be discriminative (Table 2, Figure 2). We 
 
 
Note. Loadings <.30 are omitted. Adopted items into the factors are shown bold.  
Table 2. PPSSS items and factor loadings for the rotated ten factors 
 
Pervasive Developmental Disorder- not Otherwise Specified: Specifying and Differentiating 
 
23 
 retained all components with eigenvalue (a measure of explained variance) greater than 
unity. Ten factors had eigenvalues greater than 1.0, which is a common criterion for a factor 
to be useful. When ten factors were requested, Kaiser-Meyer-OIkin (KMO) measure was 
adequate (.66), and Bartlett’s Test of Spherity was significant (p<.001). These measures mean 
that the variables are correlated highly enough to provide a reasonable basis for factor 
analysis. We considered all variables with factor loadings 0.3 or larger in the appropriate 
factor matrices to define the underlying factor and we took these variables as a cluster of 
variables for the factor. The two rotation procedures produced similar results. When there 
were differences, we took the Promax solution as the preferred one. After rotation, ten 
factors accounted for 66.3% of the variance. 
 
 
Factor 1 includes “lack of eye contact”, “stereotypies”, “inappropriate laughing”, “frequent startles”, 
“highly interestedness in TV”, and “tactile oversensitiveness”;  
Factor 2 includes “poor social interaction”, “language retardation”, and “not responsive”  
Factor 3 includes “inattentiveness”, “hyperactivity”, and “impatiente, impulsiveness” 
Factor 4 includes “aggressiveness” and “conduct problems” 
Factor 5 includes “confusing pronouns”, “echolalia”, and “articulation/ prosody problems” 
Factor 7 includes “fastidiousness, choosiness” and “obsessions” 
Factor 8 includes “poor appetite”, “stubbornness”, and “persistence with sameness” 
Fig. 2. The significantly discriminative factors of the diagnostic groups. 
We found significant differences in the toal number of symptoms between three diagnostic 
groups in the factors 1 (p<.001), 2 (p<.001), 3 (p<.001), 4 (p=.004), 5 (p<.001), 7 (p=.026), and 
8 (p=.006). The scores in the factors 1, 2, 3, and 8 were significantly higher in the autism 
group compared to the PDD-NOS group. The scores in the factors 1, 2, 5, and 7 were 
significantly higher in the PDD-NOS group compared to the ADHD group. Inversely, the 
scores in the factors 3, 4, and 8 were significantly higher in the ADHD group compared to 
the PDD-NOS group (Figure 2).  
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Based on the assumption that the items were predicted to index three constructs: symptoms 
related to autism, ADHD, and PDD-NOS, in a further analysis three factors were requested 
(Karabekiroglu & Akbas, In press). The first factor seemed to index core autism spectrum, 
the second factor, disruptive behaviors spectrum, and the third factor seemed to index 
symptoms to be interpreted as anxiety spectrum. Four in twenty-seven items do not seem to 
load with any of the factors. When the total number of the symptoms in each factor were 
compared between the diagnostic groups, the core autism spectrum and the disruptive behavior 
spectrum factors revealed significant differences between the groups (p<.001). Post-hoc 
analysis showed that in the core autism spectrum factor, the autistic group had significantly 
more symptoms than the PDD-NOS group (4.87 vs. 2.14) (p<.001), and the PDD-NOS group 
had significantly more symptoms than the ADHD group (2.14 vs. 0.81) (p<.001). On the 
other hand, on the disruptive behavior spectrum factor, both the ADHD (3.62 vs. 2.19) (p<.001) 
and the autistic groups (4.55 vs. 2.19) (p<.001) had significantly more symptoms than the 
PDD-NOS group. The anxiety spectrum factor did not reveal a significant difference between 
diagnostic groups. 
4. Discussion 
Because the diagnostic agreement for PDD-NOS was generally considered to be weak 
(Tanguay 2004, Walker et al. 2004), and differentiation of PDD-NOS from the non-PDD 
disorders, such as ADHD was not well-defined, we conducted a factor analysis including 
the data from all three diagnosis groups (Autism, PDD-NOS, and ADHD) (Karabekiroglu & 
akbas, in press). A factor analysis revealed three symptom clusters, core autistic spectrum, 
disruptive behavior spectrum, and anxiety spectrum. As would be expected, the children with 
autism had higher rates of symptoms in the autistic spectrum factor and the children with 
ADHD had higher rates of symptoms in the disruptive behavior spectrum factor. The PDD-
NOS group had lower rates of symptoms on both factors. 
In a recent study (Kamp-Becker et al., 2009), the dimensional structure of higher functioning 
autism phenotype was investigated by factor analysis. The goal of this study was to identify 
the degree to which early symptoms of autism (measured using the ADI-R) could be 
predictive of the current symptoms of autism as identified using the ADOS, the adaptive 
behavior scales, IQ scores and theory of mind scores. The authors reported that the social 
interaction and communication domains were closely related to one factor namely: Social 
communication. An additional factor implies anxious and compulsive behavior which is 
associated with current social communication functioning. Another study compared the 
behavioral symptomatology in 26 children and adolescents with autism and 25 children and 
adolescents with PDD-NOS (Pearson et al., 2006). Relative to individuals with PDD-NOS, 
those with autism had more symptoms of depression, social withdrawal, atypical behavior, 
and immature social skills, and fewer family problems. These differences remained even 
when group differences in intellectual ability were controlled statistically. No group 
differences emerged in somatization, anxiety, or hyperactivity. Their findings suggested 
that, although both groups demonstrated considerable evidence of behavioral and 
emotional problems, those with autism were at particularly high risk for co-morbid 
behavioral and emotional disabilities (Pearson et al., 2006). 
In a recent study (Mandy et al., 2011) authors aimed, first, to improve the reliability and 
replicability of PDD-NOS by operationalizing its DSM-IV-TR description and, second, to test 
its validity through comparison with autistic disorder (AD) and Asperger’s disorder (AsD). 
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In a sample of 256 young people (mean age: 9.1 years) [AD (n:97), AsD (n:93) and PDD-NOS 
(n:66)], groups were compared on independent measures of core PDD symptomatology, 
associated autistic features, and intelligence. Contrary to the assumption that PDD-NOS is 
heterogeneous, almost all (97%) of those with PDD-NOS had one distinct symptom pattern, 
namely impairments in social reciprocity and communication, without significant repetitive 
and stereotyped behaviors (RSB). Compared to AD and AsD, they had comparably severe 
but more circumscribed social communication difficulties, with fewer non-social features of 
autism, such as sensory, feeding and visuo-spatial problems. These individuals appear to 
have a distinct variant of autism that does not merely sit at the less severe end of the same 
continuum of symptoms.  
The symptoms of ASD may change with development (Luyster et al., 2005). PDD-NOS has 
been assumed significantly less stable as a diagnosis (Lord et al., 2006). In a study (Kleinman 
et al., 2008), 77 children received a diagnostic and developmental evaluation between 16 and 
35 months and also between 42 and 82 months. Diagnoses based on clinical judgment, 
Childhood Autism Rating Scale, and the Autism Diagnostic Observation Schedule were 
stable over time. Diagnoses made using the Autism Diagnostic Interview were slightly less 
stable. According to clinical judgment, 15 children (19%) moved off the autism spectrum by 
the second evaluation; none moved onto the spectrum. Results indicate diagnostic stability 
at acceptable levels for diagnoses made at age 2. Nevertheless, diagnoses of autism and 
PDD-NOS by experienced clinicians on the basis of multiple measures were valid and 
reliable over time (Lord et al., 2006). If a child is given an ASD diagnosis (either autism or 
PDD-NOS) at age 2 years, it is highly likely to apply at age 9, although there may be some 
shifting within the range of ASD diagnostic categories (Lord et al., 2006). Generally, it 
appears that the overall picture of development for autism and PDD-NOS is similar, with 
most children experiencing continued impairment. Based on these two studies, there does 
not appear to be evidence for qualitatively discrete groups (i.e., autism versus PDD-NOS), 
but differences appear to be quantitative (Lord et al., 2006; Turner, et al., 2006).  
A recent meta-analysis (Rondeau et al., 2010) conducted on the eight longitudinal studies on 
PDD-NOS that have been published from 1996 to 2009 showed that PDD-NOS diagnosis 
was less stable than autistic disorder diagnosis. When established before 36 months, the 
overall stability rate was 35% at 3-year follow-up. Consistent with the previous literature on 
the reliability of the PDD-NOS diagnosis in young children, our metaanalysis did not 
support the discriminant and predictive validity of this category. Thus, from a clinical 
standpoint, children whose PDD-NOS diagnosis was established before 36 months should 
be re-assessed at a later age (Rondeau et al., 2010). 
Similar to previous reports (Allen et al., 2001, deBruin et al., 2006, Matson, et al., 2007, 
Szatmari et al. 2002), in our study (Karabekiroglu & Akbas, in press) mental retardation was 
significantly more prevalent in the autism than in the PDD-NOS or ADHD groups. Several 
investigators suggested that exploring the presence of mental retardation may be more 
useful in terms of planning treatment and predicting outcome than a classification based on 
symptom number alone (Szatmari et al., 2002). However, IQ may be a poor measure of level 
of functioning, based as it is on performance in a highly artificial setting (Szatmari et al. 
2002). In a study (Scheirs & Timmers, 2009) an attempt was made to distinguish among the 
three groups (ADHD, PDD-NOS, and ADHD plus PDD-NOS) on the basis of intelligence 
(WISC-III) profiles. It was found that the PDD-NOS group had higher verbal and 
performance IQ’s, as well as higher WISC-III index scores than the ADHD group. Subtests 
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Block Design and Mazes discriminated best. It was concluded that based on intelligence 
scores, only PDD-NOS and ADHD emerged as distinct categories, whereas the combined 
diagnosis did not. Allen et al. (2001) compared 18 preschool children with PDD-NOS to 176 
children with autistic disorder and 311 non-autistic children with developmental language 
disorders (DLD) (N = 201) or low IQ (N = 110). The children with PDD-NOS did not differ 
significantly from either the children with autism or the children with DLD in verbal and 
adaptive skills. They suggested that the similarity of PDD-NOS children to autistic children 
in maladaptive behaviors and an intermediate position between autistic and DLD groups on 
virtually all measures helped to explain the difficulty clinicians encounter in classifying 
children with PDD-NOS (Allen et al., 2001). 
Rates of comorbid psychiatric conditions in children with PDD-NOS are hardly available, 
although these conditions are often considered as more responsive to treatment than the 
core symptoms of PDD-NOS (deBruin  et al., 2007). In our sample (Karabekiroglu & Akbas, 
in press), 53.2% of the children with PDD-NOS had at least one co-morbid psychiatric 
disorder, including disruptive behavior disorders (40.4%), and anxiety disorders (18.0%). 
With respect to the PDD-NOS group, the ADHD group had significantly higher rates of co-
morbid disruptive behavior disorders, learning disabilities, tic disorders, elimination 
disorders, and social anxiety disorder. On the other hand, the PDD-NOS group had 
significantly higher rates of co-morbid obsessive compulsive disorder with respect to the 
ADHD group. In a previous study, DeBurin et al. (2007) explored the comorbidity in ninety-
four children with PDD-NOS, aged 6-12 years. At least one co-morbid psychiatric disorder 
was present in 80.9% of the children; 61.7% had a co-morbid disruptive behavior disorder, 
and 55.3% fulfilled criteria of an anxiety disorder. Compared to those without co-morbid 
psychiatric disorders, children with a co-morbid disorder had more deficits in social 
communication.  
5. Conclusion 
The overall results suggest that children with PDD-NOS have a high number of common 
features with patients having autism and ADHD. The symptoms of all three diagnostic 
groups appeared to form three clusters, “autistic spectrum,” “ADHD spectrum,” and 
“anxiety spectrum.” Many features including language and motor development, 
“presenting” and/or “reported” symptom distribution, and gender distribution were found 
to be similar in the PDD-NOS and the autism groups. Mental retardation rate and symptom 
severity (e.g., “poor social interaction”, “lack of eye contact”, “stereotypies”) were 
significantly higher in the autism group with respect to the PDD-NOS group. In addition, 
most of the previous studies supported quantitative discrimination rather than assuming 
that PDD-NOS and autism are qualitatively discrete groups. Therefore, PDD-NOS may be 
assumed as a partial subtype of autism and that it lies on a continuum of social-
communication skill deficits. On the other hand, some of the studies suggest that these 
individuals appear to have a distinct variant of autism that does not merely sit at the less 
severe end of the same continuum of symptoms. They emphasize that compared to other 
disorders in PDD category, the children diagnosed with PDD-NOS had comparably severe 
but more circumscribed social communication difficulties, with fewer non-social features of 
autism. Therefore, we still need to investigate further the clinical features of children with 
PDD-NOS that distinguish them from children with autism and other non-PDD conditions. 
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1. Introduction 
Autism is a developmental disorder defined as a severe and persistent restriction in 
communicative skills, including lack of social and emotional reciprocity, as well as 
stereotyped and repetitive behaviours. Such an impairment of social interaction was already 
described in 1919 by the Swiss psychiatrist Eugen Bleuler within the framework of the 
negative symptom complex of schizophrenia. In the following decades in particularly the 
German language areas of Switzerland, autism was viewed by Kretschmer (1921) as a 
schizoid temperament whereas later, he viewed it as a special form of schizophrenia. In the 
late fifties, Leonhard (1957) assigned this specific disturbance in communication to the so 
called systematic schizophrenias. In 1943, the immigrated American child psychiatrist from 
Austria, Leo Kanner, originally described early infantile autism as Autistic Disturbance of 
Affective Contact. In a study of 11 children, four behavioural characteristics were 
distinguished: severe social withdrawal behavior, obsessive desire for repetitiveness, 
persistent fascination with specific objects or thoughts, and severe language impairments. 
One year later, the Austrian pediatrician Hans Asperger reported comparable findings 
under the title ‘Die ‘Autistischen Psychopathen’ in Kindesalter’. Both Kanner (1943, 1971) 
and Asperger (1944) considered autism a communication disorder for children with severely 
impoverished relations with the environment (i.e., ‘autistic aloneness’).  
Up until the beginning of the 1960s, under the influence of the then prevalent 
psychodynamic theories, autism was largely attributed to family and environmental factors. 
Rutter (1968) placed autism in a different perspective and demarcated the phenotypical 
presentation of both early infantile autism and schizophrenia from their biological 
underpinnings. Lorna Wing (1981) can be credited for bringing the descriptions of Asperger 
from 1944 back to our attention in the 1980s and, on the basis of extensive childhood 
epidemiological research, for placing autism in a broader diagnostic context and developing 
diagnostic criteria (Wing & Gould, 1979). Wing introduced the term ‘autism spectrum 
disorder’, which can be described on the basis of information from three domains: (a) social 
reciprocity, (b) verbal and non-verbal communication and imagination, and (c) a restricted, 
stereotyped pattern of interests and activities. These elements still constitute the diagnostic 
criteria from e.g. the DSM-IV category of Pervasive Developmental Disorders that include 
Autistic Disorder, Rett’s Disorder, Childhood Disintegrative Disorder, Asperger’s Disorder, 
and Pervasive Developmental Disorder Not Otherwise Specified (overview: Kumbier et al. 
2010). 
 
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment 
 
30
World Health Organization (WHO) (1993), The International Classification of Diseases and 
Disorders-10 (ICD-10) Classification of Mental and Behavioural Disorders: Diagnostic 
Criteria for Research. Geneva: World Health Organization   
3 
Autism and Genetic Syndromes 
Willem Verhoeven, Jos Egger and Ilse Feenstra 
Erasmus University Medical Centre, Rotterdam 
Radboud University Nijmegen, Nijmegen 
Vincent van Gogh Institute, Venray 
The Netherlands 
1. Introduction 
Autism is a developmental disorder defined as a severe and persistent restriction in 
communicative skills, including lack of social and emotional reciprocity, as well as 
stereotyped and repetitive behaviours. Such an impairment of social interaction was already 
described in 1919 by the Swiss psychiatrist Eugen Bleuler within the framework of the 
negative symptom complex of schizophrenia. In the following decades in particularly the 
German language areas of Switzerland, autism was viewed by Kretschmer (1921) as a 
schizoid temperament whereas later, he viewed it as a special form of schizophrenia. In the 
late fifties, Leonhard (1957) assigned this specific disturbance in communication to the so 
called systematic schizophrenias. In 1943, the immigrated American child psychiatrist from 
Austria, Leo Kanner, originally described early infantile autism as Autistic Disturbance of 
Affective Contact. In a study of 11 children, four behavioural characteristics were 
distinguished: severe social withdrawal behavior, obsessive desire for repetitiveness, 
persistent fascination with specific objects or thoughts, and severe language impairments. 
One year later, the Austrian pediatrician Hans Asperger reported comparable findings 
under the title ‘Die ‘Autistischen Psychopathen’ in Kindesalter’. Both Kanner (1943, 1971) 
and Asperger (1944) considered autism a communication disorder for children with severely 
impoverished relations with the environment (i.e., ‘autistic aloneness’).  
Up until the beginning of the 1960s, under the influence of the then prevalent 
psychodynamic theories, autism was largely attributed to family and environmental factors. 
Rutter (1968) placed autism in a different perspective and demarcated the phenotypical 
presentation of both early infantile autism and schizophrenia from their biological 
underpinnings. Lorna Wing (1981) can be credited for bringing the descriptions of Asperger 
from 1944 back to our attention in the 1980s and, on the basis of extensive childhood 
epidemiological research, for placing autism in a broader diagnostic context and developing 
diagnostic criteria (Wing & Gould, 1979). Wing introduced the term ‘autism spectrum 
disorder’, which can be described on the basis of information from three domains: (a) social 
reciprocity, (b) verbal and non-verbal communication and imagination, and (c) a restricted, 
stereotyped pattern of interests and activities. These elements still constitute the diagnostic 
criteria from e.g. the DSM-IV category of Pervasive Developmental Disorders that include 
Autistic Disorder, Rett’s Disorder, Childhood Disintegrative Disorder, Asperger’s Disorder, 
and Pervasive Developmental Disorder Not Otherwise Specified (overview: Kumbier et al. 
2010). 
 
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment 
 
32
In her retrospective ‘Reflections on opening Pandora’s box’ presented a few years back, 
Lorna Wing (2005) warns about stretching the boundaries of the autistic spectrum, which 
presently includes those who have normal to extremely high intelligence at the one end and 
those with a severe intellectual disability and limited social and communicative skills at the 
other end. In such a manner, the diagnostic label of ‘autistic spectrum disorder’ can possibly 
be misused to attain care (Volkmar et al., 2009). This is certainly not  inconceivable in light of 
the quadrupled prevalence of pervasive developmental disorders across a period of 40 years 
(4.1 per 10,000 to 16.8 per 10,000), including somatic/neurological disorders that accompany 
autism (Fombonne, 2003; Rice, 2009). Moreover, autism and Asperger’s disorder are 
regularly associated with other syndromes (Gillberg & Gillburg, 1989; Gillberg and Billstedt, 
2000). As elegantly stated by Gillberg already in 1991 in his Emanuel Miller Memorial 
Lecture, researchers and clinicians, rather than allow themselves to be guided by stereotypic 
(sub)classifications, should be guided by a more balanced view of autism as belonging to a 
group of empathy disorders and thereby start the search for autism-relevant 
endophenotypes (Gillberg, 1992). 
In the following sections, a brief overview of the current neuropsychological and genetic 
explanatory models will first be given. Thereafter, a selection of syndromes with a known 
genetic etiology that are seen to accompany autism will be discussed. To conclude, the 
manner in which modern genetics can be utilized in daily diagnostic practice will be 
elucidated. 
2. Neuropsychological models 
Roughly three explanatory models can be discerned for the pattern of disorders encountered 
in cases of autism. The first model is based upon the weak central coherence (WCC) 
hypothesis, which claims that patients with autism are inclined to attend to details as 
opposed to the whole during the processing of context-based information (i.e., strictly 
feature-based perception). As a consequence, the information is not understand as a 
meaningful whole and thus remains fragmented and confusing (Happé & Frith, 2006; Frith, 
1989). 
The second model draws upon the concept of Theory of Mind, which refers to the capacity to 
attribute thoughts, desires, and intentions to others. This capacity starts to develop around 
the age of three to four years and allows humans to take the perspectives of others into 
consideration in their own thinking. Deficiencies in this domain can easily lead to social 
misinterpretations and socially inadequate behavior, which form the basis of the severe 
communication problems that people with autism show (Baron-Cohen, 1989). In this 
connection, the more general notion of social cognition may be called upon and a link made 
to, for example, diminished activity of the amygdala and deviant perceptions of one’s own 
emotions (Kethrapal, 2008). 
In the last model, that of the dysexecutive functioning hypothesis, disturbed executive 
functions are assumed to play an important role. The executive functions (EF) are of major 
importance for the integration, steering, and control of processes required to execute 
purposeful behavior in new or complex situations. At a structural level, four frontal-
subcortical circuits are involved in EF. The dorsolateral-prefrontal circuit has been related to 
executive cognitive dysfunctioning; the ventromedial circuit has been related to activation 
and motivation problems; and the medial- and lateral-orbitofrontal circuits have been 
related to disturbed affect regulation and disturbed social behavior, respectively (Chow & 
 
Autism and Genetic Syndromes 
 
33 
Cummings, 2007; Alvarez & Emory, 2006). EF often involves the overruling of automatic 
responses in favour of more intentional behaviour. A capacity to flexibly switch between 
different behavioral repertoires (i.e., monitoring and shifting) is required for such overruling 
and typically found to be a problem in cases of autism. Barnes-Holmes and colleagues view 
EF as rule-governed behaviour and thus behaviour that stands in contrast to contingency-
shaped behaviour, which has been automatized. EF thus defined, is verbal behaviour that 
precedes other behaviour (i.e., verbal antecedent behavior) and therefore distracts the 
individual from his usual, automatic reaction pattern. Stated differently, the probability of 
an alternative behavior is changed in the direction of a particular objective. In such a 
manner, thus, recent research on rule-governed behaviour connects EF with autism and an 
underlying Theory of Mind (Barnes-Holmes et al., 2004; McHugh et al, 2004). 
3. Genetic models 
Autism can be viewed as a classic example of a disorder with a strong genetic basis. A 
distinction must nevertheless be made between the Autistic disorder as originally described 
by Kanner and the autism spectrum disorder, which can be viewed as a component of an 
array of clinical pictures and syndromes that are sometimes referred to as secondary or 
syndromic autism (Benvenuto et al., 2009). Given the complex interplay between genes and 
autism, a search for at least two types of genetic factors is of importance, namely: (rare) 
chromosomal  abnormalities or gene alterations that can be directly related to core (i.e., 
classic) autism and  genetic copy number variants that correlate with a vulnerability to 
develop an autistic disorder. 
In several studies from the 1980s and 1990s that use a strict definition of autism, a 69% to 
95% concordance has been demonstrated in monozygotic twins, while the chance in 
dizygotic twins is only 0% to 24%. The contribution of the hereditary components is 
estimated to be 90%. The male-female ratio is between 3-4 to 1 (Brkanac et al., 2008). In order 
to advance the understanding of the genetic heterogeneity of autistic disorders, various 
techniques can be used such as (molecular) cytogenetic research, linkage studies, and 
association studies.  
Linkage studies search for those parts of a chromosome that are found to be the same for all 
affected individuals in a family but different for the non-affected family members. A gene 
that contributes to the occurrence of a vulnerability for autism may lie in such a shared 
region. These studies have revealed a wide variety of loci, from which a considerable genetic 
heterogeneity can be concluded as well as the absence of single, specific locations for autism 
(Szatmari et al., 2007). Recently, in a very large-scale linkage study, two new locations have 
been found on chromosomes 6 and 20 (6q27 and 20p13, respectively) for which the 
functional significance has yet to be clarified (Weiss et al., 2009). 
The same holds for candidate genes that have been implicated in a large series of association 
studies. These studies investigate significant genetic differences between large groups of 
patients, on the one hand, and groups of healthy individuals, on the other hand (Vorstman 
et al., 2006a). The research findings make it clear, however, that the pathophysiology of 
autism involves genes that code for proteins from the family of neurexins and neuroligins 
that play, in turn, a role in the development and functioning of synaptic and in particular 
glutamatergic and GABA-ergic networks (Lisé & El-Husseini, 2006; Buchsbaum, 2009). The 
first X-linked mutations in genes involved in the coding of neuroligin were revealed in 
patients with autism in two Swedish families in 2003 (Jamin et al., 2003). 
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Cummings, 2007; Alvarez & Emory, 2006). EF often involves the overruling of automatic 
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When the classic microscopic cytogenetic route is followed, structural chromosomal 
aberrations are found in 3% to 7% of patients with autism and developmental delay. This 
finding concerns mainly maternal duplications on the long arm of chromosome 15 (q11-13) 
(Hogart et al., 2010) and deletions on the long arm of chromosome 2 (q37) (Falk & Casas, 
2007), chromosome 7 (q22 and q31) (Alarcón et al., 2002) and chromosome 22 (q11) 
(Niklasson at al., 2009) and (q13) (overview: Kumar & Christian, 2009). The fluorescence-in-
situ-hybridization (FISH) technique is used to search for specific submicroscopic deletions 
and is used primarily to confirm a clinical diagnosis such as the 22q11 deletion syndrome. 
Disadvantages of this technique are its labor intensiveness and that only one or a few 
chromosome regions can be examined per experiment. 
More commonly used these days is the whole-genome microarray technique. Here, details 
more than a hundred times smaller can be perceived when compared to microscopic 
cytogenetic examination (de Vries et al., 2005; Veltman & de Vries, 2006). With the aid of 
such a ‘DNA chip’, the complete genome with a high resolution can be examined for the 
presence of microdeletions and duplications or so-called copy-number variations (CNVs). 
Of principal concern here are small quantitative, structural variations that are paired with a 
loss or gain of chromosome material. Furthermore, the ‘targeted genomic array’ technique 
can be applied to study specific regions such as the subtelomeric chromosome regions or 
well-known microdeletion syndrome regions (Lintas & Persico, 2009). 
For various neuropsychiatric disorders including autism, CNVs possibly involved in the 
vulnerability for the development of a disorder within the autism spectrum have been 
demonstrated using the array technique (Jacquemont et al., 2006; Cook & Scherer, 2008). For 
some of these CNVs, a clear correlation has been demonstrated, e.g., a maternal 15q11-q13 
duplication was shown for 1-3% of patients with an autistic spectrum disorder. Another 
frequently occurring CNV is found on the chromosome 16p11.2 which present with a 
deletion or duplication in approximately 1% of the patients (Weiss et al., 2008; Fernandez et 
al., 2010).  
There are, however, also CNVs found with an, as yet, unknown significance; because, for 
example, the same change can be traced back to a healthy parent. A precise interpretation of 
the array results with the aid of bio-informatics, literature databases, data from the pedigree 
and clinical investigation of affected individuals, is therefore essential. 
Another interesting perspective is the neuropeptide concept. It has been known for quite 
some time that the nonapeptide oxytocine (OXT) is involved in affiliation behaviour and 
social cognition via an improvement of social memory, including the recall and 
understanding of affective events (Hollander et al., 2007; Insel, 2010; Green & Hollander, 
2010). For these reasons, research has been performed on the association between single 
nucleotide polymorphisms (SNPs) in the OXT gene and the OXT receptor gene (OXTr). 
Relative to the normal population, more SNPs were present in the OXTr for a subgroup of 
patients with autism, which could indicate a genetically determined vulnerability for the 
development of autism (Lerer et al., 2008; Lee et al., 2009). In line with these observations, 
Gregory et al. (2009) found that epigenetic regulation of OXTr is implicated in the 
development of autism. 
To summarize, in linkage and association studies among patients with autistic disorders up 
until now, a large number of candidate genes and gene locations have been found for which 
it can be assumed that they may be involved in the development of functional processes of 
the central nervous system. In Table 1, a selective overview is presented.  In the following 
section, the most well-known genetic disorders associated with autism will be discussed. 
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Chromosome Candidate Gene Network/Function 
2p16.3 NRXN1 Synapse formation 
2q12.3-q14.2 DPP10 Neurotransmission 
3p24-26 OXTr Neurotransmission 
3p26-p25 CNTN4 Synapse formation 
4p14-q21.1 GABRG/GABRA GABA neurotransmission 
7q31.1 ST7 Tumor suppression 
7q35-q36 CNTNAP2 Synapse formation 
8p23 DLGAP2 NMDA neurotransmission 
15q11-q14 GABRA/GABRB/GABRG GABA neurotransmission 
15q13 APBA2 Neurotransmission 
16p11.2 DOC2A Neurotransmission 
22q11 PRODH Neuromodulation 
22q13 SHANK3 Synapse formation 
Xp22.3 NLGN4 Synapse formation 
Xp11.4 TSPAN7 Neuronal growth and development 
Xp22.1-p21.3 IL1RAPL1 Interleukin receptor 
Table 1. Selection of genes and functions possibly involved in autism (adapted from 
Guilmatre et al., 2009 and El-Fishawy & State, 2010) 
4. Genetic syndromes and autism 
4.1 Fragile X syndrome 
The fragile X syndrome (FXS; Figure 1) is the most well-known genetic disorder related to 
autism. Brown and colleagues (1982) were the first to report on this. Initially, FXS was 
described by Lubs (1969), who detected a fragile site at the end of the long arm of the X 
chromosome by using classical microscopic cytogenetic techniques. FXS is caused by 
hypermethylation of an expanded trinucleotide repeat (CGG) in the ‘fragile X mental 
retardation 1 (FMR1) gene’ (Xq27.3). In normal individuals, the number of CGG repeats is 5 
to 45 which is stably transmitted to the next generation. In case of a FMR1 premutation, 
there is a small expansion of 55 to 200 repeats. In FXS, the number of repeats exceeds 200. As 
a result of this enlarged number of repeats, hypermethylation of the FMR1 gene occurs 
which leads, in turn, to a shortage or complete loss of the FMR1 protein that is essential for 
dendrite formation, synapse formation, and experiential learning (Marco & Skuse, 2006; 
Hernandez et al., 2009). 
FXS is an X-linked disorder with an incidence of about 1 in 4000 newborn males. Affected 
males show a variable degree of developmental delay, behaviour problems, and distinctive 
dysmorphic features such as a long face and large, prominent ears. Female carriers with a 
full mutation (>200 repeats) may present with or without impaired level of intelligence. 
Females with FXS and normal intelligence, however, have an increased risk of mood and 
anxiety disorders and a schizotypical personality disorder (Franke et al., 1998).  
In males with a premutation (50-200 repeats), there is an increased probability of the 
development of the so-called fragile-X-associated tremor/ataxia syndrome (FXTAS). Its 
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symptoms emerge at a later age, and the syndrome has a progressive course. The clinical 
picture comprises intention tremor, frequent falling, Parkinsonian symptoms, and disturbed 
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Fig. 1. Fragile X syndrome and the FMR1 gene 
Schematic representation of the location of the FMR1 gene on the long arm of the X chromosome. (a) 
The FMR1 gene comprises a polymorph repetition of the base pairs cytosine-guanine-guanine (CGG) 
at the start of the gene. In healthy individuals, this number of CGG repeats varies from 5 to about 45 
units. (b) Affected individuals have more than 200 CGG repeats: the full mutation. (c) The expansion 
to a full mutation (>200 repeats is usually associated with hypermethylation of the CGG repetition 
and the adjacent area, which leads to a  transcription stop resulting in the absence of the FMR1 
protein. This results in intellectual disability and other symptoms of the Fragile X syndrome among 
men, and in >50% of the women who are carriers of a full mutation. Carriers with 55 and 200 repeats 
are asymptomatic and are thus called premutation carriers 
For decades, it has been known that the severity of intellectual disability and the intensity of 
related behaviour problems is proportional to the number of repeats. The 
psychopathological phenotype of FXS includes, in addition to the developmental delay, 
multiform anxiety symptoms, obsessive-compulsive characteristics, hyperactivity / 
impulsivity, and aggression. Epileptic phenomena are frequent. Predominant, however, are 
autism-related symptoms such as social anxiety and withdrawal behaviour, stereotypies like 
flapping or biting of the hands, perseverations, extreme sensitivity to environmental stimuli, 
and, in general, decreased social reciprocity with an avoidance of eye contact (Hagerman, 
2005).  
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Using neuroimaging techniques, various structural abnormalities of the central nervous 
system can be demonstrated, in particular enlargement of hippocampus, amygdala, 
caudatus, and thalamus with a reduction of the cerebellar vermis (Hessl et al., 2004). These 
neuronal changes are caused by an overabundance of immature dendritic spines. In normal 
conditions, dendritic spines are essential for the formation of new neuronal connections that, 
in turn, form the basis for learning and memory. In FXS, the cognitive dysfunctions in the 
domains of attention, (working) memory, mathematical skills, executive functioning and 
social cognition largely correspond to the observed abnormalities of the central nervous 
system.  
The treatment of patients with FXS is primarily symptomatic and aimed at the reduction of 
the most prominent behavioural problems or psychiatric symptoms, such as anxiety, 
hyperactivity, impulsivity and distractibility (Garber et al., 2008). Since the extremely 
heightened sensitivity to environmental stimuli is assumed to underlie the above mentioned 
symptoms, it is essential to reduce excessive environmental sensory activation. This can be 
achieved with a more structured daily program of activities, the promotion of a realistic 
pattern of expectations among parents/caregivers, individualized instruction and, most 
importantly, the dissemination of knowledge about the persistence of the FXS behavioral 
phenotype. 
4.2 Rett syndrome 
Rett syndrome (RS) was first described in 1966 by Andreas Rett. This syndrome is inherited 
in an  X-linked manner, caused by a mutation in the Methyl-CpG-Binding Protein 2 
(MECP2) gene (Xq28). In Figure 2, the location of the MECP2 gene is depicted. RS occurs 
almost exclusively in girls and its prevalence is estimated to be between 1/10,000 - 1/20,000. 
In boys, the disorder is nearly always lethal. In rare male cases, an extra X chromosome or 
mosaicism of the MECP2 mutation has been found.  
RS is characterized by an apparently normal development in the first 6 to 18 months of life 
after which development stagnates, acquired skills get lost and development finally stops. 
This stagnation of development also becomes manifest in a retarded and disproportionate 
growth in head circumference, decrease of eye contact, and both cognitive and motor 
deterioration. Already in the first year of life, autistic behavioural elements are present such 
as social withdrawal, declining speech and communication, limited eye contact, grinding of 
the teeth, and characteristic hand stereotypies (Ben Zeev, 2007; Gonzales & LaSalle, 2010). In 
the majority of the patients, the syndrome is associated with severe epilepsy. The first 
decade is dominated by severe neurological dysfunctions and an irregular respiration 
pattern as a result of an immaturely developed brainstem. In addition, a prolonged QT 
interval is often present with, as a consequence, risk for sudden cardiac arrhythmia. From 
the age of 10, a developmental plateau occurs and the patient becomes severely 
neurologically handicapped with profound intellectual disability. 
In 80% to 90% of the patients with RS, a mutation that almost always occurs de novo, can be 
demonstrated in the MECP2 gene. This gene is expressed particularly in neurons and to a 
lesser extent in glial cells, and involved in neuronal maturation in the postnatal period. 
MECP2 is involved in the expression of the gene that codes for brain derived neurotrophic 
factor (BDNF), which is essential for neuronal maturation and plasticity. The 
pathophysiology of RS thus lies conceivably in a MECP2–mediated disturbance in the 
regulation of BDNF. It is assumed that the severity of the disorder and the progression over 
time of the successive stages corresponds with a polymorphism in BDNF (Matijevic et al., 
2009; Ben Zeev et al., 2009). 
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RS is one of the better examples of an autism-related disorder with a proven genetic 
pathophysiology. While there are clear differences between classical autism and the 
phenotypic presentation of autism in RS (i.e., characteristic stereotypy such as hand-
wringing at chest level and a relative maintenance of eye contact), research in RS could 
nevertheless contribute to a better understanding of involvement of central nervous system 
dysfunctions in autism.  
 



















Fig. 2. Rett syndrome and the MECP2 Gene 
Schematic representation of the location of the MECP2 gene on the long arm of the X chromosome. 
(a) The MECP2 gene is constituted by 4 coding exons.The majority of mutations among patients with 
Rett syndrome are found in exon 4. In addition, in more than 10% of the patients, a deletion of the 
last part of exon 4 is present. The terms 5’ UTR (UnTranslated Region) and 3’ UTR indicate the 
direction in which the gene is read; from 5’ UTR to 3’ UTR 
4.3 Tuberous sclerosis 
Tuberous sclerosis complex (TSC) of Bourneville-Pringle was first described in 1880 by 
Bourneville and is a multi-organ disorder with a autosomal dominant inheritance. The 
prevalence is 1 in the 6,000 - 10,000 births. TSC is caused by mutations in two genes, the TSC 
1 and 2 gene. The TSC1 gene is located on chromosome 9 (9q34.3) and codes for hamartin 
while the TSC2 gene is located on chromosome 16 (16p13.3) and codes for tuberin. In 
approximately 85% of patients with a clinically confirmed diagnosis of TSC, a change in one 
of these two genes can be demonstrated. Usually, a de novo mutation is present, although 
30% of the index patients has one or more affected family members. Mutations in both genes 
can lead to abnormal cell growth and differentiation in multiple organ systems. In the brain, 
this is expressed by the formation of cortical and subcortical hamartomas including tubers. 
In addition, various organ systems can be affected leading to the development of cystic 
kidneys, angiofibromas of the face, and rhabdomyomas. The structural abnormalities of the 
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central nervous system are associated with various forms of epilepsy, cognitive 
dysfunctions and symptoms of autism (Datta et al., 2008). There is, however, a great 
variability in the severity of the clinical characteristics across TSC patients, also within one 
single family. 
Already in 1932 and thus before Kanner’s publication, Critshley and Earl described the autistic 
characteristics associated with TSC, being decreased social contact, stereotypies, disturbed 
speech, and withdrawal behaviour. Research during the last few decades has shown autism to 
occur in about 25 to 60 percent of TSC patients, although its symptom profile differs 
qualitatively from that seen in classical autism. A higher level of social-cognitive functioning 
as well as less pronounced stereotypies are characteristic of patients with TSC. Moreover, in 
contrast to autism, the male-female ratio in TCS is about equal (Wiznitzer, 2004). 
The neurobiological substrate for autism in TSC is still unclear. For both hamartin and 
tuberin, it is assumed that both proteins modulate cell function and play a role in neuronal 
migration, differentiation, and development and that they together form a functional 
complex (Asato et al., 2004). The latter can be considered as a type of ’neuronal polarity’ in 
which over expression of the TSC1/TSC2 complex suppresses the formation of axons while 
an under expression is associated with the formation of tubers (Choi et al., 2008). This 
TSC1/TSC2 functional integration may explain that a mutation in one of the two genes can 
result in the same phenotype (Orlova & Crino, 2010). Finally, it has been demonstrated that 
the number of tubers in the brain correlates with the incidence of autism and that their 
localization corresponds with the type of epilepsy (Marcotte & Crino, 2006). 
In sum, also for TSC, it is clear that the presence of autistic behavioural characteristics 
relates to a well-defined gene defect. This knowledge from TSC research may further 
elucidate the pathophysiology of autism. 
4.4 22q11 deletion syndrome  
The 22q11 deletion syndrome (22q11DS) was first described in 1978 by Shprintzen as velo-
cardio-facial syndrome and is caused by an interstitial deletion of chromosome 22 (22q11.2). In 
Figure 3, a micro-array profile of chromosome 22 from a patient with 22q11DS is depicted. 
This syndrome is associated with, among others, congenital heart and conotruncal defects, 
cleft palate, hypoparathyroidism, and facial dysmorphisms. The prevalence of 22q11DS is 
1:4,000 with an equal male-female distribution. The deletion involved in this syndrome can 
encompass multiple genes, with the T-box 1 (TBX1) gene as the most important. Its encoded 
protein is crucial for the development of specific brain areas, heart, face, and limbs (Paylor et 
al., 2006). It is, however, doubtful whether this gene also plays a role in the etiology of 
psychiatric disorders that often accompany 22q11DS (Funke et al., 2007). 
During the past decades, it has become clear that psychiatric disorders often occur in 
22q11DS patients. These include psychoses in particular (Vogels et al., 2002; van Amelsvoort 
et al., 2004; Verhoeven et al., 2007), but also anxiety, mood, and obsessive-compulsive 
disorders (Shprintzen, 2000). In addition, in 15% to 30% of the patients with 22q11DS, 
autistic features are present such as withdrawal behaviour, impaired social interaction, 
reduced facial expression, and cognitive deficits, e.g., perseveration, reduced mental 
flexibility, and restricted problem-solving capacities (Fine et al., 2005; Vorstman et al., 2006b; 
Anshel et al., 2007; Niclasson et al., 2009). Closer inspection of the psychopathological 
profile has demonstrated that both the psychotic and the autistic symptoms evolve from a 
diminished comprehension of abstract and symbolic language, in addition to a limited 
capacity to correctly estimate the intentions, emotions, and behaviour of others (Sphrintzen, 
2000; Verhoeven et al., 2007).  
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RS is one of the better examples of an autism-related disorder with a proven genetic 
pathophysiology. While there are clear differences between classical autism and the 
phenotypic presentation of autism in RS (i.e., characteristic stereotypy such as hand-
wringing at chest level and a relative maintenance of eye contact), research in RS could 
nevertheless contribute to a better understanding of involvement of central nervous system 
dysfunctions in autism.  
 



















Fig. 2. Rett syndrome and the MECP2 Gene 
Schematic representation of the location of the MECP2 gene on the long arm of the X chromosome. 
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In sum, for 22q11DS, it is obvious that detailed analysis of the cognitive, emotional, and 
psychiatric profile is of critical importance for the choice of an individual treatment strategy.  
 
Fig. 3. Microarray profile of chromosome 22 from a patient with 22q11DS  
(a) Representation of a microarray profile of chromosome 22 from a patient with a 22q11 deletion. (b) 
The ideogram  of chromosome 22 with the indication of short p arm and the long q arm is depicted 
underneath.. In the upper portion, every individual clone is represented separately by a red dot on the 
X axis running between the end of the p arm (left) and the end of the q arm (right). On the Y axis, the 
amount of DNA from the patient as compared to that from control samples (CK) can be read. In case 
of an equal amount, the log2 ratio approximates zero. In cases of deletion, this  will be -1 or lower. In 
cases of duplication, this will be +1 or higher. The p arm of chromosome 22 is not represented in the 
microarray profile because it only consists of satellites and non-coding material 
4.5 Metabolic disorders  
While genetically determined metabolic disorders are relatively rare, nevertheless, they 
often manifest with disorders along the autistic spectrum. The establishment of such a 
diagnosis is of importance for not only treatment and prognosis but also for gaining more 
insight into the pathophysiology of autism. Primarily involved are disturbances in amino 
acid metabolism such as phenylketonuria, disorders in purine metabolism, creatine 
deficiency syndromes, Smith-Lemli-Opitz syndrome (i.e., an inherited defect in the 
synthesis of cholesterol), urea cycle disorders, and mitochondrial disorders (Manzi et al., 
2008; Zecavati & Spence, 2009; see Table 2). The latter may even have its debut with 
symptoms from an autism spectrum disorder (Weissman et al., 2008). 
From the metabolic disorders, the creatine deficiency syndromes represent a recently 
recognized group of diseases that are caused by inherited defects in the biosynthesis and 
transport of creatine. Two defects in the biosynthesis have been reported that include 
deficiencies of the enzymes L-arginine-glycine amindinotransferase (AGAT) and 
guanidinoacetate methyltransferase (GAMT). The third is a functional defect involving the 
creatine transporter mechanism. The latter is an X-linked syndrome caused by a defective 
creatine transporter and was first described by Salomons et al. (2001). It appeared to be the 
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result of a mutation in the creatine transporter gene called SLC6A8 that was mapped to 
Xq28. Its prevalence is estimated to be at least 2% of X-linked mental retardation syndromes 
(Rosenberg et al., 2004). Since the SLC6A8 gene is expressed in most tissues (e.g. skeletal 

















































Depending on organ system None 
Table 2. Metabolic disorders and autism (adapted from Zecavati & Spence, 2009 and Manzi 
et al., 2008) 
The main organ involved in creatine deficiency syndromes is the central nervous system. 
Patients show severe neurodevelopmental delay and, from early infancy on, mental 
retardation, epilepsy, disturbances in active and comprehensible speech, autism and self-
injurious behaviour become prominent (Salomons et al., 2003; Béard and Braissant, 2010). In 
patients with GAMT or AGAT deficiency, early oral creatine substitution treatment might 
effectively prevent neurological sequelae. In those with a defect in the creatine transporter 
gene SLC6A8, however, suppletion with L-arginine is not effective at all (Nasrallah et al., 
2009). 
Although metabolic syndromes should always be involved in the differential diagnosis of 
autism spectrum disorder, systematic screening of such patients is only mandatory in case 
of a suggestive actual symptomatology and/or developmental history. An example is the 
Sanfilippo B syndrome, a mucopolysaccharidosis caused by a mutation in the NAGLU gene, 
which leads to an accumulation of heparan sulfate with, as a consequence, damage to the 
central nervous system and various organ systems. This diagnosis was recently determined 
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for an older, mild intellectually disabled patient who was referred for behavior problems 
with a history of limited verbal and emotional communication, stereotypies, impulsivity, 
and anxieties (Verhoeven et al., 2010). 
5. Closing remarks 
The majority of patients with autism present with a mild to severe intellectual disability. In a 
substantial number of cases, moreover, the autistic disorder appears to be part of a genetic 
disorder. It is quite remarkable therefore, that only one genetic disorder from the array of 
genetic disorders associated with autism, is included in the DSM-category of autistic 
disorders, namely the neurodegenerative Rett syndrome. It should, however, be 
emphasized that the identification of autistic behaviours and the diagnosis of an autism 
spectrum disorder is extremely difficult in patients with severe intellectual disability in the 
context of a genetic syndrome (Moss & Howlin, 2009). It is also evident that in case of 
exceptionally high intelligence, Asperger’s disorder or atypical autism are usually the 
autistic disorders involved. For this specific group of patients, however, no information on 
genetics is available as yet. These patients are often subsumed under the general DSM 
category ’Pervasive Developmental Disorder,Not Otherwise Specified’. 
Apart from the changes of diagnostic concepts over the past decades, research on the genetic 
underpinnings of autism and related disorders confronts three major complexities. First, 
there is the large degree of genetic heterogeneity, which means that different genes can 
contribute in a varying way to the emergence of a disorder. A second difficulty is the 
polygenetic inheritance; that is, the simultaneous presence of multiple genetically-
determined vulnerabilities that may be responsible for the development of a particular 
syndrome. A third problem lies in the well-known interaction between environmental and 
genetic factors during development from early conception on (Volkmar et al., 2009).  
All mutations that are causative for the aforementioned disorders concern genes involved in 
the early development of the central nervous system. The search for susceptibility genes has 
made it clear that disturbed synaptic transmission in, for example, the neuroligin network is 
involved in the pathophysiology of a certain, albeit small, percentage of cases with autism. 
This kind of knowledge might be relevant for the development of putative future 
pharmacological treatment strategies for a subgroup of patients with autism. In this context, 
the earlier mentioned significance of the neuropeptide OXT could also be noteworthy. 
The results from a large number of studies during the past decades lead to several 
conclusions. It is clear that autism, both phenotypically and genotypically, is a very 
heterogeneous disorder and that the quest for the grail of a single-high-impact gene will 
never succeed. In general, mutations or common variants in genes are thought to be 
involved in the neuronal domains, synaptic interaction, neurotransmission, and cell 
migration and growth (Freitag et al., 2010). Attention should therefore be shifted to large-
scale screening for de novo mutations and CNVs that can influence the functioning of a gene 
(Sebat et al., 2007; Vissers et al., 2010).  
Recently, all information available on the vulnerability genes and CNVs associated with 
autism has become available via the Autism Genetic Database (AGD), that can be freely 
accessed at http://wren.bcf.ku.edu (Matuszek & Talebizadeh, 2009). In addition, modern 
fMRI techniques may be of use to map neuronal endophenotypes that are critical for further 
genetic studies of autism (Losh et al., 2008; Piggot et al., 2009).  
For daily clinical practice, facial dysmorphisms in patients with autism in addition to 
intellectual disabilities, constitute the initial indication for modern genetic investigation. 
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Epilepsy at young age and gradual deterioration of previously acquired skills warrant 
further search for a metabolic disorder. Future scientific studies may reveal to which extent 
sets of genes are involved in the pathophysiology of autism and autism related disorders 
per se, but also of neuropsychiatric disorders in general (Lichtenstein et a., 2010). In all cases 
it is clear that detailed information about developmental history, neuropsychiatric/ 
neuropsychological profile as well as an elaborative inventory of family characteristics is 
mandatory for appropriate genetic search. This holds true for both the individual patient 
and for a group of well defined patients. 
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1. Introduction 
Autism is a neurodevelopmental disorder of complex etiology and is amongst the most 
heritable of neuropsychiatric disorders while sharing genetic liability with other 
neurodevelopmental disorders such as intellectual disability (ID). Autism spectrum 
disorders (ASDs) are defined more broadly and include autism, Asperger syndrome, 
childhood disintegrative disorder and pervasive developmental disorder not otherwise 
specified. Under the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition 
Revised (DSM-IVTR), these disorders are grouped together with Rett syndrome (“Rett’s 
disorder”) as pervasive developmental disorders. However, Rett syndrome has a reportedly 
distinct pathophysiology, clinical course, and diagnostic strategy (Levy & Schultz, 2009) and 
will likely be removed in the impending publication of DSM-V (APA, 2010). The new 
diagnostic manual will formally adopt the single diagnostic category “ASDs”, which is used 
here. Reported prevalence rates for ASDs range from 20 (Newschaffer et al. 2007) to 116 
(Baird et al., 2006) per 10,000 children, and vary in accordance with diagnostic, sampling, 
and screening criteria. The Centers for Disease Control and Prevention (CDC) suggest that 
in the United States, the prevalence of ASDs is 1 in 110 (1/70 in boys and 1/315 in girls) 
(ADDM, 2009). The three primary characteristics of ASDs are communication impairments, 
social impairments, and repetitive/stereotyped behaviors. The DSM-IVTR, ICD-10, and 
many other diagnostic instruments require impairment in each of these domains for a 
diagnosis of autistic disorder.  
Within the last decade, a number of major technological developments have transformed 
our understanding of the genetic causes of autism, and the field continues to evolve rapidly. 
In this chapter, we will review three approaches to identifying genetic factors that contribute 
to the pathogenesis of ASDs: 1) common variants and genome-wide association studies 
(GWAS); 2) rare variants and copy number variation (CNV) studies, and 3) familial forms of 
autism and the role of next-generation sequencing (NGS) methods. Data from all three 
approaches underscores the conclusion that autism is a highly complex and heterogeneous 
disorder, involving a multifactorial etiology. Moreover, it is becoming increasingly apparent 
that autism is not a unitary disorder, and that the spectrum may consist of any number of 
different autisms that share similar symptoms or phenotypes. This conclusion has important 
implications for evaluation and treatment, which are discussed in the conclusion.  
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2. Heritability of ASDs  
Although Skuse (2007) cautions that heritability estimates of ASDs may have been skewed 
by the co-inheritance of (low) intelligence or other variables, there is little doubt that genetic 
factors play a key role in autism. In the most widely-cited twin study, Bailey et al. (1995) 
report that monozygotic twins are 92% concordant on a broad spectrum of cognitive or 
social abnormalities, compared with only 10% for dizygotic twins. Parents and siblings of 
individuals with ASDs often exhibit subsyndromal levels of impairment (Piven et al., 1997), 
and having an affected sibling is the single biggest risk factor for developing an ASD. In an 
analysis of 943,664 Danish children (Lauritsen et al., 2005), the strongest predictors of autism 
were siblings with ASDs, who conferred a 22-fold increased risk, while Fombonne (2005) 
suggested that this risk may be even greater.  
3. Early insight from Rett syndrome and fragile X 
Early efforts to identify the genetic causes of ASDs utilized linkage and association 
approaches. Linkage studies, more prominent in the 1980s and 1990s, typically focus on 
families or larger pedigrees and is well powered to identify rare genetic variants. The most 
common linkage approach is the affected sib-pair design (see O’Roak & State, 2008), which 
examines the transmission of genomic segments through generations. Linkage studies 
helped define the locus containing FMR1, which is mutated in fragile X syndrome (e.g. 
Richards et al., 1991), and is a common cause of autism in fragile X syndrome, affecting 
~30% of children who are diagnosed with fragile X (Rogers et al., 2001; Harris et al., 2008). 
Similarly, this approach has been important to identifying MECP2 as the major cause of Rett 
syndrome (e.g. Curtis et al., 1993).  
Association studies take the opposite approach, scanning the genome from the top down, 
with the goal of determining post-hoc whether identified variants are more or less common 
in affected individuals. Early association studies (i.e. pre HapMap) were complementary 
with the linkage approach, and in many designs, linkage primed target loci for this more 
fine-grained analysis. These early insights have played a significant role in shaping our 
current understanding of ASDs, and functional studies of FMR1 and MECP2 have 
highlighted the importance of synaptic dysfunction (Ramocki & Zoghbi, 2008) as a unifying 
factor that could extend into the more common forms of autism. This is significant because it 
provides a means of linking neural correlates with genomic data, as well as related clinical 
phenotypes such as seizures and cognitive deficits (Hagerman et al., 2009). The Alzheimer’s 
paradigm, which includes functional models of how molecular, biochemical, and neural 
systems interact is instructive in this regard (e.g. Cissé et al., 2011).  
4. Genome wide association and common variants  
Aside from notable successes with fragile X and Rett syndrome, early linkage and 
association studies have been inconsistent in resolving more complex genetic correlates of 
ASDs, with candidate genes often not being replicated between studies. These challenges 
may in part accounted-for by their relatively low resolution, which makes it difficult to 
detect candidate loci other than those of major effect. In the past decade however, 
association studies have become increasingly more sophisticated, with the whole-genome 
approach, allowing us to examine thousands of individuals on a mass scale, using hundreds 
of thousands of markers.  
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Genome-wide association studies (GWAS) examine the frequency of single nucleotide 
polymorphisms (SNPs) in cases versus control populations and can adopt either a case-
control or family-based approach. The former allows researchers to avoid the often complex 
process of acquiring diagnostic/phenotype data from a patient’s family, and can incorporate 
very large numbers of control datasets that may be more readily available. The latter 
controls for the often confounding phenomenon of population stratification, where variants 
more common to specific racial groups may either be erroneously identified as causal, or 
obscure actual causal variants. A major caveat with family-based designs is the often 
unfounded assumption that unaffected family members do not share causal variants.  
GWAS test for common variants (>1% population frequency), with the assumption that 
ASDs are at least in part caused by the coinheritance of multiple risk variants, each of small 
individual effect (odds ratios between 1:1 and 1:5). This assumption is known as the 
common disease-common variant (CDCV) model (Risch and Merikangas, 1996).  
A 2009 paper by Wang et al. (2009) from our laboratory was the first to identify common 
variants for ASDs on a genome-wide scale. We examined 780 families (3,101 individuals) 
with affected children, a second group of 1,204 affected individuals, and 6,491 controls, all of 
whom were of European ancestry. We identified six genetic markers on chromosome 5 in 
the 5p14.1 region that confirmed susceptibility to ASDs. The region straddles two genes, 
CDH9 and CDH10. Both genes encode type II classical cadherins, transmembrane proteins 
that promote cell adhesion. The association of cadherins is consistent with the cortical-
disconnectivity model of autism (e.g. Gepner & Féron, 2009), which postulates that ASDs 
may result from an increase or decrease in functional connectivity and neuronal 
synchronization in relevant neural pathways. Functional studies suggest that under-activity 
between and within networks are correlated with social, communication, cognitive, and 
sensorimotor impairments (Müller et al., 2011).  
The study design utilized two independent replication cohorts and the key SNP at this locus 
has also been replicated in two additional independent cohort studies (Ma et al., 2009; St 
Pourcain et al., 2010), lending further support that genetic factors at the 5p14 locus, which is 
flanked by two relevant cadherin genes, represent strong candidates for aligning molecular 
function with known neural deficits in ASDS. The original report by Wang and colleagues, 
also demonstrated that there was an enrichment in Catherin associated genes in ASDs in 
general, based on gene-pathway analysis (Wang et al, 2009). Cadherins represent a large 
family of transmembrane proteins that mediates calcium-dependent cell–cell adhesion and, 
via cell adhesion, has been shown to generate synaptic complexity in the developing brain 
(Redies, 2000). Other common GWAS variants reported have not been replicated in 
independent studies and will not be covered here. 
4.1 Replicated common variants from candidate gene studies  
Other common variants from candidate gene studies include CNTNAP2, EN2, and MET, 
which are reviewed briefly below. A more in depth review of these genes can be derived 
from catalogs at http://www.genome.gov/26525384 and http://w w w.ncb.nlm.nih.gov/o 
mim/209850.  
Located on chromosome 7q35, Contactin Associated Protein 2 (CNTNAP2) was identified by 
Alarcón et al. (2002) as a candidate for the age at first word endophenotype. A subsequent 
follow-up by the same group (Alarcón et al. 2008) using linkage, association, and gene-
expression analyses, found CNTNAP2 to be the only autism-susceptibility gene to reach 
significance across all approaches. An independent linkage analysis by Arking et al. (2008) 
also highlighted CNTNAP2 as a significant ASD candidate gene. CNTNAP2 is part of the 
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also highlighted CNTNAP2 as a significant ASD candidate gene. CNTNAP2 is part of the 
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neurexin family, which have repeatedly been associated with autism (see below). 
Interestingly, Vernes et al. (2008) showed that CNTNAP2 binds to FOXP2, which is a well-
established correlate of language and speech disorders (Lai et al., 2001) – a common 
phenotype in ASDs.  
Engrailed 2 (EN2) is a homeobox gene that is critical to the development of the midbrain and 
cerebellum. Like other homeobox genes, it regulates morphogenesis. EN2 is a human homolog 
of the engrailed gene, which is found in Drosophila. En2 mouse mutants have anatomic 
phenotypes in the cerebellum that resemble cerebellar abnormalities reported in autistic 
individuals (Cheng et al., 2010). Benayed et al. (2005, 2009) have reported and replicated in 
three separate datasets a significant association with broad and narrow ASD phenotypes. 
Wang et al. (2008) also found an association between EN2 and ASDs in a Chinese Han sample, 
although Zhong et al. (2003) failed to find evidence of an underlying association.  
The oncogene MET is also strongly linked to ASD etiology, having been supported by a 
number of studies in the past decade (e.g. IMGSAC, 2001; Campbell et al., 2006, 2008; Sousa 
et al., 2009). Recently, Eagleson et al. (2011) reported a role for Met signaling in cortical 
interneuron development in vitro in a mouse model. 
4.2 Unexplained variance  
For the most significant discovery SNP identified in the Wang et al. study above (rs4307059), 
the risk allele frequency was 0.65 in cases with an odds ratio of 1.19, which is comparable 
with common variant discoveries in other psychiatric disorders including schizophrenia 
(Glessner & Hakonarson, 2009; Glessner et al., 2010); bipolar disorder (Ferreira, 2008), and 
attention-deficit/hyperactivity disorder (Arcos-Burgos et al. 2010). While it is important not 
to undermine the significance of these findings, it should be noted that the predictive value 
of such ratios is relatively low (Dickson et al. 2010), often explaining less than 5% of the total 
risk (review at http://www.genome.gov/26525384). However, it is also possible that these 
common SNPs may be tagging a more rare causative variant (i.e., synthetic association), 
where the effect sizes may be markedly underestimated by the GWAS variant as we recently 
reported (Dickson et al. 2010). In one example, Wang et al. (2010), examined the NOD2 locus 
as a cause of Crohn disease. Using resequencing data, they found that three causal variants 
explain > 5% of the genetic risk, where GWAS had estimated the risk at ~1%. Careful 
phenotyping of cohorts is important to ensure that the phenotypes produced by rare-
variants are not being “filtered-out”and thereby missed as a consequence. A long range 
haplotype analysis of the GWAS data at the respective loci is therefore recommended in an 
attempt to enrich for individuals with rare-causative variants, who should be picked out of 
the cohort and subsequently sequenced for confirmation (Wang et al., 2010). This is clearly a 
critical point, particularly in relation to psychiatric disorders, where diagnoses can be more 
contingent upon subjective observation than, for example, the genetics of height, which can 
utilize more intrinsically quantitative data.  
The possibility that common variants are not the major cause of ASDs is also gaining 
increased support from the preponderance of copy number variation (CNV) studies, which 
are identifying rare variants with a stronger causal impact.  
5. Copy number variation in ASDs 
Copy number variations (CNVs) are insertions, deletions, or translocations in the human 
genome that are universal in the general population but more commonly found in genic 
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regions in individuals with neuropsychiatric disorders (e.g. Pinto et al., 2010). CNVs can be 
detected by the same SNP arrays used in GWAS, and vary in length from many megabases 
to 1 kilobase or smaller. They are often not associated with any observable phenotype.  
One of the most widely-known CNVs is Down syndrome, which is characterized by an 
extra chromosome 21. Rett syndrome is also caused by a CNV, which includes a deletion in 
MECP2. CNVs can be inherited or occur de novo, the cause of which is thus far unknown. 
Common disease-causing CNVs are infrequent but rare CNVs, with a frequency of less than 
1%, have been identified for a range of disorders including ADHD (e.g. Williams et al., 
2010), schizophrenia (e.g. Glessner et al., 2010; Levinson et al., 2011), bipolar disorder (e.g. 
Chen et al., 2010) and many others. A substantial portion of autism appears to be caused by 
rare CNVs. De novo CNVs that are greater than 100kb in size are more common in genic 
regions in individuals with ASDs than in the general population.  
Sebat et al. (2007) provided some relevant early insights into the genomic features of CNVs. 
Firstly, they noted that de novo CNVs were individually rare – from 118 ASD cases, none of 
the identified variants were observed more than twice, with the majority seen just once. This 
confirmed the widely-held assumption that many different loci can contribute to the same 
ASD phenotype. Secondly, the authors affirmed the utility of population-study approaches 
that analyze sporadic and multiplex (i.e. more than one family member affected) families 
separately. The rate of de novo mutation in large (mostly genic) loci in multiplex families was 
significantly lower than for the sporadic cases (p = 0.04). While this observation remains to 
be replicated in a larger study, the finding implies two mechanisms of genetic susceptibility 
– spontaneous mutation and inheritance. Finally, the sheer volume of loci identified by this 
approach (multiple loci on 20 chromosomes) affirms the extraordinarily complexity of 
ASDs.  
A number of subsequent studies have greatly expanded the number of candidate loci. Our 
laboratory (Bucan et al. (2009)) reported 150+ CNVs in 912 ASD families that were not found 
in 1,488 controls. Critically, 27 of these loci were replicated in an independent cohort of 859 
ASD cases and 1,051 controls. Some of the rare variants we identified had previously been 
associated with autism, including NRXN1 and UBE3A, which are established ASD 
candidate genes (Guilmatre et al., 2009). Samaco et al. (2005) previously identified significant 
deficits in ube3a expression in mecp2-deficient mice, suggesting a shared pathological 
pathway with Rett syndrome (as well as Angelman syndrome, and autism). Similarly, Kim 
et al. (2008) associated NRXN1 with a balanced chromosomal abnormality at chromosome 
2p16.3 in two unrelated ASD individuals. Rare variants in the coding region included two 
missense changes. 
Glessner et al. (2009) identified and reported CNVs in two major gene networks, including 
neuronal cell adhesion molecules (such as NRXN1) and the ubiquitin gene family (such as 
UBE3A). Interestingly, four of the most prominent genes enriched by CNVs in ASD cases 
(UBE3A, PARK2, RFWD2 and FBXO40) are all part of the ubiquitin gene family. 
Ubiquitination can alter protein function after translation, and degrade target proteins in 
conjunction with proteasomes. The ubiquitin–proteasome system operates at pre- and post-
synapses, whose functions includes regulating neurotransmitter release, recycling synaptic 
vesicles in pre-synaptic terminals, and modulating changes in dendritic spines and post-
synaptic density (Yi & Ehlers, 2005). As well as implicating an ubiquitination network in 
relation to ASDs, we also identified a second pathway involving NRXN1, CNTN4, NLGN1, 
and ASTN2. Genes in this group mediate neuronal cell-adhesion, and contribute to 
neurodevelopment by facilitating axon guidance, synapse formation and plasticity, and 
neuron–glial interactions. We also note that ubiquitins are involved in recycling cell-
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neurexin family, which have repeatedly been associated with autism (see below). 
Interestingly, Vernes et al. (2008) showed that CNTNAP2 binds to FOXP2, which is a well-
established correlate of language and speech disorders (Lai et al., 2001) – a common 
phenotype in ASDs.  
Engrailed 2 (EN2) is a homeobox gene that is critical to the development of the midbrain and 
cerebellum. Like other homeobox genes, it regulates morphogenesis. EN2 is a human homolog 
of the engrailed gene, which is found in Drosophila. En2 mouse mutants have anatomic 
phenotypes in the cerebellum that resemble cerebellar abnormalities reported in autistic 
individuals (Cheng et al., 2010). Benayed et al. (2005, 2009) have reported and replicated in 
three separate datasets a significant association with broad and narrow ASD phenotypes. 
Wang et al. (2008) also found an association between EN2 and ASDs in a Chinese Han sample, 
although Zhong et al. (2003) failed to find evidence of an underlying association.  
The oncogene MET is also strongly linked to ASD etiology, having been supported by a 
number of studies in the past decade (e.g. IMGSAC, 2001; Campbell et al., 2006, 2008; Sousa 
et al., 2009). Recently, Eagleson et al. (2011) reported a role for Met signaling in cortical 
interneuron development in vitro in a mouse model. 
4.2 Unexplained variance  
For the most significant discovery SNP identified in the Wang et al. study above (rs4307059), 
the risk allele frequency was 0.65 in cases with an odds ratio of 1.19, which is comparable 
with common variant discoveries in other psychiatric disorders including schizophrenia 
(Glessner & Hakonarson, 2009; Glessner et al., 2010); bipolar disorder (Ferreira, 2008), and 
attention-deficit/hyperactivity disorder (Arcos-Burgos et al. 2010). While it is important not 
to undermine the significance of these findings, it should be noted that the predictive value 
of such ratios is relatively low (Dickson et al. 2010), often explaining less than 5% of the total 
risk (review at http://www.genome.gov/26525384). However, it is also possible that these 
common SNPs may be tagging a more rare causative variant (i.e., synthetic association), 
where the effect sizes may be markedly underestimated by the GWAS variant as we recently 
reported (Dickson et al. 2010). In one example, Wang et al. (2010), examined the NOD2 locus 
as a cause of Crohn disease. Using resequencing data, they found that three causal variants 
explain > 5% of the genetic risk, where GWAS had estimated the risk at ~1%. Careful 
phenotyping of cohorts is important to ensure that the phenotypes produced by rare-
variants are not being “filtered-out”and thereby missed as a consequence. A long range 
haplotype analysis of the GWAS data at the respective loci is therefore recommended in an 
attempt to enrich for individuals with rare-causative variants, who should be picked out of 
the cohort and subsequently sequenced for confirmation (Wang et al., 2010). This is clearly a 
critical point, particularly in relation to psychiatric disorders, where diagnoses can be more 
contingent upon subjective observation than, for example, the genetics of height, which can 
utilize more intrinsically quantitative data.  
The possibility that common variants are not the major cause of ASDs is also gaining 
increased support from the preponderance of copy number variation (CNV) studies, which 
are identifying rare variants with a stronger causal impact.  
5. Copy number variation in ASDs 
Copy number variations (CNVs) are insertions, deletions, or translocations in the human 
genome that are universal in the general population but more commonly found in genic 
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regions in individuals with neuropsychiatric disorders (e.g. Pinto et al., 2010). CNVs can be 
detected by the same SNP arrays used in GWAS, and vary in length from many megabases 
to 1 kilobase or smaller. They are often not associated with any observable phenotype.  
One of the most widely-known CNVs is Down syndrome, which is characterized by an 
extra chromosome 21. Rett syndrome is also caused by a CNV, which includes a deletion in 
MECP2. CNVs can be inherited or occur de novo, the cause of which is thus far unknown. 
Common disease-causing CNVs are infrequent but rare CNVs, with a frequency of less than 
1%, have been identified for a range of disorders including ADHD (e.g. Williams et al., 
2010), schizophrenia (e.g. Glessner et al., 2010; Levinson et al., 2011), bipolar disorder (e.g. 
Chen et al., 2010) and many others. A substantial portion of autism appears to be caused by 
rare CNVs. De novo CNVs that are greater than 100kb in size are more common in genic 
regions in individuals with ASDs than in the general population.  
Sebat et al. (2007) provided some relevant early insights into the genomic features of CNVs. 
Firstly, they noted that de novo CNVs were individually rare – from 118 ASD cases, none of 
the identified variants were observed more than twice, with the majority seen just once. This 
confirmed the widely-held assumption that many different loci can contribute to the same 
ASD phenotype. Secondly, the authors affirmed the utility of population-study approaches 
that analyze sporadic and multiplex (i.e. more than one family member affected) families 
separately. The rate of de novo mutation in large (mostly genic) loci in multiplex families was 
significantly lower than for the sporadic cases (p = 0.04). While this observation remains to 
be replicated in a larger study, the finding implies two mechanisms of genetic susceptibility 
– spontaneous mutation and inheritance. Finally, the sheer volume of loci identified by this 
approach (multiple loci on 20 chromosomes) affirms the extraordinarily complexity of 
ASDs.  
A number of subsequent studies have greatly expanded the number of candidate loci. Our 
laboratory (Bucan et al. (2009)) reported 150+ CNVs in 912 ASD families that were not found 
in 1,488 controls. Critically, 27 of these loci were replicated in an independent cohort of 859 
ASD cases and 1,051 controls. Some of the rare variants we identified had previously been 
associated with autism, including NRXN1 and UBE3A, which are established ASD 
candidate genes (Guilmatre et al., 2009). Samaco et al. (2005) previously identified significant 
deficits in ube3a expression in mecp2-deficient mice, suggesting a shared pathological 
pathway with Rett syndrome (as well as Angelman syndrome, and autism). Similarly, Kim 
et al. (2008) associated NRXN1 with a balanced chromosomal abnormality at chromosome 
2p16.3 in two unrelated ASD individuals. Rare variants in the coding region included two 
missense changes. 
Glessner et al. (2009) identified and reported CNVs in two major gene networks, including 
neuronal cell adhesion molecules (such as NRXN1) and the ubiquitin gene family (such as 
UBE3A). Interestingly, four of the most prominent genes enriched by CNVs in ASD cases 
(UBE3A, PARK2, RFWD2 and FBXO40) are all part of the ubiquitin gene family. 
Ubiquitination can alter protein function after translation, and degrade target proteins in 
conjunction with proteasomes. The ubiquitin–proteasome system operates at pre- and post-
synapses, whose functions includes regulating neurotransmitter release, recycling synaptic 
vesicles in pre-synaptic terminals, and modulating changes in dendritic spines and post-
synaptic density (Yi & Ehlers, 2005). As well as implicating an ubiquitination network in 
relation to ASDs, we also identified a second pathway involving NRXN1, CNTN4, NLGN1, 
and ASTN2. Genes in this group mediate neuronal cell-adhesion, and contribute to 
neurodevelopment by facilitating axon guidance, synapse formation and plasticity, and 
neuron–glial interactions. We also note that ubiquitins are involved in recycling cell-
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adhesion molecules, which is a possible mechanism by which these two networks are cross 
linked.  
In a similar approach, Pinto et al. (2010) further confirmed the importance of rare CNVs as 
causal factors for ASDs. Interestingly, the group did not observe a significant difference 
between cases and controls in terms of raw number of CNVs or estimated CNV size. 
However, the number of CNVs in genic regions was significantly greater in ASDs compared 
to controls. Again, loci enriched for CNVs include a number of genes known to be important 
for neurodevelopment and synaptic plasticity, such as SHANK2, SYNGAP1, and DLGAP2. 
Between 5.5% and 5.7% of ASD cases have at least one de novo CNV, further confirming the 
significance of de novo genetic events as risk factors for autism. Similar to the Glessner study, 
the Pinto group mapped CNVs to a series of networks involved in the development and 
regulation of the central nervous system functions. Implicated networks include neuronal 
cell adhesion, GTPase regulation (important for signal transduction and biosynthesis), and 
GTPase/Ras signaling, also involved in ubiquitination.  
Finally, Gai et al. (2011) took a slightly different approach, focusing exclusively on inherited 
CNVs. While underlying loci were not necessarily common to those identified by the 
Glessner and Pinto groups, enrichment in pathways involving central nervous system 
development, synaptic functions and neuronal signaling processes was again confirmed. 
The Gai et al. study also emphasized the role of glutamate-mediated neuronal signals in 
ASDs.  
Collectively, these CNV studies suggest that certain hotspots on the genome are particularly 
vulnerable to ASDs, which include loci on chromosomes 1q21, 3p26, 15q11-q13, 16p11, and 
22q11. These hotspots are part of large gene networks that are important to neural signaling 
and neurodevelopment and have additionally been associated with other neuropsychiatric 
disorders.  
In particular, a number of CNV studies in schizophrenia have highlighted structural 
mutations incorporating chromosomes 1q21, 15q13, and 22q11 (e.g. McClellan and King 
2010; Glessner et al., 2010), which are significantly enriched in cases versus controls, with 
NRXN1 being a standout in this regard. From a phenotype perspective, autism and 
schizophrenia seem very different, both in behavioral manifestation and age of onset, and it 
may seem counter-intuitive that associated loci should overlap. Some authors have 
addressed this peculiarity by proposing that schizophrenia and autism may in fact be 
different poles of the same spectrum. Thus, Crespi and Braddock (2008) suggest that social 
cognition is underdeveloped in ASDs and over-developed in the psychotic spectrum, with a 
similar polarization of language and behavioral phenotypes. Although speculative, this 
hypothesis has gained some traction. In the next several years, genomic, imaging, and 
model-systems approaches will likely shed further light on the relationship between autism, 
schizophrenia and other neuropsychiatric disorders.  
6. Sequencing familial forms of ASDs  
To this point, we have focused primarily on the complex interactions of polygenic networks 
as the major cause of ASDs. However, this is not exclusively the case. Paralleling the recent 
spate of CNV is a renewed focus on rare disorders, including familial forms of complex 
diseases that potentially are monogenic or with less complex inheritance pattern. At the 
outset of this chapter, we emphasized the overlap with fragile X syndrome, where one third 
of cases are co-morbid for ASD. As mentioned, fragile X is caused by a failure to express the 
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protein coded by FMR1. However, mutations in FMR1 do not always result in fragile-X and 
can result in a phenotype more representative of ASDs. Thus, Muhle et al. (2004) found that 
7-8% of idiopathic ASD cases may have mutations at the FMR1 locus. Likewise, although 
mutations in MECP2 are the common cause of Rett syndrome, certain mutations at the same 
locus have been associated with idiopathic autism (Carney et al. (2003).  
X-linked genes encoding neurologins NLGN3 and NLGN4 and SHANK3 (a neuroligin 
binding partner) are other prominent examples of distinct rare genetic causes, and a parallel 
can be drawn with these studies and mental retardation and epilepsy, which include many 
rare syndromes that collectively account for a substantial proportion of the two disorders 
(Morrow et al., 2008). Indeed it is perhaps more than coincidence that autism is heavily co-
morbid with these two conditions, with >40%( Bölte et al., 2009) and ~40% (Danielsson et al., 
2005) of ASD cases meeting diagnostic criteria for mental retardation and epilepsy 
respectively. It also is noteworthy that many of these monogenic-related genes are also 
major players in neurodevelopment and synapse activity. Other prominent examples 
include TSC1, TSC2 (Osborne et al., 1991; Franz, 1998), NF1, and UBE3A (see Morrow et al. 
(2008). 
The identification of monogenic or possibly oligogenic autisms is likely to accelerate in the 
next several years as next-generation sequencing becomes more widely available. We 
recently encountered a family of two parents, six healthy siblings, and two siblings with 
severe autism suggestive of autosomal recessive inheritance. Unsuccessful attempts using 
linkage and CNV approaches failed to identify a causal locus, but whole-exome sequencing 
at 20x coverage identified four genes, including one with a non-synonymous SNP in the 
protocadherin alpha 4 isoform1 precursor (PCDHA4) gene, which presents a strong 
candidate gene, currently under validation. Protocadherins are part of the cadherin family 
that facilitates neuronal cell adhesion and this discovery is consistent genomically and 
neurobiologically with the findings addressed above in relation to CDH9 and CDH10.  
Known syndromes with ASD features include fragile-x, neurofibromatosis type 1, down 
syndrome, tuberous sclerosis, neurofibromatosis (which confers a 100-fold increased risk for 
ASDs Li et al. (2005), Angelman, Prader-Willi and related 15q syndromes, and at least 
several dozen others (see Zafeiriou et al., 2007 for a comprehensive review). Table 1 from 
Volkmar et al. (2005) lists the most commonly associated syndromes with median rate and 
range. It is likely that many more unidentified rare syndromes with Mendelian causes have 
ASD phenotypes. As of March 2011, the Online Mendelian Inheritance in Man (OMIM) 
database listed 6,727 known or suspected Mendelian diseases (MD), with 2,993 (44%) of 
these having an identified molecular basis. Since OMIM derives its data from published 
reports, these figures likely under-represent rare disorders, which may go unreported. It has 
been proposed that as many as 30,000 genetic disorders may exist, suggesting that many 
Mendelian disorders have no genetic etiology identified to date. Given the large-
representation of autism phenotypes in known syndromes, we can assume a similar trend in 
unreported disease.  
It remains to be determined whether rare variants will account for the majority of autisms. 
Irrespective, as with many other aspects of scientific inquiry, the study of rare variants will 
continue to play an important role in explicating the pathogenesis of ASDs. El-Fishawy and 
State (2010) point to hypercholesterolemia and hypertension (Brown, 1974; Lifton et al., 2001) 
as examples where rare mutations have been successful in driving a molecular 
understanding of the disease as opposed to identifying risk factors in the general 
 
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment 
 
56
adhesion molecules, which is a possible mechanism by which these two networks are cross 
linked.  
In a similar approach, Pinto et al. (2010) further confirmed the importance of rare CNVs as 
causal factors for ASDs. Interestingly, the group did not observe a significant difference 
between cases and controls in terms of raw number of CNVs or estimated CNV size. 
However, the number of CNVs in genic regions was significantly greater in ASDs compared 
to controls. Again, loci enriched for CNVs include a number of genes known to be important 
for neurodevelopment and synaptic plasticity, such as SHANK2, SYNGAP1, and DLGAP2. 
Between 5.5% and 5.7% of ASD cases have at least one de novo CNV, further confirming the 
significance of de novo genetic events as risk factors for autism. Similar to the Glessner study, 
the Pinto group mapped CNVs to a series of networks involved in the development and 
regulation of the central nervous system functions. Implicated networks include neuronal 
cell adhesion, GTPase regulation (important for signal transduction and biosynthesis), and 
GTPase/Ras signaling, also involved in ubiquitination.  
Finally, Gai et al. (2011) took a slightly different approach, focusing exclusively on inherited 
CNVs. While underlying loci were not necessarily common to those identified by the 
Glessner and Pinto groups, enrichment in pathways involving central nervous system 
development, synaptic functions and neuronal signaling processes was again confirmed. 
The Gai et al. study also emphasized the role of glutamate-mediated neuronal signals in 
ASDs.  
Collectively, these CNV studies suggest that certain hotspots on the genome are particularly 
vulnerable to ASDs, which include loci on chromosomes 1q21, 3p26, 15q11-q13, 16p11, and 
22q11. These hotspots are part of large gene networks that are important to neural signaling 
and neurodevelopment and have additionally been associated with other neuropsychiatric 
disorders.  
In particular, a number of CNV studies in schizophrenia have highlighted structural 
mutations incorporating chromosomes 1q21, 15q13, and 22q11 (e.g. McClellan and King 
2010; Glessner et al., 2010), which are significantly enriched in cases versus controls, with 
NRXN1 being a standout in this regard. From a phenotype perspective, autism and 
schizophrenia seem very different, both in behavioral manifestation and age of onset, and it 
may seem counter-intuitive that associated loci should overlap. Some authors have 
addressed this peculiarity by proposing that schizophrenia and autism may in fact be 
different poles of the same spectrum. Thus, Crespi and Braddock (2008) suggest that social 
cognition is underdeveloped in ASDs and over-developed in the psychotic spectrum, with a 
similar polarization of language and behavioral phenotypes. Although speculative, this 
hypothesis has gained some traction. In the next several years, genomic, imaging, and 
model-systems approaches will likely shed further light on the relationship between autism, 
schizophrenia and other neuropsychiatric disorders.  
6. Sequencing familial forms of ASDs  
To this point, we have focused primarily on the complex interactions of polygenic networks 
as the major cause of ASDs. However, this is not exclusively the case. Paralleling the recent 
spate of CNV is a renewed focus on rare disorders, including familial forms of complex 
diseases that potentially are monogenic or with less complex inheritance pattern. At the 
outset of this chapter, we emphasized the overlap with fragile X syndrome, where one third 
of cases are co-morbid for ASD. As mentioned, fragile X is caused by a failure to express the 
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protein coded by FMR1. However, mutations in FMR1 do not always result in fragile-X and 
can result in a phenotype more representative of ASDs. Thus, Muhle et al. (2004) found that 
7-8% of idiopathic ASD cases may have mutations at the FMR1 locus. Likewise, although 
mutations in MECP2 are the common cause of Rett syndrome, certain mutations at the same 
locus have been associated with idiopathic autism (Carney et al. (2003).  
X-linked genes encoding neurologins NLGN3 and NLGN4 and SHANK3 (a neuroligin 
binding partner) are other prominent examples of distinct rare genetic causes, and a parallel 
can be drawn with these studies and mental retardation and epilepsy, which include many 
rare syndromes that collectively account for a substantial proportion of the two disorders 
(Morrow et al., 2008). Indeed it is perhaps more than coincidence that autism is heavily co-
morbid with these two conditions, with >40%( Bölte et al., 2009) and ~40% (Danielsson et al., 
2005) of ASD cases meeting diagnostic criteria for mental retardation and epilepsy 
respectively. It also is noteworthy that many of these monogenic-related genes are also 
major players in neurodevelopment and synapse activity. Other prominent examples 
include TSC1, TSC2 (Osborne et al., 1991; Franz, 1998), NF1, and UBE3A (see Morrow et al. 
(2008). 
The identification of monogenic or possibly oligogenic autisms is likely to accelerate in the 
next several years as next-generation sequencing becomes more widely available. We 
recently encountered a family of two parents, six healthy siblings, and two siblings with 
severe autism suggestive of autosomal recessive inheritance. Unsuccessful attempts using 
linkage and CNV approaches failed to identify a causal locus, but whole-exome sequencing 
at 20x coverage identified four genes, including one with a non-synonymous SNP in the 
protocadherin alpha 4 isoform1 precursor (PCDHA4) gene, which presents a strong 
candidate gene, currently under validation. Protocadherins are part of the cadherin family 
that facilitates neuronal cell adhesion and this discovery is consistent genomically and 
neurobiologically with the findings addressed above in relation to CDH9 and CDH10.  
Known syndromes with ASD features include fragile-x, neurofibromatosis type 1, down 
syndrome, tuberous sclerosis, neurofibromatosis (which confers a 100-fold increased risk for 
ASDs Li et al. (2005), Angelman, Prader-Willi and related 15q syndromes, and at least 
several dozen others (see Zafeiriou et al., 2007 for a comprehensive review). Table 1 from 
Volkmar et al. (2005) lists the most commonly associated syndromes with median rate and 
range. It is likely that many more unidentified rare syndromes with Mendelian causes have 
ASD phenotypes. As of March 2011, the Online Mendelian Inheritance in Man (OMIM) 
database listed 6,727 known or suspected Mendelian diseases (MD), with 2,993 (44%) of 
these having an identified molecular basis. Since OMIM derives its data from published 
reports, these figures likely under-represent rare disorders, which may go unreported. It has 
been proposed that as many as 30,000 genetic disorders may exist, suggesting that many 
Mendelian disorders have no genetic etiology identified to date. Given the large-
representation of autism phenotypes in known syndromes, we can assume a similar trend in 
unreported disease.  
It remains to be determined whether rare variants will account for the majority of autisms. 
Irrespective, as with many other aspects of scientific inquiry, the study of rare variants will 
continue to play an important role in explicating the pathogenesis of ASDs. El-Fishawy and 
State (2010) point to hypercholesterolemia and hypertension (Brown, 1974; Lifton et al., 2001) 
as examples where rare mutations have been successful in driving a molecular 
understanding of the disease as opposed to identifying risk factors in the general 
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population. Rare mutations, particularly when they are Mendelian, carry large effects and 
are typically in genic regions. These characteristics make the resolution of underlying 
networks distinctly less complex and, moreover, are amenable to modeling in other systems.  
Recent groundbreaking studies by Marchetto et al. (2010) and Muotri et al. (2010), who 
created a cell culture model of Rett syndrome, are potentially exciting developments in this 
regard. Here, the researchers used skin biopsies from four Rett’s patients, each carrying a 
different MeCP2 mutation, to culture induced pluripotent stem cells (iPS). Once the iPS cells 
developed into neurons, they showed a decreased number of neurons and dendritic spines, 
consistent with neurodevelopmental disruptions. Intervention with insulin-like growth 
factor 1 (IGF1), which is known to regulate neurodevelopment, was subsequently shown to 
reverse Rett-like symptoms in a mouse model of the disease. This innovative approach is an 
exciting model of how rare gene approaches can stimulate our understanding of the 
pathophysiology and potential reversibility of ASDs. 
 
Syndrome  Number of Studies Median Rate Range % 
Tuberous sclerosis  11 1.1 0–3.8 
Fragile X  9 0.0 0–8.1 
Down syndrome  12 0.7 0–16.7 
Neurofibromatosis 1 6 0 0–1.4 
Table 1. Associated disorders and their rate in autism (from Volkmar et al., 2005 in Zafeiriou 
et al. 2007) 
7. Conclusions 
ASDs are clearly highly heritable disorders and advances in gene-finding technology in the 
past decade have rapidly accelerated gene discovery. As is typically the case, successive 
developments have made the problem more complex such that there are dozens of 
candidate genes, many of which remain to be replicated. In spite of this complexity, we can 
observe a number of patterns beginning to unfold 1) the relative scarcity of causal common 
variants, 2) the growing list of causal rare variants, and 3) the emergence of monogenic 
disorders with primary and secondary ASD phenotypes.  
The monogenic autisms are particularly interesting from a treatment perspective, as they 
provide a mechanism for studying ASD phenotypes in model systems and an obvious target 
for drug intervention. They are also amenable to clinical testing and the decreasing cost of 
research technologies means that this capacity is more widely available to clinicians. In fact, 
as the resolution of clinical instruments becomes more sophisticated, it is likely that the 
clinic will become a primary workplace for syndromic discovery.  
A key requirement in driving gene discovery is the necessity of high-quality phenotype 
data. ASDs are notoriously heterogeneous, and are fractionated in terms of symptoms and 
trajectory. Mandy & Skuse (2008) reviewed seven factor analysis studies of ASDs symptoms, 
and found that all but one dissociated social and non-social factors. In a non-clinical sample 
of 3,000 twin pairs, Happé et al. (2006) examined autistic-like traits and found consistently 
low correlations (r = 0.1-0.4) between each of the core deficits on the autism spectrum. 
Endophenotypes, sub-components or sub-processes of the broader phenotype, may provide 
a productive avenue to disentangling some of this complexity. By filtering out all but a few 
discrete measures, we can theoretically increase the signal-to-noise ratio in genotype-
phenotype associations. A number of endophenotypes for ASDs have been identified 
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associated with disease genes, including head circumference (associated with the HOXA1 
A218G polymorphism, Conciatori et al., 2004), age at first word (associated with a 
quantitative trait locus on 7q35, Alarcón et al. 2005), delayed magnetoencephalography 
evoked responses to auditory stimuli (Roberts et al., 2010), and enhanced perception 
(Mottron et al., 2006). The endophenotype approach is arguably more consistent with rare-
/mono-genic discovery, where a mutated network may not yield a diagnosis of autism per 
se, but nevertheless cause associated abnormalities. Note, this approach does not diminish 
the pleiotropic effects of genes involved in neurodevelopment, and only serves to make the 
point that the relevant genotype may associate with some but not all ASD features.  
The converse, of course, is also true with a large number of candidate genes contributing to 
the majority of known ASDs. With ~80% of genes expressed in the brain it is likely that this 
number will continue to grow, and here again careful phenotyping is critical to identifying 
functional consequences. Ultimately, the primary goal is not to determine the frequency of 
variation/mutation in cases versus controls, but to determine the pathway(s) and gene 
networks that lead to pathology. This will be no mean feat, with other major players such as 
epigenetic factors, RNA regulatory elements, and environmental exposures also an 
important part of the equation. While daunting, the elucidation of these elements will 
doubtlessly take us closer to developing effective treatments for ASDs. Given the current 
rate of progress, we have cause for cautious optimism in this regard.  
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exciting model of how rare gene approaches can stimulate our understanding of the 
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1. Introduction 
Although autism is considered to be one of the most highly heritable psychiatric disorders, 
molecular mechanisms underlying its pathogenesis remain largely unresolved. A strong 
genetic component underlying autism spectrum disorders (ASD) has been firmly 
established from various lines of studies ranging from whole genome scans to genetic 
association studies. Recent genomic advances have led to steep growth in the number of 
diverse genetic loci linked to ASD, including candidate genes containing rare or common 
variants, chromosomal aberrations, and submicroscopic copy number variations. 
Additionally, autism is consistently associated with a number of single gene mutation 
disorders such as Fragile X Syndrome. Most genetic variations fail to replicate between 
studies and populations, further complicating our understanding of ASD disease etiology.  
Here we review recent expansion of heterogeneity in the genetic landscape for ASD. First 
we define the types of genetic risk factors implicated in this disorder. We then 
comparatively analyze the pools of ASD candidate genes identified as of the end of years 
2006 and 2010, profiling both their distribution and molecular function. We highlight 
bioinformatics tools for ASD which can be used to build and evaluate networks of ASD 
genes as the number of risk factors grows. Finally, we discuss the impact of genetic 
heterogeneity on theories of ASD pathogenesis.  
2. Genes 
In the post-genomic era, continuous identification of new ASD risk factors has rapidly 
expanded the types of candidate genes implicated in the pathogenesis of this disorder. Until 
2003, single gene mutations in ASD were derived from well-characterized genetic 
syndromes such as Fragile X Syndrome and Rett Syndrome, in which subpopulations of 
individuals develop autistic symptoms. Later that year, Thomas Bourgeron’s group first 
identified single gene mutations/disruptions in neuroligins in siblings with ASD (Jamain et 
al., 2003). This seminal work opened up the field of ASD research in two major areas: first, a 
strong genetic foundation to non-syndromic forms of ASD and, second, a focus on the 
synaptic model for the disorder. Since then, high throughput genetic studies have rapidly 
identified additional genetic risk factors, vastly expanding the pool of ASD-linked genes.  
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al., 2003). This seminal work opened up the field of ASD research in two major areas: first, a 
strong genetic foundation to non-syndromic forms of ASD and, second, a focus on the 
synaptic model for the disorder. Since then, high throughput genetic studies have rapidly 
identified additional genetic risk factors, vastly expanding the pool of ASD-linked genes.  
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Candidate genes for ASD can currently be defined into four distinct sets:  
1. Rare: genes implicated in rare monogenic forms of ASD. The types of allelic variants 
within this class include rare polymorphisms and single gene disruptions/mutations 
directly linked to ASD. Examples include NRXN1 and SHANK3.  
2. Syndromic: genes implicated in syndromes in which a significant subpopulation 
develops autistic symptoms. Examples include FMR1 (Fragile X Syndrome) and MECP2 
(Rett Syndrome).  
3. Association: genes with common polymorphisms that confer small risk for ASD and 
have been identified from genetic association studies of ASD derived from unknown 
cause (known as “idiopathic ASD”). Examples include MET and GABRB1.  
4. Functional: genes with functions relevant for ASD biology and not included in any of 
the other genetic categories. Examples include CADSP2, for which knockout mouse 
models exhibit autistic characteristics, but the gene itself has not been directly tied to 
known cases of ASD. 
Of these four gene categories, Rare and Syndromic contain the strongest evidence of links to 
ASD (for review, El-Fishawy & State, 2010). Association genes lack replication of their 
relationship to ASD, and Functional genes have no documented direct link to ASD. Over 200 
ASD candidate genes have been reported thus far in the scientific literature (Table 1). These 
genes are distributed at discrete regions throughout the entire genome (Figure 1).  
 
 
Fig. 1. Ideogram of all currently known ASD candidate genes. To the left of each 
chromosome are genes that fall within either the association category (red) or the functional 
category (black), whereas to the right of each chromosome are genes that fall within either 
the rare mutation category (green) or the syndromic category (blue). * = gene also identified 
by genome-wide association studies. 
3. Chromosomes 
Microscopically visible large-scale chromosomal rearrangements have long been implicated 
in the onset and progression of a host of developmental disorders. Deletions of the 15q11-
q13 region on the maternal chromosome lead to Angelman syndrome (Williams et al., 2008), 
whereas the corresponding deletion on the paternal chromosome gives rise to Prader-Willi 
syndrome (Cassidy & Schwartz, 2009). Deletions, duplications, translocations, and 
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inversions larger than 3 Mb responsible for these and other syndromes have traditionally 
been identified by microscopic techniques such as karyotyping and, more recently, 
fluorescent in situ hybridization (FISH). In recent years, technological and computational 
advances have provided researchers with the sensitivity and accuracy to identify structural 
variation in chromosomes less than 3 Mb in size, which could not have previously been 








81 ANKRD11, A2BP1*, APC*, ASTN2, AUTS2, BZRAP1, 
C3orf58, CA6, CACNA1H, CADM1, CENTG2*, CNTN4, 
CNTNAP2*, CNTNAP5, CXCR3, DIAPH3, DLGAP2, DPP10, 
DPP6, DPYD, EIF4E, FABP5*, FABP7*, FBXO40, FHIT, 
FRMPD4, GALNT13, GLRA2, GRPR, HNRNPH2, 
IL1RAPL1, IMMP2L*, JMJD1C, KCNMA1, KIAA1586, 
MBD1, MBD3, MBD4, MCPH1, MDGA2, MEF2C, NBEA, 
NLGN1, NLGN3, NLGN4X, NOS1AP, NRXN1, ODF3L2, 
OPHN1, OR1C1, PARK2, PCDH9, PCDH10, PCDH19, 
PDZD4, PLN, PPP1R3F, PSMD10, PTCHD1, RAB39B*, 
RAPGEF4, RB1CC1, REEP3, RFWD2, RIMS3, RPL10, 
RPS6KA2, SCN1A, SCN2A, SEZ6L2, SH3KBP1, SHANK2, 
SHANK3, SLC4A10, SLC9A9, ST7, SUCLG2, TMEM195, 
TSPAN7, UBE3A*, WNK3 
Syndromic 
21 ADSL, AGTR2, AHI1*, ALDH5A1, ARX, CACNA1C, 
CACNA1F, CDKL5, DHCR7, DMD, DMPK, FMR1, MECP2, 
NF1, NTNG1, PTEN, SLC6A8, SLC9A6, TSC1, TSC2, XPC 
Association 
84 ABAT, ADA, ADORA2A, ADRB2, AR, ARNT2, ASMT, 
ATP10A, AVPR1A, C4B, CACNA1G, CCDC64, CDH10, 
CDH22, CDH9, CTNNA3, CYP11B1, DISC1, DLX1, DLX2, 
DRD3, EN2, ESR1, ESRRB, FBXO33, FEZF2, FOXP2, FRK, 
GABRA4, GABRB1, GABRB3, GLO1, GPX1, GRIK2, 
GRIN2A, GRM8, GSTM1,HLA-A, HLA-DRB1, HOXA1, 
HRAS, HS3ST5, HSD11B1, HTR1B, HTR3A, HTR3C, INPP1, 
ITGA4, ITGB3, LAMB1, LRFN5, LRRC1, LZTS2, MACROD2, 
MARK1, MET, MTF1, MYO16, NOS2A, NPAS2, NRCAM, 
NRP2, NTRK1, NTRK3, OXTR, PER1, PIK3CG, PITX1, 
PON1, PRKCB1, PTGS2, RELN, RHOXF1, SLC1A1, 
SLC25A12, SLC6A4, STK39, SYT17, TDO2, TPH2, UBE2H, 
VASH1, WNT2 
Functional 
23 ALOX5AP, ASS, CACNA1D, CADPS2, CBS, CD44, CNR1, 
DAB1, DAPK1, DCUN1D1, DDX11, EGR2, F13A1, FLT1, 
ITGB7, MAOA, MAP2, OPRM1, RAI1, ROBO1, SDC2, 
SEMA5A, TSN 
Table 1. Genetic classification of all currently identified ASD candidate genes. (* = gene 
replicated by independent association studies.)  
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inversions larger than 3 Mb responsible for these and other syndromes have traditionally 
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advances have provided researchers with the sensitivity and accuracy to identify structural 
variation in chromosomes less than 3 Mb in size, which could not have previously been 
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RPS6KA2, SCN1A, SCN2A, SEZ6L2, SH3KBP1, SHANK2, 
SHANK3, SLC4A10, SLC9A9, ST7, SUCLG2, TMEM195, 
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21 ADSL, AGTR2, AHI1*, ALDH5A1, ARX, CACNA1C, 
CACNA1F, CDKL5, DHCR7, DMD, DMPK, FMR1, MECP2, 
NF1, NTNG1, PTEN, SLC6A8, SLC9A6, TSC1, TSC2, XPC 
Association 
84 ABAT, ADA, ADORA2A, ADRB2, AR, ARNT2, ASMT, 
ATP10A, AVPR1A, C4B, CACNA1G, CCDC64, CDH10, 
CDH22, CDH9, CTNNA3, CYP11B1, DISC1, DLX1, DLX2, 
DRD3, EN2, ESR1, ESRRB, FBXO33, FEZF2, FOXP2, FRK, 
GABRA4, GABRB1, GABRB3, GLO1, GPX1, GRIK2, 
GRIN2A, GRM8, GSTM1,HLA-A, HLA-DRB1, HOXA1, 
HRAS, HS3ST5, HSD11B1, HTR1B, HTR3A, HTR3C, INPP1, 
ITGA4, ITGB3, LAMB1, LRFN5, LRRC1, LZTS2, MACROD2, 
MARK1, MET, MTF1, MYO16, NOS2A, NPAS2, NRCAM, 
NRP2, NTRK1, NTRK3, OXTR, PER1, PIK3CG, PITX1, 
PON1, PRKCB1, PTGS2, RELN, RHOXF1, SLC1A1, 
SLC25A12, SLC6A4, STK39, SYT17, TDO2, TPH2, UBE2H, 
VASH1, WNT2 
Functional 
23 ALOX5AP, ASS, CACNA1D, CADPS2, CBS, CD44, CNR1, 
DAB1, DAPK1, DCUN1D1, DDX11, EGR2, F13A1, FLT1, 
ITGB7, MAOA, MAP2, OPRM1, RAI1, ROBO1, SDC2, 
SEMA5A, TSN 
Table 1. Genetic classification of all currently identified ASD candidate genes. (* = gene 
replicated by independent association studies.)  
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Of particular interest in the field of submicroscopic structural variants are deletions and 
duplications collectively categorized as copy number variants. A copy number variant 
(CNV) is typically defined as a ≥1 kb DNA segment that is present at a differing copy 
number compared to a reference genome (Feuk et al., 2006). CNVs can either arise de novo or 
be inherited on the maternal and/or paternal chromosome. Much like many single 
nucleotide polymorphisms, apparently benign CNVs exist in the general population at 
relatively high frequencies; as such, CNVs that exist in the general population at a rate of 1% 
or higher are generally described as CNV polymorphisms (Feuk et al, 2006). Submicroscopic 
copy number variants have come under increased scrutiny in recent years as a potential 
causative agent in the onset and progression of developmental disorders, including 
neuropsychiatric disorders such as ASD. 
3.1 Copy number variation in autism spectrum disorders 
As more syndromes were subsequently shown to be associated with both microscopic and 
submicroscopic chromosomal structural variation, it became apparent that a subset of 
patients diagnosed with some of these syndromes also developed ASD or displayed autistic 
traits. For example, DiGeorge Syndrome (also called Velocardiofacial Syndrome), which is 
frequently characterized by congenital heart anomalies, palatal abnormalities, immune 
system deficits and some degree of facial dysmorphism, has been found to result from a ~3 
Mb deletion in chromosome 22 (McDonald-McGinn et al., 2005). Individuals diagnosed with 
this syndrome, also referred to as 22q11.2 deletion syndrome, frequently experience learning 
disabilities; however, approximately 20% of patients with this syndrome also develop ASD. 
Given that a subset of patients with syndromes caused by chromosomal structural 
abnormalities also display autistic traits, as well as the high prevalence of ASD in 
individuals with cytogenetically visible duplications of the Angelman/Prader-Willi 
syndrome region (15q11-q13) on the maternal chromosome (Cook Jr. et al., 1997; Schroer et 
al., 1998), a number of studies in the past decade have focused on identifying 
submicroscopic structural variants, in particular CNVs, in individuals with ASD and 
subsequently determining the importance of these variants in disease pathogenesis. In order 
to more fully ascertain the pathogenic risk associated with copy number variants, only 
patients with idiopathic cases of ASD have typically been used; patients with mutations in 
genes previously implicated in ASD, such as the FMR1 gene, or with gross chromosomal 
abnormalities have frequently been excluded from these studies.  
The advent of genome-wide scanning technologies has enabled researchers to identify and 
subsequently confirm >1200 potentially pathologically relevant CNVs located within over 
490 distinct loci in autistic populations since 2007 (Sebat et al., 2007; Szatmari et al., 2007; 
Marshall et al., 2008; Cuscó et al., 2009; Glessner et al., 2009; Gregory et al., 2009; van der 
Zwaag et al., 2009; Pinto et al., 2010; Bremer et al., 2011). Confirmation or validation of a 
CNV by an independent approach following its discovery is essential not only to remove 
false positives, but also to more accurately identify the boundaries of a CNV. Validated 
CNVs in autistic individuals have been located in loci on all 22 somatic chromosomes and 
the X chromosome (Figure 2).  
While many of the CNVs identified by these methods are singletons and require additional 
replication to more accurately assess their potential role in disease, there are rare, recurring 
CNVs at particular loci that have been identified across multiple autistic populations that 
have emerged as strong risk-conferring candidates in ASD pathogenesis. Ten loci that have 
been identified multiple times in autistic case populations are described in Table 2. Perhaps 
the most intensely studied of these recurring CNVs, aside from duplications in the 15q11-13 
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loci, are ~500 kb deletions and duplications that occur at the 16p11.2 locus. A recently 
published meta-analysis of the 16p11.2 locus in autistic populations discovered that CNVs at 
the 16p11.2 locus have a prevalence of 0.76%, with deletions occurring approximately twice 
as frequently with duplications (Walsh & Bracken, 2011). CNVs in autistic individuals have 
been identified in regions previously associated with other deletion-duplication syndromes, 
such as the 1q21.1, 22q11.21 and 22q13.33 loci (McDonald-McGinn et al., 2005; Phelan, 2007; 
Haldeman-Englert & Jewett, 2011). Other strong candidate CNV loci to emerge from 
genome-wide scanning assays include 2p16.3, 3p26.3, 6q26, 7q11.22, and 15q13.3. In some 
cases, CNVs at these “hot-spot” loci appear to target genes that have previously been 





Fig. 2. Validated copy number variants (CNVs) identified in genome-wide scanning arrays 
from nine published reports (Sebat et al., 2007; Szatmari et al., 2007; Marhall et al., 2008; 
Cuscó et al., 2009; Glessner et al., 2009; Gregory et al., 2009; van der Zwaag et al., 2009;  
Pinto et al., 2010; Bremer et al., 2011). The red lines to the left of each chromosome represent 
the >1200 validated CNVs identified in these studies. Especially long CNVs that overlap 
smaller CNVs are represented with thinner red lines. The green lines to the right of 
chromosomes 1, 2, 3, 6, 7, 15, 15, and 22 represent ten rare, recurring CNV loci identified in 
at least three of the nine aforementioned publications (described in more detail in Table 2). 
Increasingly, targeted assays using methods such as quantitative PCR are being used to 
characterize CNVs at particular loci that have been previously identified by more global 
scanning approaches, given the relatively high frequency of these CNVs in autistic case 
cohorts. CNVs are now considered one of the most common, genetic causes of ASD, with  
10-20% of ASD cases believed to be the result of submicroscopic deletions and duplications 
(Miles et al., 2010). 
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Fig. 2. Validated copy number variants (CNVs) identified in genome-wide scanning arrays 
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Increasingly, targeted assays using methods such as quantitative PCR are being used to 
characterize CNVs at particular loci that have been previously identified by more global 
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cohorts. CNVs are now considered one of the most common, genetic causes of ASD, with  
10-20% of ASD cases believed to be the result of submicroscopic deletions and duplications 
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CNV locus Candidate gene(s) CNV Type References
1q21.1 Deletion-Duplication Szatmari et al., 2007; Gregory et al., 2009; Pinto et al., 2009
2p16.3 NRXN1 Deletion-Duplication
Szatmari et al., 2007; Glessner et al., 2009; Pinto et al., 2010; 
Bremer et al., 2011
3p26.3* CNTN4 Deletion-Duplication Glessner et al., 2009; Pinto et al., 2010; Bremer et al., 2011
6q26 PARK2 Deletion-Duplication
Szatmari et al., 2007; Glessner et al., 2009; Pinto et al., 2010; 
Bremer et al., 2011





Sebat et al., 2007; Marshall et al., 2008; Glessner et al., 2009; 
Pinto et al., 2010
15q13.3* CHRNA7 Deletion-Duplication Gregory et al., 2009; Pinto et al., 2010; Bremer et al., 2011
16p11.2 Deletion-Duplication
Sebat et al., 2007; Marshall et al., 2008; Glessner et al., 2009; 
Pinto et al., 2010; Bremer et al., 2011
22q11.21 Deletion-Duplication
Szatmari et al., 2007; Marshall et al., 2008; Glessner et al., 2009; 
Pinto et al., 2010; Bremer et al., 2011
22q13.33 SHANK3 Deletion-Duplication
Szatmari et al., 2007; Marshall et al., 2008; Glessner et al., 2009; 
van der Zwaag et al., 2009; Pinto et al., 2010; Bremer et al., 2011  
Table 2. Examples of loci in which rare, recurring, potentially risk-conferring CNVs are 
frequently observed in autistic populations. Potential candidate genes within the locus, the 
type of CNV that targets each locus, and the articles in which these CNV loci were identified 
are included. *, CNV locus which overlaps with adjacent loci in at least one of the 
publications listed. 
A more detailed analysis of the nine published research articles used to construct the 
ideogram in Figure 2 reveals that, while the percentage of previously unidentified CNV loci 
has steadily declined since 2007, new CNV loci still constitute a very high percentage of the 
total CNV loci identified and validated in these studies (Table 3). Therefore, while recurring 
CNVs such as 16p11.2 and others continue to be observed across multiple autistic 
populations and CNV studies, novel CNVs in autistic populations are still being identified, 
indicating that there are likely multiple potential targets for the pathogenic properties of 
CNVs throughout the human genome. It is likely that other novel CNVs in autistic 
individuals have not yet been identified, and as such their identification will shed new light 
on the pathways adversely affected in ASD. 
 
Year 2007 2008 2009 2010-11 
# of published reports 2 1 4 2 
# total CNV loci identified 98 32 56 396 
# previously unidentified CNV loci 97 27 47 320 
% of CNV loci previously unidentified 98.98 84.38 83.93 80.81 
Table 3. Analysis of the nine papers used to construct the ideogram in Figure 2. while the 
overall percentage of previously unidentified CNV loci has decreased from year to year, 
novel CNV loci still constitute the majority of the total CNV loci that have been identified 
and confirmed in these studies. 
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3.2 Risk-conferring vs. benign copy number variants 
Although advances in genome-wide and targeted scanning assays have enabled researchers 
to discover potentially risk-conferring CNVs in autistic individuals, significant issues 
remain in the determination of which CNVs are pathologically relevant or benign in nature. 
This is of particular importance in terms of potentially using genetic screening for risk-
conferring CNVs as a tool to assess the risk of ASD in unborn children. The diagnostic 
accuracy of such a screening protocol would be entirely dependent on knowing which 
CNVs would confer the greatest potential risks for ASD pathogenesis. In order to 
distinguish between risk-conferring and benign CNVs in an autistic population, a 
comparison must be made between both the existence and frequency of CNVs between 
affected and unaffected individuals. To account for possible genetic differences between 
ethnic groups, it is critical that a control population of comparable size and ethnic 
background be included in any CNV study. For example, CNVs at loci thought to confer a 
high risk of ASD susceptibility, such as deletions and duplications at the 16p11.2 locus, have 
also been identified in healthy individuals, although at a much lower frequency than in 
autistic populations. Given the increased frequency of CNVs at the 16p11.2 loci in autistic 
populations versus control populations, CNVs at this region remain classified as high risk-
conferring CNVs. In addition, there are online databases such as the Database of Genomic 
Variants (http://projects.tcag.ca/variation/) and the Copy Number Variant resource at the 
Children’s Hospital of Philadelphia (http://cnv.chop.edu/) available that describe 
previously identified CNVs in healthy individuals. These tools provide a means to further 
filter out likely benign CNVs from autistic case studies and enrich for potentially pathogenic 
variants. However, it should be noted that seemingly benign CNVs may be involved in 
more subtle phenotypes in autistic individuals when occurring in combination with other 
factors. Likewise, additional meta-analysis studies of CNV loci across multiple published 
autistic populations, such as that described for the 16p11.2 locus, will be required to 
compare frequencies of CNV a in order to more fully determine the global risk potential 
associated with any given CNV at a particular locus. 
3.3 De novo vs. inherited copy number variants 
As previously stated, CNVs can either arise de novo, or be inherited from the mother and/or 
father. Considerable interest has been placed in the pathogenic importance of de novo CNVs 
as a cause of ASD compared to inherited variants, especially within the context of sporadic 
vs. familial ASD cases. Indeed, some studies have found that the rate of de novo CNVs is 
higher in sporadic cases compared to familial cases (Sebat et al., 2007; Marshall et al., 2008), 
while Bremer et al. (2011) found that the rate of rare inherited CNVs was higher in familial 
cases compared to sporadic cases. These findings would suggest that de novo CNVs are 
predominantly responsible for ASD in sporadic cases, whereas inherited CNVs are 
primarily responsible for familial cases of ASD. However, Pinto et al. (2010) found no 
significant difference between the frequencies of de novo CNVs in sporadic vs. familial cases. 
It has been reported that validated de novo CNVs strongly associate with ASD (Sebat et al., 
2007). However, there is no firm evidence that de novo CNVs confer a higher probability or 
severity of disease than inherited variants. On the other hand, the dynamics of CNV 
inheritance and subsequent susceptibility to ASD has its own issues: an autistic individual 
with a potential risk-conferring CNV may inherit that CNV from a parent who fails to 
exhibit autistic traits; an autistic individual may have unaffected siblings who have likewise 
inherited the identical CNV; or one affected sibling in a multiple family may have a risk-
conferring CNV, whereas other affected siblings may not.  
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CNV locus Candidate gene(s) CNV Type References
1q21.1 Deletion-Duplication Szatmari et al., 2007; Gregory et al., 2009; Pinto et al., 2009
2p16.3 NRXN1 Deletion-Duplication
Szatmari et al., 2007; Glessner et al., 2009; Pinto et al., 2010; 
Bremer et al., 2011
3p26.3* CNTN4 Deletion-Duplication Glessner et al., 2009; Pinto et al., 2010; Bremer et al., 2011
6q26 PARK2 Deletion-Duplication
Szatmari et al., 2007; Glessner et al., 2009; Pinto et al., 2010; 
Bremer et al., 2011





Sebat et al., 2007; Marshall et al., 2008; Glessner et al., 2009; 
Pinto et al., 2010
15q13.3* CHRNA7 Deletion-Duplication Gregory et al., 2009; Pinto et al., 2010; Bremer et al., 2011
16p11.2 Deletion-Duplication
Sebat et al., 2007; Marshall et al., 2008; Glessner et al., 2009; 
Pinto et al., 2010; Bremer et al., 2011
22q11.21 Deletion-Duplication
Szatmari et al., 2007; Marshall et al., 2008; Glessner et al., 2009; 
Pinto et al., 2010; Bremer et al., 2011
22q13.33 SHANK3 Deletion-Duplication
Szatmari et al., 2007; Marshall et al., 2008; Glessner et al., 2009; 
van der Zwaag et al., 2009; Pinto et al., 2010; Bremer et al., 2011  
Table 2. Examples of loci in which rare, recurring, potentially risk-conferring CNVs are 
frequently observed in autistic populations. Potential candidate genes within the locus, the 
type of CNV that targets each locus, and the articles in which these CNV loci were identified 
are included. *, CNV locus which overlaps with adjacent loci in at least one of the 
publications listed. 
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Year 2007 2008 2009 2010-11 
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3.2 Risk-conferring vs. benign copy number variants 
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3.4 Copy number variation and phenotypic heterogeneity 
Detailed studies attempting to correlate genotype with phenotype have demonstrated that 
there is significant phenotypic heterogeneity between individuals with CNVs at a particular 
chromosomal locus, both in terms of disease presence and severity of disease. Studies in 
autistic populations containing CNVs at the 15q13.3 (Miller et al., 2009; Ben-Shachar et al., 
2009) and 16p11.2 (Fernandez et al., 2010) loci, for example, have shown that autistic 
phenotypes, such as the extent of facial dysmorphism and the extent of intellectual 
disability, can vary from one patient to the next with the same CNV. One model that has 
been designed to address some of the issues as to how CNVs contribute to ASD states that 
certain CNVs at particular loci increase the susceptibility of an individual to developing an 
ASD based on a “threshold” of disease severity (Cook & Scherer, 2008). Chief among these 
high susceptibility CNVs are maternal duplications at 15q11-q13, deletions at 16p11.2, and 
deletions at the loci encoding for cell adhesion proteins such as neuroligins. Other rare 
recurring CNVs that have been identified in autistic populations may confer a lower overall 
risk of ASD pathogenesis, or a decreased severity of disease, such as CNVs at 1q21.1, 2p16.3, 
and 22q11.21. However, even these CNVs can result in the onset of ASD, or more severe 
disease phenotypes, when in combination with other genetic and non-genetic factors. These 
genetic factors may include additional CNVs (indeed, many autistic individuals have more 
than one CNV within their genome) or single gene mutations, such as those described 
elsewhere in this chapter, whereas non-genetic factors can be environmental, sex-related, or 
epigenetic in nature. Epigenetic regulation of gene expression may be of particular importance 
with regards to phenotypic heterogeneity in autistic individuals with 15q11-q13 duplications, 
as this region contains a number of potentially critical imprinted genes. Further studies 
involving more detailed analysis of genotype-phenotype correlations in autistic individuals 
with CNVs will be instrumental in determining the role of CNVs in ASD. 
3.5 Mechanism of action of copy number variants 
The general mechanism by which a CNV might contribute to ASD pathogenesis remains 
unclear. The simplest mechanism of action involves gene dosage, by which deletion or 
duplication of a gene or genes within a particular CNV locus, or the deletion or duplication 
of gene regulatory elements, subsequently results in altered or disrupted levels of gene 
product. A deletion at a particular locus might also result in the unmasking of a recessive 
gene on the corresponding chromosomal locus, which would then be able to elicit a 
deleterious effect. Such a mechanism might be involved in disease pathogenesis in an 
autistic individual with a 10 Mb maternally inherited deletion in chromosome 13q and a 
point mutation in the DIAPH3 gene on the paternal chromosome (Vorstman et al., 2010). As 
the proband’s unaffected sibling also had the DIAPH3 mutation, but lacked the 
corresponding deletion, it is tempting to argue that the maternal deletion unmasked a 
recessive mutation in the paternal DIAPH3 gene, and that in turn influenced the onset of 
ASD in the proband. Given that many CNVs are large enough to include up to 50 or more 
genes, identifying which genes are of functional relevance in ASD pathogenesis within a 
particular CNV loci remains a challenging task. Much in the same way that genes that 
confer susceptibility to ASD have been found to fall within intriguing functional categories, 
bioinformatic analysis of genes that lie within or adjacent to recurring CNV loci may yield 
similar results and aid in both identifying new candidate genes and in discovering 
conserved pathways potentially targeted by copy number variation. Indeed, analysis 
designed to identify potentially relevant functional pathways containing genes located in 
copy number variants have been performed (Pinto et al., 2010). 
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4. Comparative analysis of ASD genes  
To analyze recent evolution of the ASD molecular landscape, we profiled ASD genes identified 
as of the end of years 2006 and 2010. To define pools of ASD candidate genes existing at these 
time points, we used the ASD database AutDB (www.mindspec.org/autdb.html), a publicly 
available, curated, web-based, searchable genetic database for ASD created by our laboratory 
(see Section 5). We then examined the genetic and functional expansion of these gene sets. 
4.1 Genetic expansion  
To quantify the total number of ASD candidate genes identified as of 2006 and 2010, we 
sorted existing ASD candidate genes according to year of first publication. We discovered 
that the total number of ASD candidate genes more than doubled in the past four years: 
whereas 91 genes were linked to ASD as of 2006, this number rapidly grew to 209 genes in 
2010.  
To compare genetic distribution within these datasets, we defined ASD candidate genes 
according to the classification system described in Section 2: rare variants (Rare), syndromic 
genes (Syndromic), genes identified by association studies (Association), and genes whose 
functions have been implicated in ASD (Functional). We found that expansion of the total 
ASD gene pool was largely due to steep growth of both Rare and Association gene sets, with 
a slight increase in the numbers of identified Syndromic and Functional genes (Figure 3). 
Notably, the near quadrupling of the number of rare mutations supports the Rare Allele, 
Common Disease as a plausible theory of ASD pathogenesis (see Section 6).  
 
 
Fig. 3. Genetic distribution of ASD candidate genes identified as of the end of years 2006 and 
2010. 
4.2 Functional expansion 
Recent large-scale ASD studies have used a systems biology approach to translate genetic 
information into functional maps. For instance, Glessner et al. (2009) showed that ASD-
linked genes cluster in synaptic processes such as cell adhesion and ubiquitin-mediated 
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degradation. Additionally, in the largest ASD study performed to date, Pinto et al. (2010) 
found that genes affected by rare CNVs were enriched in functions such as neuronal 
development and GTPase/Ras signaling.  
To build upon these functional maps, we used a well-known synaptic proteome 
classification system (Husi et al., 2000), to organize ASD gene sets from 2006 and 2010 into 
eight broad categories of molecular function, defined by corresponding subcategories:  
1. Cell Adhesion (cell adhesion molecule, cell adhesion/axon guidance, extracellular 
matrix, extracellular secreted protein) 
2. Guidance/Outgrowth (axon guidance, cell migration, cell surface glycoprotein, 
cytoskeletal remodeling, dendritic spine morphology, animal model evidence) 
3. Neurotransmission (adaptor protein, G-protein coupled receptors, ligand-gated ion 
channel, neuromodulator receptor, neuromodulator receptor-associated protein, 
neuromodulator synthesis, neurotransmitter receptor, neurotransmitter synthesis, 
presynaptic release, scaffolding protein, sensory receptor, transporter, voltage-gated ion 
channel, voltage-gated ion channel modulator) 
4. Signaling (glycosylation, kinase, kinase substrate, phosphatase, proteoglycan, small G-
protein or modulator, tyrosine receptor kinase, other signal) 
5. Degradation (proteasome-related protein, ubiquitin ligase) 
6. Transcription (circadian protein, cofactor, DNA binding, DNA damage response protein, 
DNA methylation, estrogen receptor, histone demethylation protein, homeodomain 
protein, preinitiation complex, purine metabolism, transcription factor) 
7. Translation (ribosomal protein, RNA binding, RNA metabolism, RNA structure) 
8. Other (antioxidant, endosome regulation, energy production, fatty acid binding protein, 
immune system, membrane biosynthesis, mitochondrial carrier protein, mitochondrial 
targeting protein, oxidation, prostaglandin, unknown function).  
The functional distribution of ASD risk genes vastly expanded from 2006 to 2010 (Figure 4). 
Because Rare and Syndromic genes contain the strongest links to ASD (see Section 2), we 
examined this combined “Rare/Syndromic” set as one dataset. We comparatively assessed 
them with Association genes as a separate gene set. Both Rare/Syndromic and Association gene 
datasets followed the same trend: whereas Neurotransmission and Signaling were by far the 
largest functional categories in 2006, the number of genes in all other functional categories 
increased over the past four years such that all are becoming relatively equalized. The most 
dramatic increases occurred in Cell Adhesion, Degradation, Transcription, and Other.  
This functional expansion has led to shifting theories of ASD pathogenesis. In 2006, the 
largest percentage of ASD susceptibility genes resided in the Neurotransmission or Signaling 
categories, supporting specific theories of dysfunction, such as serotonin transport (Cook & 
Leventhal, 1996). However, rapid expansion of nearly all functional categories throughout 
2010 indicates that ASD susceptibility genes are actually widespread in neurobiological 
function. Such functional expansion supports broad theories of pathogenesis such as the 
proposed enhancement of brain excitability in ASD (Rubenstein & Merzenich, 2003). Each 
designated functional category includes neurobiological factors that contribute to brain 
excitability, reinforcing the idea that mutations in vastly different genes may facilitate 
similar outcomes in brain function by contributing to shared molecular pathways. Together, 
accelerated identification of ASD risk genes with widespread neurobiological functions is 
leading to a convergent model of ASD pathogenesis.  
 
















Fig. 4. Functional profile of ASD candidate genes identified as of the end of years 2006 and 
2010.  
5. Bioinformatics of ASD 
The enormous amount of data currently being generated by large-scale genomic studies 
poses a critical challenge for its storage and analysis. To process this information, 
bioinformatics tools are becoming increasingly vital to the scientific community. Here we 
highlight several ASD-related databases which researchers can use to navigate this data and 
shed insight into the molecular pathways underlying ASD pathogenesis.  
5.1 AutDB 
Our laboratory created the ASD database AutDB (www.mindspec.org/autdb.html), the first 
publicly available, curated, web-based, searchable genetic database for ASD (Basu et al., 
2009; Kumar et al., 2011). In AutDB, evidence regarding ASD candidate genes is 
systematically extracted from peer-reviewed, primary scientific literature and manually 
curated by our researchers. To provide high-resolution view of various components linked 
to ASD, we developed detailed annotation rules based on the biology of each data type and 
generated controlled vocabulary for data representation. AutDB is widely used by 
individual laboratories (Crespi et al., 2010; Elia et al., 2010; Gillis et al., 2010; Toro et al., 
2010) and consortiums (Simons Foundation) for understanding genetic bases of ASD. 
With a systems biology approach, AutDB integrates various modules encompassing 
different types of data relevant for ASD:  
Human Gene: This original module of AutDB includes all genes whose mutations have 
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associated with these disorders (Basu et al., 2009). ASD-related genes are classified into the 
four categories described in Section 2: 1) Rare: genes implicated in rare monogenic forms of 
ASD; 2) Syndromic: genes implicated in syndromic forms of ASD where a subpopulation 
with a specific genetic syndrome develops autistic symptoms; 3) Association: small risk-
conferring candidate genes with common polymorphisms identified from genetic 
association studies in idiopathic ASD; and, 4) Functional: candidates genes with functions 
relevant for ASD biology, not covered by any of the previous genetic categories. All known 
ASD-specific mutations at the DNA sequence level will be available by late 2011.  
Animal Model: This module provides a comprehensive collection of all mouse models 
linked to ASD (Kumar et al., 2011). The core behavioral features of ASD involve higher 
order human brain functions like social interactions and communications, which can only be 
approximated in animal models, so the annotation strategy for this module includes four 
broad areas: 1) core behavioral features of ASD, 2) ASD-related traits such as seizures and 
circadian rhythms that are heritable and more easily quantified in animal models; 3) 
neuroanatomical features, and 4) molecular profiles. To this end, we developed PhenoBase, 
a classification table for systematically annotating models with controlled vocabulary. 
PhenoBase contains 16 major categories and >100 standardized phenotype terms.  
Protein Interaction (PI): This module serves as a repository for all known protein-protein 
interactions of ASD candidate genes. It documents five major types of direct interactions: 1) 
protein binding, 2) promoter binding, 3), RNA binding, 4) protein modification, and 5) 
direct regulation. One of the newest additions to AutDB, a beta version of this module was 
released in April 2011, with a full version scheduled for release in late 2011. Its content is 
envisioned to have immediate application for network biology analysis of molecular 
pathways involved in ASD pathogenesis. 
Copy Number Variant (CNV): This module is a comprehensive, up-to-date reference for all 
known copy number variants (CNVs) implicated in ASD (see Section 3). It originates from a 
multi-level annotation model including data such as chromosomal location, size, and 
relevance to ASD. Like the PPI module, a beta version of the CNV module was released in 
May 2011, with a full version scheduled for release in late 2011.  
5.2 ASD Chromosome Rearrangement Database  
The ASD Chromosome Rearrangement Database (http://projects.tcag.ca/ASD/) is a web-
based, searchable genetic database hosted by The Centre for Applied Genomics at the 
Hospital for Sick Children in Toronto, Canada (Marshall et al., 2008). The ASD Chromosome 
Rearrangement Database provides information not only on submicroscopic CNVs, that have 
been identified by microarray studies, but also data on microscopic structural variants 
identified by cytogenetic studies. This database is updated both from published research 
articles and in-house experimental results. 
5.3 ASD Genetic Database  
The ASD Genetic Database (http://wren.bcf.ku.edu/) is another web-based, searchable 
genetic database developed by researchers at the University of Kansas (Matuszek & 
Talabizadeh, 2009). Much like AutDB and the ASD Chromosome Rearrangement Database, 
the ASD Genetic Database provides information on genes and CNVs believed to impart 
susceptibility to ASD. However, this database also includes information on known non-
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coding RNAs and chemically-induced fragile sites in the human genome. Non-coding 
RNAs, such as microRNAs, have come under increased scrutiny with regards to their 
potential pathogenic role in ASD. For example, the 15q11-q13 region contains a number of 
small nucleolar RNAs (snoRNAs). Duplication of a region of mouse chromosome 7 that has 
conserved linkage with human chromosome 15q11-q13 in mouse model of ASD resulted in 
overexpression of the snoRNA MBII52 (the mouse ortholog of the human snoRNA HBII52), 
which could potentially alter serotonergic signaling and contribute in part to the autistic 
traits exhibited by these mice (Nakatani et al., 2009). Spontaneous breakage during DNA 
replication at rare chromosomal fragile sites may also play a role in the pathogenesis of 
neuropsychiatric disorders such as ASD. The chromosomal fragile site FRAXA has been 
implicated in fragile X syndrome, and other fragile sites have been identified that associate 
with ASD, such as FRA2B, FRA6A, and FRA13A (Smith et al., 2010). 
6. Discussion 
6.1 Rare vs. common alleles 
At the beginning of this decade, few single mutations for ASD had been identified. As of 
2003, single mutations in only two genes were known: neuroligins 3 and 4, published in a 
single report (Jamain et al., 2003).  This led to predominance of the Common Allele Common 
Disease theory, which proposes that ASD is caused by combined effects of multiple common 
polymorphisms.  
However, evidence from two recent major studies led to the emergence of an alternative 
Rare Allele Common Disease theory for ASD pathogenesis. First, comparative genomic 
hybridization with subsequent confirmation showed a strong association between de novo 
CNVs mutations and ASD (Sebat et al., 2007). Second, homozygosity mapping identified 
numerous single gene mutations in families with ASD (Morrow et al., 2008).  
According to the Rare Allele Common Disease theory, the genetics underlying complex 
neuropsychiatric disorders such as ASD is highly heterogeneous. It proposes that ASD is 
caused by numerous rare, highly penetrant mutations that may even by caused by “private 
mutations” specific to individual families; a similar theory has been proposed to explain the 
genetic complexity of schizophrenia (McClellan et al., 2007). The identification of rare 
variants has more than quadrupled in the past four years (see Section 4), lending credibility 
to this theory.  
At present, it appears that the Rare Allele Common Disease  theory is a highly relevant genetic 
paradigm for ASD and other complex disorders.  A few recent papers have identified 
common variants associated with ASD (Campbell et al., 2006; Wang et al., 2009; Weiss et al., 
2009; Anney et al., 2010), but these mutations are still far outnumbered by known rare single 
gene mutations. With increased availability of various types of sequencing technologies, it is 
projected that additional rare mutations/variations will be discovered or validated rapidly 
in upcoming years, making clinical genomics of ASD an option for affected families. 
6.2 Prioritization of genetic ASD risk factors 
In future, ASD risk genes should be prioritized based on careful definitions at both genetic 
and functional levels. High priority genes should show evidence for replication or 
participate in a molecular pathway exhibiting multiple ASD-linked mutations. Examples 
include the cell adhesion molecule CNTNAP2, a neurexin family member in which both 
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associated with these disorders (Basu et al., 2009). ASD-related genes are classified into the 
four categories described in Section 2: 1) Rare: genes implicated in rare monogenic forms of 
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conferring candidate genes with common polymorphisms identified from genetic 
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circadian rhythms that are heritable and more easily quantified in animal models; 3) 
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a classification table for systematically annotating models with controlled vocabulary. 
PhenoBase contains 16 major categories and >100 standardized phenotype terms.  
Protein Interaction (PI): This module serves as a repository for all known protein-protein 
interactions of ASD candidate genes. It documents five major types of direct interactions: 1) 
protein binding, 2) promoter binding, 3), RNA binding, 4) protein modification, and 5) 
direct regulation. One of the newest additions to AutDB, a beta version of this module was 
released in April 2011, with a full version scheduled for release in late 2011. Its content is 
envisioned to have immediate application for network biology analysis of molecular 
pathways involved in ASD pathogenesis. 
Copy Number Variant (CNV): This module is a comprehensive, up-to-date reference for all 
known copy number variants (CNVs) implicated in ASD (see Section 3). It originates from a 
multi-level annotation model including data such as chromosomal location, size, and 
relevance to ASD. Like the PPI module, a beta version of the CNV module was released in 
May 2011, with a full version scheduled for release in late 2011.  
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based, searchable genetic database hosted by The Centre for Applied Genomics at the 
Hospital for Sick Children in Toronto, Canada (Marshall et al., 2008). The ASD Chromosome 
Rearrangement Database provides information not only on submicroscopic CNVs, that have 
been identified by microarray studies, but also data on microscopic structural variants 
identified by cytogenetic studies. This database is updated both from published research 
articles and in-house experimental results. 
5.3 ASD Genetic Database  
The ASD Genetic Database (http://wren.bcf.ku.edu/) is another web-based, searchable 
genetic database developed by researchers at the University of Kansas (Matuszek & 
Talabizadeh, 2009). Much like AutDB and the ASD Chromosome Rearrangement Database, 
the ASD Genetic Database provides information on genes and CNVs believed to impart 
susceptibility to ASD. However, this database also includes information on known non-
 
Genetic Heterogeneity of Autism Spectrum Disorders 
 
77 
coding RNAs and chemically-induced fragile sites in the human genome. Non-coding 
RNAs, such as microRNAs, have come under increased scrutiny with regards to their 
potential pathogenic role in ASD. For example, the 15q11-q13 region contains a number of 
small nucleolar RNAs (snoRNAs). Duplication of a region of mouse chromosome 7 that has 
conserved linkage with human chromosome 15q11-q13 in mouse model of ASD resulted in 
overexpression of the snoRNA MBII52 (the mouse ortholog of the human snoRNA HBII52), 
which could potentially alter serotonergic signaling and contribute in part to the autistic 
traits exhibited by these mice (Nakatani et al., 2009). Spontaneous breakage during DNA 
replication at rare chromosomal fragile sites may also play a role in the pathogenesis of 
neuropsychiatric disorders such as ASD. The chromosomal fragile site FRAXA has been 
implicated in fragile X syndrome, and other fragile sites have been identified that associate 
with ASD, such as FRA2B, FRA6A, and FRA13A (Smith et al., 2010). 
6. Discussion 
6.1 Rare vs. common alleles 
At the beginning of this decade, few single mutations for ASD had been identified. As of 
2003, single mutations in only two genes were known: neuroligins 3 and 4, published in a 
single report (Jamain et al., 2003).  This led to predominance of the Common Allele Common 
Disease theory, which proposes that ASD is caused by combined effects of multiple common 
polymorphisms.  
However, evidence from two recent major studies led to the emergence of an alternative 
Rare Allele Common Disease theory for ASD pathogenesis. First, comparative genomic 
hybridization with subsequent confirmation showed a strong association between de novo 
CNVs mutations and ASD (Sebat et al., 2007). Second, homozygosity mapping identified 
numerous single gene mutations in families with ASD (Morrow et al., 2008).  
According to the Rare Allele Common Disease theory, the genetics underlying complex 
neuropsychiatric disorders such as ASD is highly heterogeneous. It proposes that ASD is 
caused by numerous rare, highly penetrant mutations that may even by caused by “private 
mutations” specific to individual families; a similar theory has been proposed to explain the 
genetic complexity of schizophrenia (McClellan et al., 2007). The identification of rare 
variants has more than quadrupled in the past four years (see Section 4), lending credibility 
to this theory.  
At present, it appears that the Rare Allele Common Disease  theory is a highly relevant genetic 
paradigm for ASD and other complex disorders.  A few recent papers have identified 
common variants associated with ASD (Campbell et al., 2006; Wang et al., 2009; Weiss et al., 
2009; Anney et al., 2010), but these mutations are still far outnumbered by known rare single 
gene mutations. With increased availability of various types of sequencing technologies, it is 
projected that additional rare mutations/variations will be discovered or validated rapidly 
in upcoming years, making clinical genomics of ASD an option for affected families. 
6.2 Prioritization of genetic ASD risk factors 
In future, ASD risk genes should be prioritized based on careful definitions at both genetic 
and functional levels. High priority genes should show evidence for replication or 
participate in a molecular pathway exhibiting multiple ASD-linked mutations. Examples 
include the cell adhesion molecule CNTNAP2, a neurexin family member in which both 
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common and rare variants have been associated with ASD (Arking et al., 2008). CNTNAP2 is 
also regulated by FOXP2, a candidate ASD gene highly relevant for human language 
development (Gong et al., 2004). Additionally, the role of synaptic scaffolding proteins in 
ASD has been strengthened by recent identification of recurrent mutations in SHANK2 
(Berkel et al., 2010; Pinto et al., 2010). Furthermore, if multiple genes contribute to 
syndromic ASD, each gene should only be considered high priority when accompanied by a 
documented direct genetic link to ASD.  
CNVs should likewise be prioritized based on a number of factors. A high risk-conferring 
structural variant should not only display a high prevalence in autistic populations, but also 
an enrichment in autistic populations compared to control populations. Meta-analysis 
studies, such as that previously described for the 16p11.2 locus in multiple autistic case 
studies (Walsh & Bracken, 2011), will aid greatly in determining which CNVs meet these 
criteria. Furthermore, a high priority CNV locus should either contain a gene or genes, or 
the regulatory elements for a gene or genes, which demonstrate potential participation in a 
molecular pathway exhibiting multiple ASD-linked single gene mutations. CNV loci 
containing genes that have already been associated with increased risk of autism, such as 
2p16.3 (NRXN1), are of particular interest in this regard. 
6.3 Synaptic theory of ASD 
A hypothesis for ASD as a synaptic disorder is well recognized, largely based on strong 
evidence from rare mutations in neuroligins, neurexins and SHANK3 (Bourgeron, 2009). 
Rapid expansion of the ASD risk gene pool has supported this synaptic theory of ASD by 
identifying rare mutations in numerous additional synapse-related genes, including 
SHANK2 (Berkel et al., 2010; Pinto et al., 2010) and PTCHD1 (Marshall et al., 2008; Noor et 
al., 2010; Pinto et al., 2010). Additionally, functional maps generated from large-scale studies 
of ASD have enriched this synaptic hypothesis of ASD, identifying categories ranging from 
cell adhesion and ubiquitin-mediated degradation (Glessner et al., 2009) to neuronal 
development and GTPase/Ras signaling (Pinto et al., 2010). 
Our functional profile of all ASD candidate genes identified as of 2010 supports this 
synaptic hypothesis (see Section 4). The majority of ASD-linked genes function in synaptic 
processes such as cell adhesion, guidance/outgrowth, neurotransmission, signaling, 
degradation, transcription, and translation. A smaller fraction of ASD risk genes possessed 
unknown functions or “Other” non-synaptic functions. Examples of synaptically enriched 
ASD gene functions are modeled in Figure 5. 
7. Conclusion 
In conclusion, the broadened molecular landscape for ASD suggests that an integrated 
approach is required to understand functional pathways underlying ASD. An unbiased 
view of ASD risk gene datasets emphasizes the importance of overall synaptic networks for 
human cognition. Higher order functions require efficient information processing, and 
mutations in any synaptic component could lead to the range of impairments present in 
ASD. Future spatiotemporal mapping of ASD gene expression patterns may provide clues 
to how shared susceptibility genes give rise to different forms of ASD. Moreover, 
identification of new ASD-associated genes using advanced techniques like deep sequencing 
will increasingly sharpen our functional understanding of ASD synapse biology.  
 




Fig. 5. Synaptic enrichment of ASD candidate genes. ASD risk genes are concentrated in 
numerous synaptic functions, including cell adhesion (examples: NLGN1, NLGN3,  
NLGN4X, NRXN1), synaptic scaffolds (examples: SHANK2-3), degradation (example: 
UBE3A), translation (example: FMR1), and neurotransmission (examples: CACNA1C, 
CACNA1G, GABRB3).  
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1. Introduction 
Autism is a developmental lifelong condition of the human brain, and a behavioral 
characterization as a spectrum (autism spectrum disorder: ASD) is the best way to illustrate 
this complex trait (Frith, 2001; Rapin, 1997; Wing, 1997). The predominant presence of 
autistic cases without comorbidity (idiopathic or primary ASD) (Freitag, 2007) clearly means 
that the biological effects associated with the known concomitant medical conditions 
(cytogenic abnormalities, fragile X syndrome, tuberous sclerosis, congenital infections, 
maternal thalidomide use, epilepsy, etc.) cannot be the common prerequisite for ASD at 
least in the majority of the cases. The presence of a strong genetic contribution is evident 
from the results of twin studies, which demonstrated that 70-90% of monozygotic twins are 
concordant for ASD, and the concordance in dizygotic twins and the recurrence rate in the 
proband’s siblings are both less than 10% (Rapin & Katzman, 1998). A broadening of the 
criteria of diagnosis leads the monozygotic concordance ratio to more than 90%, but 100% 
concordance is never obtained (Rapin & Katzman, 1998). Therefore, it is claimed that genetic 
factors contribute about 90% to ASD with environmental factors contributing no more than 
10% (Garber, 2007). Although a flood of genetic information in the field of ASD is 
continuously growing, even the newest genome-wide molecular studies cannot detect the 
universal genetic prerequisite for idiopathic cases with ASD, compelling some researchers to 
speculate that ASD has a huge inter-case heterogeneity of the related gene variants.  
Many gene variants, which seem to affect brain development and synaptic functions, have 
been reported in association with the autistic development (Betancur, 2011; Garber, 2007; 
Persico & Bourgeron, 2006; Pinto et al., 2010). In families with the candidates for autism gene 
variants, however, the strict co-segregation, in which the gene variant is found only in 
individuals with ASD among family members including parents, is still exceptional (Table 
1). To explain this fact, the broader distribution of the more primary phenotype or pre-
behavioral phenotype (endophenotype) beyond the categorical border is introduced as the 
speculative solution through this research maze (Viding & Blakemore, 2007). It may be quite 
difficult to detect and evaluate such endophenotypes because of the configurational or 
hierarchical structures of human cognitions and behaviors. Even if such speculations were 
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all true, it is too early to conclude that “a single gene variant causes a small percentage of 
cases with this complex trait” (Garber, 2007; Beaudet, 2007). As clearly demonstrated in the 
case of human disease-associated mutations found as wild-type alleles in normal chimpanzee 
(L. Azevedo et al., 2006), a deleted or mutated allele does not necessarily contribute to the 
disease development. Because evidence consistent with a theory is not proof of that theory 
(Cannell, 2010), until one could delineate the molecular or biological trajectory underlying 
autistic development which is quantitatively different from the parents, there is still a huge 
black box between the de novo variant allele and complex human behaviors in the sporadic 
cases with idiopathic ASD. The reported gene variants are, at present, nothing but one of the 
concomitants in a small percentage of cases (5-7%, in Table 1). The possibility that the 
variantsare mere relative risk factors remains to be elucidated (Jones & Szatmari, 2002). As a 





SHANK3 variants In ASD families 15 / 227 (6.6%)a (Durand et al., 2007) 
 Co-segregated cases 3 / 227 (1.3%)b 
 In controls 5 / 270 (1.9%)a 
SHANK3 variants In ASD families 3 / 400 (0.8%)c (Moessner et al., 2007) 
SHANK3 variants In ASD individuals 34 / 427 (8.0%) (Gauthier et al., 2009) 
 In controls 16 / 190 (8.4%) 
SHANK3 deletion In ASD individuals 1 / 427 (0.2%)c (Gauthier et al., 2009) 
 In controls 0 / 190 
SHANK3 deletion In ASD individuals 2 / 2,195 (0.1%) (Glessner et al., 2009) 
 In controls 2 / 2,519 (0.1%) 
SHANK2 de novo deletion In ASD individuals 2 / 996 (0.2%) (Pinto et al., 2010) 
 In controls 0 / 1,287, 0 / 3,677
NLGN3 variants In ASD individuals 0 / 96 (Yan et al., 2005) 
NLGN3 duplication In ASD individuals 1 / 2,195 (0.05%) (Glessner et al., 2009) 
 In controls 0 / 2,519 
NLGN4 variants In ASD individuals 4 / 148 (2.7%)d (Yan et al., 2005) 
 In controls 0 / 336 
NRXN1 deletion In ASD families 1 / 1,181 (0.1%) (AGPC, 2007) 
NRXN1α variants In ASD individuals 5 / 116 (4.3%) (Yan et al., 2008) 
 In controls 1 / 192 (0.5%)
NRXN1 deletion In ASD individuals 10 / 2,195 (0.5%) (Glessner et al., 2009) 
 In controls 0 / 2,519
NRXN1 de novo variants In ASD families 4 / 996 (0.4%) (Pinto et al., 2010) 
 In controls 5 / 1,287 (0.4%)
NRXN1β variants In ASD individuals 4 / 203 (2.0%)d,e (Feng et al., 2006) 
 In controls 0 / 535
NRXN2β variants In ASD individuals 0 / 72 (Feng et al., 2006) 
NRXN3β variants In ASD individuals 0 / 72 (Feng et al., 2006) 
CNTN4 deletion In ASD individuals 10 / 2,195 (0.5%) (Glessner et al., 2009) 
 In controls 0 / 2,519
CNTN4 duplication In ASD individuals 9 / 2,195 (0.4%)c (Glessner et al., 2009) 
 In controls 1 / 2,519 (0.04%) 
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AUTS2 In ASD individuals 1 / 2,195 (0.05%) (Glessner et al., 2009) 
 In controls 0 / 2,519 
DDX53/PTCHD1 deletion In ASD cases 7 / 996 (0.7%) (Pinto et al., 2010) 
(maternally inherited) In controls 0 / 1,287, 0 / 3,677
CNVs at 15q11-13 In ASD individuals 15 / 2,195 (0.7%)f (Glessner et al., 2009) 
(UBE3A) In controls 0 / 2,519 
CNVs at 15q11-13 In ASD individuals 4 / 522 (0.8%)g (Depienne et al., 2009) 
CNVs at 16p11.2 In ASD families 12 / 751 (1.6%) (Weiss et al., 2008) 
 In controls 5 / 4,234 (0.1%) 
 In ASD individuals 3 / 299 (1.0%) 
 In controls 7 / 18,834 (0.04%) 
16p11.2 duplication In ASD individuals 9 / 2,195 (0.4%)c (Glessner et al., 2009) 
 In controls 4 / 2,519 (0.2%) 
16p11.2 deletion In ASD individuals 8 / 2,195 (0.4%)h (Glessner et al., 2009) 
 In controls 4 / 2,519 (0.2%) 
CNV gain at 1q21 In ASD families 3 / 1,181 (0.3%)d (AGPC, 2007) 
CNV at 17p12 In ASD families 3 / 1,181 (0.3%)i (AGPC, 2007) 
CNV gain at 22q11.2 In ASD families 2 / 1,181 (0.2%)d (AGPC, 2007) 
22q11.2 duplication In ASD individuals 9 / 2,195 (0.4%) (Glessner et al., 2009) 
 In controls 0 / 2,519 
De novo CNVs In ASD families 10 / 1,181 (0.8%) (AGPC, 2007) 
 Co-segregated cases 3 / 1,181 (0.3%)j 
De novo CNVs In ASD individuals 14 / 195 (7.2%)k (Sebat et al., 2007) 
 In sporadic cases 12 / 118 (10.2%) 
 In multiplex families 2 / 77 (2.6%) k 
 In controls 2 / 196 (1.0%) 
De novo CNVs In ASD families 27 / 427 (6.3%) (Marchall et al., 2008) 
 In sporadic cases 4 / 56 (7.1%) 
 In multiplex families 1 / 49 (2.0%) 
De novo CNVs In ASD families 50 / 876 (5.7%)l (Pinto et al., 2010) 
 In simplex families 22 / 393 (5.6%) 
 In multiplex families 19 / 348 (5.5%) 
ASDs: autism spectrum disorders; NLGN: neuroligin gene; NRXN: neurexin gene; CNTN: contactin 
gene; AUTS: autism susceptibility candidate gene; CNV: copy number variation; AGPC: the Autism 
Genome Project Consortium. aTwo nonsynonymous SHANK3 mutations were revealed in 4 ASD 
families and 2 control individuals. bIn the SHANK3 study, de novo truncating mutations in two families 
and a chromosomal rearrangement in one family were demonstrated as the strict co-segregated cases 
whose gene variants were found only in individuals with ASD among family members including 
parents. cOne de novo case is included. dStrict co-segregation was not shown. eTwo cases with mild facial 
dysmorphism are included. fTwo de novo cases are included. gThree de novo cases are included. hFive de 
novo cases are included. iOne case is included as a co-segregated family. jIn ASD families with two or 
more affected individuals (multiplex families), three de novo CNVs were found in both ASD sibs. kTwo 
multiplex families whose variant-phenotype co-segregation is not mentioned are included. l>0.6% cases 
are carrying two or more de novo events. 
Table 1. The prevalence of variants in gene regions recently implicated in idiopathic ASD 
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2003), and high heritability does not vindicate the condition as a diagnostic category (Keller 
& Miller, 2006). There is as yet no qualitative biological marker including microscopic 
lesions that can reliably help to categorize a genetically homogeneous autism subtype 
(Amaral et al., 2008; Moldin et al., 2006; Santangelo & Tsatsanis, 2005; Schmitz & Rezaie, 
2008). In this article, the significance of gene variants which have currently been detected in 
autistic individuals is carefully reconsidered and the outstanding questions are addressed 
from multidisciplinary points of view. Such an attempt may highlight the importance of the 
notion that the evolutionally survived trait is the phenotypic diversity itself, in which ASD 
is included as an extreme tail. In addition, important concepts and mechanisms for the 
genetic basis of phenotypic diversity are also reviewed. 
2. Facts and questions 
Although some authorities appreciated the smooth behavioral continuum between 
individuals with ASD and the non-autistic majority (Frith, 2001; Happé, 1999; Rapin, 1997; 
Wing, 1997), idiopathic ASD has sometimes been misinterpreted as a qualitative disorder 
which can be clearly distinguished from normal development. The boundary between 
individuals with low-functioning ASD and a communicative subtype (Asperger syndrome) 
has also been misrepresented as to be qualitatively distinct (Simpson, 2003). Even the 
differentiation between Asperger syndrome and high-functioning ASD could be made with 
authority (Kamp-Becker et al., 2010). These biased constructions may be attributable to 
referral bias in general practice or increased probability of clinical ascertainment in 
individuals with low achievement (Skuse, 2007). Although ASD can still be documented as a 
categorical entity in clinically ascertained samples (Frazier et al., 2010), the fact that the 
autistic phenotype extends beyond its formal diagnostic boundaries has underscored the 
significance of quantitative evaluations (Lamb et al., 2000; Maestrini et al., 2000), and many 
population studies revealed that ASD including high-functioning subtypes are best 
characterized as an extreme of some bell-shaped behavioral dimensions that distribute 
quantitatively (Constantino & Todd, 2000; Constantino & Todd, 2003; Happé et al., 2006; 
Hoekstra et al., 2007; Posserud et al., 2006; Ronald et al., 2005; Ronald et al., 2006a, 2006b; 
Skuse et al., 2005). The description ‘qualitative’ in the autism criteria in the Diagnostic and 
Statistical Manual of Mental Disorders (DSM) is removed and Asperger’s disorder 
(Asperger syndrome) is subsumed into ASD in the draft of DSM-5 (http://www.dsm5.org 
/Pages/Default.aspx). The three quantitative domains including sociability, 
communication, and rigid/repetitive behavior correlate modestly to each other in the 
population (Dworzynski et al., 2007; Ronald et al., 2005, 2006a, 2006b), and the coincidence 
of these phenotypic extremes is also observed in hyperactive individuals with attention-
deficit/hyperactivity disorder (AD/HD) (Hattori et al., 2006; Ijichi & Ijichi, 2007; Reiersen et 
al., 2007; Ronald et al., 2008). The diagnosis of autism is highly affected by the circumstantial 
consequence of social adaptability and autistic recognition and behavior sometimes does not 
become fully manifest until social demands exceed the individual’s limited capacities (the 
draft of DSM-5). The clinical picture can change with increasing age and in different 
circumstances (Wing, 1997), and the behavioral plasticity or clinical improvement is evident 
in supportive circumstances by structured behavioral interventions, mentoring, and/or 
social involvement with appropriate accommodation (Garcia-Villamisar & Hughes, 2007; 
Ijichi & Ijichi, 2007; McGovern & Sigman, 2005; Tonge et al., 1994). 
The most unique and potentially meaningful property of autistic cognition is savant skill. 
The estimated prevalence of the cognitive superiority in ASD varies from 10% to surprising 
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numbers (Dawson et al., 2007; Happé, 1999; Rapin & Katzman, 1998). The supposed 
common ‘high intelligence’ in autistic individuals with low IQ may involve high processing 
speed, prodigious memory capacities, and heightened primary sensory processing 
(Boddaert et al., 2005; McCleery et al., 2007; Scheuffgen et al., 2000). These cognitive 
superiorities are believed to have the same origin as the social difficulties in ASD (Brosius & 
Kreitman), and the term, ‘autistic savant skills’, is used to describe one of the core cognitive 
features of ASD (Badcock & Crespi, 2006; Scheuffgen et al., 2000). As a unifying explanation 
which covers the manifold autistic characteristics, excessive neuronal processing (a hyper-
functionality model) is also implicated as opposed to usual hypo-functionality explanations 
(Markram et al., 2007). 
The ratio of sibling recurrence risk to population prevalence is approximately 50 with an 
overwhelming predominance of sporadic cases, suggesting the multifactorial nature of ASD 
(AGPC, 2007). The high monozygotic concordance rate in twins and the modest recurrence 
risk in dizygotic twins and among siblings may also suggest that the genetic architecture for 
ASD has the same complexity as those for human physical appearances including facial 
characteristics and brain gray matter volume (Ijichi & Ijichi, 2004). In traditional views, the 
modest correlation between autistic behavioral domains in population studies implies that 
there is no single (genetic or endophenotypical) cause for the three autistic extreme 
characteristics and a mere coincidence of the phenotypic extremes might be the true nature 
of autistic social difficulties (Happé et al., 2006). Although positive assortative mating might 
cause phenotypic anticipation and a negative assortative mating between the couple might 
gather the non-overlapping genetic components in a baby (Ijichi et al., 2008), there is no 
evidence for such assortative mating (Hoekstra et al., 2007). 
As exemplified in Table 1, there is, so far, no universal genetic marker which is co-
segregated with ASD in the affected families. In contrast to the early prediction (30-40%) 
(Beaudet, 2007), no more than 5-7% of ASD cases may be traceable to single or multiple 
genetic concomitant(s) (Table 1). Although many whole-genome scans for autism 
susceptibility loci have identified a lot of linkage peaks, the reproduction of the results is 
exceptional and association studies have failed to identify the gene variants (Sykes & Lamb, 
2007). The regions of structural variants including copy number variations (CNVs) seldom 
conform to the linkage peaks (Sebat, 2007). The lack of an unambiguous pathophysiological 
marker is also one of the important characteristics of idiopathic autism (Amaral et al., 2008; 
Moldin et al., 2006; Santangelo & Tsatsanis, 2005; Schmitz & Rezaie, 2008). The only 
anatomical candidate which can be consistently co-segregated with ASD including masked 
autistic savants may be a quantitative increase in the number of processing units of cortex 
(minicolumns) (Casanova, et al., 2002, 2007). The increase in the number of minicolumns is 
thought to be associated with mammalian brain evolution, and the finding can explain other 
apparent tendencies revealed in some autistic individuals, including increases in the volume 
of brain structures and the prevalence of epilepsy (Casanova et al., 2006). Recent 
preliminary findings suggest that the tendency of brain overgrowth originates prenatally 
(Hobbs et al., 2007; Leonard et al., 2008). Furthermore, there is no biological deficit including 
chemical and molecular findings which is universal in individuals with ASD or can reliably 
help to identify putative subgroups that are genetically homogeneous (Lauritsen & Ewald, 
2001). Over-expression of neuron-associated genes is still one of the candidates for 
molecular markers (Lepagnol-Bestel et al., 2008; Maussion et al., 2008; Rinaldi et al., 2007). 
The scientific puzzle, which is metaphorically described as “myopic investigators are still 
patting the elephant” (Rapin, 1999) remains to be solved (Baron, 2008). Why is the male to 
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female ratio biased (3-4 to 1)? Why cannot the behavioral uniformity with strong genetic 
contribution be interpreted by common gene variant alleles? Why is the disparity between 
monozygotic and dizygotic concordances so large? Why do the autistic behavioral domains 
correlate modestly? Although these questions may provide very important clues and are 
encouraging researchers to speculate on reasons, the jigsaw is still incomplete. Missing 
puzzle pieces include the solution of the evolutionary mystery of autism prevalence. Human 
conditions can be selected and survive when it is somehow associated with increased 
reproductive success (Nesse & Williams, 1994). However, in spite of the hypo-reproductive 
tendency of behaviors in extreme cases with ASD (Lord et al., 2000), the estimated high 
prevalence has never declined (Baird et al., 2006; CDC, 2009; Fombonne, 2009). 
3. Genetic and environmental explanations 
It is recently recognized that ASD has the highest prevalence (more than 0.5%) in childhood 
neurodevelopmental conditions (CDC, 2009; Fombonne, 2009). In traditional frameworks, in 
which researchers are searching the human genome for the condition-specific genetic variants, 
three genetic models should be considered as the genetic mechanism for such a common 
phenotypic condition (Gibson, 2009). The quite low effect size of each ASD-related variant is 
suggested to be the cause of difficulty in replication of the positive findings in the common 
disease-common variant (CD-CV) model (Anney, 2010). Although a rare alleles of major effect 
(RAME) model is one of the core principles for recent genome-wide association studies in ASD 
(Gibson, 2009), the replication may also be complicated by chance findings, as well as 
differences in ascertainment, because of the modest relative risk of the rare alleles (Anney, 
2010). The third model, the infinitesimal model, can make an excuse for the situation of genetic 
studies, because it is very hard to identify rare variants of small effect by genetic means 
(Manolio et al., 2009). It is, anyhow, clear that it’s time to reconsider and question simple 
intuitive models that link a human complex condition to mutation (Gibson, 2009). 
3.1 Genetic factors 
The non-universality of the candidate gene variants which have previously been implicated 
in ASD may be consistent with the speculation that heterogeneous sets of gene variants can 
contribute to ASD (Betancur, 2011; Beaudet, 2007; Garber, 2007). Furthermore, in order to 
explain the modest correlations between the three autistic behavioral domains, the presence 
of domain-specific heterogeneous sets of gene variants are also suggested (Happé et al., 
2006). However, even novel genetic means including whole genome screening using 
microarray-based hybridization cannot fully confirm these speculations (Table 1). The 
frequent absence of diagnostic history of ASD in the parents of an idiopathic ASD proband 
may suggest that the supposed variants should be carried by a non-ASD parent (incomplete 
penetrance) or the proband should have de novo mutations (Beaudet, 2007; Constantino & 
Todd, 2005; Zhao et al., 2007) (Table 2). However again, such genetic transmission is still one 
of the hypotheses and the concomitant de novo variants can be detected only in a minor part 
of the cases (Table 1). The number of candidate gene regions is still increasing without a 
convincing and comprehensive demonstration of the link between such variants and autistic 
developmental trajectory (Glessner et al., 2009). 
The genetic contribution to a quantitative trait may be attributable to the cumulative effect 
of a set of quantitative trait loci (QTLs) (Plomin et al., 1994, 2009; Plomin & Kosslyn, 2001). 
Each QTL is neither necessary nor sufficient for the overall phenotypic outcomes, the effect 
size of each QTL may fluctuate according to other genetic backgrounds (epistasis, non-
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additive gene-gene interactions) and the environment (gene-environment interactions), and a 
QTL may affect more than one phenotypic trait (pleiotropy). The concept of epistasis had 
initially been introduced for ASD as an alternative explanation of the incomplete penetrance or 
as a risk factor model (Bradford et al., 2001; Folstein & Rosen-Sheidley, 2001; Jones & Szatmari, 
2002). Because natural chromosomal and segmental shuffling during normal meiosis is a 
strong random modifier of epstatic effects among QTLs in a sib-pair and dizygotic twins, the 
big disparity between monozygotic and dizygotic concordances in autism may be explained 
by the presence of epistatic QTLs. Pleiotropy can account for the presence of autistic savants. 
The modest correlation among autistic behavioral domains can also illustrated by 
unsynchronized epistatic pleiotropy (Ijichi et al., 2008). To explain the sporadic manner of the 
prevalence and the survival of hypo-reproductive autistic extremes, the implication of 
epistasis-associated intergenerational oscillation of phenotypic outcomes was introduced 
(Ijichi et al., 2008). Some candidates for autism QTLs have been reported (Ashley-Koch et al., 
2006; Coutinho et al., 2007; Jiang et al., 2004; Weiss et al., 2007), linkage analysis with 
quantitative measures of some autistic characteristics revealed QTL signals (Alarcón et al., 
2002, 2005; Chen et al., 2006; Duvall et al., 2007), and a quantitative covariance analysis can 
confirm the high genetic correlation between ‘social motivation’ and ‘range of 
interest/flexibility’ (Sung et al., 2005). Although the supposed contribution of QTLs ought to 
be traced in family studies or genome scans according to a traditional logic, “the causal gene 
variant can be cosegregated with the phenotypic variant”, the delay and difficulty in detecting 
the causal variant alleles at QTLs is strangely common to all idiopathic quantitative traits 
including autism, physical and physiological characteristics, and personalities (de Geus et al., 
2001; Fullerton, 2006; Palmert & Hirschhorn, 2003; Willis-Owen & Flint, 2006). 
 
Facts and questions Explanations 
Penetrance De novo QTLs Environment 
The quantitative feature (○) － ○ (○) 
Partial behavioral plasticity － － － ○ 
The presence of autistic savants － － (○) － 
Strong genetic contribution ○ ○ ○ － 
Usually sporadic without family history (○) ○ (○) ○ 
Domain-specific genetic factors － － (○) － 
Lack of the common genetic marker ○ ○ ○ － 
Lack of the common pathological lesion － － － － 
Lack of the common chemical marker － － － － 
Lack of the common molecular marker － － － － 
Why is the male to female ratio biased? (○) (○) (○) (○) 
Why is it so difficult to detect autism 
genes? 
－ － － － 
Why do hypo-reproductive extremes 
survive? 
－ ○ － (○) 
Penetrance: Poor penetrance of heterogeneous gene variants; De novo: De novo involvement of 
heterogeneous gene variants; QTLs: Quantitative trait loci; Environment: Environmental contribution; ○: 
explainable; (○): unexplainable by itself but explainable with some further speculation; －: hard to explain 
Table 2. Genetic and environmental explanations for the facts and outstanding questions in 
idiopathic autism researches 
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3.2 Epigenetic factors and ASD 
Phenotypic outcomes with robustness or plasticity cannot be exclusively determined by the 
DNA sequence itself which looks like the core genetic factor of the phenotype (Goldberg et 
al., 2007). Epigenetics is the study of changes in gene expression that occur without a change 
in DNA sequence and the epigenotype is meiotically and mitotically transmissible (Morris, 
2005; van Vliet et al., 2007). Although the significance of the contribution made by epigenetic 
factors to human complex traits remains unclear, it is speculated that epigenetic factors can 
influence gene-environment interactions and the liability/outcomes of the traits (van Vliet et 
al., 2007). Epigenetic changes in gene expression are achieved through RNA-associated 
silencing, DNA methylation, and histone modifications (Morris, 2005), and cis-acting 
expansion of the epigenetic influences on the flanking genes is referred to as genomic 
imprinting which results in parent of origin-specific gene expression (Pauler et al., 2007). 
The epigenetic factors and genomic imprinting may be implicated in syndromic autistic 
individuals with some single gene/chromosomal disorders including Rett syndrome, fragile 
X syndrome, Prader-Willi syndrome, and Angelman syndrome, and a variety of factors 
associated with epigenetic modifications have been considered as candidates for autism 
genes (Badcock & Crespi, 2006; Jiang et al., 2004; Persico & Bourgeron, 2006; Schanen, 2006; 
Skuse, 2000; van Vliet et al., 2007). These factors, however, cannot be the common 
prerequisite for idiopathic ASD at least in the majority of the cases (Jiang et al., 2004; Persico 
& Bourgeron, 2006), and the power of epigenetic factors are recognized as an accidental cue 
to shift the quantitative distribution of the autistic traits in a threshold model (Skuse, 2000). 
If the epigenetic factors act only in gene-environment interactions in idiopathic cases, the 
epigenetic contribution should be modest in the overall underpinnings. Given an unforeseen 
transmissible powerful architecture connecting genotype and phenotype for phenotypic 
diversity independent of genetic diversity, the epigenetic mechanism should be referred to 
as merely one of the molecular-level environments derived from gene networks. 
3.3 Environmental factors 
Environmental factors contribute no more than 10% to ASD (Garber, 2007). However, the 
environmental factors including rubella, thalidomide, and valproic acid embryopathies may 
still be important as additive triggers of the clinical manifestation (Jones & Szatmari, 2002; 
Persico & Bourgeron, 2006). Environmental contributions including behavioral experiences 
are originally misunderstood to explain the patterns of familial recurrence risks observed in 
autism studies (Jorde et al., 1991). Because the genetic components affecting autistic traits 
seem to be the same across the sexes (Constantino & Todd; Hoekstra et al., 2007), it can be 
speculated that the lower prevalence of autistic traits in girls is the result of increased 
sensitivity to early environmental influences that operate to promote social competency 
(Constantino & Todd, 2003). The minimal contribution of shared environmental influences 
(Ronald et al., 2006a) may be associated with the autistic behavioral manifestations 
including resistance to change or insistence on sameness. 
Combinations of the traditional theories (poor penetrance, de novo mutations, and QTLs and 
the environmental contribution) may answer not a few of the outstanding questions in 
idiopathic autism research (Table 2). However, in spite of the presence of a big genetic 
contribution to the autistic development, the question, “Why is it difficult to detect autism 
gene variants?”, still remains to be resolved. In addition, the significance of both de novo 
mutations and the environmental modification is just a speculation in a part of the ASD 
cases. 
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4. Evolutionary explanations 
Does idiopathic ASD really represent many distinct conditions with numerous etiologies 
(Geschwind, 2007)? Is it really time to give up on a single explanation for autism (Baron, 
2008; Happé et al., 2006)? A variety of qualitative concomitants, including gene variants and 
environmental factors, have already been demonstrated in part of autistic cases as 
exemplified above. However, it may be still too early to reach the conclusion even in such 
frameworks, because no single qualitative process associated with the concomitants can 
indicate the molecular or chemical differences between the autistic developmental extremes 
and the non-autistic majority. In order to understand human complex traits, genetic, 
molecular, and biochemical explanations should be combined with evolutionary 
explanations (Nesse & Williams, 1994). In autistic individuals, ASD per se does not shorten 
the span of life (Gillberg et al., 2010). Although high or preserved androgenic competence is 
suspected in ASD (Tordjman et al., 1997), the extreme cases almost never marry (Lord et al., 
2000). The hypo-fertility results from reduced opportunity or behavioral ability in the 
mating arena. Therefore, we must probe into who is enjoying the reproductive benefits of 
the genetic architecture for ASD in the evolutionary framework (Table 3). 
 
Who gets the reproductive 
benefits? 
Hypotheses or mechanisms References 
None (an inevitable 
outcome) 
Mutation-selection balance theory (Keller & Miller, 2006) 
Unaffected carriers of genetic 
factors 
Hyper-systemizing theory 
(extreme male brain theory) 
Extreme imprinted brain theory 
(Baron-Cohen, 2002) 
 
(Badcock & Crespi, 2006) 
All of the non-autistic 
majority 
Population benefit theory 
Monomorphic loci theory 
(Fitzgerald, 2002) 
(Ijichi et al., 2011) 
Table 3. Evolutionary explanations for the survival of autistic extremeness 
4.1 Mutation-selection balance theory 
In the mutation-selection balance theory, individuals with a high load of mutations are 
postulated to be at higher chance of passing risk on to their offspring, and it is not necessary 
that there are individuals with the reproductive benefits (Keller & Miller, 2006). 
Importantly, according to the proposed model, everyone alive has minor brain deviations 
that cause them to be a little bit abnormal in behavioral and cognitive dimensions (Keller & 
Miller, 2006). The non-autistic majority in the population is regarded as the genetic carrier-
state for ASD and the mutation load and the risk of having autistic offspring may vary 
quantitatively. In the mutation-selection balance theory, balancing selection for genetic 
diversity is recognized to be unsuitable to explain persistent heritability in human 
conditions (Keller & Miller, 2006; Zhang & Hill, 2005). One of the grounds of this exclusion 
of balancing selection is the absence of an ongoing homeostatic mechanism that counteracts 
the homogenizing effect of genetic drift and stabilizing selection, and the reproductive 
benefits of the genetic burden for autism are not addressed (Keller & Miller, 2006). The 
mutation-selection perspective can be an evolutionary interpretation of a cumulative effect 
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3.2 Epigenetic factors and ASD 
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of de novo mutations and is at least consistent with the quantitative distribution of autistic 
domains. 
4.2 Extreme male brain theory 
The second is a group of theories in which only a part of the population is regarded as the 
genetic carrier-state for ASD. The prevalence or maintenance of positive assortative mating 
between the non-autistic carriers is critical to accumulate genetic factors in these theories, 
and the remaining non-autistic majority does not have the genetic components for ASD. In 
the hyper-systemizing theory, the unaffected carriers of the genetic factors are high 
systemizers and ASD is the result of both parents being the high systemizers (Baron-Cohen, 
2002, 2004, 2006). Systemizing is the drive to understand and predict the next step of 
inanimate events and acts contrary to empathizing. In males, the systemizing mechanism is 
set at a slightly higher level than non-autistic males (Baron-Cohen, 2004). This extreme male 
brain theory of autism had originally been proposed by Asperger in 1944. Individuals 
including both parents of individuals with autism, who are placed in the adjacent part to the 
autistic extremeness, systemize at a higher level than average (above average systemizers) 
and account for approximately a half of the vast majority. Over successive generations, the 
above average systemizers carry the genetic components for ASD and might enjoy the 
reproductive benefits. As one of the genetic bases of the hyper-systemizing theory, the 
extreme imprinted brain theory had been proposed (Badcock & Crespi, 2006). 
4.3 Population benefit theory and individual benefit theory 
In the third framework, it is suggested that the evolutionarilly selected and conserved 
phenotype is not the hypo-reproductive extremeness but the whole quantitative distribution 
itself. A group selection theory has been introduced to bring sense into the link between 
autism and exceptional creativity (Fitzgerald, 2003). In this population benefit theory, the 
creativity, which can be concomitant with autism, benefits all members of the human 
community and the community can survive. On the other hand, the third framework can 
also include individual benefit concepts (the monomorphic loci theory) (Ijichi et al., 2011). In 
the individual benefit concepts, everybody has both the genetic architecture for ASD and the 
possibility to enjoy the reproductive benefits of autism genes. Each phenotypic outcome, 
however, varies individually mainly according to the differences in genetic background 
noise and environmental factors, whose functions are not necessarily related to ASD 
phenotypes directly. In the process of reaching the monomorphic loci theory, the epistasis-
mediated intergenerational oscillation of phenotypic outcomes has been advanced in a QTL 
model (Ijichi et al., 2008). The monomorphic loci theory does not dismiss the comprehensive 
view of the known genetic contributions, including major gene effects and additive genetic 
networks (Ijichi et al., 2011). The postulated involvement of monomorphic loci can be valid 
as merely one of the genetic constituents in complex (additive and/or non-additive) 
interactions with polymorphic loci.  
4.4 The monomorphic loci theory and gene networks 
Because both positive and negative epistasis may be byproducts of evolution (L. Azevedo et 
al., 2006; R.B.R. Azevedo et al., 2006; Harrison et al., 2007), the invisibility of the contribution 
of monomorphic epistatic loci from the traditional genetic view is an attractive candidate for 
the explanation of the black box between polymorphic genotype and phenotypic diversity 
(Ijichi et al., 2011). Complex phenotypes have hierarchical structures, including RNA 
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(transcript traits), protein, metabolite, and functional levels. It has been suggested that less 
heritability of metabolite traits than transcript traits is associated with the difference in the 
quantity of biological noise between the genetic determinants and the trait (Rowe et al., 
2008). The more steps that are involved between genotype and the trait level, the more 
biological noise may reside in the process. Such biological noise originates from inter-locus 
interactions and gene-environment interactions, and the inter-locus interactions may have 
an important role in the biological noise. Additive and/or non-additive inter-locus 
interactions with other loci are available in a variety of processes including cis-, trans-, and 
inter-cellular interactions (Figure 1). The presence of gene-environment-gene circuits may 
make it difficult to distinguish inter-locus interactions from gene-environment interactions 
in the biological noise (Ijichi et al., 2011). In these interactions, an intergenerational change in 
the number or property of factors (environment and/or other related loci) in the regulatory 
circuit may easily individualize the balance of each hierarchical trajectory (coding RNA, 
non-coding RNA, translation, autocrine, paracrine, and endocrine levels) and individually 
determine the developmental outcomes. The net non-additive effects of the biological noise 
are metaphorically interpreted as hub-and-spoke structures of regulatory networks among 
polymorphic loci (Benfey & Mitchell-Olds, 2008). 
 
 
Fig. 1. Cellular and molecular interactions of biological noise in regulatory networks around a 
gene locus (A). Additive and/or non-additive phenomena can be involved in each interaction 
(Ijichi et al., 2011). In this explanation, an arrow represents the net contribution between loci 
and the gene-environment relationship. The locus A can interact with other loci in association 
with coding RNA and/or non-coding RNA level in cis-acting manner (①, ②) and trans-acting 
manner (③, ④). The cis-acting interactions are involved in genetic imprinting. After 
translation, interactions can be mediated through autocrine, paracrine, and endocrine 
mechanisms (⑤, ⑥). Gene-environment interactions can modify penetrance of the outcomes 
affected by the locus A. The network constituents can change the sensitivity to environmental 
influences (⑦), that can provide gene-environment-gene circuits. In the monomorphic loci 
theory, the gene A can be monomorphic and the link between monomorphic A and the A-
associated polymorphic noise is usually invisible in the context of traditional genetics. 
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5. Quantitative domains and genetic factors 
The distributional shift of a bell-shaped curve and the change in the curve shape illustrates 
the mean value change and the variance alteration of the quantitative dimension, 
respectively (Gibson, 2009). These changes can affect the proportion of individuals with 
autism to those without as determined by a liability threshold. The biased male to female 
ratio (3-4 to 1) in ASD is plausibly interpreted as a distributional shift of the quantitative 
bell-shaped curve as a gender gap. In the hyper-systemizing theory, the male systemizing 
mechanism is set at a slightly higher level than in females (Baron-Cohen, 2004). In an 
imprinted-X liability threshold model, actions of some X-linked genes, which are expressed 
only from paternal X-chromosome, are suggested to be associated with the male 
predisposition to ASD (Skuse, 2000). The gender is a bimorphic genetic variation and there 
is a gender gap in sensitivity or vulnerability to environmental factors (Constantino & Todd, 
2003). The relationship between a bell-shaped quantitative distribution and the genetic 
factors underlying the complex phenotype still remains to be elucidated. 
5.1 Polygenic liability model 
The traditional concept of polygenic liability supposes a normal distribution of frequencies 
of susceptibility variant alleles (Gibson, 2009). The manner of the allele contribution is 
additive, and each allele contribution usually results in a positive or negative effect on the 
phenotype in the carrier individual and the quantitative population dimension results from 
such additive allele contributions. To explain the smooth normal distribution, an 
environmental variance of each allele contribution is addressed in this model. 
In a genetic model, oligogenicity with epistasis, the contributing genes are likely to be 
common ones in the population (Folstein & Rosen-Sheidley, 2001). There is no evidence that 
the genetic causative processes affecting the autistic extreme are different from those 
contributing the autistic dimension including individuals without autism (Ronald et al., 
2006a). If the presence of epistasis, pleiotropy, and gene-environment interactions are all 
supposed, the polymorphic genetic underpinning is referred to as QTLs (Plomin et al., 1994, 
2009; Plomin & Kosslyn, 2001). However, it is also the fact that the delay and difficulty in 
detecting the causal variant alleles at QTLs is common to all idiopathic quantitative traits 
including ASD, physical and physiological characteristics, and personalities (de Geus et al., 
2001; Fullerton, 2006; Palmert & Hirschhorn, 2003; Willis-Owen & Flint, 2006).  
If the genetic factors for a tail of the bell-shaped curve are different from those for the 
majority and have extremity-specific properties including serious involvement of coding 
gene segments (Mitchison, 2000), the variant alleles should be more detectable. Because the 
genetic contribution in ASD is the biggest in human complex traits and the environmental 
influence on ASD is quite minimal as described above, the difficulty in finding the universal 
genetic marker for ASD warrants the necessity of a paradigm shift. 
5.2 Additive and non-additive interactions between mono- and poly-morphic loci 
It has been emphasized that the three behavioral domains of ASD modestly correlate to each 
other and the set of genes for each domain may be partly different (Dworzynski et al., 2007; 
Happé et al., 2006; Ronald et al., 2005, 2006a, 2006b). The speculated modest genetic overlap 
among autistic domains may be indistinguishable from that among human complex 
phenotypes including ASD, bipolar disorder, and schizophrenia (Rzhetsky et al., 2007), 
suggesting that the autistic domains and these psychiatric conditions might share the same 
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genetic architecture at least in part (Craddock & Owen, 2010). In an argument about 
domain-specific genes for cognitive functions, it is expected that the domain-general genes 
are responsible for the brain infrastructure including receptors, neurotransmitters, dendritic 
spines, synapse vesicles, and axonal filaments (Marcus & Rabagliati, 2006). Although the 
universality of the domain-general genes for cognitive functions among other human 
complex phenotypes is controversial, genes for the brain infrastructure are also current 
topics in the field of ASD (Garber, 2007; Persico & Bourgeron, 2006). Both the heterogeneity 
of genetic markers for ASD and the modest correlation among autistic core domains can be 
explained by epistasis-mediated oscillation of the domain-general effect values and 
unsynchronized epistatic pleiotropy in the monomorphic loci theory, which never dismiss 
the comprehensive view of the known genetic contributions, including major gene effects 
and additive genetic networks (Ijichi et al., 2011). The assumption of the random outcomes 
mediated by the non-additive interactions between functional monomorphic loci and 
polymorphic backgrounds may transform the traditional complementary roles of some 
monomorphic loci (Gjuvsland et al., 2007) to active and leading roles for the phenotypic 
diversity (Ijichi et al., 2011). However, the controversy concerning the importance of non-
additive effects in phenotypic diversity still exists (Gale et al., 2009; Hill et al., 2008; 
Malmberg & Mauricio, 2005). 
5.3 Social environmental changes and decanalization 
The decanalization concept may have sizable significance in searching the cause of the 
maintained or increasing prevalence of ASD. Canalization is an evolutionary phenomenon 
characterized by robustness to genetic or environmental perturbation, and most individuals 
tend to cluster around the optimal phenotype in canalized populations (Gibson, 2009). If the 
phenotypic dimension consists of multiple endophenotypic vectors which have nonlinear 
relationships to each other and are partially determined by genetic factors, overt 
environmental perturbations for one of the endophenotypes can be the cue of 
decanalization, which changes the shape of the phenotypic demensional distribution 
(Gibson, 2009). Social environmental perturbations may also shift the entire distribution of 
ASD liability, or move the liability threshold. 
6. Conclusions 
The difficulty in detecting the universal biological marker for the predisposition to ASD 
presents significant challenges and conflicts to researchers in related fields. The reported 
gene variants in some sporadic cases with idiopathic ASD are nothing but one of the 
concomitants, until the molecular or biological trajectory underlying autistic development is 
clearly delineated or association studies reproduce the causal relationship. Before the 
speculation that idiopathic ASD represents many distinct conditions with numerous 
etiologies, the quantitative manner of the distribution of the behavioral domains and the fact 
that ASD is a mere tail of the behavioral dimensions should strictly be considered and 
emphasized. Even combinations of traditional theories including poor penetrance, de novo 
mutations, quantitative trait loci, and environmental contribution cannot fully account for 
the entire genetic underpinning. Importantly, the almost monolithic insight into the 
prevalence of ASD can only be obtained in an evolutionary framework on the assumption 
that the complex genetic networks are responsible not for the individual cases but for the 
human behavioral diversity itself. Gender differences, environmental factors, epigenetic 
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the genetic causative processes affecting the autistic extreme are different from those 
contributing the autistic dimension including individuals without autism (Ronald et al., 
2006a). If the presence of epistasis, pleiotropy, and gene-environment interactions are all 
supposed, the polymorphic genetic underpinning is referred to as QTLs (Plomin et al., 1994, 
2009; Plomin & Kosslyn, 2001). However, it is also the fact that the delay and difficulty in 
detecting the causal variant alleles at QTLs is common to all idiopathic quantitative traits 
including ASD, physical and physiological characteristics, and personalities (de Geus et al., 
2001; Fullerton, 2006; Palmert & Hirschhorn, 2003; Willis-Owen & Flint, 2006).  
If the genetic factors for a tail of the bell-shaped curve are different from those for the 
majority and have extremity-specific properties including serious involvement of coding 
gene segments (Mitchison, 2000), the variant alleles should be more detectable. Because the 
genetic contribution in ASD is the biggest in human complex traits and the environmental 
influence on ASD is quite minimal as described above, the difficulty in finding the universal 
genetic marker for ASD warrants the necessity of a paradigm shift. 
5.2 Additive and non-additive interactions between mono- and poly-morphic loci 
It has been emphasized that the three behavioral domains of ASD modestly correlate to each 
other and the set of genes for each domain may be partly different (Dworzynski et al., 2007; 
Happé et al., 2006; Ronald et al., 2005, 2006a, 2006b). The speculated modest genetic overlap 
among autistic domains may be indistinguishable from that among human complex 
phenotypes including ASD, bipolar disorder, and schizophrenia (Rzhetsky et al., 2007), 
suggesting that the autistic domains and these psychiatric conditions might share the same 
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genetic architecture at least in part (Craddock & Owen, 2010). In an argument about 
domain-specific genes for cognitive functions, it is expected that the domain-general genes 
are responsible for the brain infrastructure including receptors, neurotransmitters, dendritic 
spines, synapse vesicles, and axonal filaments (Marcus & Rabagliati, 2006). Although the 
universality of the domain-general genes for cognitive functions among other human 
complex phenotypes is controversial, genes for the brain infrastructure are also current 
topics in the field of ASD (Garber, 2007; Persico & Bourgeron, 2006). Both the heterogeneity 
of genetic markers for ASD and the modest correlation among autistic core domains can be 
explained by epistasis-mediated oscillation of the domain-general effect values and 
unsynchronized epistatic pleiotropy in the monomorphic loci theory, which never dismiss 
the comprehensive view of the known genetic contributions, including major gene effects 
and additive genetic networks (Ijichi et al., 2011). The assumption of the random outcomes 
mediated by the non-additive interactions between functional monomorphic loci and 
polymorphic backgrounds may transform the traditional complementary roles of some 
monomorphic loci (Gjuvsland et al., 2007) to active and leading roles for the phenotypic 
diversity (Ijichi et al., 2011). However, the controversy concerning the importance of non-
additive effects in phenotypic diversity still exists (Gale et al., 2009; Hill et al., 2008; 
Malmberg & Mauricio, 2005). 
5.3 Social environmental changes and decanalization 
The decanalization concept may have sizable significance in searching the cause of the 
maintained or increasing prevalence of ASD. Canalization is an evolutionary phenomenon 
characterized by robustness to genetic or environmental perturbation, and most individuals 
tend to cluster around the optimal phenotype in canalized populations (Gibson, 2009). If the 
phenotypic dimension consists of multiple endophenotypic vectors which have nonlinear 
relationships to each other and are partially determined by genetic factors, overt 
environmental perturbations for one of the endophenotypes can be the cue of 
decanalization, which changes the shape of the phenotypic demensional distribution 
(Gibson, 2009). Social environmental perturbations may also shift the entire distribution of 
ASD liability, or move the liability threshold. 
6. Conclusions 
The difficulty in detecting the universal biological marker for the predisposition to ASD 
presents significant challenges and conflicts to researchers in related fields. The reported 
gene variants in some sporadic cases with idiopathic ASD are nothing but one of the 
concomitants, until the molecular or biological trajectory underlying autistic development is 
clearly delineated or association studies reproduce the causal relationship. Before the 
speculation that idiopathic ASD represents many distinct conditions with numerous 
etiologies, the quantitative manner of the distribution of the behavioral domains and the fact 
that ASD is a mere tail of the behavioral dimensions should strictly be considered and 
emphasized. Even combinations of traditional theories including poor penetrance, de novo 
mutations, quantitative trait loci, and environmental contribution cannot fully account for 
the entire genetic underpinning. Importantly, the almost monolithic insight into the 
prevalence of ASD can only be obtained in an evolutionary framework on the assumption 
that the complex genetic networks are responsible not for the individual cases but for the 
human behavioral diversity itself. Gender differences, environmental factors, epigenetic 
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mechanisms including genetic imprinting, and major gene effects may all be mere accidental 
modifiers of the relationship between the diversity and the liability threshold. 
7. Acknoledgment 
The authors greatly thank Professor Bryan H. King for his helpful suggestions. 
8. References 
Alarcón, M., Cantor, R.M., Liu, J., Gilliam, T.C., the Autism Genetic Resource Exchange 
Consortium & Geschwind, D.H. (2002). Evidence for a language quantitative trait 
locus on chromosome 7q in multiplex autism families. Am J Hum Genet, 70, 60-71 
Alarcón, M., Yonan, A.L., Gilliam, T.C., Cantor, R.M. & Geschwind, D.H. (2005). 
Quantitative genome scan and ordered-subsets analysis of autism endophenotypes 
support language QTLs. Mol Psychiatry, 10, 747-757 
Amaral, D.G., Schumann, C.M. & Nordahl, C.W. (2008). Neuroanatomy of autism. Trends 
Neurosci, 31, 137-145 
Anney, R., Klei, L., Pinto, D., Regan, R., Conroy, J., Magalhaes, T.R. et al. (2010). A genome-
wide scan for common alleles affecting risk for autism. Hum Mol Genet, 19, 4072-
4082 
Ashley-Koch, A.E., Mei, H., Jaworski, J., Ma, D.Q., Ritchie, M.D., Menold, M.M. et al. (2006). 
An analysis paradigm for investigating multi-locus effects in complex disease: 
examination of three GABAA receptor subunit genes on 15q11-q13 as risk factors 
for autistic disorder. Ann Hum Genet, 70, 281-292 
Autism Genome Project Consortium, Szatmari, P., Paterson, A.D., Zwaigenbaum, L., 
Roberts, W., Brian, J., Liu, X.Q. et al. (2007). Mapping autism risk loci using genetic 
linkage and chromosomal rearrangements. Nat Genet, 39, 319-328 
Azevedo, L., Suriano, G., van Asch, B., Harding, R.M. & Amorim, A. (2006). Epistatic 
interactions: how strong in disease and evolution? Trends Genet, 22, 581-585 
Azevedo, R.B.R., Lohaus, R., Srinivasan, S., Dang, K.K. & Burch, C.L. (2006). Sexual 
reproduction selects for robustness and negative epistasis in artificial gene 
networks. Nature, 440, 87-90 
Badcock, C. & Crespi, B. (2006). Imbalanced genomic imprinting in brain development: an 
evolutionary basis for the aethiology of autism. J Evol Biol, 19, 1007-1032 
Baird, G., Simonoff, E., Pickles, A., Chandler, S., Loucas, T., Meldrum, D. et al. (2006). 
Prevalence of disorders of the autism spectrum in a population cohort of children 
in South Thames: the special needs and autism project (SNAP). Lancet, 368, 210-215 
Baron, I.S. (2008). Autism spectrum disorder: complex, controversial, and confounding. 
Neuropsychol Rev, 18, 271-272 
Baron-Cohen, S. (2002). The extreme male brain theory of autism. Trends Cogn Sci, 6, 248-254 
Baron-Cohen, S. (2004). The cognitive neuroscience of autism. J Neurol Neurosurg Psychiatry, 
75, 945-948 
Baron-Cohen, S. (2006). The hyper-systemizing, assortative mating theory of autism. Progr 
Neuropsychopharmacol Biol Psychiatry, 30, 865-872 
Beaudet, A.L. (2007). Autism: highly heritable but not inherited. Nat Med, 13, 534-536 
Benfey, P.N. & Mitchell-Olds, T. (2008). From genotype to phenotype: systems biology 
meets natural variation. Science, 320, 495-497 
The Genetic Basis of Phenotypic Diversity: 
Autism as an ExtremeTail of a Complex Dimensional Trait 
 
97 
Betancur, C. (2011). Etiological heterogeneity in autism spectrum disorders: more than 100 
genetic and genomic disorders and still counting. Brain Res, 1380, 42-77 
Boddaert, N., Barthélémy, C., Poline, J.B., Samson, Y., Brunelle, F. & Zilbovicius, M. (2005). 
Autism: functional brain mapping of exceptional calender capacity. Br J Psychiatry, 
187, 83-86 
Bradford, Y., Haines, J., Hutcheson, H., Gardiner, M., Braun, T., Sheffield, V. et al. (2001). 
Incorporating language phenotypes strengthens evidence of linkage to autism. Am 
J Med Genet, 105, 539-547 
Brosius, J. & Kreitman, M. (2000). Eugenics: evolutionary nonsense? Nat Genet, 25, 253 
Cannell, J.J. (2010). On the aetiology of autism. Acta Paediatrica, 99, 1128-1130 
Casanova, M.F., Buxhoeveden, D.P., Switala, A.E. & Roy, E. (2002). Neuronal density and 
architecture (gray level index) in the brains of autistic patients. J Child Neurol, 17, 
515-521 
Casanova, M.F., van Kooten, I.A.J., Seitala, A.E., van Engeland, H., Heinsen, H., Steinbusch, 
H.W., et al. (2006). Minicolumnar abnormalities in autism. Acta Neuropathol, 112, 
287-303 
Casanova, M.F., Awitala, A.E., Trippe, J. & Fitzgerald, M. (2007). Comparative 
minicolumnar morphometry of three distinguished scientists. Autism, 11, 557-569 
CDC. (2009). Autism and Developmental Disabilities Monitoring Network Surveillance Year 
2006 Principal Investigators. Prevalence of autism spectrum disorders: Autism and 
Developmental Disabilities Monitoring Network, United States, 2006. MMWR 
Surveill Summ, 58, 1-20 
Chen, G.K., Kono, N., Geschwind, D.H. & Cantor, R.M. (2006). Quantitative trait locus 
analysis of nonverval communication in autism spectrum disorder. Mol Psychiatry, 
11, 214-220 
Constantino, J.N. & Todd, R.D. (2000). Genetic structure of reciprocal social behavior. Am J 
Psychiatry, 157, 2043-2045 
Constantino, J.N. & Todd, R.D. (2003). Autistic traits in the general population: a twin study. 
Arch Gen Psychiatry, 60, 524-530 
Constantino, J.N. & Todd, R.D. (2005). Intergenerational transmission of subthreshold 
autistic traits in the general population. Biol Psychiatry, 57, 655-660 
Coutinho, A.M., Sousa, I., Martins, M., Correia, C., Morgadinho, T., Bento, C. et al. (2007). 
Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the 
determination of platelet serotonin levels. Hum Genet, 121, 243-256 
Craddock, N. & Owen, M.J. (2010). The Kraepelinian dichotomy – going, going…but still not 
gone. Br J Psychiatry, 196, 92-95 
Dawson, M., Soulières, I., Gernsbacher, M.A. & Mottron, L. (2007). The level and nature of 
autistic intelligence. Psychol Sci, 18, 657-662 
de Geus, E.J., Wright, M.J., Martin, N.G. & Boomsma, D.I. (2001). Genetics of brain function 
and cognition. Behav Genet, 6, 489-495 
Depienne, C., Moreno-De-Luca, D., Heron, D., Bouteiller, D., Gennetier, A., Delorme, R. et 
al. (2009). Screening for genomic rearrangements and methylation abnormalities of 
the 15q11-q13 region in autism spectrum disorders. Biol Psychiatry, 66, 349-359 
Durand, C.M., Betancur, C., Boeckers, T.M., Bockmann, J., Chaste, P., Fauchereau, F. et al. 
(2007). Mutations in the gene encoding the synaptic scaffolding protein SHANK3 
are associated with autism spectrum disorders. Nat Genet, 39, 25-27 
 
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment 
 
96
mechanisms including genetic imprinting, and major gene effects may all be mere accidental 
modifiers of the relationship between the diversity and the liability threshold. 
7. Acknoledgment 
The authors greatly thank Professor Bryan H. King for his helpful suggestions. 
8. References 
Alarcón, M., Cantor, R.M., Liu, J., Gilliam, T.C., the Autism Genetic Resource Exchange 
Consortium & Geschwind, D.H. (2002). Evidence for a language quantitative trait 
locus on chromosome 7q in multiplex autism families. Am J Hum Genet, 70, 60-71 
Alarcón, M., Yonan, A.L., Gilliam, T.C., Cantor, R.M. & Geschwind, D.H. (2005). 
Quantitative genome scan and ordered-subsets analysis of autism endophenotypes 
support language QTLs. Mol Psychiatry, 10, 747-757 
Amaral, D.G., Schumann, C.M. & Nordahl, C.W. (2008). Neuroanatomy of autism. Trends 
Neurosci, 31, 137-145 
Anney, R., Klei, L., Pinto, D., Regan, R., Conroy, J., Magalhaes, T.R. et al. (2010). A genome-
wide scan for common alleles affecting risk for autism. Hum Mol Genet, 19, 4072-
4082 
Ashley-Koch, A.E., Mei, H., Jaworski, J., Ma, D.Q., Ritchie, M.D., Menold, M.M. et al. (2006). 
An analysis paradigm for investigating multi-locus effects in complex disease: 
examination of three GABAA receptor subunit genes on 15q11-q13 as risk factors 
for autistic disorder. Ann Hum Genet, 70, 281-292 
Autism Genome Project Consortium, Szatmari, P., Paterson, A.D., Zwaigenbaum, L., 
Roberts, W., Brian, J., Liu, X.Q. et al. (2007). Mapping autism risk loci using genetic 
linkage and chromosomal rearrangements. Nat Genet, 39, 319-328 
Azevedo, L., Suriano, G., van Asch, B., Harding, R.M. & Amorim, A. (2006). Epistatic 
interactions: how strong in disease and evolution? Trends Genet, 22, 581-585 
Azevedo, R.B.R., Lohaus, R., Srinivasan, S., Dang, K.K. & Burch, C.L. (2006). Sexual 
reproduction selects for robustness and negative epistasis in artificial gene 
networks. Nature, 440, 87-90 
Badcock, C. & Crespi, B. (2006). Imbalanced genomic imprinting in brain development: an 
evolutionary basis for the aethiology of autism. J Evol Biol, 19, 1007-1032 
Baird, G., Simonoff, E., Pickles, A., Chandler, S., Loucas, T., Meldrum, D. et al. (2006). 
Prevalence of disorders of the autism spectrum in a population cohort of children 
in South Thames: the special needs and autism project (SNAP). Lancet, 368, 210-215 
Baron, I.S. (2008). Autism spectrum disorder: complex, controversial, and confounding. 
Neuropsychol Rev, 18, 271-272 
Baron-Cohen, S. (2002). The extreme male brain theory of autism. Trends Cogn Sci, 6, 248-254 
Baron-Cohen, S. (2004). The cognitive neuroscience of autism. J Neurol Neurosurg Psychiatry, 
75, 945-948 
Baron-Cohen, S. (2006). The hyper-systemizing, assortative mating theory of autism. Progr 
Neuropsychopharmacol Biol Psychiatry, 30, 865-872 
Beaudet, A.L. (2007). Autism: highly heritable but not inherited. Nat Med, 13, 534-536 
Benfey, P.N. & Mitchell-Olds, T. (2008). From genotype to phenotype: systems biology 
meets natural variation. Science, 320, 495-497 
The Genetic Basis of Phenotypic Diversity: 
Autism as an ExtremeTail of a Complex Dimensional Trait 
 
97 
Betancur, C. (2011). Etiological heterogeneity in autism spectrum disorders: more than 100 
genetic and genomic disorders and still counting. Brain Res, 1380, 42-77 
Boddaert, N., Barthélémy, C., Poline, J.B., Samson, Y., Brunelle, F. & Zilbovicius, M. (2005). 
Autism: functional brain mapping of exceptional calender capacity. Br J Psychiatry, 
187, 83-86 
Bradford, Y., Haines, J., Hutcheson, H., Gardiner, M., Braun, T., Sheffield, V. et al. (2001). 
Incorporating language phenotypes strengthens evidence of linkage to autism. Am 
J Med Genet, 105, 539-547 
Brosius, J. & Kreitman, M. (2000). Eugenics: evolutionary nonsense? Nat Genet, 25, 253 
Cannell, J.J. (2010). On the aetiology of autism. Acta Paediatrica, 99, 1128-1130 
Casanova, M.F., Buxhoeveden, D.P., Switala, A.E. & Roy, E. (2002). Neuronal density and 
architecture (gray level index) in the brains of autistic patients. J Child Neurol, 17, 
515-521 
Casanova, M.F., van Kooten, I.A.J., Seitala, A.E., van Engeland, H., Heinsen, H., Steinbusch, 
H.W., et al. (2006). Minicolumnar abnormalities in autism. Acta Neuropathol, 112, 
287-303 
Casanova, M.F., Awitala, A.E., Trippe, J. & Fitzgerald, M. (2007). Comparative 
minicolumnar morphometry of three distinguished scientists. Autism, 11, 557-569 
CDC. (2009). Autism and Developmental Disabilities Monitoring Network Surveillance Year 
2006 Principal Investigators. Prevalence of autism spectrum disorders: Autism and 
Developmental Disabilities Monitoring Network, United States, 2006. MMWR 
Surveill Summ, 58, 1-20 
Chen, G.K., Kono, N., Geschwind, D.H. & Cantor, R.M. (2006). Quantitative trait locus 
analysis of nonverval communication in autism spectrum disorder. Mol Psychiatry, 
11, 214-220 
Constantino, J.N. & Todd, R.D. (2000). Genetic structure of reciprocal social behavior. Am J 
Psychiatry, 157, 2043-2045 
Constantino, J.N. & Todd, R.D. (2003). Autistic traits in the general population: a twin study. 
Arch Gen Psychiatry, 60, 524-530 
Constantino, J.N. & Todd, R.D. (2005). Intergenerational transmission of subthreshold 
autistic traits in the general population. Biol Psychiatry, 57, 655-660 
Coutinho, A.M., Sousa, I., Martins, M., Correia, C., Morgadinho, T., Bento, C. et al. (2007). 
Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the 
determination of platelet serotonin levels. Hum Genet, 121, 243-256 
Craddock, N. & Owen, M.J. (2010). The Kraepelinian dichotomy – going, going…but still not 
gone. Br J Psychiatry, 196, 92-95 
Dawson, M., Soulières, I., Gernsbacher, M.A. & Mottron, L. (2007). The level and nature of 
autistic intelligence. Psychol Sci, 18, 657-662 
de Geus, E.J., Wright, M.J., Martin, N.G. & Boomsma, D.I. (2001). Genetics of brain function 
and cognition. Behav Genet, 6, 489-495 
Depienne, C., Moreno-De-Luca, D., Heron, D., Bouteiller, D., Gennetier, A., Delorme, R. et 
al. (2009). Screening for genomic rearrangements and methylation abnormalities of 
the 15q11-q13 region in autism spectrum disorders. Biol Psychiatry, 66, 349-359 
Durand, C.M., Betancur, C., Boeckers, T.M., Bockmann, J., Chaste, P., Fauchereau, F. et al. 
(2007). Mutations in the gene encoding the synaptic scaffolding protein SHANK3 
are associated with autism spectrum disorders. Nat Genet, 39, 25-27 
 
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment 
 
98
Duvall, J.A., Lu, A., Cantor, R.M., Todd, R.D., Constantino, J.N. & Geschwind, D.H. (2007). 
A quantitative trait locus analysis of social responsiveness in multiplex autism 
families. Am J Psychiatry, 164, 656-662 
Dworzynski, K., Ronald, A., Hayiou-Thomas, M., Rijsdijk, F., Happé, F., Bolton, P.F. et al. 
(2007). Aetiological relationship between language performance and autistic-like 
traits in childhood: a twin study. Int J Lang Commun Disord, 42, 273-292 
Feng, J., Schroer, R., Yan, J., Song, W., Yang, C., Bockholt, A. et al. (2006). High frequency of 
neurexin 1β signal peptide structural variants in patients with autism. Neurosci Lett, 
409, 10-13 
Fitzgerald, M. (2003). Autism and creativity: is there a link between autism in men and exceptional 
ability?, Brunner-Routledge, ISBN 978-1583912133, Hove and New York 
Folstein, S.E. & Rosen-Sheidley, B. (2001). Genetics of autism: complex aetiology for a 
heterogeneous disorder. Nat Rev Genet, 2, 943-955 
Fombonne, E. (2009). Epidemiology of pervasive developmental disorders. Pediatr Res, 65, 
591-598 
Frazier, T.W., Youngstrom, E.A., Sinclair, L., Kubu, C.S., Law, P., Rezai, A. et al. (2010). 
Autism spectrum disorders as a qualitatively distinct category from typical 
behavior in a large, clinically ascertained sample. Assessment, 17, 308-320 
Freitag, C.M. (2007). The genetics of autistic disorders and its clinical relevance: a review of 
the literature. Mol Psychiatry, 12, 2-22 
Frith, U. (2001). Mind blindness and the brain in autism. Neuron, 32, 969-979 
Fullerton, J. (2006). New approaches to the genetic analysis of neuroticism and anxiety. 
Behav Genet, 36, 147-161 
Gale, G.D., Yazdi, R.D., Khan, A.H., Lusis, A.J., Davis, R.C. & Smith, D.J. (2009). A genome-
wide panel of congenic mice reveals widespread epistasis of behavior quantitative 
trait loci. Mol Psychiatry, 14, 631-645 
Garber, K. (2007). Autism’s cause may reside in abnormalities at the synapse. Science, 317, 
190-191 
Garcia-Villamisar, D. & Hughes, C. (2007). Supported employment improves cognitive 
performance in adults with autism. J Intellect Disabil Res, 51(Pt 2), 142-150 
Gauthier, J., Spiegelman, D., Piton, A., Lafrenière, R.G., Laurent, S., St-Onge, J. et al. (2009). 
Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B 
Neuropsychiatr Genet, 150B, 421-424 
Geschwind, D. (2007). Autism: searching for coherence. Biol Psychiatry, 62, 929-950 
Gibson, G. (2009). Decanalization and the origin of complex disease. Nat Rev Genet, 10, 134-
140 
Gillberg, C., Billstedt, E., Sundh, V. & Gillberg, I.C. (2010). Mortality in autism: a prospective 
longitudinal community-based study. J Autism Dev Disord, 40, 352-357 
Gjuvsland, A.B., Hayes, B.J., Omholt, S.W. & Carlborg, Ö. (2007). Statistical epistasis is a 
generic feature of gene regulatory networks. Genetics, 175, 411-420 
Glessner, J.T., Wang, K., Cai, G., Korvatska, O., Kim, C.E., Wood, S. et al. (2009). Autism 
genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature, 
459, 569-573 
Goldberg, A.D., Allis, C.D. & Bernstein, E. (2007). Epigenetics: a landscape takes shape. Cell, 
128, 635-638 
Happé, F. (1999). Autism: cognitive deficit or cognitive style? Trends Cogn Sci, 3, 216-222 
The Genetic Basis of Phenotypic Diversity: 
Autism as an ExtremeTail of a Complex Dimensional Trait 
 
99 
Happé, F., Ronald, A. & Plomin, R. (2006). Time to give up on a single explanation for 
autism. Nat Neurosci, 9, 1218-1220 
Harrison, R., Papp, B., Pál, C., Oliver, S.G. & Delneri, D. (2007). Plasticity of genetic 
interactions in metabolic networks of yeast. Proc Natl Acad Sci U S A, 104, 2307-2312 
Hattori, J., Ogino, T., Abiru, K., Nakano, K., Oka, M. & Ohtsuka, Y. (2006). Are pervasive 
developmental disorders and attention-deficit/hyperactivity disorder distinct 
disorders? Brain Dev, 28, 371-374 
Hill, W.G., Goddard, M.E. & Visscher, P.M. (2008). Data and theory point to mainly additive 
genetic variance for complex traits. Plos Genetics, 4, e1000008 
Hobbs, K., Kennedy, A., DuBray, M., Bigler, E.D., Petersen, P.B., McMahon, W. et al. (2007). 
A retrospective fetal ultrasound study of brain size in autism. Biol Psychiatry, 62, 
1048-1055 
Hoekstra, R.A., Bartels, M., Verweij, C.J.H. & Boomsma, D.I. (2007). Heritability of autistic 
traits in the general population. Arch Pediatr Adolesc Med, 161, 372-377 
Ijichi, S. & Ijichi, N. (2004). The prenatal autistic imprinting hypothesis: developmental 
maladaptation to the environmental changes between womb and the social world. 
Med Hypotheses, 62, 188-194 
Ijichi, S. & Ijichi, N. (2007). Computerized lifelong mentoring support using robot for autistic 
individuals. Med Hypotheses, 68, 493-498 
Ijichi, S., Ijichi, N., Ijichi, Y., Kawamura, Y., Hashiguchi, T. & Morioka, H. (2008). For others: 
epistasis and the evolutionary survival of an extreme tail of the quantitative 
distribution of autistic assets. Med Hypotheses, 70, 515-521 
Ijichi, S., Ijichi, N., Ijichi, Y., Sameshima, H., Saeki, Y., Hall, W.W. & Morioka, H. (2011). 
Non-additive interactions between monomorphic and polymorphic loci: a 
theoretical explanation of the genetic underpinning for complex traits, In: Advances 
in Medicine and Biology. Vol. 13., Berhardt, L.V., editor, 133-148, Nova Science (New 
York),  
https://www.novapublishers.com/catalog/product_info.php?products_id=22873 
Jiang, Y.H., Sahoo, T., Michaelis, R.C., Bercovich, D., Bressler, J., Kashork, C.D. et al. (2004). 
A mixed epigenetic/genetic model for oligogenic inheritance of autism with a 
limited role for UBE3A. Am J Med Genet, 131, 1-10 
Jones, M.B. & Szatmari, P. (2002). A risk-factor model of epistatic interaction, focusing on 
autism. Am J Med Genet, 114, 558-565 
Jorde, L.B., Hasstedt, S.J., Ritvo, E.R., Mason-Brothers, A., Freeman, B.J., Pingree, C. et al. 
(1991). Complex segregation analysis of autism. Am J Hum Genet, 49, 932-938 
Kamp-Becker, I., Smidt, J., Ghahreman, M., Heinzel-Gutenbrunner, M., Becker, K. & 
Remschmidt, H. (2010). Categorical and dimensional structure of autism spectrum 
disorders: the nosologic validity of Asperger syndrome. J Autism Dev Disord, 40, 
921-929 
Keller, M.C. & Miller, G. (2006). Resolving the paradox of common, harmful, heritable 
mental disorders: which evolutionary genetic models work best? Behav Brain Sci, 
29, 405-452 
Lamb, J.A., Moore, J., Bailey, A. & Monaco, A.P. (2000). Autism: recent molecular genetic 
advances. Hum Mol Genet, 9, 861-868 
Lauritsen, M.B. & Ewald, H. (2001). The genetics of autism. Acta Psychiatr Scand, 103, 411-27. 
 
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment 
 
98
Duvall, J.A., Lu, A., Cantor, R.M., Todd, R.D., Constantino, J.N. & Geschwind, D.H. (2007). 
A quantitative trait locus analysis of social responsiveness in multiplex autism 
families. Am J Psychiatry, 164, 656-662 
Dworzynski, K., Ronald, A., Hayiou-Thomas, M., Rijsdijk, F., Happé, F., Bolton, P.F. et al. 
(2007). Aetiological relationship between language performance and autistic-like 
traits in childhood: a twin study. Int J Lang Commun Disord, 42, 273-292 
Feng, J., Schroer, R., Yan, J., Song, W., Yang, C., Bockholt, A. et al. (2006). High frequency of 
neurexin 1β signal peptide structural variants in patients with autism. Neurosci Lett, 
409, 10-13 
Fitzgerald, M. (2003). Autism and creativity: is there a link between autism in men and exceptional 
ability?, Brunner-Routledge, ISBN 978-1583912133, Hove and New York 
Folstein, S.E. & Rosen-Sheidley, B. (2001). Genetics of autism: complex aetiology for a 
heterogeneous disorder. Nat Rev Genet, 2, 943-955 
Fombonne, E. (2009). Epidemiology of pervasive developmental disorders. Pediatr Res, 65, 
591-598 
Frazier, T.W., Youngstrom, E.A., Sinclair, L., Kubu, C.S., Law, P., Rezai, A. et al. (2010). 
Autism spectrum disorders as a qualitatively distinct category from typical 
behavior in a large, clinically ascertained sample. Assessment, 17, 308-320 
Freitag, C.M. (2007). The genetics of autistic disorders and its clinical relevance: a review of 
the literature. Mol Psychiatry, 12, 2-22 
Frith, U. (2001). Mind blindness and the brain in autism. Neuron, 32, 969-979 
Fullerton, J. (2006). New approaches to the genetic analysis of neuroticism and anxiety. 
Behav Genet, 36, 147-161 
Gale, G.D., Yazdi, R.D., Khan, A.H., Lusis, A.J., Davis, R.C. & Smith, D.J. (2009). A genome-
wide panel of congenic mice reveals widespread epistasis of behavior quantitative 
trait loci. Mol Psychiatry, 14, 631-645 
Garber, K. (2007). Autism’s cause may reside in abnormalities at the synapse. Science, 317, 
190-191 
Garcia-Villamisar, D. & Hughes, C. (2007). Supported employment improves cognitive 
performance in adults with autism. J Intellect Disabil Res, 51(Pt 2), 142-150 
Gauthier, J., Spiegelman, D., Piton, A., Lafrenière, R.G., Laurent, S., St-Onge, J. et al. (2009). 
Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B 
Neuropsychiatr Genet, 150B, 421-424 
Geschwind, D. (2007). Autism: searching for coherence. Biol Psychiatry, 62, 929-950 
Gibson, G. (2009). Decanalization and the origin of complex disease. Nat Rev Genet, 10, 134-
140 
Gillberg, C., Billstedt, E., Sundh, V. & Gillberg, I.C. (2010). Mortality in autism: a prospective 
longitudinal community-based study. J Autism Dev Disord, 40, 352-357 
Gjuvsland, A.B., Hayes, B.J., Omholt, S.W. & Carlborg, Ö. (2007). Statistical epistasis is a 
generic feature of gene regulatory networks. Genetics, 175, 411-420 
Glessner, J.T., Wang, K., Cai, G., Korvatska, O., Kim, C.E., Wood, S. et al. (2009). Autism 
genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature, 
459, 569-573 
Goldberg, A.D., Allis, C.D. & Bernstein, E. (2007). Epigenetics: a landscape takes shape. Cell, 
128, 635-638 
Happé, F. (1999). Autism: cognitive deficit or cognitive style? Trends Cogn Sci, 3, 216-222 
The Genetic Basis of Phenotypic Diversity: 
Autism as an ExtremeTail of a Complex Dimensional Trait 
 
99 
Happé, F., Ronald, A. & Plomin, R. (2006). Time to give up on a single explanation for 
autism. Nat Neurosci, 9, 1218-1220 
Harrison, R., Papp, B., Pál, C., Oliver, S.G. & Delneri, D. (2007). Plasticity of genetic 
interactions in metabolic networks of yeast. Proc Natl Acad Sci U S A, 104, 2307-2312 
Hattori, J., Ogino, T., Abiru, K., Nakano, K., Oka, M. & Ohtsuka, Y. (2006). Are pervasive 
developmental disorders and attention-deficit/hyperactivity disorder distinct 
disorders? Brain Dev, 28, 371-374 
Hill, W.G., Goddard, M.E. & Visscher, P.M. (2008). Data and theory point to mainly additive 
genetic variance for complex traits. Plos Genetics, 4, e1000008 
Hobbs, K., Kennedy, A., DuBray, M., Bigler, E.D., Petersen, P.B., McMahon, W. et al. (2007). 
A retrospective fetal ultrasound study of brain size in autism. Biol Psychiatry, 62, 
1048-1055 
Hoekstra, R.A., Bartels, M., Verweij, C.J.H. & Boomsma, D.I. (2007). Heritability of autistic 
traits in the general population. Arch Pediatr Adolesc Med, 161, 372-377 
Ijichi, S. & Ijichi, N. (2004). The prenatal autistic imprinting hypothesis: developmental 
maladaptation to the environmental changes between womb and the social world. 
Med Hypotheses, 62, 188-194 
Ijichi, S. & Ijichi, N. (2007). Computerized lifelong mentoring support using robot for autistic 
individuals. Med Hypotheses, 68, 493-498 
Ijichi, S., Ijichi, N., Ijichi, Y., Kawamura, Y., Hashiguchi, T. & Morioka, H. (2008). For others: 
epistasis and the evolutionary survival of an extreme tail of the quantitative 
distribution of autistic assets. Med Hypotheses, 70, 515-521 
Ijichi, S., Ijichi, N., Ijichi, Y., Sameshima, H., Saeki, Y., Hall, W.W. & Morioka, H. (2011). 
Non-additive interactions between monomorphic and polymorphic loci: a 
theoretical explanation of the genetic underpinning for complex traits, In: Advances 
in Medicine and Biology. Vol. 13., Berhardt, L.V., editor, 133-148, Nova Science (New 
York),  
https://www.novapublishers.com/catalog/product_info.php?products_id=22873 
Jiang, Y.H., Sahoo, T., Michaelis, R.C., Bercovich, D., Bressler, J., Kashork, C.D. et al. (2004). 
A mixed epigenetic/genetic model for oligogenic inheritance of autism with a 
limited role for UBE3A. Am J Med Genet, 131, 1-10 
Jones, M.B. & Szatmari, P. (2002). A risk-factor model of epistatic interaction, focusing on 
autism. Am J Med Genet, 114, 558-565 
Jorde, L.B., Hasstedt, S.J., Ritvo, E.R., Mason-Brothers, A., Freeman, B.J., Pingree, C. et al. 
(1991). Complex segregation analysis of autism. Am J Hum Genet, 49, 932-938 
Kamp-Becker, I., Smidt, J., Ghahreman, M., Heinzel-Gutenbrunner, M., Becker, K. & 
Remschmidt, H. (2010). Categorical and dimensional structure of autism spectrum 
disorders: the nosologic validity of Asperger syndrome. J Autism Dev Disord, 40, 
921-929 
Keller, M.C. & Miller, G. (2006). Resolving the paradox of common, harmful, heritable 
mental disorders: which evolutionary genetic models work best? Behav Brain Sci, 
29, 405-452 
Lamb, J.A., Moore, J., Bailey, A. & Monaco, A.P. (2000). Autism: recent molecular genetic 
advances. Hum Mol Genet, 9, 861-868 
Lauritsen, M.B. & Ewald, H. (2001). The genetics of autism. Acta Psychiatr Scand, 103, 411-27. 
 
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment 
 
100 
Leonard, H., Nassar, N., Bourke, J., Blair, E., Mulroy, S., de Klerk, N. et al. (2008). Relation 
between intrauterine growth and subsequent intellectual disability in a ten-year 
population cohort of children in Western Australia. Am J Epidemiol, 167, 103-111 
Lepagnol-Bestel, A.M., Maussion, G., Boda, B., Cardona, A., Iwayama, Y., Delezoide,A.L. et 
al. (2008). SLC25A12 expression is associated with neurite outgrowth and is 
upregulated in the prefrontal cortex of autistic subjects. Mol Psychiatry, 13, 385-397 
Lord, C., Cook, E.D., Leventhal, B.L. & Amaral, D.G. (2000). Autism spectrum disorders. 
Neuron, 28, 355-363 
Maestrini, E., Paul, A., Monaco, A.P. & Bailey, A. (2000). Identifying autism susceptibility 
genes. Neuron, 28, 19-24 
Malmberg, R.L. & Mauricio, R. (2005). QTL-based evidence for the role of epistasis in 
evolution. Genet Res, 86, 89-95 
Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter, D.J. et al. 
(2009). Finding the missing heritability of complex diseases. Nature, 461, 747-753 
Marcus, G.F. & Rabagliati, H. (2006). Genes and domain specificity. Trends Cogn Sci, 10, 397-
398. 
Markram, H., Rinaldi, E. & Markram, K. (2007). The intense world syndrome: an alternative 
hypothesis for autism. Front Neurosci, 1, 77-96 
Marshall, C.R., Noor, A., Vincent, J.B., Lionel, A.C., Feuk, L., Skaug, J. et al. (2008). Structural 
variation of chromosomes in autism spectrum disorder. Am J Hum Genet, 82, 477-
488 
Maussion, G., Carayol, J., Lepagnol-Bestel, A.M., Tores, F., Loe-Mie, Y., Mibreta, U. et al. 
(2008). Convergent evidence identifying MAP/microtubule affinity-regulating 
kinase 1 (MARK1) as a susceptibility gene for autism. Hum Mol Genet, 17, 2541-2551 
McCleery, J.P., Allman, E., Carver, L.J. & Dobkins, K.R. (2007). Abnormal magnocellular 
pathway visual processing in infants at risk for autism. Biol Psychiatry, 62, 1007-
1014 
McGovern, C. & Sigman, M. (2005). Continuity and change from early childhood to 
adolescence in autism. J Child Psychol Psychiatry, 46, 401-408 
Mitchison, N.A. (2000). Polymorphism in regulatory gene sequences. Genome Biol, 2, 
comment2001.1-6 
Moessner, R., Marshall, C.R., Sutcliffe, J.S., Skaug, J., Pinto, D., Vincent, J. et al. (2007) 
Contribution of SHANK3 mutations to autism spectrum disorders. Am J Hum 
Genet, 81, 1289-1297 
Moldin, S.O., Rubenstein, J.L.R. & Hyman, S.E. (2006). Can autism speak to neuroscience? J 
Neurosci, 26, 6893-6896 
Morris, K.V. (2005). siRNA-mediated transcriptional gene silencing: the potential 
mechanism and a possible role in the histone code. Cell Mol Life Sci, 62, 3057-3066 
Nesse, R.M. & Williams, G.C. (1994). Why we get sick: the new science of Darwinian medicine, 
Vintage Books, ISBN 0-679-74674-9, New York 
Palmert, M.R. & Hirschhorn, J.N. (2003). Genetic approaches to stature, pubertal timing, and 
other complex traits. Mol Genet Metab, 80, 1-10 
Pauler, F.M., Koerner, M.V. & Barlow, D.P. (2007). Silencing by imprinted noncoding RNAs: 
is transcription the answer? Trends Genet, 23, 284-292 
Persico, A.M. & Bourgeron, T. (2006). Searching for ways out of the autism maze: genetic, 
epigenetic and environmental clues. Trends Neurosci, 29, 349-358 
The Genetic Basis of Phenotypic Diversity: 
Autism as an ExtremeTail of a Complex Dimensional Trait 
 
101 
Pinto, D., Pagnamenta, A.T., Klei, L., Anney, R., Merico, D., Regan, R., et al. (2010). 
Functional impact of global rare copy number variation in autism spectrum 
disorders. Nature, 466, 368-372 
Plomin, R., Owen, M.J. & McGuffine, P. (1994). The genetic basis of complex human 
behaviors. Science, 264, 1733-1739 
Plomin, R. & Kosslyn, S.M. (2001). Genes, brain and cognition. Nat Neurosci, 4, 1153-1155 
Plomin, R., Haworth, C.M.A. & Davis, O.S.P. (2009). Common disorders are quantitative 
traits. Nat Rev Genet, 10, 872-878 
Posserud, M.B., Lundervold, A.J. & Gillberg, C. (2006). Autistic features in a total population 
of 7-9-year-old children assessed by the ASSQ (Autism Spectrum Screening 
Questionnaire). J Child Psychol Psychiatry, 47, 167-175 
Rapin I. (1997). Autism. (author reply). N Engl J Med, 337, 1556-1557 
Rapin, I. & Katzman, R. (1998). Neurobiology of autism. Ann Neurol, 43, 7-14 
Rapin, I. (1999). Autism in search of a home in the brain. Neurology, 52, 902-904 
Reiersen, A.M., Constantino, J.N., Volk, H.E. & Todd, R.D. (2007). Autistic traits in a 
population-based ADHD twin sample. J Child Psychol Psychiatry, 48, 464-472 
Rinaldi, T., Kulangara, K., Antoniello, K. & Markram, H. (2007). Elevated NMDA receptor 
levels and enhanced postsynaptic long-term potentiation induced by prenatal 
exposure to valproic acid. Proc Natl Acad Sci U S A, 104, 13501-13506 
Ronald, A., Happé, F. & Plomin, R. (2005). The genetic relationship between individual 
differences in social and nonsocial behaviours characteristic of autism. Dev Sci, 8, 
444-458 
Ronald, A., Happé, F., Bolton, P., Butcher, L.M., Price, T.S., Wheelwright, S. et al. (2006a). 
Genetic heterogeneity between the three components of the autism spectrum: a 
twin study. J Am Acad Child Adolesc Psychiatry, 45, 691-699 
Ronald, A., Happé, F., Price, T.S., Baron-Cohen, S. & Plomin, R. (2006b). Phenotypic and 
genetic overlap between autistic traits at the extremes of the general population. J 
Am Acad Child Adolesc Psychiatry, 45, 1206-1214 
Ronald, A., Simonoff, E., Kuntsi, J., Asherson, P. & Plomin, R. (2008). Evidence for 
overlapping genetic influences on autistic and ADHD behaviours in a community 
twin sample. J Child Psychol Psychiatry, 49, 535-542 
Rowe, H.C., Hansen, B.G., Halkier, B.A. & Kliebenstein, D.J. (2008). Biochemical netwerks 
and epistasis shape the Arabidopsis theliana metabolome. Plant Cell, 20, 1199-1216 
Rzhetsky, A., Wajngurt, D., Park, N. & Zheng, T. (2007). Probing genetic overlap among 
complex human phenotypes. Proc Natl Acad Sci U S A, 104, 11694-11699 
Santangelo, S.L. & Tsatsanis, K. (2005). What is known about autism: genes, brain, and 
behavior. Am J Pharmacogenomics, 5, 71-92 
Schanen, N.C. (2006). Epigenetics of autism spectrum disorders. Hum Mol Genet, 15, R138-
150 
Scheuffgen, K., Happé, F., Anderson, M. & Frith, U. (2000). High “intelligence,” low “IQ”? 
speed of processing and measured IQ in children with autism. Dev Psychopathol, 12, 
83-90 
Schmitz, C. & Rezaie, P. (2008). The neuropathology of autism: where do we stand? 
Neuropahtol Appl Neurobiol, 34, 4-11 
Sebat, J. (2007). Major changes in our DNA lead to major changes in our thinking. Nature 
Genet, 39(Suppl), S3-5 
 
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment 
 
100 
Leonard, H., Nassar, N., Bourke, J., Blair, E., Mulroy, S., de Klerk, N. et al. (2008). Relation 
between intrauterine growth and subsequent intellectual disability in a ten-year 
population cohort of children in Western Australia. Am J Epidemiol, 167, 103-111 
Lepagnol-Bestel, A.M., Maussion, G., Boda, B., Cardona, A., Iwayama, Y., Delezoide,A.L. et 
al. (2008). SLC25A12 expression is associated with neurite outgrowth and is 
upregulated in the prefrontal cortex of autistic subjects. Mol Psychiatry, 13, 385-397 
Lord, C., Cook, E.D., Leventhal, B.L. & Amaral, D.G. (2000). Autism spectrum disorders. 
Neuron, 28, 355-363 
Maestrini, E., Paul, A., Monaco, A.P. & Bailey, A. (2000). Identifying autism susceptibility 
genes. Neuron, 28, 19-24 
Malmberg, R.L. & Mauricio, R. (2005). QTL-based evidence for the role of epistasis in 
evolution. Genet Res, 86, 89-95 
Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter, D.J. et al. 
(2009). Finding the missing heritability of complex diseases. Nature, 461, 747-753 
Marcus, G.F. & Rabagliati, H. (2006). Genes and domain specificity. Trends Cogn Sci, 10, 397-
398. 
Markram, H., Rinaldi, E. & Markram, K. (2007). The intense world syndrome: an alternative 
hypothesis for autism. Front Neurosci, 1, 77-96 
Marshall, C.R., Noor, A., Vincent, J.B., Lionel, A.C., Feuk, L., Skaug, J. et al. (2008). Structural 
variation of chromosomes in autism spectrum disorder. Am J Hum Genet, 82, 477-
488 
Maussion, G., Carayol, J., Lepagnol-Bestel, A.M., Tores, F., Loe-Mie, Y., Mibreta, U. et al. 
(2008). Convergent evidence identifying MAP/microtubule affinity-regulating 
kinase 1 (MARK1) as a susceptibility gene for autism. Hum Mol Genet, 17, 2541-2551 
McCleery, J.P., Allman, E., Carver, L.J. & Dobkins, K.R. (2007). Abnormal magnocellular 
pathway visual processing in infants at risk for autism. Biol Psychiatry, 62, 1007-
1014 
McGovern, C. & Sigman, M. (2005). Continuity and change from early childhood to 
adolescence in autism. J Child Psychol Psychiatry, 46, 401-408 
Mitchison, N.A. (2000). Polymorphism in regulatory gene sequences. Genome Biol, 2, 
comment2001.1-6 
Moessner, R., Marshall, C.R., Sutcliffe, J.S., Skaug, J., Pinto, D., Vincent, J. et al. (2007) 
Contribution of SHANK3 mutations to autism spectrum disorders. Am J Hum 
Genet, 81, 1289-1297 
Moldin, S.O., Rubenstein, J.L.R. & Hyman, S.E. (2006). Can autism speak to neuroscience? J 
Neurosci, 26, 6893-6896 
Morris, K.V. (2005). siRNA-mediated transcriptional gene silencing: the potential 
mechanism and a possible role in the histone code. Cell Mol Life Sci, 62, 3057-3066 
Nesse, R.M. & Williams, G.C. (1994). Why we get sick: the new science of Darwinian medicine, 
Vintage Books, ISBN 0-679-74674-9, New York 
Palmert, M.R. & Hirschhorn, J.N. (2003). Genetic approaches to stature, pubertal timing, and 
other complex traits. Mol Genet Metab, 80, 1-10 
Pauler, F.M., Koerner, M.V. & Barlow, D.P. (2007). Silencing by imprinted noncoding RNAs: 
is transcription the answer? Trends Genet, 23, 284-292 
Persico, A.M. & Bourgeron, T. (2006). Searching for ways out of the autism maze: genetic, 
epigenetic and environmental clues. Trends Neurosci, 29, 349-358 
The Genetic Basis of Phenotypic Diversity: 
Autism as an ExtremeTail of a Complex Dimensional Trait 
 
101 
Pinto, D., Pagnamenta, A.T., Klei, L., Anney, R., Merico, D., Regan, R., et al. (2010). 
Functional impact of global rare copy number variation in autism spectrum 
disorders. Nature, 466, 368-372 
Plomin, R., Owen, M.J. & McGuffine, P. (1994). The genetic basis of complex human 
behaviors. Science, 264, 1733-1739 
Plomin, R. & Kosslyn, S.M. (2001). Genes, brain and cognition. Nat Neurosci, 4, 1153-1155 
Plomin, R., Haworth, C.M.A. & Davis, O.S.P. (2009). Common disorders are quantitative 
traits. Nat Rev Genet, 10, 872-878 
Posserud, M.B., Lundervold, A.J. & Gillberg, C. (2006). Autistic features in a total population 
of 7-9-year-old children assessed by the ASSQ (Autism Spectrum Screening 
Questionnaire). J Child Psychol Psychiatry, 47, 167-175 
Rapin I. (1997). Autism. (author reply). N Engl J Med, 337, 1556-1557 
Rapin, I. & Katzman, R. (1998). Neurobiology of autism. Ann Neurol, 43, 7-14 
Rapin, I. (1999). Autism in search of a home in the brain. Neurology, 52, 902-904 
Reiersen, A.M., Constantino, J.N., Volk, H.E. & Todd, R.D. (2007). Autistic traits in a 
population-based ADHD twin sample. J Child Psychol Psychiatry, 48, 464-472 
Rinaldi, T., Kulangara, K., Antoniello, K. & Markram, H. (2007). Elevated NMDA receptor 
levels and enhanced postsynaptic long-term potentiation induced by prenatal 
exposure to valproic acid. Proc Natl Acad Sci U S A, 104, 13501-13506 
Ronald, A., Happé, F. & Plomin, R. (2005). The genetic relationship between individual 
differences in social and nonsocial behaviours characteristic of autism. Dev Sci, 8, 
444-458 
Ronald, A., Happé, F., Bolton, P., Butcher, L.M., Price, T.S., Wheelwright, S. et al. (2006a). 
Genetic heterogeneity between the three components of the autism spectrum: a 
twin study. J Am Acad Child Adolesc Psychiatry, 45, 691-699 
Ronald, A., Happé, F., Price, T.S., Baron-Cohen, S. & Plomin, R. (2006b). Phenotypic and 
genetic overlap between autistic traits at the extremes of the general population. J 
Am Acad Child Adolesc Psychiatry, 45, 1206-1214 
Ronald, A., Simonoff, E., Kuntsi, J., Asherson, P. & Plomin, R. (2008). Evidence for 
overlapping genetic influences on autistic and ADHD behaviours in a community 
twin sample. J Child Psychol Psychiatry, 49, 535-542 
Rowe, H.C., Hansen, B.G., Halkier, B.A. & Kliebenstein, D.J. (2008). Biochemical netwerks 
and epistasis shape the Arabidopsis theliana metabolome. Plant Cell, 20, 1199-1216 
Rzhetsky, A., Wajngurt, D., Park, N. & Zheng, T. (2007). Probing genetic overlap among 
complex human phenotypes. Proc Natl Acad Sci U S A, 104, 11694-11699 
Santangelo, S.L. & Tsatsanis, K. (2005). What is known about autism: genes, brain, and 
behavior. Am J Pharmacogenomics, 5, 71-92 
Schanen, N.C. (2006). Epigenetics of autism spectrum disorders. Hum Mol Genet, 15, R138-
150 
Scheuffgen, K., Happé, F., Anderson, M. & Frith, U. (2000). High “intelligence,” low “IQ”? 
speed of processing and measured IQ in children with autism. Dev Psychopathol, 12, 
83-90 
Schmitz, C. & Rezaie, P. (2008). The neuropathology of autism: where do we stand? 
Neuropahtol Appl Neurobiol, 34, 4-11 
Sebat, J. (2007). Major changes in our DNA lead to major changes in our thinking. Nature 
Genet, 39(Suppl), S3-5 
 
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment 
 
102 
Sebat, J., Lakshmi, B., Malhotra, D., Troge, J., Lese-Martin, C., Walsh, T. et al. (2007). Strong 
association of de novo copy number mutations with autism. Science, 316, 445-449 
Simpson, D. (2003). Autism spectrum disorder is not as certain as implied. BMJ, 326, 986 
Skuse, D.H. (2000). Imprinting, the X-chromosoem, and the male brain: explaining sex 
differences in the liability to autism. Pediatr Res, 47, 9-16 
Skuse, D.H., Mandy, W.P.L. & Scourfield, J. (2005). Measuring autistic traits: heritability, 
reliability and validity of the Social and Communication Disorders Checklist. Br J 
Psychiatry, 187, 568-572 
Skuse, D.H. (2007). Rethinking the nature of genetic vulnerability to autistic spectrum 
disorders. Trends Genet, 23, 387-395 
Sung, Y.J., Dawson, G., Munson, J., Estes, A., Schellenberg, G.D. & Wijsman, E.M. (2005). 
Genetic investigation of quantitative traits related to autism: use of multivariate 
polygenic models with ascertainment adjustment. Am J Hum Genet, 76, 68-81 
Sykes, N.H. & Lamb, J.A. (2007). Autism: the quest for the genes. Expert Rev Mol Med, 9, 1-15. 
Tonge, B.J., Dissanayake, C. & Brereton, A.V. (1994). Autism: fifty years on from Kanner. J 
Paediatr Child Health, 30, 102-107 
Tordjman, S., Ferrari, P., Sulmont, V., Duyme, M. & Roubertoux, P. (1997). Androgenic 
activity in autism. Am J Psychiatry, 154, 1626-1627 
van Vliet, J., Oates, N.A. & Whitelaw, E. (2007). Epigenetic mechanisms in the context of 
complex diseases. Cell Mol Life Sci, 64, 1531-1538 
Viding, E. & Blakemore, S.J. (2007). Endophenotype approach to developmental 
psychopathology: implications for autism research. Behav Genet, 37, 51-60 
Weiss, L.A., Purcell, S., Waggoner, S., Lawrence, K., Spektor, D., Daly, M.J. et al. (2007). 
Identification of EFHC2 as a quantitative trait locus for fear recognition in Turner 
syndrome. Hum Mol Genet, 16, 107-113 
Weiss, L.A., Shen, Y., Korn, J.M., Arking, D.E., Miller, D.T., Fossdal, R. et al. (2008). 
Association between microdeletion and microduplication at 16p11.2 and autism. N 
Engl J Med, 358, 667-675 
Willis-Owen, S.A. & Flint, J. (2006). The genetic basis of emotional behaviour in mice. 
European J Hum Genet, 14, 721-728 
Wing, L. (1997). The autistic spectrum. Lancet, 350, 1761-1766 
Yan, J., Oliveira, G., Coutinho, A., Yang, C., Feng, J., Katz, C. et al. (2005). Analysis of the 
neuroligin 3 and 4 genes in autism and other neuropsychiatric patients. Mol 
Psychiatry, 10, 329-335 
Yan, J., Noltner, K., Feng, J., Li, W., Schroer, R., Skinner, C. et al. (2008). Neurecin 1α 
structural variants associated with autism. Neurosci Lett, 438, 368-370 
Zhang, X.S. & Hill, W.G. (2005). Genetic variability under mutation selection balance. Trends 
Ecol Evol, 20, 468-470 
Zhao, X., Leotta, A., Kustanovich, V., Lajonchere, C., Geschwind, D.H., Law, K. et al. (2007). 
A unified genetic theory for sporadic and inherited autism. Proc Natl Acad Sci U S 
A, 104, 12831-12836 
7 
A New Genetic Mechanism for Autism 
Julie Gauthier and Guy A. Rouleau 
Université de Montréal 
Canada 
1. Introduction  
It has been almost half a century since Leo Kanner first described the clinical phenotype 
associated with Autism1. Since Kanner's descriptions, much effort has been devoted to 
understanding and identifying the factors which may contribute to Autism. It was not until 
the early 80’s that compelling evidence started to accumulate suggesting that Autism is a 
disorder of abnormal brain development. It is now generally accepted that both genetic and 
environmental factors are implicated in the etiology of this intriguing condition. In the 
current chapter, we will focus on the role of genetic factors involved in the pathogenesis of 
Autism. While multiple hypotheses have been proposed to account for the genetic origin of 
Autism, some have received more empirical support than others. While it is likely that more 
than one genetic mechanisms is involved in the pathogenesis of this disorder, this chapter 
will focus on a recent hypothesis implicating de novo mutations in synaptic genes. This 
hypothesis is based on the proposition that rare, highly penetrant mutations affecting any of 
many different genes which code for synaptic molecules, and which are specific to single 
families, predispose to Autism. Empirical lines of evidence for this hypothesis will be 
presented, along with examples, some of which are derived from work by our group.  
1.1 The role of genetics in autism 
Over the last two decades many studies aimed at identifying the genetic causes of Autism 
have shown that genetic factors play a predominant role in the genesis of this disorder. 
Twin studies predict that the heritability (i.e. the degree to which a given trait is controlled 
by inheritance) of Autism is between 70-90% (Bailey et al., 1995; Marco & Skuse, 2006; 
Lichtenstein et al., 2010). The relatively low concordance rate in dizygotic twins, the sharp 
decrease in recurrence risk of Autism in second- and third-degree relatives of autistic 
subjects (0.18% and 0.12% respectively) as well as a low risk in first-degree relatives of 
autistic subjects (3-7%) (Chakrabarti & Fombonne, 2001; Muhle et al., 2004) predicts two 
different genetic scenarios: 1) Autism could be explained by the co-inheritance in one 
individual of multiple disease-predisposing alleles, each with a small but additive effect, 
resulting in disease, or 2) by de novo mutations (i.e. not inherited from either parent). The 
first scenario is a polygenic inheritance, where the effect of multiple risk genes acting 
additively or multiplicatively results in disease. The second, very recently considered for 
Autism, argues that a fraction of the cases would result from incompletely penetrant new 
                                                 
1 In this chapter the term Autism refers to the autism spectrum disorders which include Autism 
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mutations or de novo mutations, such that only identical twins would share the genetic 
predisposition to Autism, hence the much higher monozygotic concordance than dizygotic 
concordance. Familial aggregation studies demonstrate that the risk of developing Autism is 
greater in offspring than in the parents. There are many possible explanations, one of which 
is that new mutations cause a fraction of Autism cases.  
Dozens of genome-wide genetic linkage studies have been conducted in Autism kindred, 
identifying genetic signals of various significance levels on almost every arm of every 
human chromosome. There are few instances of consistent replication of linkage to any one 
site. Fine-mapping of these loci has been difficult, mainly because of genetic heterogeneity, 
so researchers have frequently opted to look at candidate genes directly based on the 
linkage results and/or on relevant gene functions. Association studies have also been used 
to search for genes in Autism. Although, in general, most studies have not been replicated, a 
few have been yielding a crop of possible susceptibility genes. Although the few replicated 
positive association studies are promising, it is surprising that no causative mutations or 
sequence variants have been identified in any of the loci associated with the disorder. In the 
absence of such mutations, the role of these genes in Autism remains unproven.  
A number of genes have been strongly associated with Autism. For example, the X-linked 
neuroligin genes, NLGN3 and NLGN4, two synaptic molecules, have been found to be 
associated with Autism. In the original report, two families with affected brothers (one with 
autism disorder and the other with Asperger syndrome) have a frameshifting and a 
missense mutation within the coding region of NLGN4 and NLGN3, respectively (Jamain et 
al., 2003). Interestingly, both were new mutations that occurred in the mother of the affected 
brothers. Other mutations have since been described in these genes further supporting their 
role in the pathogenesis of Autism. NLGN3 and NLGN4 belong to the neuroligin family of 
postsynaptic cell adhesion molecules that are widely expressed in the brain (Philibert et al., 
2000). The products of these genes are involved in late steps of synaptogenesis, mediating 
the specific recruitment of pre- and postsynaptic proteins to the site of initial synaptic 
contact. Two independent studies have shown in vitro that the frameshifting and the 
missense mutations described in humans alter the formation of presynaptic terminals (Chih 
et al., 2004; Comoletti et al., 2004). Since this discovery, mutations in other genes have been 
linked to Autism (discussed below). These findings support our hypothesis, which will be 
discussed in section below, that Autism is mainly a synaptic disorder largely caused by de 
novo mutations in synaptic genes. 
2. The concept of “de novo” mutations 
Recent studies on the direct measurement of human mutation rate have revealed that in any 
single conceptus there is approximately 1.1 x 10-8 (0.76 x 10-8 to 2.2 x 10-8) mutation per base per 
generation (Awadalla et al., 2010; Lynch, 2010; Roach et al., 2010). A newborn is thought to 
have acquired about sixty new mutations in his/her genome. Among these, approximately 
0.86 new deleterious mutation will lead to an altered amino acid, which corresponds to an 
average of about 1 new coding mutation per conceptus (Eyre-Walker & Keightley, 1999; 
Giannelli et al., 1999; Crow, 2000). De novo or spontaneous germline mutations can lead to 
serious clinical consequences, such as a disease, when affecting critical genes. 
2.1 Common disease and common variants  
Classical linkage and association studies, as mentioned earlier, have largely failed to identify 
predisposing genes for Autism as well as a number of other psychiatric disorders. The main 
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reason for this lack of success is likely to be allelic and non-allelic genetic heterogeneity, 
with dozens to perhaps hundreds of genes predisposing to Autism, with each gene having 
many allelic variants. Such heterogeneity would require an enormous sample size to detect 
predisposing genes using population genetic approaches. It is likely that this heterogeneity 
results mostly from our limited ability to sub-phenotype brain disorders, particularly 
behavioural disabilities. The diagnosis of most psychiatric disorders remains largely based 
on clinical criteria, which define broad categories of dysfunction that may or may not be 
biologically linked. To date, there is no consistent, biologically validated method for 
defining these sub-phenotypes. Simply stated, Autism, as currently defined, probably result 
from so many different genes and alleles that classical genetic methods will prove inefficient 
in the identification of susceptibility genes for this disorder. 
The hypothesis that a common disease may be caused by common variants was the 
favoured model for the genetic architecture of Autism until recently. Indeed, the 
constellation of published association studies reflects the widespread belief of the 
involvement of common variants in Autism. This hypothesis was appealing to many 
investigators since the common variants should be identifiable using methods such as 
linkage disequilibrium (Reich & Lander, 2001). Unfortunately, there are very few examples 
to support this hypothesis, particularly for brain disorders. Clinicians argue that Autism is a 
highly heterogeneous group of disorders, and none of them can be explained by single or 
even a few common variants. If this were the case, the plethora of genetic studies performed 
over the years should already have identified some of these variants. The widely distributed 
linkage and association positive signals scattered all over the genome rejects the existence of 
one or a few major predisposing common variants in this disorder. Furthermore, the few 
genes that have been found to definitely predispose to Autism explain only a small fraction 
of cases. This is not to say that some common variants will not be found for some 
predisposing genes, but this mechanism is unlikely to explain all the genetics of this 
condition.  
It has recently been recognized that many complex disorders may result from a mix of 
common and rare variants. Let us consider breast cancer as an example (Nathanson et al., 
2001): BRCA1 and BRCA2 genes contribute to a relatively common genetic disorder, but 
have many different rare mutations, even in a founder population (the Ashkenazim). For a 
complex trait such as Autism, the occurrence of many rare variants in many different 
disease predisposing genes seems to better predict the genetic architecture of the disorders 
(Pritchard, 2001; Pritchard & Cox, 2002; Smith & Lusis, 2002).  
As a final point on the common disease common variant hypothesis, most studies looking at 
disease-causative mutations for Autism report mutations that are not recurrent, i.e. not 
observed more than once and specific to one individual. Again this suggests that mutations 
at many different loci may contribute to Autism, a result consistent with the failure to find 
common heritable variants with a major effect on disease risk. Lack of recurrence of 
mutations may in fact reflect the possibility that autistic traits can result from many different 
genetic defects. 
2.2 Rare variants and new mutations 
While not all amino acid substitutions will be deleterious, a significant fraction will be and 
may lead to disease. Therefore, for a disorder that may result from dysfunction in any one of 
hundreds of different genes, new mutations may be responsible for a significant fraction of 
cases. For example, should dysfunction in any of 100 different genes potentially lead to 
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Autism, and assuming amino acid changes lead to gene dysfunction in one fifth of instances, 
new mutations could cause Autism in one case out of 1,000 births, which would correspond 
to over 10% of cases based on the overall population incidence.  
Looking at simple Mendelian traits, we can see that new mutations are common. For 
example, 1 in 6,000 live births harbour a novel mutation causing neurofibromatosis type 1  
(Stephens et al., 1992; Grimm et al., 1994; Hudson et al., 1997). The frequency of new point 
mutations in Duchenne Muscular Dystrophy is similar, 1 in 10,500 live births (Grimm et al., 
1994). One can argue that these are large genes, allowing for high mutation rate.  
Nonetheless, these are surprisingly high numbers of novel deleterious mutations. Let us 
consider Rett syndrome, which is closely related to Autism, and results from mutations in 
the relatively small MECP2 gene (4 exons, 498 amino acids). The incidence of Rett syndrome 
is one in 10,000-15,000 females. Because 99-99.5% of all cases are sporadic with new 
mutations, this represents a new mutation rate of one in 5,000-7,500 live births for this small 
gene of 498 amino acids (Hagberg, 1985; Hagberg & Hagberg, 1997; Van den Veyver & 
Zoghbi, 2001). This example clearly shows that, for neurodevelopmental disorders, new 
mutations can act dominantly and can occur with a high enough frequency to explain the 
relatively high incidence of Autism. A high rate of new mutations can in part explain why 
genetic studies have so far failed to identify many Autism genes, and why diseases have 
been identified for a mere 3% of genes in the human genome. Mutations in genes leading to 
severe outcome where there is a strong negative selection against the phenotype, such as 
lethality in embryonic stages or reduced reproductive fitness, will not be transmitted to 
multiple family members, and therefore will not be detected by linkage gene mapping.  
3. The role of de novo mutation in autism 
Though we predict that de novo mutations will be a frequent cause of Autism, we do not 
think that it will be the only genetic explanation. The alternative genetic hypothesis for 
complex traits, mentioned previously, predicts that disease results from a combination or 
pattern of genotypes at different susceptibility loci. In recent years, statisticians have 
developed analytical methods that capture contributions from multiple susceptibility loci, 
and provide evidence for the localization of disease genes on human chromosomes (Sherriff 
& Ott, 2001; Hoh & Ott, 2003; Carlson et al., 2004). However, such analyses are very complex 
and yield few successful examples, even considering the simplest scenarios (Tiret et al., 
1994; Bolk et al., 2000; Zetterberg et al., 2003). It seems that genome-wide searches using 
realistic sample sizes may not have the power to detect potential multi-gene interactions. 
The existence of new mutations, which contribute to this heterogeneity, makes classical 
genetic approaches even more difficult. Thus, the failure of conventional linkage and 
genome-wide association studies to identify but a few causative Autism genes is most likely 
due to two main confounding factors: phenotypic and genetic heterogeneity. Phenotypic 
heterogeneity is due to the inability to distinguish closely related clinical subtypes in the 
autism spectrum of behavioural disturbances. Genetic heterogeneity refers to fact that many 
different genes (and/or alleles of the same genes) lead to the same phenotype.  
3.1 Monozygotic and dizygotic concordance  
De novo mutations in identical twins would result in their sharing the same genetic 
predisposition to Autism. These alleles would be highly but not completely penetrant; hence 
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the high monozygotic concordance and the low dizygotic concordance, as in the latter case 
the unaffected twin would not share the novel disease predisposing allele. Instances of non-
penetrance would explain the fact that monozygotic twin concordance is not 100%. A de 
novo or spontaneous mutation can arise from different mechanisms and in different periods 
in the development of an individual. This kind of mutation can occur in the gametes (sperm 
or eggs), very early in the developing foetus or later in life as observed in cancer.  The partial 
phenotypic concordance in monozygotic twin could also be in part explained by the 
occurrence of a de novo mutation early in the development of one twin, but not the other.  
3.2 Reduced reproductive fitness  
In the general population, the mutational load can be thought of as a balance between 
selection against a deleterious gene and its acquisition of new mutations. Lower rates of 
reproduction constitute a negative selection factor that should reduce the number of mutant 
alleles in the population, ultimately leading to decreased disease prevalence. These selective 
pressures tend to be of different intensity in different environments. In the case of Autism, 
only rarely do individuals with Autism have children, particularly the more severely 
affected individuals (Nicolson & Szatmari, 2003). Thus, Autism has a lower reproductive 
fitness (which is the ability to pass on genes by having offspring) due to an early age of 
onset and severely impaired cognitive and social functions. This observation should 
influence the disorders incidence and prevalence; but this is not what we observe. Autism 
incidence and prevalence seems to be relatively constant worldwide..  
Studies of monogenic diseases2 indicate that rare diseases with strong negative selection 
generally exhibit very large allelic diversity, hence many different mutations (Smith & Lusis, 
2002). One exception to this pattern of high allelic diversity occurs when disease alleles also 
provide protection from negative environmental selective pressures. One example is the 
thalassemias, which confer resistance to malaria. Once arisen, the strong positive selective 
pressure conferred by these alleles allowed their relatively rapid spread through a specific 
population. However, such phenomena are usually regional, in response to specific regional 
environmental pressures. There are no examples of such phenomena occurring with equal 
strength in all cultural and geographical parts of the world, which needs to be the case to 
have a uniform incidence of Autism throughout the world. De novo mutations could explain 
this relatively uniform high incidence of disease, as new disease predisposing alleles will 
continually be introduced at a similar rate in all parts of the world. 
3.3 Effects of paternal age 
The male-to-female ratio of de novo mutations is estimated at about 4–6:1, presumably due to 
a higher number of germ-cell divisions with age in males(Crow, 2000). Therefore, one would 
predict that de novo mutations would more frequently come from males, particularly older 
men (Li et al., 2002).  At the genetic level, increased risk for a disease with increasing 
paternal age can be explained by spermatogonial stem cell divisions that occur over the 
lifetime of males contributing to higher mutational rates in the sperm of older men. A higher 
paternal origin of de novo mutations has been shown for many diseases, including Apert 
syndrome (Moloney et al., 1996), Crouzon syndrome (Glaser et al., 2000), Multiple endocrine 
neoplasia type II (Carlson et al., 1994) and neurofibromatosis type 1  (Jadayel et al., 1990).  
                                                 
2 Disorders caused by the inheritance of a single defective gene 
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the high monozygotic concordance and the low dizygotic concordance, as in the latter case 
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Rett syndrome, a neurodevelopmental disease closely related to Autism, results almost 
entirely from new mutations which are exclusively of paternal origin (Girard et al., 2001; 
Trappe et al., 2001). A role for de novo mutations in Autism would predict that the incidence 
of disease should increase with increasing paternal age. Indeed, multiple recent studies 
reported advancing paternal age as a significant risk factor for Autism (Miller, 2006; Cantor 
et al., 2007; Croen et al., 2007; Puleo et al., 2008). Some authors have predicted a high 
incidence of male-derived novel mutations in many mental disorders (Preuss et al., 2004). 
Similar observation has been reported for schizophrenia (Malaspina et al., 2001) and  
intellectual disabilities (Malaspina et al., 2005), two conditions phenotypically related to 
Autism. These observations provide strong evidence that accumulation of de novo mutations 
in paternal sperm contributes to the overall risk of Autism. 
3.4 Worldwide incidence  
Data from a worldwide amalgam of studies show that the incidence of Autism has been 
maintained at a constant, relatively high prevalence in the worldwide population across a 
wide range of cultures and countries (McDonald & Paul, 2010). This occurs despite a strong 
negative selection against this condition. Indeed and with the exception of variants which 
date back to speciation, one would expect that common variants would result in a detectable 
uneven disease incidence across different populations due to migration, different 
population growth and isolation. This is not the case for Autism. In addition, this is not 
what one would predict in diseases with reduced reproductive fitness like Autism, unless 
there was a high new mutation rate. These observations emphasize the importance of de 
novo mutations in the pathogenicity of Autism.  
Taken together, the high prevalence, the high monozygotic twin concordance, the predicted 
high level of allelic and non-allelic genetic heterogeneity, the uniform worldwide high 
incidence despite significantly reduced reproductive fitness, constitute evidences that 
Autism may result at least in part, from de novo mutations.  
4. De novo mutations in genes associated with autism  
The fact that a growing number of studies, several from our group, report the association of 
rare genetic variants with Autism constitutes strong evidence for the de novo hypothesis. 
Indeed, among causal genes identified for Autism, Rett syndrome and intellectual disability 
(three closely related disorders), the predisposing mutations, whether they be copy number 
variations, insertions/deletions or point mutations, are very frequently of de novo origin. A 
good example of such a gene is SHANK3 encoding a synaptic scaffolding protein. Two of 
the first three mutations reported in the first manuscript linking SHANK3 to Autism were 
actually of de novo origin; one a deletion of the terminal 22q13 and the other a G insertion 
leading to a frameshift that was carried by two affected brothers (Durand et al., 2007). None 
of these mutations were found in the parents. Many subsequent reports on mutation 
screening of SHANK3 gene in Autim also find novel de novo mutations (Moessner et al., 
2007; Gauthier et al., 2009). Other examples, such as the neuroligins genes, NLGN3 and 
NLGN4, also clearly demonstrate the importance of de novo mutations in Autism. Jamain et 
al. found a single nucleotide insertion in two affected brothers, one with typical autism and 
the other with Asperger that arose de novo in the mother (Jamain et al., 2003). The NRXN1 
gene has also been found to harbour de novo pathogenic mutations in persons with Autism, 
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as well as in intellectual disabilities and in schizophrenia (Ching et al., 2010). Ching et al. 
found twelve deletions in NRXN1 in patients with Autism and four were de novo copy 
number variations not identified in either parent (Ching et al., 2010). SYNGAP1 (Hamdan et 
al.) and IL1RAPL1 (Piton et al., 2008) are two other examples where we found de novo 
mutations in individuals with Autism and/or intellectual disability. Actually, de novo 
mutations are also a common cause of intellectual disability (Hamdan et al.; Vissers et al., 
2010). As expected and as recently observed in Autism, de novo mutations have all been 
identified in different genes. For example, our group found six de novo deleterious mutations 
in females individuals with intellectual disability in SYNGAP1 gene (encoding synaptic Ras 
GTPase activating protein 1) (Hamdan et al.; Piton et al., 2008; Hamdan et al., 2009).  
In our recent study on the direct measurement of the de novo mutation rate in Autism and 
schizophrenia, we found a significant excess of potentially deleterious de novo mutations in 
individuals with Autism and schizophrenia (Awadalla et al., 2010). In this study, we 
examined variants identified by direct re-sequencing of 401 genes in a cohort of 285 autistic 
or schizophrenic individuals and for a subset of these genes in population control 
individuals. For the analysis, we distinguished functional from non-functional sites based 
on the effect of a mutation on the transcription or translation of the protein at a given 
position. Among trios3 without family history of Autism, we observed a significant 
enrichment of functional de novo mutations (p = 0.003 in one-tail binomial test; p = 0.022 
Fisher’s exact test). Using a binomial test, our observed number of missense to nonsense de 
novo mutations was also significantly higher than the neutral expectation (p = 0.04), 
suggesting that some of the mutations are likely to be pathogenic. All of our reported 
observations suggest an excess of potentially disease-predisposing de novo mutations in the 
Autism and schizophrenia cohorts. Indeed, in this study, from sequencing only 8% of genes 
of the human genome, functional de novo mutations were found in 5% of individuals with no 
family history of Autism, exhibiting a wide range of clinical phenotypes. These few 
examples and many others recently published collectively provide strong evidence for a 
major role of de novo mutations in Autism. 
5. Altered synaptic connectivity in autism  
The synapse is the locus of neural communication which is critical for human brain function. 
Defects in synaptic transmission are thought to underlie many common developmental 
brain disorders that are characterized by grossly normal brain structure (Zoghbi, 2003; 
Levitt et al., 2004). At a cellular level, there are presynaptic nerve endings specialized for the 
activity-dependent release of transmitter into the synaptic cleft, which is encapsulated by 
glial cells and contains adhesive molecules that keep presynaptic endings in register with 
postsynaptic specializations (“densities”) on neural cell bodies and branches. In the mature 
nervous system these structures signal by chemical transmission and thus integrate and 
propagate the electrical signals that communicate through the brain. Synapses are thought 
to form in the embryo largely by genetically pre-programmed, activity-independent and 
evolutionarily conserved mechanisms (Goodman & Shatz, 1993). During post-natal 
development, which is the period during which many developmental brain diseases start to 
manifest themselves, synaptic activity is required to select, refine and stabilize mature 
connectivity patterns (Katz & Shatz, 1996). Thus cells that fire together wire together.  
                                                 
3 A trio constitutes an affected individual and both his/her biological parents 
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Multiple indirect lines of evidence support the hypothesis of altered synaptic connectivity in 
Autism. These come in part from brain-imaging and neuropathological studies showing 
numerous alterations to both gross and microscopic structures of the brain of autistic 
individuals. For instance, an increased brain volume (Piven et al., 1996), increased brain 
weight (Bailey et al., 1998), abnormal neuronal morphology, with decreased complexity of 
dendritic branching and underdeveloped neuronal arbors (Bauman & Kemper, 1985; 
Raymond et al., 1996) have all been observed in autistic individuals. An abnormal neuronal 
density in the cerebellar hemispheres has also been observed (Bauman & Kemper, 1985). 
Notably, several components of the limbic system, including the amygdala (Lotspeich & 
Ciaranello, 1993) and the hippocampus (Raymond et al., 1996), have been found to be 
abnormal at the microscopic level.  Cytoarchitectural features that are frequently abnormal 
include reduced numbers of Purkinje neurons in the cerebellum and vermis and small 
tightly packed neurons in regions of the limbic system, especially in the entorhinal cortex 
and in the medially placed nuclei of the amygdala. The reduced neuronal size and 
shortened dendritic pattern found in post-mortem studies are consistent with synaptic 
alterations. This synaptic deficiency hypothesis has been also proposed for schizophrenia, a 
neurodevelopmental disorder that is also characterized by marked disruptions of 
information processing and cognition (Glantz & Lewis, 2000). More recently, in an effort to 
directly determine if spine densities, or the synaptic connectivity, are altered in autistic 
subjects, Hussler and Zhang examined the structural microcircuitry within the cerebral 
cortex i.e. dendritic spine densities on cortical pyramidal cells from autistic subjects and age-
matched control cases, on neurons located within both the superficial and deep cortical 
layers of frontal (BA 9), temporal (BA 21), and parietal lobe (BA 7). They observed several 
alterations in spine density in autistic subjects; for example the average spine densities in 
Autism were higher than those found in control cases, supporting altered synaptic 
connectivity and plasticity in the brains of individuals affected with Autism (Hutsler & 
Zhang, 2009).  
Other evidence suggesting impaired synaptic function in autistic individuals includes the 
discovery of mutations in different synaptic genes, such as the neuroligins, the neurexins 
and SHANK3 (see examples below in section 5.1).  As mentioned earlier, Rett syndrome 
shares many features with Autism. Mutations in the coding region of the MECP2 gene (a 
transcription repressor factor expressed by neurons and preferentially abundant in mature 
neurons) are known to be implicated in this severe disorder, with the vast majority of cases 
resulting from new mutations. Mutations in MECP2 gene have also been identified in 3 
females who meet the full diagnostic criteria for Autism, underscoring the similarity of these 
diseases (Carney et al., 2003). While the target genes for MECP2 protein remain unknown, 
the small brain size and the reduced neuronal and dendrite sizes in Rett Syndrome patients 
suggest that MECP2 may play a role in synaptic processes (Shahbazian et al., 2002; Balmer et 
al., 2003). Recent findings using the olfactory system as a model to study MECP2 expression 
during development suggest that it may be involved in the formation of synaptic contacts 
(Cohen et al., 2003). These data further support the possibility that Autism results mainly 
from synaptic dysfunction. 
5.1 Synaptic genes as candidates for autism 
At a molecular level, synapses are organized as macromolecular “machines” (Grant, 2003). 
These synaptic machines consist of a presynaptic release apparatus and a signalling device 
at the postsynaptic density held together in quasi-crystalline registry at the adhesive cleft. 
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Many of the proteins constituting these various components have been identified by 
decades of synaptic biochemistry and physiological genetics, and their macromolecular 
assemblies have been characterized by proteomic analysis. The presynaptic release 
apparatus consists of proteins that include those for the structural cytoskeleton, vesicular 
membrane and trafficking components, vesicle fusion grid and nerve terminal membrane 
(Phillips et al., 2001; Blondeau et al., 2004). The postsynaptic density consists of structural 
proteins as well as signalling components such as tyrosine kinases and phosphatases, while 
both pre- and post-synaptic membranes contain fast voltage-gated channels and 
neurotransmitter-gated receptors, channels, transporters and G-protein coupled receptors 
mediating neuromodulation (Walikonis et al., 2000; Satoh et al., 2002)  Rapid and selective 
communication across the synapse is ensured by the firm adhesion of each compartment at 
the cleft by cell surface as well as secreted extracellular matrix components (Huber et al., 
2003). It is therefore not surprising that synaptic genes constitute the largest class of genes 
associated to developmental brain disorders – with many more to be discovered.  Likewise, 
since many of these proteins are exposed at the extracellular surface, they could provide 
excellent “druggable” targets. 
The discovery of genes clinically relevant to Autism is accelerating, with many involved in 
the synapse including several neuroligands, as well as genes involved in the glutamatergic 
pathway (Betancur et al., 2009). Of particular interest is the example of the synaptic cell 
adhesions and associated molecules including the neuroligins-neurexins-SHANK3 genes. 
Mutations in the X-linked neuroligin-3 (NLGN3) and neuroligin-4 (NLGN4X and NLGN4Y) 
genes have been identified in brothers with autism. Laumonnier et al. identified a two base-
pair deletion in NLGN4 in 12 affected members of a French family with X-linked mental 
retardation, some of whom were also autistic (Laumonnier et al., 2004). Jamain et al. 
identified a C-to-T transition in the NLGN3 gene, in two brothers, one with autism and the 
other with Asperger syndrome (Jamain et al., 2003). The SHANK3 gene, which codes for a 
synaptic protein that binds directly to neuroligins, seems crucial for the development of 
language and social cognition. SHANK3 mutations and small cytogenetic rearrangements 
have been implicated with the Autism phenotype (Durand et al., 2007; Gauthier et al., 2009). 
Other genes involved in this pathway have been found to be mutated in autistic individuals. 
Indeed, variants in SHANK2 and LRRTM1 are reported in schizophrenia and Autism 
(Francks et al., 2007; Berkel et al., 2010). Other synaptic molecules implicated in Autism are 
the protocadherin family genes, which have been shown to be associated with Autism. 
Marshall et al. detected causative copy number variations in PCDH9 gene and a de novo 
translocation deleting the CDH18 genes in Autism (Marshall et al., 2008). Moreover, in a 
study of consanguineous families of Autism, a large homozygous deletion implicating 
PCDH10 was detected (Morrow et al., 2008). All of these examples emphasized the role of 
impaired synaptic pathways in the pathogenesis of Autism. 
6. Similar genetic architecture in other neurodevelopmental disorders  
Autism, schizophrenia, and intellectual disability are all severe neurodevelopmental 
disorders that have childhood or early adulthood onset with a lifetime disability. Clinical 
manifestations of these disorders are diverse and complex, and include abnormalities in 
neuronal excitability, processing of complex information, as well as behaviors such as 
anxiety and impaired social interactions. Pathological studies, neuroimaging and other 
clinical observations predict that these disorders result from disrupted neurodevelopment 
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other with Asperger syndrome (Jamain et al., 2003). The SHANK3 gene, which codes for a 
synaptic protein that binds directly to neuroligins, seems crucial for the development of 
language and social cognition. SHANK3 mutations and small cytogenetic rearrangements 
have been implicated with the Autism phenotype (Durand et al., 2007; Gauthier et al., 2009). 
Other genes involved in this pathway have been found to be mutated in autistic individuals. 
Indeed, variants in SHANK2 and LRRTM1 are reported in schizophrenia and Autism 
(Francks et al., 2007; Berkel et al., 2010). Other synaptic molecules implicated in Autism are 
the protocadherin family genes, which have been shown to be associated with Autism. 
Marshall et al. detected causative copy number variations in PCDH9 gene and a de novo 
translocation deleting the CDH18 genes in Autism (Marshall et al., 2008). Moreover, in a 
study of consanguineous families of Autism, a large homozygous deletion implicating 
PCDH10 was detected (Morrow et al., 2008). All of these examples emphasized the role of 
impaired synaptic pathways in the pathogenesis of Autism. 
6. Similar genetic architecture in other neurodevelopmental disorders  
Autism, schizophrenia, and intellectual disability are all severe neurodevelopmental 
disorders that have childhood or early adulthood onset with a lifetime disability. Clinical 
manifestations of these disorders are diverse and complex, and include abnormalities in 
neuronal excitability, processing of complex information, as well as behaviors such as 
anxiety and impaired social interactions. Pathological studies, neuroimaging and other 
clinical observations predict that these disorders result from disrupted neurodevelopment 
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caused by genetic and environmental factors (Lewis & Levitt, 2002). There is a significant 
overlap in clinical manifestations in these mental disorders, such as episodic psychosis 
and/or seizures, impaired cognitive functions, and language problems. Fifteen to thirty 
percent of Autism patients present with seizures and 20% of psychotic patients were 
diagnosed as having pervasive developmental disorders (Matese et al., 1994). Also, there is 
no clear clinical or neurobiological distinction between childhood schizophrenia, pervasive 
developmental disorder and autism (Mouridsen et al., 2000). Furthermore, these 
neurodevelopmental disorders can be included within the allelic spectrum of the same 
candidate gene. These observations strongly suggest that Autism, schizophrenia and 
intellectual disability may share similar pathogenic pathways and, thus, potential candidate 
genes. In addition, Autism, schizophrenia and intellectual disability have also a high 
prevalence, a high monozygotic twin concordance, a predicted high level of allelic and non-
allelic genetic heterogeneity and a uniform worldwide high incidence despite significantly 
reduced reproductive fitness. All of these observations support the notion that the de novo 
mutations model be involved in all these disorders.  
6.1 One gene, three phenotypic conditions 
We believe that Autism, schizophrenia and intellectual disability, all severe 
neurodevelopmental disorders, can be studied in a similar manner, which focuses on the 
synaptic gene de novo mutation model. In addition, in some instances mutations in the same 
gene can lead to Autism, intellectual disability or schizophrenia, three clinically distinct 
phenotypes, as defined in the Diagnostic and Statistical Manual of Mental Disorders, the 
reference manual for the classification of mental disorders. A recent example is our findings 
with the SHANK3 gene. Disruption of this synaptic gene was originally associated with the 
22q13.3 deletion syndrome [OMIM 606232] characterized by neonatal hypotonia, global 
developmental delay, normal to accelerated growth, absent to severely delayed speech, 
autistic behavior (OMIM 209850), and minor dysmorphic features. In 2007, Durand et al. 
and Moessner et al., showed that abnormal gene dosage of SHANK3 is associated with 
Autism (Durand et al., 2007; Moessner et al., 2007). In addition, we identified a de novo 
splicing mutation in SHANK3 in a patient with non-syndromic intellectual disability 
without Autism (Hamdan et al.). We also found deleterious de novo mutations in the 
SHANK3 gene in a patient diagnosed with schizophrenia plus cognitive impairment. 
Similarly, mutations in the NRXN1 gene can lead to rare forms of Autism and schizophrenia 
(Kim et al., 2008; Rujescu et al., 2009). This phenomenon has been observed in other diseases 
and, as stressed by Zoghbi and Warren in their recent paper (Zoghbi & Warren, 2010), other 
examples include the ARX gene which causes X-linked lissencephaly, agenesis of corpus 
callosum with abnormal genitalia, cognitive deficits with or without seizures, or cognitive 
deficits, dystonia, and seizures; LMNA gene, which can lead to a diversity of disorders 
including Emery-Dreifuss muscular dystrophy Type 2, Charcot-Marie-Tooth axonal 
neuropathy limb girdle muscular dystrophy Type 1B, Hutchinson-Gilford progeria 
syndrome, and many other different clinical manifestations. 
Altogether, these findings suggest that the neuroanatomical and physiological disturbances 
resulting from dysfunction of mutant genes may be influenced by the effect of genetic 
modifiers, the nature of the gene’s role in the human brain and the effect of environmental 
experiences of the affected individuals, leading to different clinical outcomes in different 
patients. Differences in the mutation types (for example, point mutation vs. large gene 
disruptions) must certainly also contribute to the phenotypic variability. Although this 
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observation is intriguing, multiple phenotypic manifestations from mutations of the same 
single gene have been described for many other diseases. Finally, the observation that one 
gene can lead to many phenotypes raised the question of whether Autism, schizophrenia 
and intellectual disability are different entities or part of a same phenotypic continuum.  
7. Gene hunting approaches and the impact of the development of new 
technologies   
In the last few years, a new generation of technologies, referred to as the next-generation 
DNA sequencing technologies have been developed which allow screening of the entire 
genome (i.e. > 20,000 genes) of single individuals within a matter of days. This new 
technology has revolutionized genetic research and has allowed new approaches in the 
search for diseases-causative genes. Before the advent of the next-generation DNA 
sequencing technologies, gene screening for the identification of disease-causative mutation 
was done one gene at a time. Next-generation DNA sequencing enable the parallel 
sequencing of all the 20,000 genes, leading to faster identification of mutations.  These 
technologies therefore constitute the ideal method of screening for rare causative variants in 
all genes simultaneously. In the context of Autism and of the above mentioned de novo 
mutation genetic mechanism, the major advantage of these technologies is to make possible 
the identification of very rare de novo mutations, by comparing the genetic variants in an 
affected subject to those in both of his/her parents (a family trio). Given sufficient coverage 
and quality in next-generation DNA sequencing datasets, identifying de novo mutations in 
trios is highly feasible.   
Sequencing of entire genomes is still rather expensive, so many groups now focus on the 
sequencing of the entire “exome” (i.e., the various coding regions of the genome) of an 
individual. Focusing on the exome is a reasonable approach as the vast majority of disease-
causing mutations identified to date disrupt the protein-coding regions of genes. Such 
mutations include nonsense, small insertion/deletions, frameshifts, splicing and missense 
mutations, whose consequences can be predicted in silico based on well-annotated reference 
datasets (e.g. the human consensus CDS (CCDS) subset of the NCBI RefSeq database 
includes 23,339 consistently annotated protein-coding transcripts).  These coding regions 
constitute less than 3% of the entire genome. Oligonucleotide hybridization-based methods 
that permit the capture and amplification of virtually all human exons at once, i.e. the 
human “exome”, are now commercially available (NimbleGen, Agilent, Illumina). Limiting 
the analysis to the exome significantly increases the number of samples that can be 
sequenced, and is more likely to identify causative genes. Since it is likely that highly 
penetrant alleles (i.e. protein-truncating or missense) in different autistic cases will result 
from mutations in dozens of different genes,  it is preferable to concentrate on re-sequencing 
only the coding regions of the genome, or the “exome”,  using targeted microarray capture 
followed by next generation sequencing. In addition mutations in coding regions are most 
easily interpreted thus making the link to the disorder easier to establish. The availability of 
these technologies is accelerating all aspects of the gene hunting process e.g. increasing 
number of genes that can be now analysed in a shorter period of time and the number of 
subjects being studied.  
7.1 Challenges for the next-generation approaches 
As next-generation DNA sequencing technologies improve, and as it becomes possible to 
rapidly produce detailed lists of variants per individual genome, the challenge will be to 
 
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment 
 
112 
caused by genetic and environmental factors (Lewis & Levitt, 2002). There is a significant 
overlap in clinical manifestations in these mental disorders, such as episodic psychosis 
and/or seizures, impaired cognitive functions, and language problems. Fifteen to thirty 
percent of Autism patients present with seizures and 20% of psychotic patients were 
diagnosed as having pervasive developmental disorders (Matese et al., 1994). Also, there is 
no clear clinical or neurobiological distinction between childhood schizophrenia, pervasive 
developmental disorder and autism (Mouridsen et al., 2000). Furthermore, these 
neurodevelopmental disorders can be included within the allelic spectrum of the same 
candidate gene. These observations strongly suggest that Autism, schizophrenia and 
intellectual disability may share similar pathogenic pathways and, thus, potential candidate 
genes. In addition, Autism, schizophrenia and intellectual disability have also a high 
prevalence, a high monozygotic twin concordance, a predicted high level of allelic and non-
allelic genetic heterogeneity and a uniform worldwide high incidence despite significantly 
reduced reproductive fitness. All of these observations support the notion that the de novo 
mutations model be involved in all these disorders.  
6.1 One gene, three phenotypic conditions 
We believe that Autism, schizophrenia and intellectual disability, all severe 
neurodevelopmental disorders, can be studied in a similar manner, which focuses on the 
synaptic gene de novo mutation model. In addition, in some instances mutations in the same 
gene can lead to Autism, intellectual disability or schizophrenia, three clinically distinct 
phenotypes, as defined in the Diagnostic and Statistical Manual of Mental Disorders, the 
reference manual for the classification of mental disorders. A recent example is our findings 
with the SHANK3 gene. Disruption of this synaptic gene was originally associated with the 
22q13.3 deletion syndrome [OMIM 606232] characterized by neonatal hypotonia, global 
developmental delay, normal to accelerated growth, absent to severely delayed speech, 
autistic behavior (OMIM 209850), and minor dysmorphic features. In 2007, Durand et al. 
and Moessner et al., showed that abnormal gene dosage of SHANK3 is associated with 
Autism (Durand et al., 2007; Moessner et al., 2007). In addition, we identified a de novo 
splicing mutation in SHANK3 in a patient with non-syndromic intellectual disability 
without Autism (Hamdan et al.). We also found deleterious de novo mutations in the 
SHANK3 gene in a patient diagnosed with schizophrenia plus cognitive impairment. 
Similarly, mutations in the NRXN1 gene can lead to rare forms of Autism and schizophrenia 
(Kim et al., 2008; Rujescu et al., 2009). This phenomenon has been observed in other diseases 
and, as stressed by Zoghbi and Warren in their recent paper (Zoghbi & Warren, 2010), other 
examples include the ARX gene which causes X-linked lissencephaly, agenesis of corpus 
callosum with abnormal genitalia, cognitive deficits with or without seizures, or cognitive 
deficits, dystonia, and seizures; LMNA gene, which can lead to a diversity of disorders 
including Emery-Dreifuss muscular dystrophy Type 2, Charcot-Marie-Tooth axonal 
neuropathy limb girdle muscular dystrophy Type 1B, Hutchinson-Gilford progeria 
syndrome, and many other different clinical manifestations. 
Altogether, these findings suggest that the neuroanatomical and physiological disturbances 
resulting from dysfunction of mutant genes may be influenced by the effect of genetic 
modifiers, the nature of the gene’s role in the human brain and the effect of environmental 
experiences of the affected individuals, leading to different clinical outcomes in different 
patients. Differences in the mutation types (for example, point mutation vs. large gene 
disruptions) must certainly also contribute to the phenotypic variability. Although this 
 
A New Genetic Mechanism for Autism 
 
113 
observation is intriguing, multiple phenotypic manifestations from mutations of the same 
single gene have been described for many other diseases. Finally, the observation that one 
gene can lead to many phenotypes raised the question of whether Autism, schizophrenia 
and intellectual disability are different entities or part of a same phenotypic continuum.  
7. Gene hunting approaches and the impact of the development of new 
technologies   
In the last few years, a new generation of technologies, referred to as the next-generation 
DNA sequencing technologies have been developed which allow screening of the entire 
genome (i.e. > 20,000 genes) of single individuals within a matter of days. This new 
technology has revolutionized genetic research and has allowed new approaches in the 
search for diseases-causative genes. Before the advent of the next-generation DNA 
sequencing technologies, gene screening for the identification of disease-causative mutation 
was done one gene at a time. Next-generation DNA sequencing enable the parallel 
sequencing of all the 20,000 genes, leading to faster identification of mutations.  These 
technologies therefore constitute the ideal method of screening for rare causative variants in 
all genes simultaneously. In the context of Autism and of the above mentioned de novo 
mutation genetic mechanism, the major advantage of these technologies is to make possible 
the identification of very rare de novo mutations, by comparing the genetic variants in an 
affected subject to those in both of his/her parents (a family trio). Given sufficient coverage 
and quality in next-generation DNA sequencing datasets, identifying de novo mutations in 
trios is highly feasible.   
Sequencing of entire genomes is still rather expensive, so many groups now focus on the 
sequencing of the entire “exome” (i.e., the various coding regions of the genome) of an 
individual. Focusing on the exome is a reasonable approach as the vast majority of disease-
causing mutations identified to date disrupt the protein-coding regions of genes. Such 
mutations include nonsense, small insertion/deletions, frameshifts, splicing and missense 
mutations, whose consequences can be predicted in silico based on well-annotated reference 
datasets (e.g. the human consensus CDS (CCDS) subset of the NCBI RefSeq database 
includes 23,339 consistently annotated protein-coding transcripts).  These coding regions 
constitute less than 3% of the entire genome. Oligonucleotide hybridization-based methods 
that permit the capture and amplification of virtually all human exons at once, i.e. the 
human “exome”, are now commercially available (NimbleGen, Agilent, Illumina). Limiting 
the analysis to the exome significantly increases the number of samples that can be 
sequenced, and is more likely to identify causative genes. Since it is likely that highly 
penetrant alleles (i.e. protein-truncating or missense) in different autistic cases will result 
from mutations in dozens of different genes,  it is preferable to concentrate on re-sequencing 
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discriminate the pathogenic variants from the benign ones and establish the link to the 
disorder. Three major challenges can be identified. The first and most technical one is the 
ability to handle very large datasets in the order of tens or hundreds of terabytes in size, and 
access to powerful computing platforms that can process these datasets, and adequate 
resources for storage, retrieval and archiving. The second is the capacity to develop robust 
yet comprehensive methods to identify variants from next-generation DNA sequencing 
datasets. Choosing the correct sequence coverage and quality filters will ensure a maximum 
of true variants to be identified, with as few false positives or false negatives as possible. 
Several programs are available that can align short sequence reads to a reference genomic 
sequence and call potential homozygous or heterozygous variants. However, the total 
number of variants identified, even using different parameters within the same program, 
can vary largely.  Intuitive paradigms and empirically determined cut off points need to be 
implemented. Furthermore, the accurate annotation of genomic variants is critical to 
classifying different variants for their potential impact on transcription, splicing or 
translation. This step must be comprehensive so that potential protein-truncating variants 
are not missed given that alternate splicing can lead to different transcripts with different 
open reading frames within a single gene. Finally, developing an experimental design based 
on the known or anticipated genetic mechanisms underlying the disease or condition, and 
on high quality diagnostic procedures, requires that affected and unaffected individuals be 
carefully selected from family groups to help prioritize variants for further analysis, and to 
maximize the chances of finding causative genes. In our case, identifying de novo mutations 
by analysing trios can very quickly lead to the identification of causative mutations and risk 
genes.  Successful mastery of these key strategic and technical competencies is necessary to 
identify potentially pathogenic variants. 
7.2 Copy number variations and autism 
The use of microarray approaches for the detection of copy number variations, which its 
continuously improving resolution, provides additional evidence for the occurrence of de 
novo genomic events in the pathogenesis of Autism. In the last decade, studies  linking copy 
number variation, and Autism have revealed that de novo and inherited copy number 
variations, including deletions and duplications, translocations, and inversions of 
chromosomes, all may significantly contribute to the pathogenesis of Autism, usually as 
penetrant rare variants (Sebat et al., 2007; Walsh et al., 2008). For example Sebat et al.  
showed that de novo copy number variations are more common in autistic patients than in 
non-autistic individuals (Sebat et al., 2007). They found that 10% of their patients with 
sporadic Autism (i.e. individuals with no history of the disorder) harboured a de novo copy 
number variation, while the frequency was only 3 % in patients with an affected first-degree 
relative and 1% in controls.  
Other similar examples include the study from Marshall et al. (Marshall et al., 2008), 
Christian et al. (Christian et al., 2008) and Szatmari et al. (Szatmari et al., 2007) and more 
recently the report of Bremer et al. (Bremer et al.), which are all consistent with the 
hypothesis that de novo or weakly recurrent copy number variations seem to be significant 
contributing factor in the pathogenesis of Autism.  Interestingly, based on the results of their 
copy number variations analyses, Marshall et al, concluded that “structural de novo were 
found in sufficiently high frequency in Autism subjects suggesting that cytogenetic and 
microarray analyses be considered in routine clinical workup” (Marshall et al., 2008). 
Although this is not the focus of this chapter, the genes identified by copy number variation 
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analysis also support the notion that there are shared biological pathways in Autism, 
intellectual disability and schizophrenia (Guilmatre et al., 2009)  
8. Conclusion and directions for future studies  
As outlined throughout this chapter, several lines of evidence support the role of de novo 
mutations in the pathogenesis of Autism. De novo mutations are a well-established genetic 
mechanism for the development of a number of disorders such as Rett Syndrome and 
certain types of cancers but have been poorly explored for common diseases like Autism. In 
general, the development of technologies often brings new challenges, but mostly allows 
research to accelerate. Indeed, this technological progress is already starting to provide data 
supporting the role of de novo mutations in Autism. This hypothesis is gaining acceptance in 
the scientific community, as reflected in the growing number of recent publications on this 
subject. Although the focus of this chapter is on the role of de novo mutations in Autism, we 
acknowledge the fact that many other genetic or non-genetic mechanisms certainly 
contribute to this disorder.  
The accessibility of next-generation DNA sequencing methodologies have enabled 
researchers to analyse a large amount of DNA and has had an important impact on gene 
hunting strategies , which have shifted from a tendency to look at single genes, one at the 
time, to multiple genes simultaneously. One interesting consequence of next-generation 
DNA sequencing is that it recently permitted to directly estimate the rate of de novo germline 
base substitution mutations in humans (Awadalla et al., 2010; Durbin et al., 2010). Based on 
these data, the challenge will be to determine if the observed de novo mutation rate detected 
in a disease is greater than the baseline rate.  
In the last few years, researchers have identified several genes contributing to Autism, and 
most encode for proteins that are part of the synaptic machinery. An important concern for 
future research, where there will be rapid identification of many potential Autism gene 
mutations, will be to determine if they have a functional relevance to the disorder. Indeed, 
this question needs to be judiciously examined for most of the variants discovered. This will 
require to study  model organism systems as proposed in our current Synapse to disease 
project (S2D; http://www.synapse2disease.ca), a large-scale medical research project 
launched in 2006 aiming to identify genes involved in several neurological and psychiatric 
diseases caused by defects in the development and functioning of the brain and nervous 
system. This project’s philosophy is that once the base changes are discovered and 
considered  likely to be  “pathogenic mutations”, biological validation must be conducted in 
vitro and in vivo in different model organism (e.g. fly, worm, fish, etc.) to determine their 
functional effects. Biological validation is an essential step often missing from most genetic 
studies and has thus severely limited data interpretation in the context of disease pathology. 
This validation will consequently help understanding pathways in neurodevelopmental 
disorders and ultimately give insights for the development of targeted therapeutic 
strategies.  
Another challenge for future research in the field is the issue of whether genomic variants 
beyond the coding regions of a gene contribute to the etiology of the disorder. As mentioned 
earlier, the majority of mutations identified in Autism are located within coding regions but 
it should not be forgotten that variants in the non-coding regions, particularly the regulatory 
gene region, can also lead to disease.  
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Finally, the accessibility of the next-generation DNA sequencing technologies is facilitating 
the gene hunting process for researchers, whereas its application for clinical diagnostic 
testing seems to be inevitable, particularly as the cost per base continues to decrease.  
Although, the clinical tests based on these technologies represent particular challenges and 
will need careful validation, the connection between research findings in the genetics of 
Autism or any other neurodevelopmental disorders and clinical applications is closer than 
ever. All these research and technological advancements are for the greatest benefit of 
families. 
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Finally, the accessibility of the next-generation DNA sequencing technologies is facilitating 
the gene hunting process for researchers, whereas its application for clinical diagnostic 
testing seems to be inevitable, particularly as the cost per base continues to decrease.  
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will need careful validation, the connection between research findings in the genetics of 
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ever. All these research and technological advancements are for the greatest benefit of 
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1.1 Definitions of ID and autism 
Intellectual disability (ID) is a common neurodevelopmental disorder that is characterized 
by an intelligence quotient (IQ) lower than 70, and deficits in at least two behaviors related 
to adaptive functioning diagnosed by 18 years of age (American Psychiatric Association, 
2000). Adaptive functioning behaviours can be defined as the ability to acquire skills that 
help an individual to live independently and to cope with everyday life, and involves skills 
such as language/communication, social skills, home living and safety. ID ranges in its 
severity and may either be present co-morbidly with many congenital syndromes, or may 
present alone. 
Autism is a severe, lifelong neurodevelopmental disorder characterized by impairments in 
three major domains: communication, socialization, and repetitive behavior. Leo Kanner 
first described this developmental disorder in 1943 as a social disorder featuring the innate 
inability to form typical, affective contact with others (Kanner, 1943). It is now known that 
the Autism Spectrum Disorder (ASD) includes a widely variable range of clinical 
phenotypes that have been grouped into individual disorders. Autistic disorder (autism), 
Asperger syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), 
Rett syndrome and child disintegrative disorder (CDD) are all currently separate diagnoses 
in the DSM-IV under the umbrella title “Pervasive Developmental Disorders”(American 
Psychiatric Association, 2000). These disorders differ from each other with regard to severity 
of symptoms, early development of language, deterioration in skills once they have 
developed, and cognitive development.  
Individuals with autism show severe deficits in all three major phenotypic domains and 
present with abnormal development before age 3 years. In addition, cognitive functioning is 
frequently delayed. Individuals with Broad Autism Phenotype (BAP) have some symptoms 
of autism, but do not meet the full criteria for autism or ASD (Hurley et al., 2007). BAP is 
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currently not a recognized diagnosis within the DSM-IV, however, it can be useful when 
looking at familiality in ASDs.  
Asperger syndrome is characterized by qualitative impairment in social interaction and 
restricted repetitive and stereotyped patterns of behavior, interests and activities. Language 
and cognitive development is relatively unaffected in these individuals, however pragmatic 
or social language is often delayed (McConachie & Diggle, 2007). Individuals with PDD-
NOS meet autism criteria and have later age of onset. These individuals may also show 
severe and pervasive impairment in one or two of the three core domains with or without 
cognitive or language delay. Rett syndrome occurs almost exclusively occurs in females and 
it is characterized by developmental arrest between 6 and 18 months of age, followed by loss 
of speech, stereotypical movements, microcephaly, seizures, and intellectual disability 
(Hagberg et al., 1983). CDD is characterized by normal development for at least the first two 
years (but up to 10 years) of life, followed by clinically significant loss of acquired skills. 
Individuals with CDD must not meet the diagnostic criteria for Rett syndrome or 
schizophrenia. They also must display at least two of the three diagnostic domains for 
autism.  
While ASDs are often associated with ID, it should be noted that not all individuals with 
ASD have cognitive deficits. The current DSM-IV statistic states that 75% of individuals with 
ASD have some degree of intellectual disability. However, this may be an outdated over-
estimate. More recent studies suggest an increasingly modest level; approximately 50-60% 
[71%(Chakrabarti & Fombonne, 2001) 63%(Bertrand et al., 2001); 40%(Baird et al., 2006), 
50%(Charman et al., 2011]. With increased awareness in the general population and a 
greater understanding of the problem by professionals, an increasing number of people with 
high functioning Autism and Asperger syndrome are diagnosed with the condition. This 
has probably changed the proportion of cases with identifiable ID among the ASD 
population. It is also possible that expanding the diagnostic criteria for ASDs, which 
historically were much more limited, might explain this decrease (Charman et al., 2011).  
The new DSM-V, which will be available in 2013, will define ASDs differently than the 
current version. The three behavioural domains will be condensed into two: Social 
communication and repetitive behaviours/narrow interests. In addition, the separate 
diagnoses within the spectrum will be removed. Autism, Rett syndrome, Asperger 
syndrome, PDD-NOS and CDD will all be classified as “autism spectrum disorder” with a 
specified etiology/syndrome if known (e.g. ASD with Rett syndrome; DSM-5 Proposed 
Revisions, 2010). In addition, a level of severity will be assigned to each diagnosis, which 
will reflect the functional level of the individual. The alteration in nomenclature reflects the 
clinical and interventional needs of the individuals and is intended to be more reflective of 
what is known of the pathology of the disorder (DSM-5 Proposed Revisions, 2010). 
1.2 Classification of ID by IQ and syndromic vs. nonsyndromic 
ID is currently subdivided into 5 categories based on intelligence quotient (IQ): mild, 
moderate, severe, profound and unable to classify (American Psychiatric Association, 2000; 
Table 1). However, epidemiological studies often use a simplified classification, grouping 
their subjects into mild ID (IQ50-70) and severe ID (IQ<50; Ropers & Hamel, 2005). IQ tests 
are a set of tasks which are administered to representative population samples for creation 
of norms. An IQ two standard deviations below the mean or lower is indicative of ID. The 
distribution of IQ in the population is normal in the main, apart from an increased number 
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of cases in the tail on the lower end of IQ. On that basis, the population prevalence of ID 
should be close to 3% at least. The studies looking at prevalence of ID were recently 
reviewed systematically. The range reported varied between 0.93 per 1000 and 156.03 per 
1000 (Maulik et al., 2011). Differences in rates of mild ID mainly account for this variation. 
The reasons are differences in definition of ID criteria, characteristics and setting of the 
sample studied and differences in methodology. The prevalence of severe ID is relatively 
stable (3-4 per 1000; (Roeleveld et al., 1997; Leonard & Wen, 2002; Emerson, 2007).  
 
Severity IQ Proportion of ID Functional Level 
Borderline 70-84 N/A Can live independently; May require 
low level support 
Mild 50-69 85% Can often live independently with 
social support 
Moderate 35-49 10% Acquire some communication and self-
help skills, require moderate 
supervision 
Severe 20-34 3-4% Acquire only basic self-help and 




<20 1-2% Require highly structured and 
supervised living conditions 
Table 1. This table indicates the categories of intellectual disabilities by IQ and ability to 
function in society as indicated by the DSM-IV-TR.  
The new DSM-5 will likely be changing the severity criteria to encompass functional 
behavioural deficits and the level of interference that these have in the lives of affected 
individuals (DSM-5 Proposed Revisions, 2010). Although the new criteria have not yet been 
established, it will likely echo the changes to the criteria for autism, focusing on functional 
level as opposed to strict IQ cut-offs. The manual will also be changing the wording of the 
ID diagnostic criteria to encourage cultural sensitivity and relevance, and to ensure that 
culturally validated psychometric tests are used to evaluate IQ and level of functioning.  
In addition to categorization by severity/IQ level, ID can also be grouped into syndromic 
intellectual disability (S-ID) and non-syndromic intellectual disability (NS-ID). In S-ID, 
individuals present with an identifiable constellation of clinical features or co-morbidities in 
addition to ID. While S-ID has a clear definition, there is debate over the classification of NS-
ID. Traditionally, NS-ID has been defined by the presence of intellectual disability as the 
sole clinical feature. However, it has been a challenge to rule out the presence of more subtle 
physical signs, neurological anomalies and psychiatric disorders in these individuals, as 
they may be less apparent, or difficult to diagnose due to the cognitive impairment. 
Additionally, the symptoms of some syndromes may be so subtle that they are extremely 
difficult to diagnose unless the features are looked for specifically in the context of a known 
genetic defect previously associated with these features (Ropers, 2006). Thus the distinction 
between S-ID and NS-ID is often blurred. 
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of cases in the tail on the lower end of IQ. On that basis, the population prevalence of ID 
should be close to 3% at least. The studies looking at prevalence of ID were recently 
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Severity IQ Proportion of ID Functional Level 
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supervision 
Severe 20-34 3-4% Acquire only basic self-help and 




<20 1-2% Require highly structured and 
supervised living conditions 
Table 1. This table indicates the categories of intellectual disabilities by IQ and ability to 
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1.3 Endophenotypes and “essential autism” versus “complex autism” 
The extreme phenotypic heterogeneity of ASD poses a challenge for the study of underlying 
etiologies. It has been argued that delineation of the clinical heterogeneity of ASD may help 
in the identification of more homogeneous sub-groups for the study of etiological factors, 
and to predict the outcome and treatment choices. While ASD has three core phenotypic 
domains, it can also be sub-grouped on the basis of presence or absence of certain clinical 
features, termed endophenotypes. Endophenotypes of ASDs include IQ level, seizures, 
brain malformations, dysmorphology and head circumference (Viding & Blakemore, 2007).  
Historically, based on non-verbal IQ testing, ~70% of autistic children were reported as 
having some form of ID (Fombonne, 2003). While it is now thought that this number may be 
lower, it is essential to look at IQ as an endophenotype of autism when predicting outcomes. 
Previously published longitudinal studies report that IQ scores can strongly predict long-
term outcomes of ASD and are directly associated with the psychopathology of autism, even 
in young children (Howlin et al., 2004). In addition, preschool cognitive functioning has 
been found to be a strong predictor of school-age functioning, and high IQ has been shown 
to be necessary but not sufficient for optimal outcome in the presence of severe language 
impairment (Stevens et al., 2000).  
Another common central nervous system (CNS) dysfunction associated with autism is the 
high risk of epilepsy (Spence & Schneider, 2009). The prevalence of seizures in autism is 
estimated to be up to 46% (Hughes & Melyn, 2005) and it has been estimated that as many 
as 32% of individuals with epilepsy may meet the diagnostic criteria for ASD (Clarke et al., 
2005). Notably, the prevalence of seizures is higher among autistic individuals with 
moderate to severe ID and individuals with overt motor abnormalities (Tuchman & Rapin, 
2002). Furthermore, individuals with autism plus epilepsy on average have lower IQs. 
Epilepsy is one of the negative factors contributing to cognitive, adaptive and 
behavioral/emotional outcomes for autistic individuals (Hara, 2007). 
Structural brain malformations, including accentuated Virchow–Robin space, acrocallosal 
syndrome and polymicrogyria have been reported to be associated with autism (Steiner et 
al., 2004; Schifter et al., 1994; Zeegers et al., 2006), however, until recently, MRIs have been 
considered to be of indeterminate value and they are not included in the standard clinical 
evaluation of autism. A recent study has revealed an unexpectedly high prevalence of brain 
abnormalities (48%) in autism patients. Some common abnormalities include white-matter 
signal abnormalities, severely dilated Virchow-Robin space and temporal lobe structural 
abnormalities (Boddaert et al., 2009). 
Generalized dysmorphology, an indicator of insult in early development, has been reported 
in 15% to 20% of individuals with autism (Miles & Hillman, 2000) and has been proposed to 
be a predictor of a poor response to early intensive behavioral intervention. According to the 
Autism Dysmorphology Measure (ADM) guidelines, the 12 body areas assessed for 
dysmorphology are: height, hair growth pattern, structure and size of ear, nose size and 
shape, face size and structure, philtrum, mouth and lips, teeth, hand size, fingers and 
thumbs, nails and feet. The ADM was developed by the Miles laboratory at the University of 
Missouri to aid clinicians who are not extensively trained in medical genetics to distinguish 
between individuals with ASD with and without dysmorphisms (Miles & Hillman, 2000). 
Besides generalized dysmorphology, head size abnormalities (microcephaly and 
macrocephaly) have also been found in autistic individuals. Microcephaly, head 
circumference <2nd centile, occurs in 5 to 15% of children with autism and is a predictor of 
poor outcome (Miles et al., 2005). On the other hand, macrocephaly, head circumference 
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>97th centile has been observed in ~30% of children with autism (Miles et al., 2000). 
Generalized dysmorphology and microcephaly have been proposed as good predictors of 
clinical outcome and may be used to classify the autism phenotype into subgroups: complex 
autism and essential autism. Complex autism consists of autistic individuals who show 
evidence of some abnormality in early morphogenesis, manifested by either significant 
dysmorphology or microcephaly. The remainder without dysmorphic features or 
microcephaly are classified as having essential autism (Miles et al., 2005), and make up 70-
80% of the autism population. 
1.4 Diagnostic approaches 
The symptoms of most ASDs are usually present by the age of three and may persist 
throughout the lifespan; however, CDD and PDD-NOS may present later. A number of 
checklists and diagnostic tools are available for diagnosis of autism. The Childhood Autism 
Rating Scale (CARS; Schopler et al., 1980) is a commonly used diagnostic checklist which 
consists of 15 questions scored by the parents and the examiner. It is a reliable and efficient 
tool that is commonly used in clinics. Another autism screening tool widely used in clinical 
settings is the Checklist for Autism in Toddlers-modified (M-CHAT). This checklist consists 
of 23 yes/no questions and is a promising tool for the early diagnosis of autism (Robins et 
al., 2001). Other such checklists include the Autism Behaviour Checklist (ABC; Witwer & 
Lecavalier, 2007) and Gilliam Autism Rating Scale (GARS; South et al., 2002).   
The Autism Diagnostic Observation Schedule (ADOS) and Autism Diagnostic Interview-
Revised (ADI-R) are two widely accepted instruments used for diagnosis of ASD in both 
clinical and research settings. ADI-R, a revised version of Autism Diagnostic Interview 
(ADI), is a semi-structured, investigator-based interview for the caregivers of children with 
autism and adults for whom autism or ASD is a possible diagnosis (Lord et al., 1994). The 
ADOS is a semi-structured, standardized assessment of social interactions, communication, 
play, and imaginative use of objects for children suspected of having ASD (Lord et al., 2000). 
It is an observational assessment of the child’s behaviour, often performed by a psychologist 
or another trained professional. Checklist tools are widely used in clinical practice because 
of their ease and efficiency; however, ADI-R and ADOS have been adapted, particularly in 
recent years, to make them more appropriate for use in clinical settings, as well as for 
diagnosis of toddlers and patients with intellectual disabilities. In particular, the shorter 
version of ADOS is becoming increasingly popular in clinics.  
All of these diagnostic tools have their own advantages and disadvantages. For example, 
ADI-R and ADOS are lengthy, require elaborate training and are suitable for use in more 
specialized settings. The Checklist for Autism in Toddlers-modified (M-CHAT), described 
earlier in this section, has been particularly useful in the frontline clinical world, as well as 
for early diagnosis of autism (Robins et al., 2001), and has overcome some of the challenges 
faced by ADI-R and ADOS. M-CHAT includes a checklist of 23 items to be filled out by 
parents and it can be administered at a much earlier stage to identify toddlers who are at  
risk of autism. A recent study has confirmed the validity of this instrument in detecting 
possible ASD at 16-30 months of age (Kleinman et al., 2008). However, the high sensitivity of 
this checklist means that some children without autism will fail the screening. It has been 
suggested that children who fail and do not have autism are at increased risk for other 
developmental disorders or delays and should be monitored accordingly (Robins et al., 
2001).  
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Over last two decades the diagnosis of syndromes based on behavioural symptoms has 
become relatively standardized, although there are some issues around the potential for 
over diagnosis of higher functioning autism and Asperger syndrome. However, the etiology 
of ASDs is largely unknown, and few genetic tests or biomarkers have been found to 
confirm an autism diagnosis. In other words, no laboratory-based means of testing for 
autism is yet widely available. While various genes have been identified that cause autism, 
none of them are common, and justification for performing individual testing is debatable. 
However, tests are currently being offered commercially for a number of these known 
genes, including CNTNAP2, PTEN and SHANK3 . Recently, microarray technology has also 
been proposed as a potential diagnostic tool, or a method to determine etiology. Because of 
the growing number of genes known to cause ASDs, an autism microarray, containing only 
verified autism causing genes, could be custom made to assess if these genes are aberrant in 
affected individuals.  The proportion of cases with known etiology at this stage will be very 
small (less than 5%) and a negative test would not mean an exclusion of the diagnosis. 
Knowing the root cause of autism may not lead to an alteration in treatment or intervention 
at this stage, but may be useful for family planning and genetic counseling, as well as for the 
emotional well being of concerned family members. Additionally, with further phenotype 
profiling and analysis of individuals with particular mutations, it may be possible to tailor 
interventions based on genetic diagnoses in the future.  
2. Causes of ID 
ID can be caused by environmental and/or genetic factors. However, for up to 60% of cases, 
there is no identifiable cause (Rauch et al., 2006). Environmental exposure to certain 
teratogens, viruses or radiation can cause ID, as can severe head trauma or injury causing 
lack of oxygen to the brain (Chelly et al., 2006). While these factors explain some cases of ID, 
it is also important to consider genetic etiology. 
Genetic causes of ID are thought to be present in 25-50% of cases, although this number 
increases proportionally with severity (McLaren & Bryson, 1987). Chromosomal 
abnormalities have been reported in ID, with a broad range of prevalence, and many 
different types of aberrations have been identified (Rauch et al., 2006). Over the past 15 
years many single gene causes of ID have been identified as well. Many of these genes cause 
a broad range of phenotypes including syndromic ID (S-ID), non-syndromic ID (NS-ID), 
autism and other neurodevelopmental and psychiatric phenotypes. This suggests that it is 
likely that other genetic modifiers or environmental factors may be involved in disease 
etiology, and that similar biological pathways, when disturbed, have the potential to lead to 
a range of these conditions. This illustrates the need for detailed study and descriptions of 
phenotypes for each gene and mutation. Most of the mutations that cause ID are highly 
penetrant and are inherited in a Mendelian fashion. Many known ID genes are on the X-
chromosome, however the number of autosomal genes associated with ID is growing 
rapidly (Kaufman et al., 2010). This is due to advances in technology which allow us to 
study the autosomes more efficiently, along with a shift in focus from the X-chromosome to 
the autosomes resulting from the realization that the X-linked genes may only account for 
~10% of ID cases, while autosomal genes may account for many more (Ropers & Hamel, 
2005). 
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3. Causes of autism 
3.1 Genetic contributions 
The causes of autism are likely far more complex than the causes of ID. Genetic factors 
clearly play a prominent role. The evidence for the involvement of genetic factors in the 
etiology of autism comes primarily from family and twin studies and is further supported 
by cytogenetic and molecular studies. Several sibling concordance studies have provided a 
strong indication that autism has a significant genetic component. Studies over the years, 
including analyses of autism probands with severe ID, evaluations of the developmental, 
social, and psychiatric histories of siblings of autistic individuals and reviews of familial 
aggregation in large autism cohorts, have all displayed higher than expected familiality 
(Baird & August, 1985; Piven et al., 1990; Bolton et al., 1994). A recent study examined the 
cognitive, adaptive, social, imitation, play, and language abilities of 42 non-autistic siblings 
(of autism probands) and 20 toddlers with no family history of autism. The siblings were 
below average in expressive language abilities and IQ. They had lower mean receptive 
language, adaptive behavior, and social communication skills. They used fewer words, 
distal gestures, and social smiles than children with no familial history of autism (Toth et al., 
2007).  
On the other hand, the familiality of autism does not imply that genetic factors are 
exclusively responsible for the disease, and role of the environmental factors, which are also 
shared by family members who live together, cannot be excluded by these studies alone. 
Twin studies provide an alternative approach for investigating the relative magnitude of 
genetic and/or environmental factors on the autism phenotype and penetrance. In 1977, a 
landmark study by Folstein and Rutter demonstrated a significant difference between 
monozygotic (MZ) and dizygotic (DZ) twins in their concordance for autism (Folstein & 
Rutter, 1977). This difference in concordance suggested a major role for genes in the etiology 
of autism and this was confirmed by subsequent studies (Ritvo et al., 1985; Steffenburg et al., 
1989). Most recently, a large scale study of 277 twin pairs (210 DZ and 67 MZ) reported 88% 
concordance of autism for MZ twins and 31% concordance of autism for DZ twins. In MZ 
twins, the authors also observed a higher prevalence of bipolar disorder and Asperger 
syndrome with a higher concordance of the latter (Rosenberg et al., 2009). The finding of 
increased bipolar disorder in twins is interesting because the co-morbidity of psychiatric 
disorders (eg. anxiety disorder, ADHD, etc) in children with autism is up to 70% (Charman 
et al., 2011), and suggests significant overlap in genetic etiology between different 
psychiatric disorders. Specific genetic causes for autism will be outlined more thoroughly 
later in this chapter.  
3.2 Epigenetic contributions 
It is widely accepted that genetic factors play a major role in the etiology of ASD, however, 
epigenetic factors may also be an important determinant of the autism phenotype. 
Epigenetic modifications include cytosine methylation and post-translational modification 
of histone proteins, and act as a mechanism to control gene expression (Samaco et al., 2005). 
The epigenetic regulation of gene expression can be influenced by exposure to 
environmental factors and can show parent of origin effects. Notably, epigenetic factors play 
a central role in pathogenesis of two single gene disorders, Rett syndrome and Fragile X 
syndrome (FXS), that are commonly associated with autism (Brown et al., 1982; Gillberg, 
1986). Rett syndrome, a progressive neurodevelopmental disorder, is classified among 
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twins, the authors also observed a higher prevalence of bipolar disorder and Asperger 
syndrome with a higher concordance of the latter (Rosenberg et al., 2009). The finding of 
increased bipolar disorder in twins is interesting because the co-morbidity of psychiatric 
disorders (eg. anxiety disorder, ADHD, etc) in children with autism is up to 70% (Charman 
et al., 2011), and suggests significant overlap in genetic etiology between different 
psychiatric disorders. Specific genetic causes for autism will be outlined more thoroughly 
later in this chapter.  
3.2 Epigenetic contributions 
It is widely accepted that genetic factors play a major role in the etiology of ASD, however, 
epigenetic factors may also be an important determinant of the autism phenotype. 
Epigenetic modifications include cytosine methylation and post-translational modification 
of histone proteins, and act as a mechanism to control gene expression (Samaco et al., 2005). 
The epigenetic regulation of gene expression can be influenced by exposure to 
environmental factors and can show parent of origin effects. Notably, epigenetic factors play 
a central role in pathogenesis of two single gene disorders, Rett syndrome and Fragile X 
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ASDs. It is caused by mutation in the MECP2 gene that encodes the methyl-CpG-binding 
protein 2, which is involved in epigenetic regulation of gene expression (Amir et al., 1999). 
JARID1C, a relatively common ID gene associated with some cases of autism (Adegbola et 
al., 2008) has been shown to regulate the methylation of histones and function in epigenetic 
transcriptional repression (Tahiliani et al., 2007). 
In addition, some autism (and ID) genes are regulated by known epigenetic mechanisms. 
FXS is caused by the expansion of a tract of CGG repeats in the 5’ untranslated region of the 
FMR1 gene. This expansion results in epigenetic silencing of the region, causing loss of 
expression of the gene, thus, FXS is caused by a genetic mutation resulting in epigenetic 
dysregulation (Hagerman et al., 2005). The RELN gene is another interesting example of 
possible contributions of epigenetic factors to ASD. The RELN gene encodes a large 
extracellular matrix protein that organizes neuronal positioning during corticogenesis and is 
regulated by epigenetic mechanisms. Several independent studies have shown an 
association between RELN and ASD (Skaar et al., 2005; Ashley-Koch et al., 2007; Holt et al., 
2010). Interestingly, reduced levels of reelin and its isoforms have been previously shown in 
autistic twins and their first degree relatives (Fatemi et al., 2005).  
Genomic imprinting is another mode of regulation of gene expression by epigenetic 
modifications and it results in parent of origin-specific gene expression. Genomic 
duplications of an imprinted region on the proximal long arm of chromosome 15 (15q11-
q13) are associated with 0.5-3.0% of autism cases (Hogart et al., 2010).  
3.3 Other factors 
Support for possible environmental factors contributing to the causation of autism comes 
from the incomplete concordance in monozygotic twins. Additionally, at this point in time, 
known genetic defects only explain a small proportion of autism patients. Furthermore, 
there is evidence that in utero exposure to valproic acid and thalidomide may increase the 
risk of ASD (Arndt et al., 2005). One long-term study of 632 children exposed to antiepileptic 
drugs during gestation, found that 6.3% of the children exposed to valproic acid in utero had 
ASD or some features of ASD. This incidence is seven times higher than the control group 
(0.9%; (Bromley et al., 2008)). Similarly, a higher incidence of autism has been reported 
among children prenatally exposed to thalidomide. In a population of 100 Swedish 
thalidomide embryopathy cases, at least four met full diagnostic criteria for autism 
(Stromland et al., 1994). Animal models have also demonstrated that early serotonergic 
neural development is disrupted in rats exposed to thalidomide or valproic acid on the 
ninth day of gestation, conferring increased risk for the development of ASD-related 
behaviours (Narita et al., 2010).  
Mercury (Hg), because of its known neurotoxicity, has drawn particular attention in relation 
to the neurodevelopment of individuals with autism, and a number of studies have 
compared the level of Hg in blood, hair, or urine in children with autism versus without 
autism. However, none of these studies have shown any substantial evidence of 
involvement of Hg in autism. Recently, a study conducted on 452 autism patients failed to 
demonstrate any difference in blood Hg level of autism patients compared to controls 
(Hertz-Picciotto et al., 2010). 
Childhood immunization is an environmental factor that has been popularized in the media 
as a potential cause of autism. The use of mercury in vaccines has been one of the prime 
sources of concern surrounding vaccines and their role in autism (Baker, 2008). However, 
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there is no consistent evidence in support of the theory that vaccines are related to the 
etiology of autism. In the late 1990s, a link between vaccines and autism was reported by 
clinical observation of the onset of autism soon after vaccination of children (Wakefield et 
al., 1998). These observations triggered a series of studies in the US, UK, Europe and Japan, 
however, none of these studies found any compelling evidence for a link between vaccines 
and autism. The original study has since been retracted (Murch et al., 2004; Anonymous, 
2010) 
Although the majority of research to date has focused on genetic factors involved in the 
etiology of autism, non-genetic factors are also likely to contribute. Our knowledge of these 
factors is, however, currently very limited. It has been suggested that distinct genetic 
features/pathways may cause distinct domains of autistic behaviour, but this has yet to be 
tested at the molecular level (Happe & Ronald, 2008). It does, however, resonate with the 
idea that autism is a genetically heterogeneous spectrum, and that multiple genetic 
aberrations may be necessary to reach the autism phenotype threshold (Cook & Scherer, 
2008). The threshold theory postulates that the cumulative effect of several genetic 
aberrations, for instance a copy number variant together with one or more single nucleotide 
variants, and possibly in combination with environmental factors, in a single individual, 
may result in an autism phenotype. These genetic aberrations may include chromosomal, 
single nucleotide or epigenetic abnormalities. It has also been noted that some genetic 
aberrations are more penetrant than others and may be more likely to result in a phenotype. 
In contrast with ID genetics, which are relatively straightforward, autism presents us with a 
convoluted, likely multigenic/multifactorial disorder for which it may be more difficult to 
delineate causes.   
4. Epidemiology 
4.1 Autism & autism spectrum disorders 
In published literature the incidence of autism is variable, and a worldwide trend of increase 
in prevalence of autism has been reported. During the 1980s, autism was thought to be rare, 
with a prevalence of less than 5 per 10,000 persons (Gillberg et al., 1991) and was not 
categorized as major public health problem. During the 1990s, the prevalence of autism was 
estimated to be 21 to 31 per 10,000 in preschool children (Fombonne, 1999). A recent review 
of epidemiologic studies reported a prevalence of 20 per 10,000 for classic autism and 60-70 
per 10,000 (1 in 150) for all ASDs (Fombonne, 2009). In addition it reported a prevalence of 
30-40 per 10,000 for PDD-NOS and 2 per 10,000 for CDD (Fombonne, 2009). Epidemiologic 
studies of Asperger syndrome have been more rare, and although current numbers estimate 
a prevalence of 6 per 10,000, there are severe limitations to calculating this prevalence 
accurately (Fombonne, 2009). Other recent large scale epidemiological studies have shown 
that as many as 1 in 100, or 1% of school age children have an ASD (Baird et al., 2006; Baron-
Cohen et al., 2009; Kogan et al., 2009). It is noteworthy that some of these studies are based 
on parents’ reporting of ASD and it could be argued that these estimates might be falsely 
high (Kogan et al., 2009). On the other hand, it has been argued that the increasing incidence 
of autism might be due to increased awareness of public and professionals coupled with the 
broadening of the diagnostic criteria (Fombonne et al., 2006). Today, the prevalence of ASDs 
is believed to be very high and this condition is now thought to be second only to 
Intellectual Disability (ID) among the most common developmental disabilities in the 
United States (Yeargin-Allsopp et al., 2003).  
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(Stromland et al., 1994). Animal models have also demonstrated that early serotonergic 
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sources of concern surrounding vaccines and their role in autism (Baker, 2008). However, 
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there is no consistent evidence in support of the theory that vaccines are related to the 
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tested at the molecular level (Happe & Ronald, 2008). It does, however, resonate with the 
idea that autism is a genetically heterogeneous spectrum, and that multiple genetic 
aberrations may be necessary to reach the autism phenotype threshold (Cook & Scherer, 
2008). The threshold theory postulates that the cumulative effect of several genetic 
aberrations, for instance a copy number variant together with one or more single nucleotide 
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may result in an autism phenotype. These genetic aberrations may include chromosomal, 
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aberrations are more penetrant than others and may be more likely to result in a phenotype. 
In contrast with ID genetics, which are relatively straightforward, autism presents us with a 
convoluted, likely multigenic/multifactorial disorder for which it may be more difficult to 
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It is also noteworthy that there is a gender bias in autism. Among children with autism, the 
ratio of affected males to females is estimated to be 4:1 (Volkmar et al., 1993) and the male to 
female ratio for Asperger syndrome is even higher. In contrast, Rett syndrome occurs almost 
exclusively in females.  
4.2 Intellectual disabilities 
ID is the most common neurodevelopmental disorder in the United States (Yeargin-Allsopp, 
et al., 2003). The prevalence of ID is between 1 and 3% (Roeleveld et al., 1997; Leonard & 
Wen, 2002) and is present in every social class and culture (Leonard & Wen, 2002). Despite 
its universal occurrence, there tends to be higher prevalence of ID in areas of lower 
socioeconomic status and developing countries, particularly for mild cases (Drews et al., 
1995; Roeleveld et al., 1997; Durkin et al., 1998; Durkin, 2002; Emerson, 2007). The variability 
of prevalence is more pronounced for mild ID than for severe forms. It has been suggested 
that this discrepancy is likely due to environmental factors (Roeleveld et al., 1997; Durkin et 
al., 1998; Emerson, 2007). 
Approximately 30% more males are diagnosed with ID than females (McLaren & Bryson, 
1987; American Psychiatric Association, 2000). However, despite a higher ratio of males to 
females among milder cases of ID, the ratio decreases as IQ decreases (McLaren & Bryson, 
1987; American Psychiatric Association, 2000). Some studies suggest that severe ID may be 
more prevalent among females (Katusic et al., 1996; Bradley et al., 2002), however these 
studies were performed in quite specific geographic locations and populations, and may not 
necessarily be generalizable to other regions. Some of this gender bias can be accounted for 
by mutations on the X-chromosome. In most cases of X-linked ID (ie. X-linked mental 
retardation; XLMR) or X-linked autism, more males are affected due to hemizygosity. 
However, in some disorders, such as Rett syndrome, this ratio is reversed because mutations 
in the Rett syndrome gene, MECP2, are generally lethal in haploid genomes. In addition, a 
rare phenomenon is apparent in female-restricted epilepsy and mental retardation (EFMR), 
in which heterozygous mutations in the gene PCDH19 cause the disease in females and in 
which there is reprieve-in-males with hemizygous PCDH19 mutations, who remain 
unaffected (Dibbens et al., 2008; Hynes et al., 2009). A possible explanation for this reprieve-
in-males phenomenon could be that carrier males have a homogenous population of mutant 
PCDH19-containing cells, whereas affected females would possess a mosaic population of 
mutant and wild-type PCDH19-containing cells. It is postulated that this mosaicism, rather 
than the effect of the mutated protein alone, may disrupt cell-cell communication, resulting 
in the clinical presentation (Dibbens et al., 2008). 
4.3 Co-morbidity of autism spectrum disorders & intellectual disability (syndromic 
and non-syndromic) 
It is often necessary to look at ASDs and ID together, as there is significant overlap between 
them both in terms of phenotype and in genetic causation. As previously noted, ID is 
present in ~50-60% of individuals with autism. Additionally, in a study performed on an ID 
population, 28% met the criteria for an autism diagnosis on the ADI-R scale and only half of 
these cases had been previously diagnosed (Bryson et al., 2008). Similar studies have also 
shown that within ID populations, the prevalence of autism is 8-20%, and that it is more 
likely for individuals with severe ID to meet criteria for ASD (Wing & Gould, 1979; Deb & 
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Prasad, 1994; Nordin & Gillberg, 1996; Stromme & Diseth, 2000; de Bildt et al., 2005; Bryson 
et al., 2008).  
ID and autism have multiple overlapping phenotypic domains. The three major phenotypic 
domains that characterize autism—language deficits, social deficits and stereotypies/ 
repetitive behaviours—can often be seen to varying degrees in individuals with ID. 
Individuals with ID often display stereotypies, which tend to become more pronounced and 
often self-injurious with decreasing IQ (Symons et al., 2005). Studies have found that 30-60% 
of individuals with ID display some form of stereotypy (Bodfish et al., 1995; Bodfish et al., 
2000; Goldman et al., 2009). Language deficits are often particularly pronounced in 
individuals with severe and profound ID.  
Many ID syndromes have an occurrence of autism that is significantly higher than the 
occurrence for the general population. For example, a current review of the literature 
indicates that up to 25-47% of individuals with Fragile X syndrome, 5-10% of individuals 
with Down syndrome, and 16-48% of individuals with tuberous sclerosis (TSC) also have an 
autism/PDD diagnosis, compared to 0.6-1% in the general population (Fombonne, 2009; 
Molloy et al., 2009). Other ID syndromes that have high occurrence of concordant autism 
include Angelman syndrome, Joubert Syndrome and Cohen syndrome.  
5. Shared genetics of autism and ID 
5.1 Shared genetic causes of autism and ID: Syndromic 
As previously noted, there is evidence that several syndromic forms of ID are more likely to 
present with autism than would be expected in the general population. The observation of 
overlap in phenotype between autism and the most common XLMR disorder, fragile X 
mental retardation syndrome (FXS) is a long-standing, albeit controversial one. The 
frequency of molecular diagnosis of FXS among autistic patients has been reported as high 
as 12.4% and as low as 0%, averaging at 7.25% (Smalley et al., 1988; Gurling et al., 1997). 
More recent studies indicate a more conservative rate of FXS of 2-4% (Wassink et al., 2001). 
Two studies of young FXS individuals demonstrated that 25% and 33% met criteria for 
autism and a review suggests that as many as 47% may have an ASD (Bailey et al., 1998; 
Rogers et al., 2001; Molloy et al., 2009); however, it has also been argued that autistic 
features are not more common among individuals with FXS than among other individuals 
with ID (Bardoni et al., 2000). Mutations in MECP2 have also been found among individuals 
with autism (Kim & Cook, 2000; Orrico et al., 2000; Beyer et al., 2002; Hammer et al., 2002). 
Autistic features are also frequently present in other ID syndromes such as Down syndrome 
and phenylketonuria (PKU).  
These disorders are rarely mistaken for autism, as other syndromic features assist with the 
correct diagnostic assignment. On the other hand, there is evidence that even for these well-
characterized syndromic forms of XLMR, there is a very broad phenotypic expression of the 
disease. For instance, mutations within the aristaless gene, ARX, are responsible for several 
distinct forms of XLMR and neurological phenotypes: West syndrome (infantile spasms 
with hypsarrhythmia; Stromme et al. 2002a), Partington syndrome (XLMR with dystonic 
hand movements; Stromme et al. 2002b), XLAG (Kitamura et al. 2002), XLMR (Bienvenu et 
al. 2002), Proud syndrome (Kato et al. 2004), and various forms of epilepsy (Stromme et al. 
2002a, b; Scheffer et al. 2002). A 24 base pair duplication in ARX has been found in families 
with West syndrome and Partington syndrome, and recently in several families previously 
identified as having non-syndromic XLMR. In these families several individuals were 
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Prasad, 1994; Nordin & Gillberg, 1996; Stromme & Diseth, 2000; de Bildt et al., 2005; Bryson 
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Individuals with ID often display stereotypies, which tend to become more pronounced and 
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As previously noted, there is evidence that several syndromic forms of ID are more likely to 
present with autism than would be expected in the general population. The observation of 
overlap in phenotype between autism and the most common XLMR disorder, fragile X 
mental retardation syndrome (FXS) is a long-standing, albeit controversial one. The 
frequency of molecular diagnosis of FXS among autistic patients has been reported as high 
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More recent studies indicate a more conservative rate of FXS of 2-4% (Wassink et al., 2001). 
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These disorders are rarely mistaken for autism, as other syndromic features assist with the 
correct diagnostic assignment. On the other hand, there is evidence that even for these well-
characterized syndromic forms of XLMR, there is a very broad phenotypic expression of the 
disease. For instance, mutations within the aristaless gene, ARX, are responsible for several 
distinct forms of XLMR and neurological phenotypes: West syndrome (infantile spasms 
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reported as having only mild intellectual impairment along with autism or autistic-like 
behaviours (Turner et al., 2002).  
5.2 Shared genetic causes of autism and ID: Non-syndromic  
The Neuroligin 4 (NLGN4) gene has been linked to autism by several studies (Jamain et al., 
2003; Laumonnier et al., 2004; Marshall et al., 2008). However, in 2004, Laumonnier et al. 
identified a family containing individuals with NS-ID, with or without ASD, segregating 
with a NLGN4 mutation (Laumonnier et al., 2004). This study was the first to suggest that 
NS-ID and autism may have overlapping genetic etiologies. A similar finding was noted 
with NRXN1, which interacts with NLGN4. Heterozygous copy number variants (CNV) in 
this gene have been found in autism while homozygous mutations of NRXN1 cause the S-ID 
disorder Pitt-Hopkins-like syndrome-2 (PTHSL2; Zweier et al., 2009). 
More recently, a truncating mutation was found in SHANK3 in an individual with NS-ID 
(Hamdan et al., 2011). SHANK3 has been found to cause autism in several studies (Durand 
et al., 2007; Marshall et al., 2008). In addition, SHANK2 CNVs and sequencing mutations 
have been found in several cases of both autism and NS-ID, displaying a significant level of 
etiological overlap between the two disorders (Berkel et al., 2010; Pinto et al., 2010). CNVs, 
or structural variation within the genome, appear to contribute significantly to the etiology 
of ID and autism. 
PTCHD1 is another X-linked gene that has been implicated in autism and NS-ID. A CNV 
which deletes PTCHD1 entirely causes NS-ID in one family (Noor et al., 2010). Another 
CNV, which results in a loss of the first exon and upstream region of PTCHD1, results in 
autism in another family (Noor et al., 2010). In addition, one CNV upstream of the gene was 
found in an individual with ADHD, suggesting that it may play a role in this phenotype as 
well (Noor et al., 2010). IL1RAPL1, which was initially identified as a cause of NS-ID, and 
has been shown to cause NS-ID in several individuals, has also been implicated in autism 
(Carrie et al., 1999; Bhat et al., 2008; Marshall et al., 2008; Piton et al., 2008; Pinto et al., 2010). 
Similarly, a missense mutation in the NS-ID gene JARID1C was found in an individual with 
autism (Adegbola et al., 2008). Most recently, a de novo CNV deletion overlapping 
SYNGAP1, a gene previously implicated in NS-ID, was identified in a female autism 
proband (Pinto et al., 2010). These genetic links are of much interest, particularly due to the 
strong phenotypic overlap seen in NS-ID and autism. These common genes will be an 
important factor in teasing out which biochemical processes are disturbed in different forms 
of developmental delay, and why a particular mutation in an individual may lead to one 
condition rather than the other.  
6. Common biological pathways (see Table 2) 
6.1 The mTOR pathway (see Figure 1) 
The common pathways shared by autism genes are also particularly interesting with respect 
to ID. While it cannot necessarily be argued that all autism genes will fall into distinct and 
neat categories, there are certain pathways which are overrepresented among autism-related 
genes identified so far. One review of the literature suggested that there appear to be two 
major pathways that known autism genes are a part of: 1. excitation and inhibition at the 
synaptic junction and 2. cellular and synaptic growth—i.e. participation in the mTOR 
pathway (Bourgeron, 2009). This categorization is valid but does not encompass all autism 
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genes, and as our knowledge of genes that contribute to the autism phenotype increases, 
more common pathways may be elucidated. 
 
Gene Name ASD or ID* Chromosomal 
Locus 
Protein Product Potential Pathogenic 
Mechanism 
Common Gene Function: Cell Adhesion 
CDH8 ASD 16q22.1 Cadherin 8 Disruption of neuronal cell 
adhesion leading to 
aberrant synaptogenesis or 
plasticity 
CDH9 ASD 5p14 Cadherin 9 As above 
CDH10 ASD 5p14.2 Cadherin 10 As above 
CDH15 ID 16q24.3 Cadherin 15 As above 
CNTNAP2 ASD 7q35 Contactin-associated 
protein-like 2 
As above 
NLGN3 ASD Xq13.1 Neuroligin 3 Disruption of neuronal cell 
adhesion specifically at the 
excitatory synapse leading 
to aberrant synaptogenesis 
or plasticity 
NLGN4 ASD/ID Xp22.33 Neuroligin 4 As above 
NRXN1 ASD/ID 2p16.3 Neurexin 1 Disruption of neuronal cell 
adhesion leading to 
aberrant synaptogenesis or 
plasticity 
PCHD10 ASD 4q28.3 Protocadherin 10 As above 
PCDH19 ID Xq13.3 Protocadherin 19 As above 
TSPAN7 ASD/ID   As above 




ASD 4p14 GABA receptors α2, 
β1, γ1 and α4 
Disruption of GABA 





ASD/ID 15q11.2-q12 GABA receptors α5, 
β3, and γ3 
Disruption of GABA 
receptor activity at the 
inhibitory synapse 
Common Gene Function: Regulation and Organization at the Excitatory Synapse 
FMR1 ASD/ID Xq27.3 Fragile X mental 
retardation 1 protein
Aberrant translational 
regulation of important 
synaptic genes 
GRIK2 ASD/ID 6q16.3-q21 Glutamate receptor, 
ionotropic, kainate 2
Disruption of Kainate 
Receptors at the excitatory 
synapse 
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Gene Name ASD or ID* Chromosomal 
Locus 
Protein Product Potential Pathogenic 
Mechanism 
IL1RAPL1 ASD/ID Xp22.1-p21.3 Interleukin 1 
receptor accessory 
protein-like 1 
Disruption of activity and 
organization at the 
excitatory synapse 








SYNGAP1 ASD/ID 6p21.3 Synaptic Ras 
GTPase activating 
protein 1 
Disruption of NMDA and 
AMPA receptors via down 
regulation of Ras/ERK 
signalling 
Common Gene Function: Transcriptional Control 




leading to alterations in 
dosage of multiple genes 
AUTS2 ASD 7q11.2 Autism 
susceptibility  
gene 2 protein 
Neuronal nuclear 
expression; Putative 
regulator of transcription 
(Kalscheuer et al., 2007) 





leading to alterations in 
dosage of multiple genes 
MECP2 ASD/ID Xq28 Methyl CpG  
binding protein 2 
As above 
Common Gene Function: Down Regulation of the mTOR Signaling Pathway 
NF1 ASD/ID 17q11.2 neurofibromin Neuronal cell overgrowth 
due to the down  
regulation of the mTOR 
pathway or down 
regulation of Ras/ERK 
signaling 






Neuronal cell overgrowth 
due to the down regulation 
of the mTOR pathway 
TSC1 ASD/ID 9q34 Tuberous Sclerosis 1 
protein (hamartin)
As above 
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Gene Name ASD or ID* Chromosomal 
Locus 
Protein Product Potential Pathogenic 
Mechanism 
TSC2 ASD/ID 16p13.3 Tuberous Sclerosis 2 
protein (tuberin) 
As above 
Common Gene Function: Varying Functionalities 
IQSEC2 ASD/ID Xp11.22 IQ motif and SEC7 
domain-containing 
protein 2 
Disruption of the ARF 
signaling pathway 
PTCHD1 ASD/ID Xp22.11 Patched domain 1 Potential disruption of the 
Hedgehog signaling 
pathway 
RELN ASD/ID 7q22 Reelin Abnormal neuronal cell 
migration and cell-cell 
interaction 
SLC6A8 ASD/ID Xq28 Solute carrier family 
6 member 8 
Creatine deficiency 
UPF3B ASD/ID Xq25-q26 UPF3 regulator of 
nonsense transcripts 
homolog B 
Dysfunction of nonsense 
mediated decay and 
mRNA surveillance 
*associated with autism spectrum disorder or intellectual disability 
Table 2. Genes associated with ASD, ID or both and chromosomal location, along with 
protein product and function, and the potential route by which the gene results in 
neurodevelopmental phenotypes. 
NF1, TSC1 and TSC2 are genes that, when mutated, may result in disorders -
neurofibromatosis and tuberous sclerosis respectively- in which there is high incidence of 
autism- neurofibromatosis and tuberous sclerosis respectively. These genes are negative 
regulators of the mTOR-raptor complex (mTORC1)—a complex that is important in 
regulation and cell growth during mitosis and likely plays an active role in synaptogenesis 
(Bourgeron, 2009). Furthermore, in hippocampus of fmr1 knockout mice, upregulation of 
mTOR activity has also been reported (Sharma et al., 2010). It can be speculated that when 
deleterious mutations occur in these genes, the mTOR pathway would become more active 
due to loss of down regulation. PTEN, another negative regulator of the mTOR pathway has 
also been implicated in autism. PTEN mutations can lead to PTEN Hamartoma-Tumor 
Syndrome (PHTS) which includes Cowden Syndrome and Bannayan-Riley-Ruvalcaba 
Syndrome, but are also present in autism probands without these syndromes (McBride et 
al., 2010). The mutations found in autism probands appear to be less penetrant than other 
PTEN mutations (McBride et al., 2010). 
With the finding that mTOR genes are involved in autism susceptibility we can propose 
several possibilities, the first of which is that regulators of the mTORC1 complex may also 
be good candidates for ID genes, based on overlapping phenotype between autism and ID. 
However, individuals with neurofibromatosis do not typically present with ID despite 
having a higher incidence of learning disabilities, ADHD and autism (Hsueh, 2007). 
Tuberous Sclerosis is associated with learning disabilities, developmental delay including 
autism and epilepsy in about 85% of cases (Curatolo et al., 2008). This specificity for autism 
susceptibility in the mTOR pathway may help us to delineate the complex association 
between autism and ID genes, and understand how autism specific phenotypes are caused.  
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The mTOR pathway has been implicated as a potential major contributor to the etiology of autism. The 
mTOR pathway is negatively regulated by NF1, TSC1/2, and PTEN (and possibly FMRP), all of which 
are involved in the etiology of autism. mTOR activation results in cell survival and proliferation. 
Negative regulation of this pathway prevents overgrowth. Some cancer syndromes are also associated 
with these genes. mTOR is a target of rapamycin, which inhibits its functioning. This is a potential 
pharmaceutical candidate for the treatment of syndromes caused by mutations in these genes, as well as 
autism resulting from mutations in these genes. This figure shows the role of NF1, TSC1/2 and PTEN in 
the mTOR pathway.  
Fig. 1. mTor Pathway in autism and ID 
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6.2 Synaptic proteins and synaptogenesis (see Figures 2 & 3) 
Most of the known genes that overlap both autism and ID are present at the synapse and are 
involved in the excitatory/inhibitory pathway, with an emphasis on excitation. For 
example, the SHANK family of genes appears to make quite a significant contribution to 
autism and ID etiologies. Both SHANK2 and SHANK3 encode scaffolding proteins present at 
the post-synaptic density and in dendrites. They are important for scaffolding in the post-
synaptic density—connecting ion channels, neurotransmitter receptors and other membrane 
proteins to the actin cytoskeleton—and act as a structural framework at this site (Boeckers et 
al., 2002; Hayashi et al., 2009). They are also likely to play a role in neuronal plasticity 
(Boeckers et al., 2002; Hayashi et al., 2009). 
 
 
Many autism genes, in particular those that overlap with intellectual disabilities, are present at 
excitatory synapses. Many of these genes encode protein products which are present in the postsynaptic 
density (PSD) including SYNGAP1, SHANK2, SHANK3, NLGN4, NLGN3, NRXN1, and IL1RAPL1. 
Glutamatergic synapses contain NMDA receptors, AMPA receptors and Kainate receptors.  Mutations 
in additional synaptic genes have been implicated in ID, e.g. CASK and STXBP1. Aberrant function at 
this synapse has been postulated to be part of both autism and ID etiology. 
 
Fig. 2. Glutamatergic Synapse in autism and ID 
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GABA is the major inhibitory neurotransmitter in the human brain. GABA receptor genes have been 
postulated as candidates for autism etiology.  Most GABA receptors cluster in certain chromosomal 
regions  some of which are associated with autism and/or ID, such as 15q11.2-q13 which contains 
GABRα5, GABRβ3, and GABRγ3, and 4p14 which contains the genes GABRα2, GABRβ1, GABRγ1 and 
GABRα4. Duplications of the 15q11.2-q13 region are present in 0.5-3% of autism cases.   
Fig. 3. GABAergic Synapse in autism and ID 
Another important gene involved in both ID and autism is SYNGAP1 which has been 
identified as a dominant cause of ID in several individuals with truncating mutations 
(Hamdan et al, 2009; Hamdan et al, 2011), as well a cause of autism in an individual with a 
CNV deletion overlapping the gene (Pinto et al. 2010). SYNGAP1 encodes SynGAP—a 
GTPase activating protein that is part of the NMDA receptor complex (NMDAR), and binds 
to the NR2B subunit (Kim et al., 2005). NMDARs play a role in glutamate-activated 
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excitation of postsynaptic neurons, and have been implicated in memory formation and 
synaptic plasticity. SynGAP is a negative regulator of NMDAR mediated ERK activation 
and causes inhibition of the Ras/ERK pathway (Kim et al., 2005). Over-expression of 
SynGAP has also been shown to down regulate GLuR1, a subunit of AMPA receptors 
(AMPAR), a class of excitatory ionotropic glutamate receptors which are regulated by the 
Ras/ERK pathway (Kim et al., 2005; Rumbaugh et al., 2006). Syngap knockout mice 
implicate SynGAP in the regulation of long term potentiation (LTP) and AMPAR expression 
(Komiyama et al., 2002). While both ID and autism probands with mutations in this gene 
were heterozygous for the mutation, individuals with ID have truncating single nucleotide 
mutations, while the individual with autism had a deleterious CNV, which is an example of 
how different aberrations within the same gene can have differential effects on phenotypic 
manifestation, i.e. allelism (Hamdan et al., 2009; Pinto et al., 2010; Hamdan et al., 2011). This 
has been shown for several other autism/ID genes as well, including IL1RAPL1, JARID1C, 
and SHANK2 (Adegbola et al., 2008; Piton et al., 2008; Berkel et al., 2010; Pinto et al., 2010).  
Other autism-related genes also bind to the NMDAR and are involved in its function. NF1 
described earlier as a down regulator of the mTOR pathway also plays a role in the negative 
regulation of the Ras signaling pathway and is known to bind directly to the NMDAR 
complex (Hsueh, 2007). This suggests an alternate mechanism for its role in autism. Within 
the context of Bourgeron’s review, this gene is actually affiliated with both “major” autism 
gene pathways.  
In addition IL1RAPL1 also appears to have an impact on NMDAR function. Mutations in 
IL1RAPL1, a gene with several known mutations in NS-ID and autism, result in the incorrect 
localization of the MAGUK family protein PSD-95 (DLG4), which is important for 
organization and function of NMDARs, ion channels and other signaling proteins at the 
post-synapse (Carrie et al., 1999; Gardoni, 2008; Pavlowsky et al., 2010). The IL1RAPL1 
protein has been shown to interact with PSD-95, and knockout of this gene decreased the 
post-synaptic density (PSD) and the localization of PSD-95 at excitatory synapses. Loss of 
IL1RAPL1 also results in a decrease of activity in the JNK pathway, which was found to lead 
to decreased phosphorylation of PSD-95 (Pavlowsky et al., 2010). IL1RAPL1 has also been 
shown to be important for the formation of excitatory synapses in vivo (Pavlowsky et al., 
2010). PSD-95 directly interacts with several known NS-ID associated proteins including: 
CASK, SynGAP, GLuR6 and neuroligins (Kim & Sheng, 2004). 
GRIK2 is a gene that is mutated in NS-ID (Motazacker et al., 2007) and has been linked by 
association studies to autism (Jamain et al., 2002; Shuang et al., 2004; Kim et al., 2007) . It 
encodes a protein called GLuR6, which is a subunit of a kainate receptor (KAR). KARs are 
ionotropic glutamate receptors which respond to the excitatory neurotransmitter l-
glutamate, similar to NMDA or AMPA receptors. They are expressed at a high level in the 
brain, particularly in the hippocampal mossy fibers, where GLuR6 has been found to 
modulate LTP in mouse models (Bortolotto et al., 1999; Contractor, Swanson and 
Heinemann., 2001). GLuR6 knockout mice show decreased LTP in mossy fibers. LTP in the 
hippocampus has been implicated as a mechanism for memory formation and learning 
(Bliss & Collingridge, 1993; Fedulov et al., 2007). While polymorphisms in GRIK2 are likely 
not responsible for an autism phenotype alone, the association suggests that this locus 
confers susceptibility to the phenotype and may contribute to the disorder in concert with 
other genetic aberrations and environmental factors.  
Additionally, FMRP, encoded for by FMR1, the fragile X syndrome (FXS) gene, is thought to 
play a role in neuronal plasticity by acting as a suppressor of local protein translation (as 
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excitation of postsynaptic neurons, and have been implicated in memory formation and 
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reviewed by Jin et al. 2004). It binds mRNA in the nucleus and carries the mRNA to its 
target destination in the cytoplasm (Bagni & Greenough, 2005). The transcripts targeted by 
FMRP include some that are relevant to autism and ID, including PSD-95, DLG1, SHANK1, 
DLGAP1-4, Grin1, Grin2b, GluR1, and GluR2 (Bassell & Warren, 2008; Schutt et al., 2009). It 
also binds other important neuronal transcripts such as itself (FMR1), SEMA3F, CamKIIα, 
GABRD, ARC, MAP1B and APP (Bassell & Warren, 2008). While FXS is an X-linked 
syndrome of variable phenotype, it is a very common cause of ID, and often is present 
together with autistic behaviours (de Vries et al., 1998). In addition, the FMR2 gene, which is 
similar to FMR1 in structure but has a poorly defined function, is also involved in the 
genetics of ID and autism (Gecz et al., 1996). Mutations in this gene result in intellectual 
disabilities with or without autistic behaviours.  
Some important synaptic genes that are present at inhibitory synaptic junctions appear to be 
associated with autism and some ID syndromes. GABA is the major inhibitory 
neurotransmitter in the human brain, and dysfunction of its receptors could result in a 
decrease of the inhibitory response. A significant amount of research has been done to study 
the role of GABA and GABA receptors in autism. In particular, GABA receptor subunits 
residing in clusters on 4p and 15q have been implicated in autism. As indicated earlier, 
genomic duplications of an imprinted region on the long arm of chromosome 15 (15q11-q13) 
are present in 0.5-3.0% of autistic individuals (Hogart et al., 2010). Deletions and uniparental 
disomy (UPD) in this region are responsible for Angelman syndrome and Prader-Willi 
syndrome depending on the parent of origin of the mutation, and both of these syndromes 
present with ID (Dykens et al., 2004), and frequently also with autism (Hogart et al., 2010). 
This region contains a cluster of three GABA receptor subunit genes: GABRα5, GABRβ3, and 
GABRγ3 (Dykens et al., 2004). Based on the frequency of this duplication in autism, it is 
possible that these genes are involved in the autism phenotype, however there are ~10 genes 
in the duplicated region, all of which may play a major, minor or no role in the autism 
phenotype. GABRα2, GABRβ1, GABRγ1 and GABRα4 on 4p14 (Ma et al., 2005; Vincent et al., 
2006; Kakinuma et al., 2008) have also been implicated in autism. Molecular work specific to 
some of these GABA receptors supports their role in autism (Ma et al., 2005; Collins et al., 
2006; Fatemi et al., 2010). It is also of note that GABA neurotransmission is strongly 
implicated in fragile X syndrome, and knockout of the fmr1 gene in mice has a hugely 
disruptive effect on the GABAergic system, and is a potential target for the treatment of 
symptoms for both Fragile-X syndrome and autism (Hagerman et al., 2005).  
Several studies have found significant genetic associations between the chromosome 4 
GABA receptor cluster and autism. In addition, specific GABA receptor genes within the 4p 
cluster have been implicated as likely contributors to autism. GABRα4 was found to be 
involved in the etiology of autism independently and through interactions with GABRβ1 
(Ma et al., 2005) and both of these genes have been linked to the autism phenotype by 
association (Collins et al., 2006). Recently, a study by Fatemi et al. indicated that the levels of 
GABA receptor mRNAs in autism brains are significantly different from controls (Fatemi et 
al., 2010). The study shows that in the BA9 region of brains acquired from individuals with 
autism, levels of GABRα4, GABRα5 and GABRβ1 mRNAs are significantly decreased, while 
in the cerebella of these brains mRNA for these same genes are increased compared to 
normal controls after normalization with housekeeping genes (Fatemi et al., 2010). In 
addition, several small studies and cases have shown that the levels of GABA in peripheral 
blood and plasma are altered in individuals with autism (Dhossche et al., 2002, Rolf et al., 
1993) but these findings are inconsistent, and more thorough and larger scale studies need 
to be done to determine whether GABA could act as stable biomarker for ASD.  
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6.3 Neuronal cell adhesion 
Neuronal cell adhesion is an interesting common pathway between ID and autism. As 
previously noted, NLGN4 and NRXN1 are both examples of genes that are mutated in cases 
of autism and ID. NLGN4 presents us with a particularly interesting genetic link between 
autism and ID, as it displayed pleiotropy within a single family, with the same mutation 
causing autism in some individuals, and NS-ID in others. The NLGN4 protein, located on 
the postsynaptic membrane, interacts with NRXN1 on the presynaptic membrane. 
Heterozygous mutations in NRXN1 appear to result in autism as well (Autism Genome 
Project Consortium et al., 2007; Kim et al., 2008). Similar disruptions in NRXN1 have also 
been documented in schizophrenia (Rujescu et al., 2009), ID, and language delays (Ching et 
al., 2010). The NLGN4 protein acts as an important element in postsynaptic differentiation, 
forming complexes with β-neurexins and PSD-95 (Ichtchenko et al., 1995; Irie et al., 1997; 
Scheiffele et al., 2000). NLGN4 is linked to glutamatergic postsynaptic proteins and 
neuroligin/neurexin complexes, which appears to be sufficient for synaptogenesis (Graf et 
al., 2009). These genes play a major role in both cell adhesion as well as synaptogenesis 
showing a role for overlap between these pathways.  
Additionally, it has been postulated that TSPAN7, an X-linked NS-ID gene, is involved in a 
complex of ß-integrins, which are involved in cell-cell and cell-matrix interactions (Zemni et 
al., 2000) and that this gene may cause autism in individuals with deleterious CNVs 
(Marshall et al., 2008). There are several other neuronal cell adhesion genes that have been 
implicated in autism, with and without ID, including NLGN3 and CNTNAP2 (Jamain et al., 
2003; Alarcon et al., 2008). This suggests that neuronal cell adhesion is a common 
mechanism by which both autism and ID occur, and may be helpful in elucidating the 
biological mechanism of these highly related, albeit different, disorders. 
In addition to these neuronal cell adhesion genes, several cadherins and protocadherins 
have been implicated in autism as well. CDH8 has been found to be disrupted by 
microdeletions in individuals with learning disabilities and autism, and is not disrupted in 
over 5000 controls (Pagnamenta et al., 2011). Additionally, a genome-wide association study 
of individuals with autism identified significant peaks at CDH9 and CDH10 (Wang et al., 
2009). PCDH10 has also been suggested as a candidate gene for autism based on a 
homozygous CNV deletion overlapping the gene in an affected individual (Morrow et al., 
2008).  
Several similar genes have been implicated in ID as well. PCDH19, a protocadherin, has 
also been implicated in epilepsy with mental retardation limited to females (EFMR; 
Dibbens et al., 2008; Hynes et al., 2009). Additionally CDH15 is an autosomal dominant 
cause of S-ID and NS-ID in several individuals. CDH15 encodes a cadherin that is 
expressed mainly in brain and skeletal muscle (Bhalla et al., 2008). Mutations of this gene 
in individuals with ID were found to decrease cell adhesion by greater than 80% (Bhalla et 
al., 2008). It is clear from these genetic links that neuronal cell adhesion is a common 
pathway in both ID and autism. Interestingly, while some of these genes overlap both ID 
and ASD, some are unique to one condition or the other. It is possible that some of these 
apparently unique genes may actually be involved in both disorders but no examples have 
been identified because mutations are so rare. It is also possible that these genes could 
only cause specific endophenotypes and may be useful for helping us tease out the 
intricate web of connections between the two disorders. 
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6.4 Transcriptional control 
Disruption of transcriptional control can have far reaching implications in terms of 
phenotypic manifestation. Genes involved in transcriptional control, when disrupted, may 
in turn affect the expression of many other genes. For example, ARX is one of the most 
frequently mutated genes in X-linked NS-ID. It is a homeobox-containing gene that is part of 
the Aristaless-related gene family. This is a family of transcription factors that are required 
for various essential events during vertebrate embryogenesis, including CNS development 
(Meijlink et al. 1999). Based on experimental data and gene structure it has been speculated 
that ARX regulates transcription by both gene activation and suppression and it is essential 
for normal development of the CNS (as reviewed by Friocourt et al. 2006). Mutations in this 
gene have been implicated in many ID syndromes, XLMR and autism/autistic features 
(Turner et al., 2002; Friocourt et al., 2006).  
Another example of a transcription factor involved in both autism and ID is MECP2, the 
causative gene for Rett syndrome: a regressive syndrome described earlier in this chapter. 
MECP2 mutations may result in various alternative phenotypic manifestations including 
MRXS13, LUBS X-linked ID syndrome and NS-ID. While genotype/phenotype data is often 
ambiguous, some studies have demonstrated a genotype/phenotype correlation in terms of 
severity, as well as for specific phenotypic measures (Ham et al., 2005; Bebbington et al., 
2008). MECP2 encodes the methyl CpG binding protein 2 (MECP2), which is believed to act 
as a transcriptional modulator that is capable of long-range chromatin re-organization 
resulting in repression or activation of genes through binding to methylated CpG DNA (As 
reviewed by Gonzales and LaSalle, 2010).  
Additionally, JARIDIC, also known as KMD5C, is another relatively common gene related to 
X-linked ID with over twenty mutations known in XLMR individuals (Tzschach et al., 2006; 
Tahiliani et al., 2007). In addition, it has been identified as a causative gene in an individual 
with autism (Adegbola et al., 2008). JARIDIC is a histone demethylase containing a PHD-
finger domain that is characteristic of zinc finger proteins and specifically demethylates di- 
and tri-methylated histone 3 lysine 4 (H3K4me2/me3) residues (Christensen et al., 2007; 
Tahiliani et al., 2007; Cloos et al., 2008). Trimethylation at this residue is extremely important 
for transcriptional regulation and chromatin structure. JARID1C is likely involved in 
repressor element silencing transcription factor (REST)-mediated transcriptional repression. 
It has been shown to regulate the expression of several REST-mediated genes, as well as 
regulate the H3K4me2/H3K4me3 levels at their promoters (Tahiliani et al., 2007). 
Determining which genes these transcriptional regulators control may give insight into the 
biological pathways involved in disease and the mechanisms by which they occur. 
The gene AUTS2 was originally identified through the mapping of a translocation 
breakpoint on chromosome 7 in a pair of autistic monozygotic twins (Sultana et al., 2002), 
and subsequently identified in a number of studies of other autism patients with cytogenetic 
aberrations (Bakkaloglu et al., 2008; Huang et al., 2010). AUTS2 has more recently been 
identified at the breakpoint for de novo translocations in three unrelated ID individuals 
(Kalscheuer et al., 2007), as well as at breakpoints of CNVs in individuals with ADHD (Elia 
et al., 2010) and epilepsy (Mefford et al.. 2010). Although the function of the protein encoded 
by AUTS2 is unknown, in silico analysis suggest the protein has similarity to known 
transcription factors (Kalscheuer et al., 2007), and expression studies show that the protein is 
highly expressed within the nucleus of neurons and neuronal progenitors during 
development of the cerebral cortex and cerebellum, as well as other regions (Bedogni et al., 
2010). As such, it is likely that AUTS2 also functions as a regulator of gene transcription. 
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7. Other genes displaying ID/autism overlap (see Table 2) 
While it is very helpful to look at overlapping autism and ID genes in common pathways, it 
is not always possible. Autism and ID both have highly variable genetic causes. Some of 
these causal genes cannot be grouped together in common pathways but are still very 
important and have been widely implicated in autism and ID. PTCHD1 is an example of 
such a gene. This gene is estimated to explain ~1% of cases of autism, as well as several 
cases of NS-ID (Noor et al., 2010). PTCHD1 is thought to encode a receptor for the hedgehog 
signaling pathway, however no definitive role for the PTCHD1 protein has yet been 
established, and as the patched-like domain present in PTCHD1 also has a potential sterol-
sensing function, there may be sterol transporting pathways implicated (Noor et al., 2010). 
Mutations at the PTCHD1 locus can occur either within the gene itself or in the region 
upstream of the gene, which are thought to disrupt PTCHD1 regulation. Additionally, 
UPF3B, a component of the nonsense mediated decay surveillance machinery, has been 
implicated in various ID cases across four families, as well as in several individuals with 
autism (Tarpey et al., 2007; Addington et al., 2010; Laumonnier et al., 2010). It has also been 
implicated in childhood onset schizophrenia and ADHD (Addington et al., 2010). IQSEC2, a 
gene that encodes a GTPase for the ARF family of proteins, is also mutated in several 
families with ID and varying degrees of ASD and epilepsy (Shoubridge et al., 2010).  
8. Summary 
In this chapter, we have explored the relationship between ASD and ID: two separate but 
often co-morbid forms of developmental disorder. They are both relatively common in the 
general population, however the incidence of ASD appears to be on the rise, while ID is 
relatively stable. Both can be impacted by environmental factors, however ASD appears to 
have a more complex etiology and may require a combination of genetic, epigenetic and 
environmental factors to manifest phenotypically. Meanwhile, genes that cause ID tend to 
be either de novo or passed down in a Mendelian fashion, and are highly penetrant.  
While ASD is co-morbid with ID in 40-70% of cases, ASD can also present with normal 
intelligence. Certain endophenotypes, such as IQ, head size, presence of dysmorphisms, 
seizures and MRI abnormalities, may help to predict the effectiveness of early intensive 
behavioural intervention. Understanding the fundamental differences between “essential” 
and “complex” autism may be the key to creating personalized behavioural programming 
that is specific not only for the skills of a particular child, but for the phenotypic specificity 
conferred by a narrower diagnosis.  
It is clear that many of the genes implicated in both ASD and ID cause variable 
developmental, intellectual and psychiatric phenotypes, with and without additional clinical 
symptoms. Understanding the molecular mechanisms that result in developmental delays 
will be useful for potential management and interventions in these disorders. 
Understanding more about the phenotypes conferred by aberrations in different genes may 
lead us to develop differential interventions based on these genotypes. Additionally, 
classification of aberrant molecular pathways may help us to identify biomarkers, which 
could be used for early diagnosis of these disorders. Individuals with ASD classically 
respond best to early intensive intervention, thus the earlier we can diagnose ASD, the 
earlier we can act to help ensure the best outcomes.  
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breakpoint on chromosome 7 in a pair of autistic monozygotic twins (Sultana et al., 2002), 
and subsequently identified in a number of studies of other autism patients with cytogenetic 
aberrations (Bakkaloglu et al., 2008; Huang et al., 2010). AUTS2 has more recently been 
identified at the breakpoint for de novo translocations in three unrelated ID individuals 
(Kalscheuer et al., 2007), as well as at breakpoints of CNVs in individuals with ADHD (Elia 
et al., 2010) and epilepsy (Mefford et al.. 2010). Although the function of the protein encoded 
by AUTS2 is unknown, in silico analysis suggest the protein has similarity to known 
transcription factors (Kalscheuer et al., 2007), and expression studies show that the protein is 
highly expressed within the nucleus of neurons and neuronal progenitors during 
development of the cerebral cortex and cerebellum, as well as other regions (Bedogni et al., 
2010). As such, it is likely that AUTS2 also functions as a regulator of gene transcription. 
Common Genetic Etiologies and Biological 
Pathways Shared Between Autism Spectrum Disorders and Intellectual Disabilities 
 
147 
7. Other genes displaying ID/autism overlap (see Table 2) 
While it is very helpful to look at overlapping autism and ID genes in common pathways, it 
is not always possible. Autism and ID both have highly variable genetic causes. Some of 
these causal genes cannot be grouped together in common pathways but are still very 
important and have been widely implicated in autism and ID. PTCHD1 is an example of 
such a gene. This gene is estimated to explain ~1% of cases of autism, as well as several 
cases of NS-ID (Noor et al., 2010). PTCHD1 is thought to encode a receptor for the hedgehog 
signaling pathway, however no definitive role for the PTCHD1 protein has yet been 
established, and as the patched-like domain present in PTCHD1 also has a potential sterol-
sensing function, there may be sterol transporting pathways implicated (Noor et al., 2010). 
Mutations at the PTCHD1 locus can occur either within the gene itself or in the region 
upstream of the gene, which are thought to disrupt PTCHD1 regulation. Additionally, 
UPF3B, a component of the nonsense mediated decay surveillance machinery, has been 
implicated in various ID cases across four families, as well as in several individuals with 
autism (Tarpey et al., 2007; Addington et al., 2010; Laumonnier et al., 2010). It has also been 
implicated in childhood onset schizophrenia and ADHD (Addington et al., 2010). IQSEC2, a 
gene that encodes a GTPase for the ARF family of proteins, is also mutated in several 
families with ID and varying degrees of ASD and epilepsy (Shoubridge et al., 2010).  
8. Summary 
In this chapter, we have explored the relationship between ASD and ID: two separate but 
often co-morbid forms of developmental disorder. They are both relatively common in the 
general population, however the incidence of ASD appears to be on the rise, while ID is 
relatively stable. Both can be impacted by environmental factors, however ASD appears to 
have a more complex etiology and may require a combination of genetic, epigenetic and 
environmental factors to manifest phenotypically. Meanwhile, genes that cause ID tend to 
be either de novo or passed down in a Mendelian fashion, and are highly penetrant.  
While ASD is co-morbid with ID in 40-70% of cases, ASD can also present with normal 
intelligence. Certain endophenotypes, such as IQ, head size, presence of dysmorphisms, 
seizures and MRI abnormalities, may help to predict the effectiveness of early intensive 
behavioural intervention. Understanding the fundamental differences between “essential” 
and “complex” autism may be the key to creating personalized behavioural programming 
that is specific not only for the skills of a particular child, but for the phenotypic specificity 
conferred by a narrower diagnosis.  
It is clear that many of the genes implicated in both ASD and ID cause variable 
developmental, intellectual and psychiatric phenotypes, with and without additional clinical 
symptoms. Understanding the molecular mechanisms that result in developmental delays 
will be useful for potential management and interventions in these disorders. 
Understanding more about the phenotypes conferred by aberrations in different genes may 
lead us to develop differential interventions based on these genotypes. Additionally, 
classification of aberrant molecular pathways may help us to identify biomarkers, which 
could be used for early diagnosis of these disorders. Individuals with ASD classically 
respond best to early intensive intervention, thus the earlier we can diagnose ASD, the 
earlier we can act to help ensure the best outcomes.  
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The term Autism Spectrum Disorders (ASD) came into use in 1988 to stress the fact that 
symptoms of autism may appear with various intensity – from very mild to very severe. The 
matter gets further complicated due to the fact that the symptoms occur in different 
combinations. Autistic deficits include not only “autistic triad”, that is disorders of speech, 
behaviour and social interactions but disturb also cognitive, and motor abilities as well as 
emotional functioning. Despite a long-term interdisciplinary studies and detailed 
descriptions of autistic symptoms diagnosis of ASD still causes a number of diagnostic 
difficulties. The diagnostic procedure has been made easier thanks to the introduction of 
two systems of classification - International Statistical Classification of Diseases and Related 
Health Problems (ICD-10)1 and DSM-IV-TR2 - but it still remains a long and arduous 
process. It happens quite often that the final diagnosis is made in the course of therapy. 
Assessment of children with ASD must takes into account their spontaneous and reactive 
behaviours as well as information gained during the interview with their parents. As 
mentioned above, dysfunctions occurring in autistic spectrum vary to a considerable degree 
in their intensity. Moreover, they are of a dynamic character and are apt to undergo changes 
as a result of a course of general development, individual experience, social conditions, 
undertaken therapy, and efficacy of stimulation. All these may hamper the process of 
evaluation, especially at the early stages of a child development. Hence, autistic children are 
often made a diagnosis of mental disability, behaviour disorders, hearing problems as well 
as strange and eccentric behaviours. To complicate the matter further the above disorders 
frequently coexist with autism. It is imperative, therefore, to be able to discriminate autism 
and other developmental disorders since the early diagnosis provides basis for creating 
effective therapeutic and educational programs.  
2. Frequency of ASD occurrence 
Recent epidemiological studies show a dramatic increase of the number of persons with 
autistic symptoms. Thus, the frequency of occurrence of ASD was rated at a level of 4 to 10,000 
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cases in the years of 1980-90, while in the last decade the number of autistic persons is 
considered to reach the level of 2 to 1000 persons, and 2 to 1000 persons in the case of Asperger 
syndrome. At the same time, the population of persons with ASD is rated at the level of 1-2 to 
100 cases in the U.S.A., the country in which the most advanced epidemiological studies are 
carried out. In addition, statistical data show that the increase of a frequency rate of ASD is 10 
– 17% a year (Newschaffer et. al., 2007). It may be due to a real increase of the occurrence of 
autism but might as well reflect refinement of assessment techniques as well as a wider scope 
of diagnostic criteria, such as lowering down the age of assessment, broadening the scope of 
diagnostic criteria as well as development of diagnostic tools and techniques. In addition, the 
awareness of the parents of disabled children has also changed lately. 
An analysis of statistical data shows also that ASD disorders are more frequent in boys than 
in girls. It is estimated as 4,3 to 1, while in the case of Asperger syndrome the occurrence of 
the disorder in boys rises to 8 in comparison to 1 girl (ICD-10, 1997). There are a number of 
theories trying to explain such a state of affairs. One of frequently cited is the theory of 
neurotoxic testosterone. It presumes that due to the unequal development of brain 
hemispheres in the prenatal stage a very high level of testosterone brings about disturbances 
in the development of the left hemisphere, which results in a very high occurrence of autistic 
disorders in boys (Geschwind, Galaburda, 1985a, 1985b, 1985c).  
The idea was further elaborated by Baron-Cohen and collaborators (2005). They conducted a 
longitudinal study, which aimed at revealing a possibility of the influence of so called foetal 
testosterone (FT) upon the development of a child in the prenatal stage of life. The study 
included pregnant women in whom level of testosterone was measured in amniotic fluid 
obtained via amniocentesis in order to evaluate the influence of difference in a level of FT 
upon a subsequent development of the child. The results described also in the following 
paper (Auyeung et al., 2009) revealed a negative correlation between FT and the 
development of language and social skills, and positive correlation with specific traits of 
autism, such as excessive concentration on details, stereotyped movements, and 
perseverations. The studies on hiper-mascunalization in ASD are carried on, since the role of 
the influence of testosterone upon the foetal development needs further verification. Yet, an 
analysis of androgens influence on the appearance of autistic disorders seems to bring 
promising results (Chakrabarti et al., 2009).  
The above presented data raises a question whether a clinical picture of autistic symptoms in 
girls differs from that observed in boys, and what - if any - is a specificity of autism occurring 
in girls. Kopp (2010) noted that autistic symptoms in girls are often neglected by professionals 
despite the reports of anxious parents. It creates the need of presenting a more detailed 
analysis of autistic disorders observed in girls. All the more that the most available 
descriptions concentrate upon the characteristics of autism based upon an analysis of boys are 
of a rather general nature. Therefore, we decided to perform an analysis of autistic symptoms 
in autistic girls from the perspective of microgenetic and microdevelopment approaches. We 
were motivated by the fact that those theories make possible the evaluation of developmental 
potential of autistic persons. In order to make the clinical picture of autism in girls as complete 
as possible the description of individual cases will be presented in some detail. 
3. Autism spectrum disorder in girls 
As mentioned above, most studies published so far give general information, which is 
mostly based upon an analysis of autistic boys. As a rule the sex of examined subjects is not 
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taken into consideration, especially as ASD is prevailing in boys. Lately, specificity of ASD 
occurring in girls has been noted, yet most authors still concentrate upon symptoms 
characteristic of autism in general, such as tendency to routine behaviours, lack of interest in 
fantasy games, difficulties in social interactions and/or distractibility leading to learning 
problems (Knopp, 2010). On the other hand, McLennan and collaborators (1993) report that 
Loveland observed lowering of general IQ in boys (N = 700), while it was not stated in girls 
(N = 300). At the same time, it was noted that no use is made of the developmental potential 
of autistic girls, which may result in lower social and communication capacities and greater 
difficulties in establishing relations with peers in girls (Lord & Schopler, 1985). In addition, 
girls score worse than boys both in verbal abilities and visual-spatial tests. According to 
Nichols (2009) it reflects higher level of expectations concerning social and communication 
skills in girls, and hence more negative evaluation of observed deviations. Inappropriate 
behaviours of girls are often interpreted as a way to make others to pay attention to them, 
while in the case of boys such behaviours are believed to reflect their attempts to get a 
desired object.  
The differences between sexes are also believed to be a result of differences in 
developmental trajectories. Some authors believe that boys exhibit more difficulties at the 
early stage of their life, while the difficulties in girls increase in the period of adolescence 
(Nichols, 2009; Nichols et al., 2008). Symptoms of brain damage, however, are more frequent 
in girls than in boys, which finds its confirmation in EEG records, which show more 
irregularities in girls. On the other hand, the autistic girls are better in performing games 
that require using rules and also show weaker tendency to stereotyped movements than 
boys (Lord et al., 1982; Nichols, 2009).  
Lord and collaborators (1985) point out that longitudinal studies revealed that girls with 
ASD did not establish any friendly relationships during a period of ten years, while several 
boys did accomplish it. According to these authors it may be due to the fact that girls tend to 
be more short-tempered and tearful (see also McLennan et al., 1993). Those discrepancies in 
behavioural and neurological functioning tend to disappear if the autistic girls are offered 
appropriate stimulants for their development. Yet, the autistic symptoms often appear again 
as the years go.  
Kopp and colleagues (2010) compared the quality of life of 100 girls with ASD and ADHD 
aged from 3 to 18 years, and it made them believe that those two types of disorders tend to 
co-occur, since ADHD was stated in 95% of autistic girls. At the same time, a higher level of 
fear, sleeping problems as well as a higher risk of depression was noted in both ASD and 
ADHD. Moreover, comparative studies of girls with ASD and ADHD revealed a regression 
in development in comparison to healthy subjects of the same age. The dysfunctions were 
observed both in psychological, motor, and social abilities so they included all aspects of 
behaviour. It needs to be stressed that a positive influence of environmental factors, 
especially of appropriate education and family conditions, proved to stimulate the 
development of autistic girls. Hambrook and collaborators (2008) observed that anorexic 
girls exhibit lack of empathy and of an ability to systemize as well as other autistic traits. It 
is emphasized that a distorted pattern of information processing characteristic of anorexia 
shows a significant similarity to the autistic spectrum. Those difficulties may take various 
forms such as a lack of cognitive flexibility or stereotyped behaviours. A good example of 
rigid patterns of response noted both in ASD and anorexia provides an inability to shift a 
plan of action. 
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4. Microgenetic approach form developmental point of view  
A traditional approach to the study of developmental processes concentrates either on a 
long period of time (longitudinal studies) or upon groups including as big numbers as 
possible (cross-sectional studies). In recent years many scholars emphasize the usefulness of 
research taking into account the scores gained by the same group of children evaluated in 
short time intervals. Such an approach has derived also from the microgenetic theory. In 
other words, it enables an observer to monitor the specific moments of transformations in 
thought and behaviour in contradistinction to classic longitudinal studies, which provide 
only a general pattern of a change of behaviour in examined subject (Levelly et al., 2005).  
Flynn and co-workers (2006) enumerate three aspects pointing to the usefulness of a 
microgenetic approach: 
1. It makes possible delineation of a whole range of a mechanism underlying a process of 
changes. 
2. Observations are conducted while the factor causing a change is at work and not only 
before and after it took place. 
3. It is possible to control a moment of passing from applying a stimulus and initiating a 
change. 
At the same time, microgenetic approach enables getting answers to the following 
questions: 
1. Is the instruction understood by the child?  
2. Does the child use innovative strategies in solving a given problem? 
3. Is the child able to discover a new more effective strategy in the course of action? 
4. What is the efficiency of actions undertaken by the child while looking for a proper 
solution? 
5. What amount of time does a child need to solve a particular problem? 
6. Is the child able to generalize an acquired strategy to solve other similar problems? 
7. In what way was a new experience acquired? 
Microgenetic approach aims at an analysis of changes occurring during solving a given 
problem that takes into account five dimensions of cognitive growth. They include path, 
rate, breadth, source, and variability (Siegler & Svetina, 2002; Calais, 2008)).  
• The path of change involves the sequence of problem solving attempts performed by 
children in their way to gaining required competence. It also shows if the change is 
qualitative or quantitative. 
• The rate of change concerns the time or amount of experience the children needed to 
start using a new strategy in a consistent way. It also includes an analysis of the nature 
of a change - whether it occurred gradually or suddenly.  
• The breadth of change reflects children’s ability widely to generalize a new approach to 
other problems and contexts.  
• The source of change takes into account factors that evoked observed changes.  
• The variability of change enables evaluation of individual traits of a child in acquiring 
other dimensions of change. In other words, it enables creating a characteristics of an 
individual child as well as comparing a pattern of change across individuals (Siegler & 
Svetina, 2002; Flynn et al. 2006; Calais, 2008)). 
It is due to the fact that concentration upon the process of change as it is occurring reveals 
what mechanisms underpin it. It thus makes possible identifying both detrimental changes 
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(areas of dysfunctions) as well as positive ones reflecting a developmental potential of a 
given child.  
5. Microgenesis from neuropsychological point of view 
A neuropsychological perspective of the microgenetic theory points to the fact that each 
action starts at lower levels of the brain and unfolds to the higher more specialized levels. It 
enables a fresh look upon the nature of symptoms observed in brain dysfunctions. As 
pointed out by Brown & Pachalska (2003) “the lesion displays phases in a transitional 
sequence from depth to surface” (p. 4). Two important notions are introduced here: 
parcelation and heterochrony. Parcelation means the elimination of cells and connections, 
which occur in over-abundance at birth, in order to achieve specificity. It is connected both 
with maturation and cognitive experience. Hence, sensory deprivation results in a diffuse 
and redundant connectivity and a loss of the ability to discriminate among perceived 
stimuli.  
In the case of function the same role as elimination is played by inhibition. Brown and 
Pachalska state: “Inhibition occurs in the development of action, in newborns, which goes 
from global movement of the hand or face (the cherubic face of the infant) to one that is 
more finely individuated” (2003, p. 6). In other words, the basic pattern of each system are 
elimination, inhibition and specification, which means sculpting away constraints at 
successive phases of cognitive activity. The authors point out that in pathology re-
generalization through disinhibition leads to a number of deviant behaviours.  
Another important notion of microgenesis is heterochrony. It assumes that the fact that 
different brain systems develop at different rates can result not only in adaptations to the 
environment but also in malfunctions and aberrations. It is connected with the phenomenon 
of neoteny, which means selective prolongation of an immature phase of development. It 
makes possible refinement of structures and functions allowing mastering higher cognitive 
processes of which verbal communication is a good example.  
As pointed out by Brown (1998, 2001) microgenesis assumes that phyletic and ontogenetic 
growth patterns are retraced in microgeny but the processes are collapsed here over a 
second or in a fraction of a second. Moreover, both mental and motor processes have a 
hierarchical structure as the later levels unfold out of earlier ones. It is, therefore, possible to 
analyze the changes in children’s behaviour when they attempt to solve a given problem 
passing from one level (or stage) to another. And that is of much help in making a course of 
therapy as effective as possible.  
6. Procedure  
The aim of our study was to delineate the cognitive abilities of autistic girls in the context of 
the microgenetic approach. The following question was asked:  
What are the characteristic traits of the cognitive development in girls?  
In order to find an answer to the above formulated question a detailed description of 
changing competence of three girls with ASD will be presented. All the three girls 
represented similar level of autistic features and of cognitive abilities. All of them were able 
to communicate verbally and all of them were diagnosed in accordance with ICD–10 
(International Statistical Classification of Diseases and Related Health Problems) criteria. 
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The control variables were: depth of autistic deficits, and the level of social, and 
communicative competence as well as interest in playing and reacting to applied incentives. 
The elapse of time between individual examinations was also controlled. The boys 
development was presented in other works (Markiewicz, 2008, 2009; Markiewicz & 
Pachalska, 2007; Markiewicz & Grochmal, 2008; Markiewicz & Mc Queen, 2008;; Markiewicz 
et al., 2009), therefore their results will be used as a background for the description of girls. 
6.1 Case one 
Ola B. was first diagnosed at the age of three with the suggestion of middle stage mental 
disability. No neurological dysfunctions were noted. But her environmental conditions were 
very bad since her mother died when the girl was 3 months old and her father was an 
alcoholic. His parental rights were juristically limited when the girl was 2 years old, and she 
was at the custody of her grandmother (the mother of mother). The first verification of the 
initial diagnosis was after the girl was 4 years old at our clinic this time. The assessment 
performed by our team indicated dysfunctions in all spheres of developmental development 
(F84) suggesting Asperger syndrome (F84.5). The results of psychological examination are 
presented below. 
6.1.1 Results from ICD-10 
The evaluation of behaviours performed with ICD-10 revealed: 
1. Qualitative impairments in social interactions, which was manifested by: 
a. Difficulties in accepting new situations (e.g. signs of frustration if a sequence of 
known activities was changed), limited social activity (she did not undertake 
interactions on her own but undertook simple forms of activity if initiated by an 
adult) 
b. Weak adaptability to surrounding stimuli, mainly social ones (e.g. she was entirely 
indifferent to the new persons in her environment) 
c. Emotional distance, lack of spontaneous expression of feelings with the use of 
speech, gestures, and facial expressions. 
2. Communication disabilities revealing in: 
a. Lack of initiating verbal contacts, and limited readiness to communicate 
b. Weak reactions to questions and commands with preserved understanding (she 
performed simple verbal commands such as ‘come here’) 
c. Weak reactions to visual and/or auditory stimuli, and limited reactivity to non-
linguistic messages 
d. Speech limited to simple sentences that often were constructed against grammatical 
rules 
e. Limited inventory of instrumental gestures and emblems (which commonly are 
used in place of speech). 
3. Behaviour disorders that revealed in: 
a. Many stereotyped reactions (turning round on tiptoes, swinging, beating a floor 
with an object, and non-functional use of objects) 
b. Lack of correct reaction to stimuli as well as inability to differentiate reactions in 
response to various character of stimuli, odd treatment of objects, making dices and 
blocks move.  
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c. Lack of emotional reactions to new toys characteristic of young children (lack of 
curiosity and pleasure connected with receiving a toy, interest in new objects) 
d. Lack of initiative to start playing. 
6.1.2 Results from PEP-R (psychoeducational profile – revised) 
The scores of Ola on the developmental scale are typical of 30-34 months of age (she was 48 
months old at that time). After taking into account emerging scores they rise to 43-47 
months of age, which makes it closer to the age of 3years and 9 months. The highest scores 
the girl gained in gross motility. At a similar level, yet significantly below her age, were 
skills of imitation, perception, fine motor, and an ability to come into relationships (relating 
and effect), sensory responses, and eye-hand coordination. Among them most promising 
proved to be sensory responses, eye-hand coordination, and cognitive processes with the 
























Fig. 1. Obtained and emerging scores of Ola on PEP-R (Psychoeducational Profile – Revised) 
Consequent examinations confirmed occurrence of the so called autistic triad, that is trouble 
getting along with others in a social circle, especially when working together, sharing 
feelings and thoughts, and making friends; impairments of communication; impairments of 
flexible imaginative functions of which restricted and repetitive behaviours and interests as 
well as difficulties in coping with changes are most characteristic. A significant variable, 
which might have influenced the development and functioning of the girl, was her 
traumatic babyhood experience. Yet, the character of developmental changes allows the 
conclusion that it had been rather a secondary factor, though the experiences of her early 
childhood might have stimulated the appearance of ASD dysfunctions.  
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The control variables were: depth of autistic deficits, and the level of social, and 
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c. Lack of emotional reactions to new toys characteristic of young children (lack of 
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6.1.3 Results from WISC-R (Wechsler intelligence scale for children – revised) 
The next examination connected with a need to assess girl’s school readiness at the age of 6;9 
revealed a considerable range of scores. They ranged form moderate intellectual disability to 
average scores. Her general IQ was in the range of <48 – 76>; the scores of verbal IQ were 
within <40 – 58>; while those of performance scale rose to <73 – 98> (p = 0.05). The highest 
scores in the verbal scale the girl got in arithmetic – they were within the average. Other 
scores were at the range of low and very low. In the case of the performance scale it were the 
block design, object assembly, and coding, which were scored at the average level. Close to 
average were also her scores on picture completion and picture assembly.  
It is also worth pointing out that the girl was able to comprehend simple commands while 
fulfilling tasks connected with examination, and she also came into verbal contact with the 
examiner. A three-way analysis revealed that only perceptual organization scored at 
average level (7.75), resistance to distracters scored below average (5), while scores of 
comprehension were very low (1).  
Thus, the scores gained by the examined girl revealed average abilities in visual analysis 
and synthesis as well as good perception of abstract stimuli, and good long-term visual 
memory. At the same time they suggest correct imagination, visual orientation, and 
visualization as well as a preserved ability to create abstract concepts. Moreover, the scores 
reflect a good level of planning skills and of simultaneous processing. The girl’s ability to 
concentrate attention upon a particular task, and an auditory perception of simple stimuli 
was below average. But most impaired were the abilities to communicate while performing 
particular tasks. This might suggest that her auditory short-memory was disordered (She 
was able to repeat only two digits). Auditory perception of complex verbal stimuli, verbal 
expression, verbal memory, and ability to remember previously learned utterances also 
proved to be on a very low level.  
6.2 Case two 
Monika J. was first diagnosed before she was 3 years old. An intellectual retardation of a 
moderate level (F71) with “some traits of autistic behaviours” was stated at the other clinics. 
The verification of this diagnosis performed by our team two years later pointed to 
persuasive developmental disorders (F84), autism in particular (F84.0).  
6.2.1 Results from ICD-10 
The evaluation of her behaviour in accordance with the criteria of ICD-10 showed:  
1. Qualitative impairment of social interactions:  
a. Inadequate evaluation of social and emotional signals, incorrect reactions to the 
emotional states of others, weak modulation of behaviour in response to a given 
social context. 
b. Low level of social skills, weak integration of social, emotional, and communicative 
behaviours 
c. Disturbances in reciprocal social interactions. 
2. Restricted, stereotyped , and repetitive interests and activities: 
a. Routine and inflexibility in everyday behaviours, and making others stick to such 
actions 
b. Stereotyped movements 
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c. Attachment to the computer appeared with age, including the interest in its 
construction. 
3. Disorders of communication: 
a. Low level of social use of language, weak synchronization and lack of reciprocation 
in dialogue  
b. Weak changeability of verbal expression; limited ability emotionally to modulate 
utterances, and weak reactions to questions and instructions as well as to 
nonverbal clues. 
c. Difficulties in differentiation of rhythm and accent to modulate communication 
d. Limited ability to use facial expressions and gestures in communication. 
6.2.2 Results from PEP-R 
The scores of PEP-R show that the actual level of the girl’s abilities is typical of the age range 
22 – 29 month both in the developmental and behavioural scale. It means that they are 
significantly below her chronological age as she was 52 months old at the moment of 
examination. She scored best in gross motor, fine motor, cognitive performance, and 
perception, while the scores of imitation, language, cognitive verbal, relating and affect as 
well as play and interest in materials were significantly below average. At the same time, 
her emerging scores indicated abilities typical of the age range 46 to 51 months so they were 
close to her chronological age. It was observed in accomplishing such tasks as cognitive 
performance, imitation, relating and affect as well as play and interest in materials, 
providing for her zone of proximal development. Scores gained by Monika during an 





Fig. 2. Obtained and emerging scores of Monika on PEP-R (Psychoeducational Profile – 
Revised) 
 
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment 
 
168 
6.1.3 Results from WISC-R (Wechsler intelligence scale for children – revised) 
The next examination connected with a need to assess girl’s school readiness at the age of 6;9 
revealed a considerable range of scores. They ranged form moderate intellectual disability to 
average scores. Her general IQ was in the range of <48 – 76>; the scores of verbal IQ were 
within <40 – 58>; while those of performance scale rose to <73 – 98> (p = 0.05). The highest 
scores in the verbal scale the girl got in arithmetic – they were within the average. Other 
scores were at the range of low and very low. In the case of the performance scale it were the 
block design, object assembly, and coding, which were scored at the average level. Close to 
average were also her scores on picture completion and picture assembly.  
It is also worth pointing out that the girl was able to comprehend simple commands while 
fulfilling tasks connected with examination, and she also came into verbal contact with the 
examiner. A three-way analysis revealed that only perceptual organization scored at 
average level (7.75), resistance to distracters scored below average (5), while scores of 
comprehension were very low (1).  
Thus, the scores gained by the examined girl revealed average abilities in visual analysis 
and synthesis as well as good perception of abstract stimuli, and good long-term visual 
memory. At the same time they suggest correct imagination, visual orientation, and 
visualization as well as a preserved ability to create abstract concepts. Moreover, the scores 
reflect a good level of planning skills and of simultaneous processing. The girl’s ability to 
concentrate attention upon a particular task, and an auditory perception of simple stimuli 
was below average. But most impaired were the abilities to communicate while performing 
particular tasks. This might suggest that her auditory short-memory was disordered (She 
was able to repeat only two digits). Auditory perception of complex verbal stimuli, verbal 
expression, verbal memory, and ability to remember previously learned utterances also 
proved to be on a very low level.  
6.2 Case two 
Monika J. was first diagnosed before she was 3 years old. An intellectual retardation of a 
moderate level (F71) with “some traits of autistic behaviours” was stated at the other clinics. 
The verification of this diagnosis performed by our team two years later pointed to 
persuasive developmental disorders (F84), autism in particular (F84.0).  
6.2.1 Results from ICD-10 
The evaluation of her behaviour in accordance with the criteria of ICD-10 showed:  
1. Qualitative impairment of social interactions:  
a. Inadequate evaluation of social and emotional signals, incorrect reactions to the 
emotional states of others, weak modulation of behaviour in response to a given 
social context. 
b. Low level of social skills, weak integration of social, emotional, and communicative 
behaviours 
c. Disturbances in reciprocal social interactions. 
2. Restricted, stereotyped , and repetitive interests and activities: 
a. Routine and inflexibility in everyday behaviours, and making others stick to such 
actions 
b. Stereotyped movements 
 
Microgenetic Approach to Therapy of Girls with ASD 
 
169 
c. Attachment to the computer appeared with age, including the interest in its 
construction. 
3. Disorders of communication: 
a. Low level of social use of language, weak synchronization and lack of reciprocation 
in dialogue  
b. Weak changeability of verbal expression; limited ability emotionally to modulate 
utterances, and weak reactions to questions and instructions as well as to 
nonverbal clues. 
c. Difficulties in differentiation of rhythm and accent to modulate communication 
d. Limited ability to use facial expressions and gestures in communication. 
6.2.2 Results from PEP-R 
The scores of PEP-R show that the actual level of the girl’s abilities is typical of the age range 
22 – 29 month both in the developmental and behavioural scale. It means that they are 
significantly below her chronological age as she was 52 months old at the moment of 
examination. She scored best in gross motor, fine motor, cognitive performance, and 
perception, while the scores of imitation, language, cognitive verbal, relating and affect as 
well as play and interest in materials were significantly below average. At the same time, 
her emerging scores indicated abilities typical of the age range 46 to 51 months so they were 
close to her chronological age. It was observed in accomplishing such tasks as cognitive 
performance, imitation, relating and affect as well as play and interest in materials, 
providing for her zone of proximal development. Scores gained by Monika during an 





Fig. 2. Obtained and emerging scores of Monika on PEP-R (Psychoeducational Profile – 
Revised) 
 
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment 
 
170 
6.2.3 Results from WISC-R 
The examination administered at the age of 6 years 11 months for the needs of evaluating 
her school readiness revealed a wide range of scores form moderate mental retardation to an 
average level. Her general IQ was within the range of <40 - 68> , the verbal IQ was within 
<34 – 53>, and the performance scores were within the range of <65 – 85>. She accomplished 
the following subtests of Wechsler Scale on the average level: object assembly, picture 
arrangement, and block design, while on similarities, vocabulary, and arithmetic subtest she 
scored very low. It should be pointed out here that despite her difficulties with defining 
terms the girl was quite good in communicating with others. She was able to understand 
simple commands and to carry on conversation. She was also surprisingly good at reading 
messages displayed on a computer screen. She was also able to solve simple puzzles and to 
put together mixed verses of a poem into a meaningful whole. Moreover, she arranged 
individual words into sentences, and knew the meaning of road signs. Her arithmetic 
abilities were also quite good as she recognized and wrote down digits starting from 0 to 
100, and she was able to compare digits within the range of ten with the use of signs: =, <, >. 
Three-way analysis revealed that her perceptual organization was at an average level, while 
the other factors, such as reasoning (1.5) and resistance to distracters (1) were on a very low 
level. Her scores suggest average level of visual analysis and synthesis, and of visual 
perception as well as a correct long-term memory. They also indicate good visual 
orientation and visualization as well as preserved ability to create abstract concepts. Her 
abilities to plan and simultaneous processing were also preserved.  
However, her abilities to concentrate upon a particular task and to interact verbally while 
performing it as well as her auditory perception of simple stimuli were limited. Very 
severely disturbed was the perception of complex stimuli, verbal expression, durability of 
verbal memory, and an ability to remember previously learned expressions.  
6.3 Case three 
Gabriel R. was first diagnosed when she was 3 years old. It suggested delay and 
disharmony of her development. The verification of initial diagnosis was done by our team 
when she reached the age of 4 years and 4 months. It indicated persuasive developmental 
disorders (F84) suggesting autism (F84.0).  
6.3.1 Results from ICD-10  
The evaluation of her behaviour performed in accordance with ICD-10 revealed: 
1. Impairment of social interactions:  
a. Lack of reciprocal social interactions 
b. Weak modulation of behaviour in response to a given social context 
c. Lack of interest in social aspects of play and/or performing tasks 
d. Lack of spontaneous interactions with the closest. 
2. Restricted repertoire of interests and activities: 
a.  Sniffing at the surrounding, liking of sharp odours 
b.  Stereotyped behaviours, turning round on tiptoes, very quick walking on tiptoes  
c. Obsessive interest in maps and diagrams of technical devices.  
3. Decreased communicative competence 
a. Lack of ability to use the language in various social interactions 
b. Inadequate reactions to verbal cues 
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c. Monotonous non-modulated utterances with agrammatisms 
d. Difficulties with understanding complex utterances  
e. Difficulties with synchronization of linguistic and non-linguistic aspects of 
communication. 
6.3.2 Results from PEP-R 
The girl’s scores are at the age range of 37-42 month of life. They are, therefore, below her 
chronological age. If we take into account emerging scores the age range rises to 50-54 
months of life, which means that her potential abilities are close to the chronological age. A 
detailed analysis reveals that the girl scored best in gross motor, fine motor, cognitive 
performance, eye-hand coordination, and perception in developmental subscales, while in 
the case of behavioural scale she scored best on play and interest in materials, and sensory 
responses. She obtained significantly low scores on language, and relating and affect 
(behavioural scale) as well as on cognitive verbal, and imitation (developmental scale). The 
zone of proximal development included relating and affect, language, imitation, and 
cognitive verbal subscales. The scores of PEP-R test administered at the age of 4 years and 4 
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Fig. 3. Obtained and emerging scores of Gabriel on PEP-R (Psychoeducational Profile – 
Revised) 
6.3.3 Results from WISC-R 
Next stages of diagnostic-therapeutic procedure confirmed the existence of an autistic triad. 
At the same time, an examination of school readiness at the age of 6 years 11 months 
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indicated the distribution of scores within the range from moderate mental retardation to 
below average. The scores were within <56 – 74> for the verbal scale, <63 – 83> for the 
performance scale, and <52 – 80> in the case of the full scale IQ (confidence level p = 0.05 ). 
The highest verbal IQ scores (ranging within average results) the girl gained on arithmetic 
and information. The remaining scores were very low. As far as the performance IQ is 
concerned she scored on average level on picture completion, block design, and object 
assembly subtests. On the remaining subtests her scores were below average (picture 
arrangement) or very low (coding). She also exhibited difficulty in defining concepts (on 
vocabulary subtest) in a way similar to the two above described autistic girls. She was, 
however, quite good at comprehending simple commands and instructions.  
To give the reader some insight into the nature of the girl’s difficulties we give some 
samples of her responses appearing in the vocabulary subtest: ‘umbrella’ – like rain; ‘clock’ – 
bim-bam; ‘alphabet’ –a,b,c…(she made an attempt to enumerate the letters of the alphabet); 
‘nail’ – it is cut or not cut; ‘bicycle’ – she lied down on the floor and showed how to ride a 
bicycle; ‘knife’ – she performed the movements of cutting.  
Three-way analysis revealed a correct level of development of perceptual organization (7.5) 
and of resistance to distracters (8.7). Yet, her score on verbal reasoning was very low (2.7). It 
may reflect her low level of linguistic and communicative competences. On the other hand, 
the above scores point to good visual processing, and preserved ability to concentrate on a 
given task. Her abilities to create abstract concepts as well as planning and simultaneous 
processing were also quite good.  
7. An example of a task on developing social interactions 
The microgenetic model makes it possible to directly observe the acquisition of cognitive 
abilities in the process of training. Below we give an example of a task that made possible 
the evaluation to what extent the child is able to comprehend the visual perspective of both 
her and of the parent. The girls were to demonstrate to the parent a toy that they had 
constructed by themselves. The following elements we assessed: 
1. The child approaches the parent 
2. The child tells the parent: “Look what I have done” 
3.  The child demonstrates the toy to the parent 
4. The child moves her eyes from the toy to the parent  
5. The child moves her eyes from the parent to the toy  
6. The child demands a commendable: ”Do you like it”  
During the experiment the examiner and the child were seated at a table, and the parent was 
seated at another table at the opposite corner of the room. The child was able to see the 
whole room, while the parent was seated diagonally at the other side. The examiner 
presented the child a puppet consisting of blocks strung on a stick with a stand. The blocks 
could be arranged in various configurations so that the shape of the puppet was changed. 
The girl constructed the puppet, and then the examiner said: 
1. Show me what you have done 
2. Look at the puppet 
3. Do I look at the puppet? 
4. Do you like the puppet? 
5. Do I like the puppet? 
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After a short period of joint play, the examiner handed the child the puppet and said: “Show 
the puppet to your mum/daddy”. The command was accompanied by pointing to the 
parent with a hand of the examiner. The parents had been instructed to: (1) put their hands 
over their eyes, (2) sit with their backs to the child. Hence, in order to demonstrate the 
puppet the child had to approach the parent and make her look at the puppet, for example 
by pulling her hand and saying “Look what I have done”. The task was evaluated in the 
following way: 
0 points - no demonstrating the puppet to the parent 
1 point - the child approaches the parent but keeps the puppet and looks at it without 
demonstrating it to the parent  
2 points - the child demonstrates the puppet to the parent with an appropriate 
statement. 
Altogether six tasks were performed during one session, and the possible maximum score 
was 12 points. The same pattern of six tasks was then repeated during three consecutive 
sessions presented at two weeks intervals, and the analysis took into account a total of all 
scores gained by the examined girls during all sessions. 
8. Results 
The scores of the girls described in the present chapter are presented in table 1. They show 
that all of them mastered a particular schema of action. During the first session only one girl 
approached her parent in the second task but she did not encourage her/him to take interest 
in the toy. The remaining two girls reached those criteria only in the fifth task. The 
qualitative analysis, however, will make it possible to delineate the strategy of forming 
reciprocal social interactions in a task schema by girls with ASD. After the first session the 
examiner demonstrated the flow diagram. The demonstration was to show the child what 
she was expected to do. During the second session the girls were shown pictures, in which 
consecutive stages of actions to be done were presented. The pictures were shown before 
each task. 
 
  Task 1 Task 2 Task 3 Task 4 Task 5 Task 6 Total 
Session I Ola  0 0 0 0 1 1 2 
Monika  0 0 1 1 1 1 4 
Gabriel  0 0 0 0 1 1 2 
 
Session II Ola  1 1 1 1 1 1 6 
Monika  1 1 2 2 2 2 10 
Gabriel  1 1 2 2 2 2 10 
 
Session III Ola  1 2 2 2 2 2 11 
Monika  2 2 2 2 2 2 12 
Gabriel  2 2 2 2 2 2 12 
Table. 1. Scores obtained by the examined girls in consecutive sessions. 
Below we present the scores of boys in accomplishing the above described task (see table 2). 
Their results from Wechsler Scale were within average and lower than average range. It 
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After a short period of joint play, the examiner handed the child the puppet and said: “Show 
the puppet to your mum/daddy”. The command was accompanied by pointing to the 
parent with a hand of the examiner. The parents had been instructed to: (1) put their hands 
over their eyes, (2) sit with their backs to the child. Hence, in order to demonstrate the 
puppet the child had to approach the parent and make her look at the puppet, for example 
by pulling her hand and saying “Look what I have done”. The task was evaluated in the 
following way: 
0 points - no demonstrating the puppet to the parent 
1 point - the child approaches the parent but keeps the puppet and looks at it without 
demonstrating it to the parent  
2 points - the child demonstrates the puppet to the parent with an appropriate 
statement. 
Altogether six tasks were performed during one session, and the possible maximum score 
was 12 points. The same pattern of six tasks was then repeated during three consecutive 
sessions presented at two weeks intervals, and the analysis took into account a total of all 
scores gained by the examined girls during all sessions. 
8. Results 
The scores of the girls described in the present chapter are presented in table 1. They show 
that all of them mastered a particular schema of action. During the first session only one girl 
approached her parent in the second task but she did not encourage her/him to take interest 
in the toy. The remaining two girls reached those criteria only in the fifth task. The 
qualitative analysis, however, will make it possible to delineate the strategy of forming 
reciprocal social interactions in a task schema by girls with ASD. After the first session the 
examiner demonstrated the flow diagram. The demonstration was to show the child what 
she was expected to do. During the second session the girls were shown pictures, in which 
consecutive stages of actions to be done were presented. The pictures were shown before 
each task. 
 
  Task 1 Task 2 Task 3 Task 4 Task 5 Task 6 Total 
Session I Ola  0 0 0 0 1 1 2 
Monika  0 0 1 1 1 1 4 
Gabriel  0 0 0 0 1 1 2 
 
Session II Ola  1 1 1 1 1 1 6 
Monika  1 1 2 2 2 2 10 
Gabriel  1 1 2 2 2 2 10 
 
Session III Ola  1 2 2 2 2 2 11 
Monika  2 2 2 2 2 2 12 
Gabriel  2 2 2 2 2 2 12 
Table. 1. Scores obtained by the examined girls in consecutive sessions. 
Below we present the scores of boys in accomplishing the above described task (see table 2). 
Their results from Wechsler Scale were within average and lower than average range. It 
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means that the intellectual level of the boys corresponded with intellectual abilities of the 
above described girls. It must be stressed, however, that all boys exhibited aggressive 
behaviours, such as screams, squeaks, throwing objects, tearing paper, psychomotor 
agitation, disobedience, and ignoring commands and prohibitions.  
 
  Task 1 Task 2 Task 3 Task 4 Task 5 Task 6 Total 
Session I Paul  0 0 0 1 0 1 2 
Jarek 0 0 0 0 0 0 0 
Martin 0 0 0 0 1 0 1 
 
Session II Paul 0 0 1 1 1 2 5 
Jarek 0 1 0 1 1 1 4 
Martin 1 1 1 1 1 1 6 
 
Session III Paul 1 1 1 2 2 2 9 
Jarek 1 1 1 1 1 2 7 
Martin 1 1 1 2 1 2 8 
Table 2. Scores obtained by boys in consecutive sessions. 
Comparison of scores obtained by girls an boys shows that :  
1. Results of the first sessions were similar to those of girls. 
2. Difference appeared in the third session since the performance of the boys was much 
worse than of girls. They did not support the demonstration of the puppet with an 
appropriate statement. 
3. Negativistic and/or aggressive behaviours were much more frequent in boys. They 
exhibited strong tendency to scream, to squeak, and were apt to break accomplishing 
the task.  
8.1 Microgenetic analysis 
The developmental microgenetic model (Siegler, Svetina, 2002; Calais, 2008) makes it 
possible to take into consideration five mentioned earlier dimensions reflecting the manner 
of solving a given problem. They are the path, rate, breadth, source, and variability of 
changes that occurred in consequence of accomplishing a particular task.  
1. An analysis of the path revealed that the changes appearing at consecutive stages of 
performing a task were mainly of quantitative nature: starting from the lack of 
demonstrating the puppet to the parent in the initial tasks of sessions, then approaching 
the parent without demonstrating it, and finally demonstration with a verbal message. 
It allows the conclusion that the change of competence took place there resulting in an 
ability to come into social interaction with parents, and to understand their point of 
view. As can be noted in table 1, two of the girls were able to improve their action 
already in the third task. The girls approached their parents, and made them look at the 
puppet. It is worth to remind here that PEP-R examination indicated high emerging 
scores in imitation subscale in all the three girls. Therefore, the above tasks made use of 
a significant zone of proximal development. 
2. An analysis of the rate of change showed that a difference between the primary and 
consequent strategy of solving a problem came into being only in the second session of 
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our study two weeks after the first session. However, it was not possible to state if the 
new strategy appeared gradually or all of a sudden. Stating it would require a more 
frequent, everyday, repetition of experimental sessions.  
3. As far as the breadth of change is concerned it seems that the girls were not able to 
modify once learned schema of behaviour. They were not acting in a spontaneous way, 
and did not express any emotional commitment. Perhaps the use of other experimental 
strategy would enable a deeper insight into the problems encountered by the examined 
girls. 
4. It was also stated that a carefully designed experimental procedure enables forming 
desired, and at the same time quite complex, actions in autistic girls. In this case the 
source of change was demonstration of expected behaviours accompanied by verbal as 
well as nonverbal clues.  
5.  It should be stressed, however, that the girls acted in an automatic way. They did not 
express any satisfaction with their work or a will to boast about their success. At the 
same time, they tended to stick to the once learned schema of action. It allows the 
conclusion that there was no variability in their behaviour as no personal traits could 
be noted in their manner of accomplishing the tasks as well.  
Yet, it was experimentally stated that an appropriate therapeutic approach makes it possible 
developing schemas of social interactions. It results in developing independence and a sense of 
agency so important for creating a sense of identity in a given child. It is also worth to remind 
that all the three girls had a high level of perceptual organization. And it is connected with 
simultaneous and global processing of information based upon visual perception, which 
enables integration of perceived elements and combining them into meaningful wholes. The 
rate of mental processes as well as eye-hand coordination were also good. They might have 
difficulties due to the necessity to work under time pressure and their weak resistance to 
distracters. On the other hand, all of them scored very low on verbal perception tasks, and 
exhibited difficulties with comprehension of verbal commands and instructions.  
It does not need reminding that communication impairment is the main diagnostic feature 
of autistic triad. Yet, the majority of studies relay heavily upon verbal instructions given to 
the examined children. The authors seem to forget that autistic children may have 
difficulties with understanding verbal commands or need some time to process the 
information included there. Hence, if the scores of sequential processing of abstract 
nonverbal concepts are within average range, it allows the conclusion that a given child is 
also able to perform logical operations on verbal material. Especially, if she is able to see 
cause and effect relationships in everyday situations. Beside communication problems 
difficulties with performing experimental tasks may also be due to the necessity of 
combining two types of clues: verbal (instruction) and nonverbal (demonstration). So the 
actions of an examiner, who intends to explain the rules of a given task, may in effect lead to 
a confusion as was the case with well known Piaget’s experiments (see Donaldson, 1978). It 
is also reflected in the phenomenon of “horizontal decaláge”. That is an inconsistency in the 
tasks healthy children can perform. For instance, they can solve Piaget’s conservation 
problem on numbers at age six, but they are not able to solve it on mass until age eight, 
while the ability to perform conservation of weight task appears only at the age of ten 
(Wortman, Loftus and Marshall, 1988).  
Bearing all this in mind we have used a number of repetitions in order to make sure that the 
child had understood what was required from her in a given experimental situation. The 
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aim of the above described task was to make it the child understand the visual perspective 
of another person. While showing her work to the parent the child established a common 
field of sharing attention. Awareness of the existence of two different points of view is an 
important indicator of developing social interactions (Meltzoff, 1995; Repacholi & Gopnik, 
1997; Gopnik, Meltzoff & Kuhl 1997). A sequence of behaviours used in the above described 
experiment was to create an awareness of different points of view in autistic children. As 
pointed out above the girls were much better in performing those tasks than the boys we 
were examining during a ten year period.  
8.2 Possible sources of differences between girls and boys 
It is often stressed in autistic literature that the symptoms of ASD exhibited by girls are 
more difficult to diagnose than those occurring in boys (Attwood, 2007; Kopp et al., 2010; 
Skuse, 2009). One of the reasons is higher than in boys’ level of social skills, such as an 
ability to come into social interactions and a style of behaviour in general. Moreover, 
deviant behaviours of children with ASD influence not only their own development but also 
the life of the whole family. At the same time, they have impact upon their relations with 
peers and adults from outside the family. It concerns their attitudes towards such children 
in particular since autistic children were believed - and often still are – to be dangerous for 
others due to their bizarre and odd behaviours. Since boys are generally believed to be more 
aggressive, another significant factor discriminating functioning of girls and boys with ASD 
may be a difference in educational treatment (Constantino et al., 2009: Jonson-Reid et al., 
2010). Beside social learning biological factors may also play an important role. One of them 
is the testosterone impact upon the foetus (Baron-Cohen et al., 2005).  
It may also be worth to point to another factor that might cause differences between 
symptoms observed in boys and girls. Namely, a well known clinical fact that female brain 
is less localized than the male brain (Moir and Jessel, 1992). In consequence, brain lesions in 
women are less disastrous than in men what may be best observed in aphasia recovery. As 
pointed out earlier, the process of brain development is connected with elimination of 
unnecessary connections, which leads to refinement of behaviour (see also Kaczmarek, 
Markiewicz, 2008). It is highly plausible that in the case of autism the selection is delayed, 
which results in over-abundance of connections, and in disinhibition leading to sensory 
overload.  
It was noted in other works (Kaczmarek, 2003; Kaczmarek, Markiewicz, 2008) that while 
creating our own image of the world we concentrate upon matters that are important for us 
and leave out less significant. Therefore, our world image is simplified to a considerable 
degree, and thanks to it the surroundings seem predictable. And it is that presumed 
predictability that gives us a feeling of safety. Thus, meeting a mentally ill person makes us 
feel a bit nervous because we do not know what to expect from him. The autistic child is not 
able to single out significant stimuli from the non-significant ones, hence her world becomes 
unpredictable, incomprehensible, and terrifying. It may lead not only to fits of aggression 
and self-aggression but also to stereotyped repetitive behaviours so characteristic of autism. 
9. Conclusion 
Our own clinical practice as well as other studies show that early diagnosis and therapeutic 
procedures connected with it facilitate socialization of children with ASD. Of particular 
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significance is the individual approach to each autistic child. It enables evaluating not only 
level of actual skills but also developmental potential of a given child, which in turn 
improves efficacy of treatment. If we know a zone of proximal development of a given child, 
we are able to concentrate on the areas in which the child is prone to succeed. Therefore, the 
microgenetic analysis of the manners in which the child strides to overcome difficulties 
while solving particular tasks proves to be of great significance. It gives a therapist tools for 
developing potential abilities of the child, and not to concentrate on her disabilities as it is 
often the case. Such an individualized and progressive approach increases the efficacy of 
therapy and gives the child a feeling of success stimulating her to work.  
Taking into account developmental profile of a particular child is a necessity since there is a 
considerable differentiation among autistic persons both in the inter- and intra-individual 
dimensions. One of them is the difference between the clinical picture of symptoms in boys 
and girls. Moreover, studies of Constantino and collaborators (2009) revealed subtle 
difficulties in communicating with others in 20 per cent of families of children with ASD. 
They were observed mainly in siblings in whom some traits of autism appear about ten 
times more often than in healthy population. The authors are of the opinion that at least 
some of specific traits of autistic spectrum may be hereditary. Therefore, they stress the 
necessity of taking into consideration sex differences while making a diagnosis of autism.  
Our study has shown that it is possible to develop a schema of action, or a script, in autistic 
girls. Moreover, the techniques we applied made it possible to analyze a given change, 
while it was actually happening, and not comparing behavioral patterns from a pre- and 
post-change as it is often done.Yet, the script remains a rigid unchangeable sequence of 
actions, while healthy people change it in accordance with the requirements of environment. 
It was also noted that the autistic symptoms in girls are less pronounced due mainly to their 
better communicative competence. For that reason their disorders are often neglected 
despite the fact that their qualitative character is not much different from the disturbances 
observed in boys. The differences are mainly of a quantitative nature. It is quite probable 
that refinement of diagnostic methods will lead to better understanding of their problems 
causing a dramatic increase of the number of autistic girls as was the case with other clinical 
syndromes.  
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1. Introduction 
Autism is a neurobehavioural disorder that includes impairment in social interaction and 
language development and communication deficits accompanied by repetitive and 
stereotyped behaviours. More recently this term has been used to define a very broad 
behavioural phenotype which is classified as different disorders that comprise the Pervasive 
Developmental Disorders (PDD) according to the Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition-DSM-IV (American Psychiatric Association [APA], 1994). It 
contains the criteria for diagnosis and specific characteristics of each disease, including 
Autism, Asperger’s syndrome, Childhood Disintegrative Disorder, Rett syndrome and 
Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).  
However, with the exception of Rett syndrome, the others make up a continuous spectrum 
rather than clinically defined diagnostic categories due to the wide variation of clinical signs 
and symptoms and the subjectivity of the criteria for differential diagnosis. For this reason 
these disorders have been included in a general conceptual category, Autism Spectrum 
Disorders (ASDs) (Snow & Lecavalier, 2011; Witwer & Lecavalier, 2008). Hence, the 
proposals for DSM-V, being prepared by the APA, which is scheduled to be published in 
2012 or 2013, recommend that Rett syndrome is not considered among the ASDs, that the 
designation PDD is no longer used and that ASD is considered a single category that 
includes Autism, Asperger's syndrome, Childhood Disintegrative Disorder and PDD-NOS. 
That is, the disorders that compose the autistic spectrum would no longer have specific 
names (APA, 2011).  
Rett syndrome almost exclusively affects girls and is characterized by normal development 
until about six months followed by regression of motor and social skills. The triad dementia-
ataxia-autism is observed as is a characteristic pattern of deceleration in the rate of head 
growth, loss of acquired manual skills, poorly coordinated gait, involuntary movements of 
the hands and the trunk and autistic features. Epilepsy may be present and a abnormal 
respiratory pattern is typical . The prevalence among women is between 1:10,000 and 
1:15,000 with most cases caused by a sporadic mutation in the MECP2 gene, located on 
Xq28. In some cases, the etiology is due to mitochondrial DNA mutations (Gonzales & 
LaSalle, 2010; Nissenkorn et al., 2010; Temudo et al., 2010). The peculiar nature and specific 
etiology, linked to a genetic defect with consequent brain damage, are among the reasons 
for not being considered within the ASDs. 
Childhood Disintegrative Disorder is basically characterized by normal development of 
children until at least two years of age followed by a process of loss of previously acquired 
intellectual and behavioural skills, which results in autistic behaviour (Homan et al., 2011). 
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Asperger’s syndrome differs from other diagnoses because of the absence of delay in 
language development, in general a preserved cognitive development, frequently 
prodigious memory, as well as "pedantic" speech, inadequate social interaction and, in 
many cases, disinterest in interpersonal relationships (Koyama & Kurita, 2008). 
Since the reports of Kanner in 1943 on "autistic disturbances of affective contact", Autism 
has been extensively discussed and investigated. Currently regarded as a developmental 
disorder that manifests before thirty months of age, it is characterized by abnormal 
responses to auditory and visual stimuli and underdeveloped or absent speech. Serious 
communication and social interaction problems occur and behaviour is ritualistic, 
aggregating abnormal routines with resistance to change. Approximately 75% of cases are 
associated with mental retardation, 15 to 40% with seizures and 20 to 50% with 
electroencephalographic abnormalities (Tuchman et al., 2010). 
PDD-NOS is a diagnosis of exclusion made when an individual presents severe impairment 
of reciprocal social interaction and verbal or nonverbal communication skill development, 
but does not satisfy the criteria for other PDDs. Atypical Autism, for which the etiology and 
prevalence remain unknown, is also included in this category (Chiappedi et al., 2010; 
Koyama & Kurita, 2008). 
ASDs occur in approximately 1:150 live births and in all ethnic groups and social classes, 
and thus can be considered a public health problem. There are discussions as to whether 
there is a real progressive increase in the prevalence of these diseases in the population and 
it is speculated that there are several risk factors. However, this increase appears to result 
from the fact that diagnosis is being made earlier as education and healthcare staff are more 
attentive to the symptoms, besides the diffusion of information, leading to the identification 
of a greater number of cases (Liu et al., 2010; Shen et al., 2010; Nassar et al., 2009). There are 
several diagnostic scales that use "checklists" and are effective in the rapid identification of 
possible cases of ASD. The degree of behavioral and cognitive functioning is highly variable 
and early diagnosis is of paramount importance because stimulation programs achieve 
much more significant results when interventions occur in the early development stages. If 
diagnosis and intervention are delayed, the results are not very promising (Biederman et al., 
2010; Marteleto et al., 2008). 
But if the classification of the autism phenotype is so difficult and so discussed, the etiology 
is even more so. Knowledge about the etiology of ASDs is increasing, but causes remain 
elusive for most cases. The truth is that autism has many etiologies. 
ASD associated with a known cause is called syndromic autism. There is an expanding list 
of medical conditions in the literature associated with autistic manifestations, ranging from 
disruptions caused by varying environmental agents to several mutations and well-defined 
syndromes, chromosomal abnormalities and metabolic diseases. In cases where the cause is 
identified, the autistic manifestation is considered secondary (Benvenuto et al., 2009). 
Among these, prenatal infections, prenatal exposure to physical and chemical agents and 
genetic disorders may be cited (Ratajczak, 2011; Zhang et al., 2010). However, the biological 
mechanisms involved in these associations are unclear.  
The clinical heterogeneity of ASDs probably reflects the complexity of the genetic profile. 
There is no doubt that different genetic mechanisms contribute to the pathogenesis of ASDs. 
Thus, when the many different etiologies of autistic phenotype are referred to, the principal 
focus is on genetic aspects. Heritability is estimated in 90% and the monozygotic twin 
concordance rate is as high as 95%. The situation is complicated by significant inter-
individual heterogeneity, the numerous loci involved and gene-environment interactions 
(Caglayan, 2010).  
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Another interesting aspect is related to the phenomenon of genetic anticipation. Since the 
first descriptions by Kanner, particular personality traits in relatives of autistic patients have 
been recognized. The findings of familial aggregation of minor variants suggest that genes 
confer susceptibility at variable severity, which is often "light", known as broad phenotype, 
and independently segregates among relatives (Losh et al., 2008; Schmidt et al., 2008).  
This suggests that this complex combination of genetic and environmental factors, is what 
really defines the risk for ASDs. The commonly accepted empirical risk estimate for a couple 
with one affected child is 2–8%, in the absence of a definablecondition (Selkirk et al., 2009).  
Karyotype analysis shows changes involving all chromosomes in 3 to 6% of ASD cases. 
However, the functional significance of these changes also remains unknown given the 
variation in the size of the regions involved and the diversity of loci. Moreover, the majority 
of rearrangements are sporadic, some are detected in other asymptomatic family members 
or are de novo in individuals with a positive family history of ASDs (Marshall et al., 2008; 
Sykes & Lamp, 2007). 
Many genes are likely to contribute to the etiology of ASDs, especially in cases of non-
syndromic autism, as they present mutations or polymorphisms. The identification is 
becoming easier as a result of advances in genetic technology. It is believed that the 
emergence of the autistic phenotype in most cases depends on a small additive effect of 
multiple genes, but all with expressions in the central nervous system. Among these are the 
CENTG2 gene mapped at 2q37.2, the SHANK3 gene mapped at 22q13.3, the GABRB3 gene 
mapped at 15q11-13, the SLC6A4 gene located at 17q11.2 and the NLGN3 gene mapped at 
Xq13.1 (Cuscó et al., 2009). 
Many studies recommend that the laboratory evaluation of ASD cases should initially 
include an analysis of G banded karyotype, preferably high resolution and a molecular 
evaluation of the FMR1 gene. But even at high resolution, abnormalities smaller than ~5Mb 
cannot be detected by karyotyping, which is problematic, particularly in subtelomeric 
chromosomal regions that are rich in genes susceptible to rearrangements. For this reason, 
karyotypic evaluation by the Fluorescent in situ Hybridization (FISH) technique is indicated 
to overcome some limitations and clarify certain karyotypic findings. However, negative 
results obtained with these techniques have not ruled out other types of genetic alterations. 
Genetic screens represent a powerful tool when dealing with monogenic disorders 
characterized by direct genotype-phenotype correlations. Current guidelines for clinical 
genetic evaluation of patients recommends carrying out a detailed physical examination, 
hearing evaluation, obtaining a detailed personal and family history, screening for inborn 
errors of metabolism and neuroimaging studies, as well as karyotype and fragile-X DNA 
testing (Lintas & Persico, 2008; Wassink et al., 2007). The identification of genes linked to 
susceptibility and investigation of pathogenic mechanisms is crucial in clinical practice and 
for adequate genetic counseling of families, but the specifications and limitations of each test 
should be considered. Some genetic testing, even as part of research protocols for ASDs, can 
only be time consuming and not appropriate in many cases. 
More recently tests to identify cryptic genomic changes have been proposed. The 
development of array-based CGH (Comparative Genomic Hybridization) and MLPA 
analysis (Multiplex Ligation-dependent Probe Amplification) has enabled detection of 
microdeletions and microduplications in patients with ASDs. These have been referred to as 
copy number variants (CNVs) and seem to play a key role in the etiology of many cases, 
more commonly among patients with non-dysmorphic ASDs (Benvenuto et al., 2009; 
Christian et al., 2008). But despite the promising genetic findings, the data are still 
 
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment 
 
182 
Asperger’s syndrome differs from other diagnoses because of the absence of delay in 
language development, in general a preserved cognitive development, frequently 
prodigious memory, as well as "pedantic" speech, inadequate social interaction and, in 
many cases, disinterest in interpersonal relationships (Koyama & Kurita, 2008). 
Since the reports of Kanner in 1943 on "autistic disturbances of affective contact", Autism 
has been extensively discussed and investigated. Currently regarded as a developmental 
disorder that manifests before thirty months of age, it is characterized by abnormal 
responses to auditory and visual stimuli and underdeveloped or absent speech. Serious 
communication and social interaction problems occur and behaviour is ritualistic, 
aggregating abnormal routines with resistance to change. Approximately 75% of cases are 
associated with mental retardation, 15 to 40% with seizures and 20 to 50% with 
electroencephalographic abnormalities (Tuchman et al., 2010). 
PDD-NOS is a diagnosis of exclusion made when an individual presents severe impairment 
of reciprocal social interaction and verbal or nonverbal communication skill development, 
but does not satisfy the criteria for other PDDs. Atypical Autism, for which the etiology and 
prevalence remain unknown, is also included in this category (Chiappedi et al., 2010; 
Koyama & Kurita, 2008). 
ASDs occur in approximately 1:150 live births and in all ethnic groups and social classes, 
and thus can be considered a public health problem. There are discussions as to whether 
there is a real progressive increase in the prevalence of these diseases in the population and 
it is speculated that there are several risk factors. However, this increase appears to result 
from the fact that diagnosis is being made earlier as education and healthcare staff are more 
attentive to the symptoms, besides the diffusion of information, leading to the identification 
of a greater number of cases (Liu et al., 2010; Shen et al., 2010; Nassar et al., 2009). There are 
several diagnostic scales that use "checklists" and are effective in the rapid identification of 
possible cases of ASD. The degree of behavioral and cognitive functioning is highly variable 
and early diagnosis is of paramount importance because stimulation programs achieve 
much more significant results when interventions occur in the early development stages. If 
diagnosis and intervention are delayed, the results are not very promising (Biederman et al., 
2010; Marteleto et al., 2008). 
But if the classification of the autism phenotype is so difficult and so discussed, the etiology 
is even more so. Knowledge about the etiology of ASDs is increasing, but causes remain 
elusive for most cases. The truth is that autism has many etiologies. 
ASD associated with a known cause is called syndromic autism. There is an expanding list 
of medical conditions in the literature associated with autistic manifestations, ranging from 
disruptions caused by varying environmental agents to several mutations and well-defined 
syndromes, chromosomal abnormalities and metabolic diseases. In cases where the cause is 
identified, the autistic manifestation is considered secondary (Benvenuto et al., 2009). 
Among these, prenatal infections, prenatal exposure to physical and chemical agents and 
genetic disorders may be cited (Ratajczak, 2011; Zhang et al., 2010). However, the biological 
mechanisms involved in these associations are unclear.  
The clinical heterogeneity of ASDs probably reflects the complexity of the genetic profile. 
There is no doubt that different genetic mechanisms contribute to the pathogenesis of ASDs. 
Thus, when the many different etiologies of autistic phenotype are referred to, the principal 
focus is on genetic aspects. Heritability is estimated in 90% and the monozygotic twin 
concordance rate is as high as 95%. The situation is complicated by significant inter-
individual heterogeneity, the numerous loci involved and gene-environment interactions 
(Caglayan, 2010).  
 
Genetic Counseling in Autistic Phenotypes 
 
183 
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inconclusive which is due to genetic heterogeneity, the likely involvement of many genes 
that interact, epistatic interactions, gene-environment interactions, variability in gene 
expression, the influence of epigenetic mechanisms and the fact that the expression of some 
genes is influenced by specific regulatory regions located at relatively long distances, even 
on other chromosomes, which makes the selection of candidate genes difficult (Zahir & 
Brown, 2011; Vorstman et al., 2006). The fact that the cost of these tests is high and the 
availability is low has to be considered as this makes access for many patients difficult. 
The high prevalence and complexity of the ASDs have motivated several studies using 
different research strategies. Genetic factors are the most studied and its potential cause in 
many cases has resulted in a significant increase in the number of referrals to clinical 
geneticists and genetic counselors. 
Genetic counselors are able to help families that have children with syndromic autism and 
even in cases with uncertainty regarding etiology. But, genetic counseling for families of 
ASD individuals is a difficult procedure. The most important aspect is that genetic 
counseling is not only a question of giving technical information related to all the 
complexity of the aforementioned features. Even so, technical information can be offered in 
several contexts such as healthcare and educational booklets and even in television shows. 
Genetic counseling is the process of providing information to individuals and families about 
the nature, inheritance, and implications of genetic disorders to help them make informed 
medical and personal decisions. It is a communication process. As such it should be 
understood as a "two-way street", i.e. as a situation of "exchange". Counselors have no 
guarantee or control that their "message" to counselees is understood as intended, nor even 
about the consequences of the process. Thus, besides the communication of biological and 
clinical information, counselors must prioritize the educational and psychological aspects of 
the process, so that all the information and emotional support given to counselees can 
support their decision making and help to reduce anxiety and guilt. It is essential to 
remember that nondirectiveness is crucial in this process (Kessler, 2001) as is the context, the 
environment chosen for the process to develop. 
Nondirectiveness is not a question of whether to give advice or not or to say what the 
counselor thinks is best or not. It is a form to promote and to enhance the autonomy and 
self-directedness of counselees. It is necessary to provide accurate, complete and unbiased 
information and to have an empathic relationship between those involved, professionals 
and family. Nondirectiveness and ethical principles applied to genetic counseling are very 
well documented in a publication of the World Health Organization in 1998 (World Health 
Organization [WHO], 1998). 
There are different methods to promote the identification of the most relevant aspects that 
must be addressed with the families. The counselor should convey all the useful information 
requested, as well as information that should have been requested by counselees, but was 
not. 
All circumstances of genetic counseling are in a complex context that involves personal 
dynamics and social interactions with the meaning and perception being very different 
among those involved (i.e., counselees and counsellor). Invariably, however, stress and 
anxiety are present in this context. It should be noted that coping strategies differ between 
individuals, ranging from seeking information or avoiding new information to reactions of 
anger or indifference, which are psychological defences against an aversive event that 
causes pain. Often, the cascade of psychological effects that begins is unpredictable. 
Certainly, at least in the first session of genetic counseling, the counselor is faced by shocked 
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and very vulnerable individuals with a great sense of loss, guilt and shame. Family issues, 
structure, emotional dynamics, religion, patterns of communication, kinds of interactions, 
ethnicity and social support must be considered during the counseling process because all 
these issues will influence the counseling. 
The diagnosis of autism is really a major stressor for families who have to adapt to a reality 
that, in addition to being new, is very heterogeneous, complex, and difficult and can result 
in conflict. This requires professionals working in this area to invest more in psychosocial 
genetic counseling skills. These issues and their applications to genetic counseling were 
detailed by Weil (2000).  
Genetic counseling generally involves a chronicity situation which is absolutely true in the 
case of autism. Chronic diseases can produce consequences such as pain, discomfort, low 
self-esteem, uncertainty about the future, suicidal thoughts, fear, panic, general and specific 
disorders of conduct, academic performance deficits, difficulties in interpersonal and family 
relationships, anxiety, and depression among others. The emotional distress associated with 
these diseases, if ignored, can lead to a significant reduction in the quality of life of patients 
and their families and negatively affect the absorption of important information and 
adherence to treatment. Thus, family members should always be considered at risk for 
developing some kind of emotional disorder. These considerations underscore the nature of 
genetic counseling as something far beyond the process of medical diagnosis and the 
establishment of the risk of occurrence/recurrence. Hence, skilled and experienced 
professionals are needed to perform this task, giving priority to communications and 
humanization of care. In the past, communication skills were not considered a priority. 
However, today these skills have become a professional demand and even the legal 
obligation of every professional in healthcare. 
Genetic counseling is developed in a continuous and integrated manner. Division in phases 
is only for teaching purposes and can be summarized as: the reception and identification of 
patient/family, understanding of the problem/complaint, the identification of antecedents, 
establishment and confirmation of the diagnosis, assessment of genetic risk, discussion 
about options and decisions, and follow up. Psychological support from the counselor is 
essential for each phase, whether in a single session or several. 
There are not a great number of reports about genetic counseling in ASDs. Maybe one of the 
reasons is related to the misunderstanding about the heritability of these disorders as 
mentioned above. Like other diseases, some cases are inherited and others are not. Then, 
what to do in each case since genetic causes may play an important role in the etiology of 
ASDs?  
The clinicians have to identify specific causes or exclude them to provide effective 
counseling and this is not always an easy job. Two situations must always be considered: 
syndromic autism and non-syndromic autism (idiopathic or primary). In the first one, there 
is a known cause related to the behavioural phenotype and that often can be identified by 
dysmorphic features. It may be associated with well-known monogenic disorders, 
chromosomal alterations and environmental events. Genetic counseling should be directed 
to information related to the cause, genetic or not. Someone could say that if the cause is not 
genetic, the patient certainly will not go to a genetic counseling service, but in practice this is 
not true. In non-syndromic cases, determined after detailed investigations, the approach will 
be different, discussing in particular the polygenic predisposition and the environmental 
contribution to the autistic phenotype.  
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2. Genetic counseling in genetic disease associated to autism 
Approximately 10% of autistic patients have a diagnosis of single gene diseases or 
chromosomal abnormalities; there are several molecular pathways potentially involved in 
the alterations that affect normal neurodevelopmental events. In cases of chromosomal 
defects, for example, these can cause alterations in neuronal migration and brain growth, 
with subsequent altered cortical organization, synaptic and dendritic changes and the ASD 
phenotype. Metabolic disorders produce an accumulation of toxic metabolites which can 
cause a reduction of myelin, neuronal loss, alterations in dopaminergic or serotonergic 
neurotransmission and ASD (Benvenuto et al., 2009). 
The most common genetic diseases associated with ASDs include Fragile-X syndrome, 
Tuberous Sclerosis, invdup(15) or idic(15), Prader-Willi and Angelman syndromes, Down 
syndrome, Joubert syndrome, macrocephaly and overground syndromes, Turner syndrome, 
Williams syndrome, Timothy syndrome, Smith-Magenis syndrome, Phelan-McDermid 
(22q13.3 deletion) syndrome, Cohen syndrome, Sanfilippo syndrome, mitochondrial 
cytopathies, among others (Caglayan, 2010; Moss & Howlin, 2009). And this list just keeps 
growing! 
A Fragile X syndrome is diagnosed in almost 5% of the children with ASDs. Faced with this, 
it is considered the most common genetic etiology of the autistic phenotype. It is the most 
common cause of inherited intellectual deficiency in men. It results from a full mutation that 
affects approximately 1 in 2500 males and 1 in 8000 females. The molecular basis involves a 
dynamic and unstable mutation characterized by the repeat expansion of the trinucleotide 
(CGG)n in the 5’ untranslated region of the first exon of the FMR-1 gene (Fragile-X Mental 
Retardation 1) mapped at Xq27.3. When the number of CGG repeats is greater than 200, the 
allele is classified as a full mutation. CpG island hypermethylation of the promoter causes 
gene inactivation. Persons with the syndrome produce little or no detectable expression of 
the encoded protein called Fragile X Mental Retardation Protein or FMRP which is essential 
for normal brain function. It is involved in synaptic maturation and its loss may alter 
neuronal plasticity. Brain damage results in, among other things, autistic behaviour. 
Individuals with intermediate CGG expansions in the range of 55–200 repeats are known as 
fragile X premutation carriers and are at increased risk for a related disorder known as 
Fragile X-Associated Tremor and Ataxia Syndrome (FXTAS) that affects primarily men over 
the age of 50. The presence of the premutation in women can also cause premature ovarian 
failure (Hampson et al, 2011). 
All the diseases associated with autism have specific molecular biological mechanisms with 
different genes involved and different types of inheritance pattern. The fact is that the 
autism phenotype is one of the clinical manifestations of the disease itself, which in one way 
or another, changes the structure and/or function of the brain. For this reason, it is spoken 
of as association rather than comorbidity because the events are not random in the same 
patient. Given this scenario, genetic counseling should be directed according to information 
relevant to that specific syndromic diagnosis with explanations of the causes, risks and 
consequences. Conduct is not so differentwhen the etiology of autism arises from the action 
of a toxic environmental agent. 
The autism phenotype, however, is a major complicating factor when combined with a 
genetic disease because the parents, who are usually very distressed, can confuse the risk of 
disease recurrence with risk of autism among those affected by it. Not all of those affected 
have the autism phenotype. It is important that counselors, in addition to background and 
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needs, identify the expectations of their genetic counseling clients. However, this scenario 
includes hundreds of possibilities of events and different strategies to solve them. Some of 
the genetic conditions are inherited while others are not. In most cases there is an important 
variability in clinical manifestations. If the disease is genetic it is incurable although often 
there may be symptomatic and palliative treatments.  
Autism phenotype can be associated with autosomal recessive disease, which was 
originated from parents who carry the deleterious gene. This is one of situations of genetic 
counseling that inherently evoke guilt. The dominant culture of the family, especially if its 
members are Latino, produces the feeling of being punished for some sin. In this case the 
guilt can be a response to new and adverse reality over which one has no control. This can 
be exacerbated if during the explanation the counselor emphasize features such as that the 
probability of the outcome was very low. 
Sometimes it is difficult for parents to 'see' the genetic disease of their children since the 
autistic symptoms appear more strongly than the dysmorphic features. By a lack of 
standardized diagnostic procedures in many syndromes and the absence of laboratory 
markers, the diagnostic process often stems from interpretation of a set of clinical signs and 
the experience of the geneticist. For some families, accustomed to different clinical 
procedures, this can also cause anxiety. 
In some cases there is a probable diagnostic hypothesis, however, the test(s) required to 
arrive at an accurate diagnosis may not be accessible to the family. This can greatly hinder 
the process of genetic counseling and create stress in the family and counselor. The 
molecular revolution observed in the last three decades has introduced many procedures 
that are not still available in public health programs of several countries and only the most 
economically advantaged families can access them, which does not correspond with the 
reality of most people. While it lasts, intercountry collaboration programmes should be 
stimulated (WHO, 2010). 
A large number of families consult the Internet before the counseling to obtain information 
about the diagnoses, treatment, and tests and so many clients arrive for genetic counseling 
with notions of the condition for which they are to have counseling (Peters & Petrill, 2011). 
This creates a series of expectations. Not always, however, information is obtained from 
reliable sources and it is for the counselor to clarify false beliefs or possible 
misinterpretation. 
Also, it must be emphasized that the search for a solution makes the Internet a tool that 
frequently causes more harm than good. The demand for treatment has increased gradually 
and cognitive behavioural intervention programmes aimed at trying to improve social 
interaction and communications are encouraged (Wood et al., 2009). The design of these 
interventions is to act during the critical period of postnatal neuronal plasticity (within the 
first three years of life). But there are other not empirically proven therapies; for this reason, 
sites selling solutions for autism have proliferated. Couples come to genetic counseling 
requesting an opinion and explanation from the counselor on "magic formulas";they become 
anguished and even feel guilty when they realize that this solution is unfeasible, especially 
as some of them have very high costs. It is for the counselor to reduce the anxiety of parents 
and explain that this is not about being for or against any type of alternative therapy, but 
that most have no scientific basis and some may even pose health hazards. Families need to 
understand the evidence for efficacy (or lack thereof) and potential side effects. More 
accurate and earlier diagnosis or the elucidation of etiological factors does not mean 
effective therapies in the short term. 
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needs, identify the expectations of their genetic counseling clients. However, this scenario 
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3. Genetic counseling in autism of unknown etiology  
On taking into account all technologies, an underlying genetic diagnosis is identified in 
around 10–15% of ASDs cases while cytogenetically visible chromosomal rearrangements 
are found in 2–6% of ASDs individuals (Bremer et al, 2011; Kumar & Christian, 2009). 
Hence, for most individuals (90%) with the autistic phenotype, there is no known genetic or 
environmental cause, which defines them as non-syndromic or "idiopathic' as previously 
mentioned. Often this condition is established after negative resultsobtained from a medical 
evaluation to identify medical issues that affect the development and behavior of nonverbal 
children, physical examinationabout metabolic, medical, or neurologic conditions, careful 
examinationof personal history, a detailed investigation of gestational antecedents and 
dysmorphic signs and after performing an odysseyof multiple testing.  
Genome-wide studies have implicated numerous minor risk alleles with low and high 
penetrance but few common variants and with many contributing loci. Among the 
candidates are genes that code for important proteins in synaptic structure, function and 
maintenance. Genetic mutations in these genes result in an aberrant synaptic process that 
could produce the ASDs phenotypes. However, the frequency of these mutations is so low 
that widespread screening does not seem to be clinically justified. Some, however, deserve 
to be investigated because of clinical findings such as mutations in the PTEN gene in 
children with macrocephaly (Lintas & Persico, 2008). 
As etiological factors are progressively being discovered, it is natural to think that the number 
of idiopathic cases will also gradually decrease. The increased resolution of CGH array testing 
in combination with new technologies, such as whole genome sequencing and bioinformatics 
programs, will play an important role in helping us to further understand the complex genetic 
basis of autism. The implementation of these high resolution techniques in the genetic research 
of ASDs may discover specific genotypes and subtypes of ASDs for which new diagnostic and 
therapeutic strategies can be developed. For this reason the identification of genetic 
abnormalities is a high priority in the study of ASD (Bremer et al., 2011). 
For now, non-syndromic cases are much more common than other forms with estimates in 
the general population reported at approximately 1 in 100. In these cases, ASD is considered 
a complex disease of multifactorial pattern inheritance (Harrington, 2010; Maenner & 
Durkin, 2010)[4] M.J. Maenner and M.S. Durkin, Trends in the prevalence of autism on the 
basis of special education data, Pediatrics 126 (2010), pp. e1018–e1025. Full Text via CrossRef 
| View Record in Scopus | Cited By in Scopus (1). About 70% of probands with autism of 
unknown cause has a first- or second-degree relative with autistic symptoms, and 15% has 
fathers with Asperger syndrome. The empiric aggregate risk to sibs of individuals with 
autism of unknown cause varies across studies but is generally considered to range from 5% 
to 10% for autism and 10% to 15% for milder symptoms, including language, social, and 
psychiatric disorders. For families with two or more affected children, the recurrence risk 
approaches 35% (Miles et al., 2010).  
All this information should be thoroughly discussed with the members of the family at their 
level of understanding. Obviously, faced with such uncertainty and heterogeneity, the 
counselor may feel uncomfortable to report these risks. It is essential that the family 
understands that when a child is diagnosed with an ASD, a range of etiological options are 
involved, which means the possibility of many different diseases. An aggravating factor is 
that the information may generate anxiety; most families have social and institutional 
barriers to carrying out more sophisticated tests. 
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4. Psychosocial aspects of genetic counseling in autism 
Throughout its development, the family goes through many changes. Each phase of the so-
called life cycle (acquisition, adolescence, maturity and final) has its own peculiarities and 
difficulties inherent to the transformations that occur. During the acquisition phase, with the 
arrival of children, accepting parenting is already difficult. The family system "grows" as a 
whole and new links and forms of communication are needed. Moreover, the "myth of 
happy motherhood" is common, influenced by sociocultural aspects. This myth may become 
unreachable and a crisis may result from this expectation, as the ideal social value is not 
achieved. If motherhood is culturally associated with well-being and achieving, when the 
son or daughter is not compatible with the one desired by the parents, as is the case of 
children born with a vulnerability, this condition does not only change the 
psychophysiological functioning of the mother and her quality of life, but can also result in 
negative consequences for the whole family. Parenthood is a relational experience of 
profound psychological meaning, experienced in family relationships, which are 
transformed over the entire life and that are restructured with the normal cycles of family 
development and, occasionally, by unforeseen events (Cerveny & Berthoud, 1997). 
The arrival of a child with ASD can be considered an unexpected contingency at any stage 
that the family is going through, because these are serious psychiatric illnesses, which 
require special needs and require much understanding and patience due to the peculiarity 
of the symptoms. Given this reality, some authors have reported that mothers of children 
with disabilities tend to depression, which may be associated with hopelessnessand 
worsened quality of life. This is also observed in the fathers and siblings of individuals with 
ASDs, with the degree of symptoms reflecting the severity of the autism of the affected 
relative (Orsmond et al., 2009; Orsmond & Seltzer, 2009). Carter and collaborators (2009) 
studied stability and individual change in depressive symptoms among mothers raising 
young children with ASD. They observed that child problem behaviors and delayed 
competence, maternal anxiety symptoms and angry/hostile mood, low parenting efficacy 
and social supports, and coping styles were associated with depression severity. Only 
maternal anxiety and parenting efficacy predicted individual change. Many mothers do not 
appear to adapt, supporting the need for early intervention for maternal well-being. 
In particular, mothers experience the reality of having an autistic child permeated by 
feelings of nullity, loneliness and solitude. They also stop living their daily lives to live the 
everyday life of the child. Brothers and sisters have more stressful conditions of life, which 
include early responsibilities, anxiety and feelings of inferiority (Benderix & Sivberg, 2007).  
Pearson et al. (2006) found that autistic individuals have more symptoms of depression, 
withdrawal from social life, atypical behaviour and immature social skills. Besides, they are 
at particularly high risk of comorbidities involving emotional and behaviour disorders, with 
direct consequences on their family. Family members have to adapt to a reality that, in 
addition to being new, is very heterogeneous, complex and difficult and that can result in 
conflicts that require intervention (Kelly et al., 2008).The disease eventually becomes the 
focus and other problems become unimportant; family members live only the disease and 
end up getting sick too (Balieiro & Cerveny, 2004).  
What is observed in practice is that when a child is diagnosed with ASD, parents experience 
a variety of very complicated feelings that are often unrelated to interventions involving the 
child, but related to the parents particular vision of the world(Wachtel & Carter, 2008). After 
all, few other diseases can pose such a great threat to the family as these do, because autism 
 
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment 
 
188 
3. Genetic counseling in autism of unknown etiology  
On taking into account all technologies, an underlying genetic diagnosis is identified in 
around 10–15% of ASDs cases while cytogenetically visible chromosomal rearrangements 
are found in 2–6% of ASDs individuals (Bremer et al, 2011; Kumar & Christian, 2009). 
Hence, for most individuals (90%) with the autistic phenotype, there is no known genetic or 
environmental cause, which defines them as non-syndromic or "idiopathic' as previously 
mentioned. Often this condition is established after negative resultsobtained from a medical 
evaluation to identify medical issues that affect the development and behavior of nonverbal 
children, physical examinationabout metabolic, medical, or neurologic conditions, careful 
examinationof personal history, a detailed investigation of gestational antecedents and 
dysmorphic signs and after performing an odysseyof multiple testing.  
Genome-wide studies have implicated numerous minor risk alleles with low and high 
penetrance but few common variants and with many contributing loci. Among the 
candidates are genes that code for important proteins in synaptic structure, function and 
maintenance. Genetic mutations in these genes result in an aberrant synaptic process that 
could produce the ASDs phenotypes. However, the frequency of these mutations is so low 
that widespread screening does not seem to be clinically justified. Some, however, deserve 
to be investigated because of clinical findings such as mutations in the PTEN gene in 
children with macrocephaly (Lintas & Persico, 2008). 
As etiological factors are progressively being discovered, it is natural to think that the number 
of idiopathic cases will also gradually decrease. The increased resolution of CGH array testing 
in combination with new technologies, such as whole genome sequencing and bioinformatics 
programs, will play an important role in helping us to further understand the complex genetic 
basis of autism. The implementation of these high resolution techniques in the genetic research 
of ASDs may discover specific genotypes and subtypes of ASDs for which new diagnostic and 
therapeutic strategies can be developed. For this reason the identification of genetic 
abnormalities is a high priority in the study of ASD (Bremer et al., 2011). 
For now, non-syndromic cases are much more common than other forms with estimates in 
the general population reported at approximately 1 in 100. In these cases, ASD is considered 
a complex disease of multifactorial pattern inheritance (Harrington, 2010; Maenner & 
Durkin, 2010)[4] M.J. Maenner and M.S. Durkin, Trends in the prevalence of autism on the 
basis of special education data, Pediatrics 126 (2010), pp. e1018–e1025. Full Text via CrossRef 
| View Record in Scopus | Cited By in Scopus (1). About 70% of probands with autism of 
unknown cause has a first- or second-degree relative with autistic symptoms, and 15% has 
fathers with Asperger syndrome. The empiric aggregate risk to sibs of individuals with 
autism of unknown cause varies across studies but is generally considered to range from 5% 
to 10% for autism and 10% to 15% for milder symptoms, including language, social, and 
psychiatric disorders. For families with two or more affected children, the recurrence risk 
approaches 35% (Miles et al., 2010).  
All this information should be thoroughly discussed with the members of the family at their 
level of understanding. Obviously, faced with such uncertainty and heterogeneity, the 
counselor may feel uncomfortable to report these risks. It is essential that the family 
understands that when a child is diagnosed with an ASD, a range of etiological options are 
involved, which means the possibility of many different diseases. An aggravating factor is 
that the information may generate anxiety; most families have social and institutional 
barriers to carrying out more sophisticated tests. 
 
Genetic Counseling in Autistic Phenotypes 
 
189 
4. Psychosocial aspects of genetic counseling in autism 
Throughout its development, the family goes through many changes. Each phase of the so-
called life cycle (acquisition, adolescence, maturity and final) has its own peculiarities and 
difficulties inherent to the transformations that occur. During the acquisition phase, with the 
arrival of children, accepting parenting is already difficult. The family system "grows" as a 
whole and new links and forms of communication are needed. Moreover, the "myth of 
happy motherhood" is common, influenced by sociocultural aspects. This myth may become 
unreachable and a crisis may result from this expectation, as the ideal social value is not 
achieved. If motherhood is culturally associated with well-being and achieving, when the 
son or daughter is not compatible with the one desired by the parents, as is the case of 
children born with a vulnerability, this condition does not only change the 
psychophysiological functioning of the mother and her quality of life, but can also result in 
negative consequences for the whole family. Parenthood is a relational experience of 
profound psychological meaning, experienced in family relationships, which are 
transformed over the entire life and that are restructured with the normal cycles of family 
development and, occasionally, by unforeseen events (Cerveny & Berthoud, 1997). 
The arrival of a child with ASD can be considered an unexpected contingency at any stage 
that the family is going through, because these are serious psychiatric illnesses, which 
require special needs and require much understanding and patience due to the peculiarity 
of the symptoms. Given this reality, some authors have reported that mothers of children 
with disabilities tend to depression, which may be associated with hopelessnessand 
worsened quality of life. This is also observed in the fathers and siblings of individuals with 
ASDs, with the degree of symptoms reflecting the severity of the autism of the affected 
relative (Orsmond et al., 2009; Orsmond & Seltzer, 2009). Carter and collaborators (2009) 
studied stability and individual change in depressive symptoms among mothers raising 
young children with ASD. They observed that child problem behaviors and delayed 
competence, maternal anxiety symptoms and angry/hostile mood, low parenting efficacy 
and social supports, and coping styles were associated with depression severity. Only 
maternal anxiety and parenting efficacy predicted individual change. Many mothers do not 
appear to adapt, supporting the need for early intervention for maternal well-being. 
In particular, mothers experience the reality of having an autistic child permeated by 
feelings of nullity, loneliness and solitude. They also stop living their daily lives to live the 
everyday life of the child. Brothers and sisters have more stressful conditions of life, which 
include early responsibilities, anxiety and feelings of inferiority (Benderix & Sivberg, 2007).  
Pearson et al. (2006) found that autistic individuals have more symptoms of depression, 
withdrawal from social life, atypical behaviour and immature social skills. Besides, they are 
at particularly high risk of comorbidities involving emotional and behaviour disorders, with 
direct consequences on their family. Family members have to adapt to a reality that, in 
addition to being new, is very heterogeneous, complex and difficult and that can result in 
conflicts that require intervention (Kelly et al., 2008).The disease eventually becomes the 
focus and other problems become unimportant; family members live only the disease and 
end up getting sick too (Balieiro & Cerveny, 2004).  
What is observed in practice is that when a child is diagnosed with ASD, parents experience 
a variety of very complicated feelings that are often unrelated to interventions involving the 
child, but related to the parents particular vision of the world(Wachtel & Carter, 2008). After 
all, few other diseases can pose such a great threat to the family as these do, because autism 
 
Autism Spectrum Disorders: The Role of Genetics in Diagnosis and Treatment 
 
190 
is still seen as an intense "stressor" (Woodgate et al.,2008; King et al., 2006). But when, for 
example, a better relationship is established between the mother and child, the autistic 
symptoms may reduce (Smith et al., 2008). 
As ASDs are related to a great need for care that directly affects the development not only of 
the individual but also of their families, the resources available to families must be 
evaluated very well (Montalbano &Roccella, 2009; Montes & Halterman , 2008). It is 
important to strengthen social networks and the availability of resources such as specialized 
schools, stimulation therapy clinics and family psychotherapy(Smith & Elder, 2010; Cahill & 
Glidden, 1996). Family support is associated with increased optimism that, in turn, predict 
higher levels of positive feelings. Even the child psychiatrist should be encouraged to 
participate in the social support network of parents, helping them on the long journey of 
raising their children (Wachtel & Carter, 2008).  
The paediatrician’s role is crucial, because with more frequent contact with the child and the 
bond of trust with the family, the doctor will able to detect symptoms early and to guide the 
investigation and treatment. Most important, according to De Ocampo and Jacobs (2006), is 
to establish close cooperation and communication between the family and all the experts 
who care for the child. 
There are many gaps in the scientific knowledge which justifies the need to define future 
research on families of children with these diseases. Health professionals must strive to 
study them and create effective support strategies. 
5. Genetic counselor and counselee: a model and an example of case 
Genetic counseling, although governed by traditional guidelines that recommend certain 
actions, phases and intentions, varies much in the way it is developed, from centre to centre, 
region to region and from country to country. Not only the emphasis on some particular 
goal may vary but the composition of the team and the different forms of participation of 
each of its members may change. 
Many kinds of questions can be used in different ways to increase the understanding, 
respect and empathy on both sides, counselor and counselees. The counselor is part of the 
system in which he acts and his personality is a determinant of how the process will be 
conducted within the basic goals of genetic counseling. Some counselors are more 
paternalistic (I suffer with you and if I could do anything for the situation to be different ...), 
and some are more authoritarian (You have to understand that I am experienced in this 
matter and definitely can help you…). There are also the many peculiarities of each team; 
never will the counseling given by one counselor in one situation be the same as that given 
by another. Also, counseling performed by one team for one family with a particular type of 
problem will not be identical to that for another family with exactly the same problem. The 
process is so dynamic that it cannot be predicted. 
We will briefly describe a model of genetic counseling which occurred in a community 
genetic service of a low-income country (Brazil). It involves a context characterized by 
certain cultural, legal and religious limitations such as the cultural fear of genetic disorders 
due to stigma and legal restrictions in respect to selective abortion, among others. The 
service in questionis located in a referral centre for health in a city of the most developed 
state of the country (São Paulo). It has an interdisciplinary team comprised of three 
counselors, three psychologists, physicians of different specialties, a social worker and two 
nurses. One of its peculiarities is that the genetic counselor and psychologist work together 
during counseling sessions of families, in a transdisciplinary way. 
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Briefly, the model can be described by the different phases through which the family passes 
after its arrival in the service: 
- After presenting at the reception, the family is asked to stay in a waiting room. There 
the family is approached by a psychologist, who presents himself, establishes a rapport 
(contact, dialogue) and investigates the characteristics, expectations and basic needs of 
the family. The psychologist makes observations about the emotional state (anger, 
sadness, anxiety, etc.), the main coping strategies (emotional, cognitive and 
behavioural), psychological functions (guidance, judgement, attention, language, mood, 
level of understanding, etc.) and beliefs or fears. Questions such as these are used: 
"What is the reason for your referral to this service?", "Who referred you?" "What do 
you know about genetic counseling?", "How do you feel?", and "What do you expect 
from genetic counseling?". The family should be guided and informed on the practical, 
structural and dynamic operation of genetic counseling, its meaning, as well as the role 
of the different professionals involved. During the psychological approach a more 
relaxed atmosphere should be created. 
- Before the counselor has contact with the family, he is informed by the psychologist on 
the data collected in the waiting room. The counselor has elements to promote a more 
focused and effective intervention, using a more targeted and personalized approach. 
- On being called for counseling, the psychologist who established the initial rapport 
with the family in the waiting room, introduces the family members to the counselor, 
enters the room and participates in the genetic counseling process. Everyone sits in a 
circle, with a small table moved to the side, just for the counselor’s note taking. The 
central table is considered an "obstacle" to establishing a relationship as it may suggest 
difference in level/hierarchical which always causes awkwardness. The psychologist 
accompanies the discussion, observes and only intervenes quickly and objectively on 
psychological aspects when requested or when he believes it is absolutely necessary. 
The phases of genetic counseling develop. It is up to the counselor to give psychological 
support inherent to the process. It is important to motivate the family to return for a 
follow up consultation, to perform exams, comply with treatment and to offer supports 
linked to the most urgent difficulties, contacting a social assistant and 
professionals/support institutions. When necessary, refer members of the family for a 
more detailed psychological assessment or for psychotherapy. 
- In all consultations, the counselor and the psychologist caring for the family should be 
the same as the first visit and even when the process is completed the team should be 
available to explain future doubts that may arise through further meetings or by 
telephone. 
All the professionals involved in the care of families of individuals with ASDs surely pass 
through difficult situations of intense learning that require much skill and compassion. 
Perhaps I can illustrate what this means using a true case. 
On one day in November 2010 ... The psychologist informed the counselor that the family 
that she was about to meet comprised of a father, a mother, a three-year-old child with a 
diagnosis of autism made one week previously, and another five-year-old apparently health 
son. He said that the family was psychologically very weak. The mother, aged 32, expressed 
much sadness and spoke only when questioned. The father, 39 years old, expressed great 
anger, was extremely anxious and said that he did not know why they had been referred for 
genetic counseling, which he thought was a waste of time. Both were well educated; she is a 
computer engineer and university professor, and he is a judge. They had already researched 
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on the Internet many details about the problem and were very shocked and confused. In the 
waiting room the psychologist explained to them about the dynamics of the process and the 
benefits they might obtain with the clearing up of their doubts and specific guidance. The 
father rejected obstinately attempts of contact and the mother reported that she was feeling 
very lonely. As they spoke, the eldest son always listened in silence. When asked how he felt 
by the psychologist, the son answered "tired".  
When called and led by the psychologist to the consultation room, the counselor noted the 
seemingly arrogant and cold attitude of the father, who entered the room in front of his wife 
that was holding the hands of both children, and sat down before anyone else. The children 
were seated in the centre of the circle where some toys had been placed so that they could 
play and so they would stay there. The counselor noted the autism phenotype of the child 
with repetitive stereotypic movements, isolation, lack of speech, among other things, 
without dysmorphic signs. The mother reported that the diagnosis was made by the team of 
psychiatrists and neurologists that had requested exams, including biochemistry, imaging, 
hearing evaluation, among other tests, which were normal. The pregnancy and delivery 
occurred without complications. Also, there was no parental consanguinity or other risk 
factors involved. She said that before the completion of the diagnosis of childhood autism, 
other professionals had partial or wrong diagnoses, which left her very confused. 
Both the father and mother started giving much information without being requested, 
including some technical information about autism. They started a kind of "competition", 
both on involving who spoke first and on the level of knowledge that each one had. Thus, 
the genetic counselor had an opportunity to observe and evaluate the couple's dynamics. At 
one point the counselor interrupted them and said, in an attempt to move on directly to 
emotional issues, "I am realizing how much you are frightened by the diagnosis that you 
received. Before I explain to you about the diagnosis, I would like to know more about your 
feelings. What made you so upset? Do you think it is very hard for you to talk about this 
now?" The couple, as they were caught by surprise, agreed to talk about it and the counselor 
asked the mother to speak first. Crying a lot, she reported that she was trying to understand 
everything that was happening and that she was not able to concentrate on her work 
anymore. She felt very guilty because her family was no longer the same, her eldest son was 
in trouble at school and that she felt very lonely. She did not know anyone with a child with 
the same problem and that, initially, the worst that she thought was that her son was deaf. 
She confessed that she always only wanted to have one child and that the second pregnancy 
was not planned. She had rejected the child and she felt that was being punished for this. 
She even felt that she was being punished too for an abortion she had as a teenager. She 
would like to talk to other people about their son but she had made a deal with her husband 
that they would not reveal the child's diagnosis to anyone; not before trying to help him to 
get better. 
The counselor told her she had some mistaken ideas and meanings but it was good to see 
that she was seeking help. Those feelings, though difficult, were natural and expected, as in 
general, no person is prepared to have a child that is different to what they expected and 
very few people are ready for this possibility. The counselor continued saying that much of 
the information that they would receive starting from the first session, might certainly help 
in this difficult emotional period that the entire family was going through. The father 
interrupted saying "Speaking of information, I need you to tell me why my son is autistic!" 
The counselor felt upset with the authoritative behavior of the father and his attempts to 
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hide his emotions. The mother broke in with the phrase "It is impossible to live with him" to 
which the father replied "You cannot talk about us because is our son who needs help!"  
Then the counselor told the father that she noted that he was also seeking help albeit in a 
different way. The counselor explained the relative proportions of autism cases in the 
population that might be attributable to various mechanisms of genetic transmission and 
that the vast majority of cases of autism remain idiopathic. The counselor asked the father 
how possible information about the cause of the autism of their son could help him, and 
why he preferred not to reveal the diagnosis to the child's relatives and friends. He replied 
that by discovering the cause there would certainly be drugs/specific therapies that would 
improve their son’s condition and that people would look less and would not feel sorry for 
their son. The anxiety about the manifestations of the autistic child was clear. He added 
saying that the child was very "stubborn"; he was being seen by a speech therapist and 
occupational therapist and was taking psychiatric drugs and did not improve much except 
for being less aggressive. In a possible attempt to justify their ways, the father said many 
members of his family were stubborn, especially his father. He had been educated in a 
traditional manner. His father was very angry and never admitted that his children, all 
male, were weak. 
The counselor noticed that the psychological defenses of father were not entirely 
unconscious. He was being “defensive” and his behavioral probably was related to a great 
sense of loss.  
The counselor provided some practical explanations about autism and coping with affected 
children, explained the importance of knowing other families, some support institutions and 
the etiology of ASDs. In 90% of the cases, the etiologies of ASDs are not known. 
As the parents had some technical knowledge from other sources, but did not understand it 
very well, the counselor re-organized the information and clearly explained it, in particular, 
in respect to idiopathic cases. It was explained that some more sophisticated genetic testing 
methods that the child had not been done, but they also had a low probability of identifying 
the cause of the disease. The counselor congratulated the parents because they were 
adhering to the proposedtreatment plan and explained the lack of specific remedies linked 
to a possible cause in this case and in most others. Finally, that she understood the 
frustration of the father, his difficulties in understanding the behaviour of his child, who 
was not stubborn, but he just could not "understand" what his father wanted from him. 
At this point the father began to cry copiously and the psychologist intervened saying that 
he was among friends who wanted to help him, and that he was in the right place to express 
his emotions without shame or fear of being judged. The counselor asked his wife to hold 
the hand of her husband and in so doing the eldest son stood up and hugged his father, a 
move which, to everyone's surprise, was followed by the autistic son, who sat on the father’s 
lap. 
After this time, the challenges and clashes that marked the start of the session were replaced 
by interest to explore and discuss all information. They expressed interest in performing the 
tests that were missing and in doing psychotherapy. The counselor reiterated that she 
perceived the sense of responsibility and parental love, fundamental for the family's 
adjustment to the new reality. The session was adjourned with the family thanking the team 
for their help and patience, who thanked them for their trust. A return visit was set for 45 
days. 
At the next session the parents came back hand in hand, the mother was more confident and 
the father more pleasant. The new tests also showed normal results and the counselor 
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restated some information. The parents were very satisfied with psychotherapy and had 
chosen couples therapy. The autistic child had begun equine therapy and the parents were 
excited and hopeful. They said that they had organized a lunch for relatives and close 
friends, where they would tell their child’s diagnosis and how they counted on the 
understanding and help of all.  
The counselor and psychologist expressed their admiration and congratulated the mother 
and father for their initiative and expressed their satisfaction with the many positive 
developments. The team of professionals knew the family’s feelings of love and of 
commitment to each other would support them through what lay ahead. At the end of the 
session, the psychologist could not contain himself and asked their eldest son: "And you, 
how are you feeling?" He just smiled and hugged his autistic brother... 
6. Conclusion 
ASDs have become a public health problem but there are many misunderstandings about 
the heritability of these disorders. The detection of genetic alterations may contribute to the 
diagnosis, allow an understanding of biological mechanisms involved in the pathogenesis, 
assist in genetic counseling of families and guide prevention and educational planning. 
Health care practitioners need to be able to provide information about general principles of 
human genetics as well as the epidemiological and molecular aspects of genetics regarding 
Autism Spectrum Disorders. In addition, they need to understand the limitations of genetic 
testing and the psychological conditions of the families. Knowledge of the genetic factors 
involved and of the psychological effects of these diseases is crucial for the establishment of 
intervention strategies that promote the bio-, psycho- and social well being of those affected 
and their families. Besides providing technical information necessary for the family to have 
a better understanding about the disease, genetic counseling can alleviate some of the 
common mistaken beliefs and provide support to families, assisting in the transformation 
and adaptation of the members. It is very important that psychoeducation programmes be 
created for parents, focused on handling stress and emotions, modifying false beliefs and 
solving the daily problems that arise from ASDs. 
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Estimated prevalence rates of autism spectrum disorders (ASDs) have increased at 
an alarming rate over the past decade; current estimates stand as high as 1 in 110 
persons in the population with a higher ratio of affected males to females.  In addition 
to their emotional impact on the affected persons and their family members (in fact, 
the latter are often unrecognized unaffected patients” themselves), the economic 
and social impacts of ASDs on society are staggering.  Persons with ASDs will need 
interdisciplinary approaches to complex treatment and life planning, including, but 
not limited to, special education, speech and language therapy, vocational skills 
training and rehabilitation, social skills training and cognitive remediation, in 
addition to pharmacotherapy.  The current book highlights some of the recent research 
on nosology, etiology, and pathophysiology. Additionally, the book touches on the 
implications of new research for treatment and genetic counseling.  Importantly, 
because the field is advancing rapidly, no book can be considered the final word or 
finished product; thus, the availability of open access rapid publication is a mechanism 
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